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Paediatric Hodgkin lymphoma (HL) and endemic Burkitt lymphoma (eBL) are Epstein-Barr 
virus (EBV) associated childhood malignancies. 
In HL, malignant Hodgkin/Reed-Sternberg (HRS) cells, are characterised by aneuploidy, and 
comprise <1% of tumour which is challenging for global genetic studies. In chapter 3, I 
describe the mutational landscape of paediatric HL using in vitro and in silico methods I 
established, including tumour DNA amplification from low numbers of (~150) microdissected 
cells. I found that protein-altering mutations converge on mitotic spindle functions and that 
EBV contributes to transcriptionally downregulate mitotic spindle genes. 
The contribution of the EBV to eBL pathogenesis remains poorly understood. In chapter 4, I 
show that the virus G protein-coupled receptor, BILF1 is apparently a latent gene expressed 
by tumour cells in a subset of BL. BILF1expression induced a transcriptional profile in 
primary human germinal centre (GC) B cells that partially recapitulates the transcriptional 
programme of EBV-positive eBL, and genes up-regulated by BILF1 have functions in 
oxidative phosphorylation and are also targets for MYC. 
In summary, my data identify novel pathogenic pathways contributing to the pathogenesis of 
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1.1 The Epstein-Barr virus 
The Epstein-Barr virus (EBV) infects approximately 95% of humans. Infection usually occurs 
in early childhood, and then persists for the rest of an individual’s life with no symptoms 
(Baer et al., 1984, Fleisher et al., 1979). More than 200,000 new cases of EBV-associated 
cancer are registered each year (2% of all cancers), and these malignancies account for about 
1.8% of all cancer deaths world-wide (zur Hausen and de Villiers, 2015, de Martel et al., 
2012, Khan and Hashim, 2014). EBV is causally associated with several types of cancer, 
including B cell tumours such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL); and 
epithelial cancers, including nasopharyngeal carcinoma (NPC) and gastric cancer (Rickinson 
and Kieff, 2007). EBV-associated tumours are more prevalent in the developing world 
compared with developed regions and contribute to cancer development in 
immunosuppressed patients (de Martel et al., 2012). 
1.2 The discovery of Epstein-Barr virus 
The events that led to the discovery of Epstein–Barr virus (EBV) as the first human oncovirus 
began on 22 March 1961 when Anthony Epstein, a young pathologist working at the 
Middlesex Hospital in London, attended a lecture entitled 'The commonest children's cancer 
in tropical Africa: a hitherto unrecognized syndrome', given by Dennis Burkitt, a surgeon 
working in Uganda. The disease in question was an unusual extranodal tumour of the jaws of 
African children, which later known as Burkitt lymphoma (BL) (Burkitt, 1958). Following 
discussions with Epstein, Burkitt agreed to send fresh tumour biopsies to Epstein's laboratory 





(Crawford et al., 2014). After a series of unsuccessful attempts to culture BL cells, Epstein 
and Yvonne Barr accidentally found viable tumour cells floating free of the main lymphoma 
mass in a delayed shipment of a BL biopsy sent by Burkitt in December 1963. Epstein and 
Barr grew these tumour cells in fresh culture medium, and thus the first cell line (now named 
the EB1 cell line after Epstein and Barr) from a human lymphoma was established in 1964 
(Epstein and Barr, 1964). Analysis of the EB1 line by electron microscopy revealed herpes-
like virus particles (Epstein, 1999). Unlike the three other human herpesviruses known at that 
time, this virus was biologically inert for all activities associated with known herpesviruses. It 
was formally identified as a new herpes virus in 1965 (Epstein, 1979). 
In the following years, a serological assay was developed against the viral capsid antigen 
(VCA) to screen for EBV infection. This screening assay revealed the presence of EBV 
infection in 90% of the adult human population (Henle et al., 1969). 
1.3 Classification and structure of EBV 
EBV (also known as human herpes virus 4) is a lymphotropic virus and belongs to the family 
Herpesviridae. The International Committee on Taxonomy of Viruses (ICTV) revised the 
family Herpesviridae in 2016, which was incorporated into the new order Herpesvirales. 
Family Herpesviridae, which retains the mammal, bird and reptile viruses, is sub-divided into 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae based on genome sequence 
homology. EBV is the only human Lymphocryptovirus (LCV) of the Gammaherpesvirinae 
and like other LCVs EBV can establish a latent infection (Bilello et al., 2006, Davison et al., 
2009, Marr-Belvin et al., 2008). 
EBV has a toroid-shaped protein-core wrapped with viral genome which is encapsulated by 
an icosahedral nucleocapsid composed of 162 capsomers containing tubular 160, 47, and 28 





tegument, containing a mixture of cellular and virally encoded proteins, is found between the 
nucleocapsid and an inner envelope as well as external glycoproteins on the surface of the 
outer envelope. The protein content of the host derived envelope is dominated by the virally 
encoded 350 or 220 k-Da glycoprotein (gp350/220) (Dolyniuk et al., 1976a, Dolyniuk et al., 
1976b, Johannsen et al., 2004). 
The complete sequence of an EBV strain (the B95-8 strain) was published in 1984 (Baer et 
al., 1984). Sequencing of the EBV genome was carried out on a Bam HI fragment cloned 
library which revealed that it is composed of 172.76 kilo base (kb) of linear double stranded 
DNA and contains 60% GC residues (Figure 1). Bam HI fragments containing open reading 
frames, genes and sites for transcription or RNA processing are depicted in descending order 
of fragment size as shown in the Figure 2.  Subsequent studies identified 82 EBV genes 
encoding 80 proteins, and 2 non-coding RNAs; however the number of genes and transcripts 
are regularly updated and are likely to increase due the advances in sequencing technology 
(Dolan et al., 2006, O'Grady et al., 2016). 
Coordinated expression of a subset of these viral genes, including the so-called latent genes, is 
responsible for in vitro B cell immortalization.  Sequencing of various virus strains revealed 
that the prototypic B95-8 sequence was unusual in that it had a 12 kb deletion in the BamHI A 
region. In 2003, de Jesus et al., replaced the 12-kb deletion in the B95-8 EBV sequence using 
the sequences obtained from the Raji strain (de Jesus et al., 2003). The latest reference EBV 
sequence is available at NCBI (GenBank accession number: AJ507799.2; last update on 26-
JUL-2016). Although it is widely believed that slow evolutionary drift is responsible for 
genetic polymorphisms in the viral genome, the origin of the two EBV types, type 1 and type 
2, remains enigmatic as both types are found in the oropharynx of most human populations. 





and EBNA3 genes (Baer et al., 1984, Dambaugh et al., 1984). Type 1 EBV is more prevalent 
worldwide except in areas endemic for BL (equatorial Africa and New Guinea) and has 
greater transforming potential (Barton et al., 2007, Zimber et al., 1986) than Type 2 EBV 
(Young et al., 1987, Sixbey et al., 1989). 
Despite a high degree of sequence similarity between EBV strains, additional variations exist 
in some viral genes, mainly in the latent genes, which give rise to functional differences 







Figure 1. Schematic representation of the EBV genome.  The origin of plasmid replication 
(OriP), Terminal repeats (TR) and origin of lytic replication (OriLyt) are shown in blue boxes. 
Exons encoding latent proteins: Epstein–Barr nuclear antigens (EBNA1, 2, 3A, 3B and 3C, 
and EBNA-LP) are shown in light blue boxes, latent membrane proteins (LMP1, 2A and 2B) 
are shown in pink boxes. Lytic cycle genes BALF1, BCRF1, BHRF1, and BHRF1 are shown 
in yellow boxes. Highly transcribed EBER1 and 2, and the EBV encoded microRNAs are 







Figure 2. Schematic depiction of the linear EBV genome with open reading frames (ORFs). 
EBV ORFs are named based on their location (ORF1, ORF2, etc.) and direction (rightward or 
leftward) within the Bam H1fragment (A to Z, in decreasing size). The EBV genes are colour 
coded as: latent gene ORFs or exons (purple, the early lytic ORFs (beige), late lytic ORFs 
(red). Yellow arrows depict ORFs of unknown gene class or are hypothetical. LMP2A and 
LMP2B are encoded across the circularized genome. The location of microRNA (miRNAs) 
and the noncoding RNAs EBER1and EBER2 encoded by the genome is also shown. Numbers 
refer to kilo-base pairs. Correction: BILF1, depicted as uncharacterized gene here in yellow is 





Table 1. Reported EBV sequences. BL, Burkitt lymphoma; EBV-GC, EBV-associated gastric 
carcinoma; HL, Hodgkin lymphoma; IM, infectious mononucleosis; LCLs, lymphoblastoid 
cell lines; NPC, nasopharyngeal carcinoma; PTLD, post-transplant lymphoproliferative 
disease (taken from Young et al., 2016). 






2003 Sample et al., 1990 
GD1 1 China NPC 2005 de Jesuset al., 2003 
AG876 2 Ghana BL 2006 Zeng et al., 2005 
GD2 1 China NPC 2011 Dolan, 2006 
HKNPC1 1 Hong Kong NPC 2012 Liu et al., 2011 
Akata 1 Japan BL 2013 Kwok et al., 2012 
Mutu 1 Kenya BL 2013 Kwok et al., 2012 
M81 1 Hong Kong NPC 2013 Lin et al., 2013 
K4123-Mi 
and K4413-Mi 
1 USA LCLs 2013 Tsai et al., 2013 
HKNPC2–HKNPC9 1 Hong Kong NPC 2014 Lei et al., 2013 
NA19114, NA19315 and 
NA19384 
1 USA LCLs 2014 Kwok et al., 2014 
71 different EBV strains 
60 type 1 
and 




















1.4 EBV induced B cell growth transformation in vitro 
The discovery of the ability of EBV to infect and transform resting B cells in vitro was critical 
to understanding its role as an oncovirus (Henle et al., 1967, Pope et al., 1968). EBV 
glycoproteins gp350 and gp42 bind to the CD21 receptor and human leukocyte antigen 
(HLA) class II molecules on the surface of B cells, resulting in infection followed by 
conversion of primary B cells to continuously proliferating lymphoblastoid cell lines (LCLs). 
LCLs usually express latency III or the 'growth programme'; where multiple copies of 
extrachromosomal circular genetic material known as episomes express all latent genes 
(Figure 1), including six Epstein–Barr nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C and 
EBNA leader protein (EBNA-LP)), latent membrane proteins LMP1 and LMP2 (which 
encodes two isoforms, LMP2A and LMP2B) and the non-coding EBV-encoded RNAs 
(EBER1 and EBER2), and viral microRNA (miRNA) (Rickinson and Kieff, 2007) .  
In LCLs, differential splicing of the same primary transcript expressed from either the Cp or 
Wp promoters, located in the Bam HI C and W fragment of the EBV genome, respectively, 
generates all EBNA mRNAs (Longnecker et al., 2013, Speck and Strominger, 1985). The 
LMP1 promoters, the proximal ED-L1 and the distal TR-L1, are regulated by different viral 
and cellular factors and can be transcribed into LMP1 mRNA (Kis et al., 2010, Noda et al., 
2011, Goormachtigh et al., 2006). For example, EBNA1 can stimulate LMP1 transcription 
from both promoters through a distal enhancer (Gahn and Sugden, 1995), whereas EBNA2 
can only activate ED-L1 (Johannsen et al., 1995). Cellular proteins such as NOTCH1, IRF7, 
STATs, upstream stimulatory factor (USF), and ATF-1/cAMP responsive element binding 
protein (CREB)-1 can also activate the ED-L1 promoter (Chang et al., 2000). Cellular 
transcription factors, including SP1/SP3 and STATs can activate the TR-L1 promoter (Tsai et 





Two separate promoters are involved in the transcription of LMP2A and LMP2B genes; the 
LMP2A promoter is present directly upstream of the first coding exon while the LMP2B 
promoter shares a bidirectional promoter with LMP1. LMP2A and LMP2B promoters are 
separated by 3 kb. These two isoforms differ only in their first exons. The exon 1 of LMP2A 
encodes a 119-amino-acid-N-terminal tail. The exon 1 of LMP2B is non-coding (Laux et al., 
1988, Laux et al., 1989, Longnecker and Kieff, 1990, Sample et al., 1989). A novel LMP2 
transcript originating in the TRs has been described recently in NK/T cell lymphomas (Fox et 
al., 2010).  
High levels of B cell activation markers such as CD23, CD30, CD39, and CD70: and cellular 
adhesion molecules such as FA1, LFA3, and ICAM1, similar to that of activated B cells, have 
been observed in LCLs, suggesting that EBV-induced immortalization in LCLs can be 
achieved through the constitutive activation of cellular pathways that normally drive B cell 
proliferation (Rowe et al., 1987a, Gregory et al., 1988, Young et al., 2000). 
1.5 EBV infection and persistence in vivo 
Although it is now well established that EBV persists as a latent infection within the memory 
B cells, it has been suggested that primary infection occurs in mucosal epithelial cells of the 
oropharynx and upon viral replication EBV spreads to B cells (Morgan et al., 1979). 
However, it has also been suggested that EBV infection of epithelial cells could also involve 
mechanism distinct from that required for B cell infection (Shannon-Lowe et al., 2009). 
NK cells, latent-antigen-specific CTLs and CD4 T helper cells recognize the B cells 
expressing a latency III programme (Williams and Greene, 2005, Hislop et al., 2007a). 
However, a fraction of these B cells can down-regulate the expression of most viral antigens, 
thereby evading immune recognition and establishing a pool of resting EBV-positive memory 





proposed to explain how this occurs. In the first model, EBV infects naïve B cells and drives 
naive cells into memory by mimicking the physiological process of antigen-driven memory 
cell development in lymphoid tissues, a process involving somatic immunoglobulin gene 
hyper-mutation during transit through a germinal centre. In the second model, EBV directly 
infects pre-existing memory cells as a direct route into memory. EBV-infected memory B 
cells (which express a so called latency 0 pattern of EBV gene expression) act as a reservoir 
and might be recruited into germinal centres of secondary follicles and switch into the viral 
latency II programme. EBV-positive GC B cells receive the necessary signals for antigen-
independent proliferation with the help of EBV-encoded surrogate T cell signals (provided by 
LMP1) and B-cell receptor (BCR) engagement stimulus (provided by LMP2A) (Caldwell et 
al., 1998, Caldwell et al., 2000, Roughan and Thorley-Lawson, 2009). Subsequently, the 
EBV-infected B cells might either re-enter the reservoir as memory cells (latency 0) or 
commit to plasma-cell differentiation and move to mucosal sites in the oropharynx and, in the 






Figure 3. Primary infection and persistent infection of EBV in vivo. a) Primary infection. Upon infection EBV establishes initial lytic replication 
in the oropharynx, after which the virus spreads throughout the lymphoid tissues as a growth-transforming (latency III) infection of B cells. 
Latent-antigen-specific primary-T-cell response removes many of these proliferating B cells, however some B cells escape by downregulating 
antigen expression. These B cells then establish a stable reservoir of resting EBV-positive memory B cells, in which viral antigen expression is 
mostly suppressed (latency 0). Two possible mechanisms of B cell infection are shown:  EBV infects naïve B cells and drives naive cells into 
memory by mimicking the physiological process of antigen-driven memory-cell development in lymphoid tissues, a process involving somatic 
immunoglobulin-gene hyper-mutation during transit through a germinal centre or alternatively EBV might directly infect pre-existing memory 
cells as a direct route into memory. b) Persistent infection. EBV-infected memory B cells acts as a reservoir and might be recruited into germinal-
centre reactions, entailing the activation of different latency programmes. Subsequently they might either re-enter the reservoir as memory cells 
or commit to plasma-cell differentiation and move to mucosal sites in the oropharynx and, in the process, activating the viral lytic cycle (taken 





1.6 Alternative forms of EBV latent infection 




In this form of latency, EBV persists in memory B cells of EBV-infected healthy humans 
where all latent genes with the exception of EBERs and the viral miRNA are suppressed 
(Babcock et al., 1999). Upon reactivation of EBV latent transcription, memory B cells enter 
germinal centres and express low levels of LMP1, LMP2A, and Qp-initiated EBNA1 
(Babcock and Thorley-Lawson, 2000) (Figure 4). 
 
Latency I 
Latency I viral expression is observed in EBV-positive BL and BL derived EBV-positive cell 
lines (Rowe et al., 1987b) Latency I is also a restricted viral latent gene expression pattern, 
characterized by the activity of the Q promoter (Qp) and suppression of Cp, Wp, and possibly 
LMP promoter activity (Schaefer et al., 1995, Nonkwelo et al., 1996). In this latency form, 
non-coding EBERs, and EBV-encoded micro RNAs (BARTs) (Cai et al., 2006) are expressed 







Figure 4. Schematic diagram of EBV latent viral transcription in the different forms of 
latency. (A) Schematic illustration of the EBV genome showing the location of coding exons 
for the nuclear antigens: EBNA1, 2, 3A, 3B, 3C, and EBNA-LP; ORF for BHRF1; and the 
three latent membrane proteins LMP1, 2A and 2B. Also shown are the latent origin of 
replication (oriP), and the terminal repeats (TR). Shown below (B) are the structures of viral 
mRNA transcripts expressed in different forms of latency. Promoters are identified by 
arrowheads, coding exons are coloured and non-coding exons are unshaded. The BART 






Latency II is another restricted form of viral latency and is observed in ‘normal’ EBV-positive 
GC B cells and in EBV-positive cancers such as HL, NPC, and gastric cancer (Fahraeus et al., 
1988, Young et al., 1988). Latency II infected cells express variable levels of LMP1 and 
LMP2 along with the non-coding EBERs, viral miRNA (BARTs), and EBNA1 (Brooks et al., 
1992, Brooks et al., 1993, Kerr et al., 1992, Deacon et al., 1993).  
 
Wp latency 
An alternative pattern of viral gene expression was identified in a minority of BL cell lines, 
which have deletions of around 6–8 kb that span the EBNA2 gene, and in their corresponding 
tumour biopsies (Kelly et al., 2002a, Kelly et al., 2005, Rowe et al., 2014a). In this form of 
latency, the W-promoter (Wp) is active and drives expression of all EBNAs except EBNA2; 
instead of Q-promoter (Qp)-driven EBNA1 expression. Importantly, latent viral gene 
expression in these Wp-restricted BLs, several latent viral genes are expressed including high 
levels of the BHRF1 gene encoding a viral  homolog of human BCL2 gene (vBCL2) that was 
previously thought to be exclusively a lytic cycle protein (Kelly et al., 2009b, Rowe, et al. 
2014). Interestingly, gene expression in Wp-restricted BL cell lines seems to be derived 




In this form of latency, in addition to the genes expressed in the latency II, the remaining 5 
EBV nuclear antigens: EBNA2, 3A, 3B, 3C, and LP are expressed from large highly spliced 





type of latency is observed in LCLs and post-transplant lymphoproliferative disease (PTLD) 
(Young et al., 1989, Gratama et al., 1991). 
 
1.7 Epstein-Barr virus latent gene products 
 
Epstein-Barr nuclear antigen 1 (EBNA1) 
EBNA1 is a nuclear antigen encoded by the EBV BKRF1 ORF. EBNA1 binding to the 
plasmid origin of viral replication (OriP) on the EBV genome is essential for EBV replication 
during latency (Lupton and Levine, 1985, Yates et al., 1985). EBNA1 is the most 
ubiquitously expressed EBV-encoded protein that is found in all forms of viral infection, with 
the exception of latency 0 (Reedman and Klein, 1973, Babcock et al., 1999). During cell 
division, EBNA1 also ensures the partitioning of viral genomes by tethering viral episomes to 
host chromosomes (Marechal et al., 1999, Sears et al., 2004). In latency I and II infections, 
EBNA1 transcripts are initiated from the Qp promoter, while in latency III infection, EBNA1 
transcripts are initiated by splicing of the large Cp or Wp promoter initiated transcripts 
(Bodescot et al., 1986, Sample et al., 1991, Speck and Strominger, 1985). EBNA1 is also 
expressed during the lytic cycle, where lytic EBNA1 transcripts are directly initiated from the 
lytic F promoter (Fp) which is located upstream of Qp. Recent studies have suggested that 
EBNA1 can regulate EBER expression by increasing pol III transcription following its 
binding to and activation of ATF2, c-MYC and TFIIIC (Owen et al., 2010). 
Evidence provided by Humme et al., contradicts the indispensable role of EBNA1 in the 
EBV-induced transformation of B cells. This group managed to grow LCLs, albeit less 
efficiently, from an EBNA1-deficient EBV mutant (Humme et al., 2003). Although EBNA1 





HL cells (Kube et al., 1999), conflicting reports of the role of EBNA1 in oncogenesis exist 
where other researchers have not able to reproduce this oncogenic effect (Wilson et al., 1996, 
Kang et al., 2005, Tsimbouri et al., 2002). Furthermore, inhibition of EBNA1 by dnEBNA1 
or RNAi reduced the proliferation and survival of EBV-positive BL cells (Kennedy et al., 
2003, Hong et al., 2006). 
 
Epstein-Barr nuclear antigen 2 (EBNA2) 
EBNA2, which is encoded by the BYRF1 ORF, is one of the first viral proteins to be 
expressed during the transformation of primary B cells by EBV. EBNA2 and EBNA-LP 
activate the adjacent Cp promoter following their expression from Wp (Bodescot et al., 1987, 
Evans et al., 1996, Jin and Speck, 1992).  
The Cp promoter acts as the dominant promoter for expression of all six EBNAs; EBNAs 1, 
2, 3A, 3B and 3C and EBNA-LP (Speck and Strominger, 1985, Woisetschlaeger et al., 1989). 
The growth transforming ability of the EBNA2 protein was demonstrated by the inability of 
the P3HR-1 strain, in which the EBNA2 gene and the last two exons of EBNA-LP are 
deleted, to transform B cells in vitro (King et al., 1982, Rickinson and Kieff, 2001, Skare et 
al., 1985). P3HR-1 showed full EBV growth transforming ability after the restoration of 
EBNA2 gene into its genome (Hammerschmidt and Sugden, 1989, Cohen et al., 1989).  
EBNA2 acts as a potent and specific transcriptional activator of both viral and cellular genes 
mainly through three domains, the RBP-Jk binding domain, the acidic activation domain, and 
the homotypic association domains (Rickinson and Kieff, 2001)). RBP-Jk, either alone or 
with Ski-interacting protein (SKIP), binds EBNA2 to its responsive elements upstream of 
cellular and viral promoters, as shown in LCLs where it has been involved in the regulation of 





al., 1990, Wang et al., 1990a), LMP2 (Zimber-Strobl et al., 1993), and the cellular genes 
CD21 (Cordier et al., 1990), CD23 (Wang et al., 1990a), and c-Fgr (Knutson, 1990). The 
RBP-Jk homolog in Drosophila is involved in signal transduction from the NOTCH receptor, 
which has also been linked to the development of T cell tumours in humans (Artavanis-
Tsakonas et al., 1995). EBNA2 can mimic a constitutively activated NOTCH receptor 
(Rabson et al., 1982) leading to the transactivation of viral and cellular downstream targets. 
EBNA2 also targets the transcription of cellular genes that are likely to be important for EBV-
induced B cell proliferation; these include c-MYC, cyclin D2 (CCND2), and cyclin-dependent 
kinase-4 (CDK4) (Jayachandra et al., 1999, Kaiser et al., 1999). EBNA2 also shown to induce 
the formation of new binding for both RBP-jκ and EBF1, two master regulators of B-cell fate. 
A strong correlation between these newly induced binding sites co-occupied by EBNA2-
EBF1-RBP-jκ and transcriptional activation of genes involved in the B-lymphoblast growth 
and survival was observed (Lu et al., 2016). 
 
The Epstein-Barr nuclear antigen 3 (EBNA3) family members 
The EBNA3 family members are the least abundant EBNA mRNAs in latently infected cells 
and are transcribed from the Cp or Wp promoters. The EBNA3A, 3B, and 3C proteins can 
interact with several cellular factors involved in transcriptional repression or silencing, 
including histone deacetylases (HDACs), and C-terminal binding protein (CtBP) 
(Hickabottom et al., 2002, Radkov et al., 1999). All three EBNA3 proteins contain a 
conserved region which is able to stably bind RBP-Jk and compete with EBNA2 and Notch 
for RBP-Jk, thus repressing the EBNA2-mediated transactivation by disrupting RBP-Jk 
binding to Notch and to EBNA2 (Johannsen et al., 1996, Robertson and Ambinder, 1997). 





transformation in vitro (Maruo et al., 2009, Lee et al., 2009). However, Hertle et al showed 
transformation of B cells by EBNA3A-deleted EBV, albeit with reduced efficiency (Hertle et 
al., 2009). Both EBNA3A and EBNA3C can transform embryonic rat fibroblasts by co-
operating with the ras oncogene (Parker et al., 1996). Recent studies have shown that 
EBNA3C can inhibit the accumulation of the CDK inhibitors p27KIP1 and p16INK4A, and 
mediates Rb degradation via the SCF ubiquitin ligase. Furthermore, EBNA3C also shown to 
stabilizes c-myc, and also involved in the inactivation of cyclinA-CDK complexes (Bajaj et 
al., 2008, Saha et al., 2009, Saha et al., 2011). 
A recent study showed that EBNA3B might act as a tumour suppressor gene, since infection 
with an EBNA3B-knockout virus (EBNA3BKO) led to aggressive, immune-evading 
monomorphic DLBCL-like tumours in NOD/SCID/γc-/- mice. Furthermore, EBNA3BKO-
infected B cells showed faster expansion and reduction in the secretion of T cell-
chemoattractant CXCL10, reducing T cell recruitment in vitro and T cell-mediated killing in 
vivo (White et al., 2012).  
 
Epstein-Barr nuclear antigen leader protein (EBNA-LP) 
EBNA-LP is the first latent protein to be expressed during B cell transformation by EBV 
(Alfieri et al., 1991), and its mRNA is transcribed from C1 C2 or W0 exons initiated by Cp or 
Wp promoters followed by transcription from a variable number of W2W1 repeats and unique 
Y1 and Y2 exons. Although EBNA-LP is not absolutely essential for the in vitro 
transformation of B cells, it is required for the efficient outgrowth of LCLs (Allan et al., 
1992). EBNA-LP can potentiate the effects of EBNA2-mediated transcriptional regulation, as 
transient transfection of EBNA-LP and EBNA2 into primary B cells induced transition of 





also enhances the EBNA2 transactivation of its downstream targets, including LMP1 (Harada 
and Kieff, 1997, Nitsche et al., 1997). 
 
Latent membrane protein 1 (LMP1) 
LMP1 is a 66 K-Da integral membrane protein encoded by the BNLF1 ORF and is essential 
for the EBV-induced transformation of B cells. LMP1 has been shown to transform rat 
fibroblasts and induce tumours in transgenic mice (Kaye et al., 1993, Moorthy and Thorley-
Lawson, 1993, Wang et al., 1985). LMP1 is a plasma membrane protein that acts as a 
constitutively active tumour necrosis factor receptor (TNFR), similar to CD40 or a 
combination of TNFRI and TNFRII (Izumi and Kieff, 1997, Mosialos et al., 1995). LMP1 
expression is critical for the transformation of B cells into LCLs and also for the growth and 
survival of LCLs, as loss of LMP1 expression in LCLs has been shown to halt cell cycle and 
result in cell death (Dirmeier et al., 2003, Kaye et al., 1993, Kilger et al., 1998).   
In primary B cells, LMP1 induces many of the changes associated with EBV infection or 
antigen presentation, including cell clumping, increased villous projections, and increased 
expression of cell-surface adhesion molecules (ICAM-1, LFA-1, and LFA-3), B cell 
activation genes (CD23, CD30, CD40, CD44,  and MHC Class II), interleukin 6 (IL-6), IL-8, 
and IL-10 (Eliopoulos et al., 1997, Eliopoulos et al., 1999, Nakagomi et al., 1994, Wang et 
al., 1990b).  LMP1 has also been shown to up-regulate several anti-apoptotic proteins, 
including MCL-1, TNFAIP3, and BCL2 (Henderson et al., 1991, Laherty et al., 1992, Wang 
et al., 1990a). 
The long cytoplasmic C-terminal domain of LMP1 contains two critical transformation sites; 
C-terminus transformation effector sites (TES) 1 and 2 (Izumi et al., 1999).  TES1 and TES2 





membrane-proximal C-terminal activating region 1 (CTAR1) and the distal C-terminal 
activating region 2 (CTAR2) (Kieser, 2008, Li and Chang, 2003, Huen et al., 1995, Mitchell 
and Sugden, 1995). The membrane-proximal CTAR1 domain contains an essential motif that 
recruits several members of the TNFR associated factor (TRAF) family, including TRAF1, 
TRAF2, TRAF3, and TRAF5 (Yi et al., 2015, Li and Chang, 2003, Mosialos et al., 1995, 
Brodeur et al., 1997). The TES2/CTAR2 interacts with TNFR-associated death domain 
(TRADD) protein and receptor-interacting protein (RIP), which are involved in TNFRI 
signalling (Wu et al., 2006a, Li and Chang, 2003, Izumi et al., 1999).  CTAR1 has been 
shown to be critical for EBV-mediated transformation, while CTAR2 is required for long-
term growth of EBV-infected cells (Wu et al., 2006b, Izumi and Kieff, 1997). It has been 
shown that the LMP1 activates NFκB via two distinct pathways. A major (canonical) pathway 
activates NFκB through the CTAR2 domain by engaging TRAF6/TAK1/IKKβ and a minor 
(non-canonical) pathway activates NFκB through the CTAR1 domain by engaging 
TRAF3/NIK/IKKα (Wu et al., 2006a). A recent study has found that the LMP1 mediates 
sumoylation of cellular proteins through its C-terminal activating region 3 (CTAR3), a 
distinct functional regulatory region of LMP1, to repress of EBV lytic promoters and maintain 
the viral genome in its latent state (Bentz et al., 2011). In LCLs, inhibition of CTAR3-
mediated protein sumoylation abrogates the binding of KAP1 (KRAB-associated protein-1) to 
EBV OriLyt and immediate early promoters; and increases sensitivity to ganciclovir treatment 
(Bentz et al., 2015). 
 
Latent membrane protein 2 (LMP2) 
In latency III, the LMP2 gene encodes two LMP2 proteins, LMP2A and LMP2B from unique 





Laux et al., 1994, Meitinger et al., 1994).  Both of these proteins have been shown to be 
essential for the EBV-induced transformation of primary B cells (Longnecker et al., 1992, 
Longnecker et al., 1993b, Longnecker et al., 1993a, Speck et al., 1999). Although it may not 
be critical for transformation, LMP2A has been shown to provide important survival and anti-
differentiation signals in B cells (Wasil et al., 2013). LMP2A expression in BL and gastric 
cancers cell lines was able to protect cells from BCR-cross linking and TGFβ associated 
apoptosis (Fukuda and Longnecker, 2004, Fukuda and Longnecker, 2005). LMP2 expression 
during B cell development in mice also decreased the expression of B cell development 
factors, E2A (a.k.a. TCF3), EBF, and Pax5 (Portis et al., 2003).  
The N-terminal domain of LMP2A is able to interact with the Src-family protein tyrosine 
kinases (SFKs), especially Lyn and Syk (Pang et al., 2009, Johnson et al., 1995, Pleiman et 
al., 1994). LMP2A binding to Lyn through its immuno-receptor tyrosine-based activation 
motif (ITAM) leads to phosphorylation of all the LMP2A tyrosine residues and to the 
recruitment of Syk and the activation of PI3K, Bruton tyrosine kinase (Btk), BLNK, and 
Protein kinase B (PKB) (Akt) (Merchant et al., 2000, Merchant and Longnecker, 2001, Swart 
et al., 2000, Pang et al., 2009).  
The function of the other LMP2 protein, LMP2B, is still largely unknown. However, Lynch et 
al., showed that LMP2B may act as an antagonist to LMP2A by co-localizing with it on the 
plasma membrane (Lynch et al., 2002). Co-expression of both these proteins has been shown 
to attenuate the LMP2A-mediated block on the activation of the EBV-lytic cycle and restore 
normal BCR signal transduction (Rechsteiner et al., 2008, Rovedo and Longnecker, 2007). 
Infection of B cells with an LMP2B deletion mutant EBV showed similar activation to wild-






EBV encoded microRNAs (miRNAs) 
There are currently 69 unique miRNAs encoded by EBV (Kozomara and Griffiths-Jones, 
2014), which show a complex pattern of expression depending on the cell type and overall 
pattern of EBV gene expression. Furthermore, most of the EBV miRNAs have also been 
shown to be expressed during the EBV lytic cycle. The BART miRNAs are abundantly 
expressed in all forms of latency, but particularly high levels in NPC cell lines. By contrast, 
BHRF1 miRNAs are exclusively expressed in B cells with latent III form of infection as these 
are derived from an intron generated by splicing of the Cp and Wp initiated transcripts (Cai et 
al., 2006, Xing and Kieff, 2007), although miR-BHRF1-2 and BHRF1-3 are also expressed in 
lytic cycle from the lytic BHRF1 promoter. 
Although EBV miRNAs are not essential for B cell transformation, as shown in the 
experiments with a B95-8 virus which has lost the majority of the EBV miRNAs, these EBV 
miRNAs are highly conserved in various lymphocryptoviruses suggesting a possible role in 
some stage of the EBV life cycle (Cai et al., 2006, Xing and Kieff, 2007).  
EBV miRNAs have been shown to modulate expression of at least two EBV genes, BALF5 
and LMP1. BALF5, which encodes the EBV DNA polymerase, is transcribed from the strand 
opposite to the strand encoding miR-BART2. Overexpression of miR-BART2 genes resulted 
in the reduction of BALF5 expression and also in the release of infectious EBV particles 
(Barth et al., 2008). The 3’ UTR region of LMP1 and miR-BART2 share partial sequence 
complementarity (Lo et al., 2007), and over-expression of miR-BART2 suppresses LMP1 
protein production, protects against apoptotic stimuli and prevents NFκB inhibition. A 
potential role for many of these EBV-encoded miRNAs is becoming increasingly apparent as 






Furthermore, recent studies have shown that BHRF1 miRNA promote cell cycle progression 
and prevent apoptosis of primary human B cells, and that BHRF1, PTEN and p27 may be the 
direct or indirect targets of the BHRF1 miRNA and thus regulate the expression of PTEN, 
p27 and of a bcl-2 Homolog (Seto et al., 2010, Bernhardt et al., 2016). Increasing number of 
novel mRNA targets for the anti-apoptotic miR-BARTs have been identified through 
systematic screening (Kang et al., 2015). 
 
Epstein-Barr virus encoded small RNAs (EBERs) 
EBV expresses two non-polyadenylated/non-coding EBER transcripts (EBER1 and EBER2) 
in all forms of latency (Alfieri et al., 1991). These are the most abundantly expressed EBV 
transcripts in latently infected cells (Arrand and Rymo, 1982, Howe and Steitz, 1986). There 
are conflicting reports of the role of EBERs during B cell transformation in vitro (Ruf et al., 
2000). Initial studies using recombinant virus lacking EBERs showed that the EBERs are not 
critical for B cell transformation (Swaminathan et al., 1991). However, more recent studies 
suggest that EBER2, but not EBER1, could be required for B cell transformation (Wu et al., 
2007, Yajima et al., 2005). 
EBERs share similar primary sequence and secondary structures to the adenovirus VA1 
(Arrand et al., 1983, Rosa et al., 1981), and have been shown to inhibit protein kinase R 
(PKR) with similar efficiencies to VA1 (Bhat and Thimmappaya, 1985, Sharp et al., 1993)As 
PKR mediates the anti-viral effect of interferons, inhibition of PKR by EBERs could be 
important for viral persistence (Clemens et al., 1994, Spanggord et al., 2002). However, Ruf 
et al., suggested EBER inhibition of alpha-interferon-induced apoptosis, and potentially other 
PKR-mediated events, is unlikely to be mediated through direct inhibition of PKR. Using 





response to interferon, it was demonstrated that the EBERs are unable to inhibit the 
phosphorylation of either cytoplasmic or nuclear PKR.  (Ruf et al., 2005). Despite the non-
coding nature of these EBERs, they are likely to play an important role in normal EBV 
infection and EBV-mediated pathogenesis.  Recent study on proteome and transcriptome of 
BJAB cells (an EBV-negative B lymphoma cell line) transfected with EBERs has identified 
upregulation of several genes and proteins that promote cell proliferation and are associated 
with EBV-mediated lymphomas, including PIK3AP1 protein, a B-cell specific protein adapter 
known to activate the PI3K-AKT signalling pathway, and oncogenes such as CCL3, CCR7, 
IL10 and VEGFA (Pimienta et al., 2015).  
 
1.8 Epstein-Barr virus lytic cycle 
Schematic depiction of the location for lytic cycle genes on the B95-8 viral genome is shown 
in Figure 5. 
The cascade of events in the EBV lytic cycle can be subdivided according to the expression of 
distinct lytic genes, into the immediate early (IE), early (E), and late (L) lytic cycle (Knipe et 
al., 2007; Tierney et al., 2015). The IE genes are expressed immediately following lytic cycle 
induction and are characterized by the activation of transactivator proteins which 
subsequently stimulate expression of early lytic genes including enzymes required for viral 
DNA replication. Finally, the late lytic genes are expressed, including viral structural proteins 
which are then assembled into virus particles enclosing newly synthesized viral DNA prior to 








Immediate-early lytic cycle genes 
Activation of the EBV lytic cycle in vivo is thought to be initiated by the differentiation of 
infected squamous epithelial cells (Tovey et al., 1978, Young et al., 1991) or by the 
differentiation of infected B cells into plasma cells following antigen stimulation of BCR 
(Laichalk and Thorley-Lawson, 2005). Furthermore, lytic replication can be stimulated by 
certain cytokines (e.g. TGFβ) (Fahmi et al., 2000), or by toxic stimuli including chemotherapy 
and radiation therapy, or by interaction between EBV-infected B cells and CD4 T 
lymphocytes (Feng et al., 2002). In vitro, lytic reactivation can be induced by Ig cross linking, 
treatment with phorbol ester, sodium butyrate, or a calcium ionophore (Angel et al., 1987, 
Flemington and Speck, 1990, Takada and Ono, 1989). 
During the IE lytic cycle two IE genes, BZLF1and BRLF1, are activated triggering the switch 
from latency to lytic cycle (Biggin et al., 1987, Countryman and Miller, 1985, Hardwick et 
al., 1988, Rooney et al., 1989). BZLF1and BRLF1 proteins are induced simultaneously from 
their respective promoters, Z-promoter (Zp) and R-promoter (Rp), of bicistronic R-Z RNA 
(Sinclair et al., 1991). In some cell lines the EBV lytic cycle can be initiated by direct 
expression of BZLF1, a homolog of the AP-1 transcription factor, whereby BZLF1 binds into 
the lytic origin of replication (OriLyt) and triggers the entire lytic cascade (Flemington and 
Speck, 1990; Rickinson and Kieff, 2007; Hammerschmidt and Sugden, 1988, Rooney et al., 
1989). The BZLF1 and BRLF1 proteins function as transcription factors which can activate 
their own and each other’s promoters amplifying the inducing effect of the initial lytic 
stimulus (Adamson et al., 2000, Flemington et al., 1991, Liu and Speck, 2003, Ragoczy and 
Miller, 2001, Sinclair et al., 1991, Speck et al., 1997, Zhang et al., 1996, Zalani et al., 1996). 
The BZLF1 and BRLF1 proteins transactivate many viral promoters of early, and 





or by BRLF1 alone, others are induced by the synergistic effects of both genes (Feederle et 
al., 2000, Gradoville et al., 1990, Kudoh et al., 2003, Ragoczy and Miller, 1999, Tsurumi et 
al., 2005). 
 
Recent study described transcriptional reprogramming of the expression of cellular genes by 
viral bZIP transcription factor, Zta (BZLF1, ZEBRA, EB1) using genome-wide ChIP-seq 
(chromatin immunoprecipitation coupled to next-generation DNA sequencing). In this study 
they identified significant change in the expression of 2263 cellular genes during the EBV 
lytic replication cycle and that Zta binds mostly to sites that are distal to transcription start 
sites of 278 of the regulated genes they analysed (Ramasubramanyan et al., 2015).  
 
Early lytic cycle genes 
In Akata cells, cross linking of surface Ig results in the expression of at least 38 early lytic 
genes (Lu et al., 2006, Yuan et al., 2006), including the EBV DNA polymerase gene, BALF5 
(Holley-Guthrie et al., 2005) and the major DNA binding protein, BALF2, which is essential 
for EBV DNA replication in Raji cells (Tsurumi et al., 1996, Decaussin et al., 1995, Polack et 
al., 1984). Other EBV early lytic genes include BMFR1, a transcriptional activator which is a 
viral DNA polymerase co-factor; and BMLF1 which shuttles un-spliced EBV lytic mRNA 
and is also required for the assembly of infectious virions (Hiriart et al., 2003).   
During the early lytic cycle, EBV also encodes two structural homologs of the anti-apoptotic 
Bcl2-protein, BHRF1 and BALF1 (Bellows et al., 2002, Henderson et al., 1993, Marshall et 
al., 1999, Pearson et al., 1983). BHRF1 is expressed in the first few days following B cell 
infection and has been shown to suppress apoptosis in lymphoid cells in response to various 





agents, chemotherapeutic drugs (McCarthy et al., 1996) and cytokines (Foghsgaard and 
Jaattela, 1997). Although BHRF1 is not essential for EBV replication (Lee and Yates, 1992, 
Marchini et al., 1991), it is highly conserved in several EBV strains (Khanim et al., 1997) and 
is important for optimal transformation efficiency (Altmann and Hammerschmidt, 2005). 
Although the role of the BALF1 protein is largely unknown, it seems to counteract the anti-
apoptotic function of BHRF1 (Bellows et al., 2002). BALF1 has been shown to exhibit anti-
apoptotic functions in HeLa cells (Marshall et al., 1999), while in BL cells it enabled growth 
in low serum (Cabras et al., 2005).  
Some of the EBV lytic genes counteract host immune responses. For example, BGLF5 acts as 
a competitive antagonist for the production of HLA class I and II molecules (Rowe et al., 
2007). The BNLF2a protein blocks both the ATP and peptide binding capacity of the 
transporter associated with antigen processing (TAP), and thus reduces the expression of 
surface HLA class I molecules (Hislop et al., 2007b). 
 
Late lytic cycle genes 
Following EBV DNA replication, lytically active cells begin to express late lytic antigens. 40 
EBV late lytic mRNAs have been identified in Akata cells following lytic cycle induction by 
engagement of the B cell receptor (Lu et al., 2006; Yuan et al., 2006). Some of these late lytic 
genes are spliced while others are not. 28 of the mRNAs are translated into virion proteins and 
assembled into viral particles ready for the encapsulation of viral DNA. For example, the 
BVRF2 gene encodes a viral protease that provides a scaffold for the assembly of virions 









Figure 5. Schematic depiction of the location for lytic cycle genes on the B95-8 viral genome. 





Late lytic cycle genes encode two major classes of protein, glycoproteins and non-
glycoproteins (Figure 1.8.1). The glycoproteins include BLLF1, BILF1, BILF2, BDLF2, 
BDLF3, BMRF2, and BXLF2, some of these are present in the classical membrane antigen 
(MA) complex (Edson and Thorley-Lawson, 1981).  The BLLF1 gene encodes gp350/220, 
which is the most abundantly expressed viral glycoprotein and is a major target of host 
neutralizing antibodies (Thorley-Lawson and Poodry, 1982). The gp350/220protein mediates 
the binding of EBV to its B cell receptor, CD21 (Fingeroth et al., 1984, Nemerow et al., 1989, 
Torrisi et al., 1989). This interaction induces the activation of the Wp promoter (Sinclair and 
Farrell, 1995, Sugano et al., 1997) as well as the penetration of B cells by EBV (Tanner et al., 
1987). 
Conflicting reports on the early/late lytic cycle status of BILF1 have been published (Paulsen 
et al., 2005, Beisser et al., 2005, Yuan et al., 2006). The BILF1 gene encodes a heavily 
glycosylated G-protein-coupled receptor (GPCR) which is localized on the plasma membrane 
similar to KSHV-encoded GPCR, ORF74, indicating that the BILF-GPCR and ORF74 may 
have similar functions during γ-herpesvirus replication progression (Paulsen et al., 2005). 
Furthermore, BILF1 sequence and genomic positions are conserved among all of the currently 
known γ-1-herpesviruses and in a subset of γ-2-herpesvirus species suggesting a possible 
important role in some stage of EBV lytic replication (Beisser et al., 2005). BILF1 can hetero-
dimerize with chemokine receptors CXCR4, CXCR3, CCR9, and CCR10 thereby alter the 
responsiveness of B lymphocytes to chemokines thereby altering homing and homeostasis of 
infected B lymphocytes. This process might be essential for EBV dissemination and/or be 
involved in EBV-induced pathogenesis (Vischer et al., 2008). Several studies have shown that 
BILF1 can down-regulate surface HLA class I expression thereby obstructing the presentation 





et al., 2013). BILF1 can also modulate various intra-cellular signalling pathways (Beisser et 
al., 2005), as the BILF1 gene has been shown to inhibit forskolin-triggered CREB activation 
via stimulation of endogenous G proteins, thereby affecting disease progression (Paulsen et 
al., 2005). Furthermore, BILF1-encoded protein increases CRE-mediated transcription in 
EBV-positive BL cells and LCL transfected with BILF1, through Gi/Go coupling (Beisser et 
al., 2005). 
The heterodimeric complex containing the BXLF2 (gH), BKRF2 (gL) and BZLF2 (gp42) 
glycoproteins participates in the endocytosis of EBV into B cells using HLA class II as co-
receptor. BALF4 is also a highly conserved gene which is thought to be involved in the 
release of virions from EBV-infected cells (Herrold et al., 1996). The non-glycoproteins 
include structural proteins, such as BcLF1, BNRF1 and BXRF1 that make up the viral capsid 
(Kieff, 1996); some of these proteins are part of the immunologically defined viral capsid 
antigen (VCA) complex. Non-structural late lytic proteins include BCRF1 or viral IL-10 (vIL-
10), which shares 90% collinear amino acid sequence with human IL-10 (Hsu et al., 1990, 
Vieira et al., 1991), and which is an autocrine growth factor capable of paracrine signalling to 
surrounding B cells. BCRF1 signalling modulates the expression of NF-κB and the JAK-
STAT signalling pathways, increases the expression of the Th1 cytokines, and enhances cell 






1.9 Epstein-Barr virus associated B cell tumours 
In this section, I describe two EBV-associated cancers, Burkitt lymphoma and Hodgkin 
lymphoma, as these are the major focus of this thesis.  
1.9.1 Burkitt lymphoma 
 
General introduction 
Endemic Burkitt lymphoma (eBL) was first described by Denis Burkitt in 1958 (Burkitt, 
1958). It has a highly unusual pathogenesis which is linked to EBV in almost every case and 
to the activation of the cellular oncogene, c-MYC. As described in the alternative forms of 
EBV latent infection section, EBV-positive BL tumours express only the EBNA1 protein 
along with the non-coding EBERs, and a collection of EBV-encoded microRNAs (Cai et al., 
2006, Rowe et al., 1987a). Two more forms of BL are also described which have a lower 
association with EBV; sporadic BL (sBL) and AIDS-associated BL. All three subtypes of BL 
display a similar histological appearance (a characteristic ‘starry sky pattern) as shown in 
Figure 6, in which the malignant population of medium to large round monomorphic B cells 
are interspersed with macrophages (Kelly and Rickinson, 2007). All three forms of BL also 
have a cell differentiation phenotype closely resembling that of the cells populating the 
proliferative compartment of germinal centres (normal centroblasts). The detection of ongoing 
Ig mutations and centroblast cell surface markers (CD10 and CD77) suggests that BL cells are 






Epidemiology of Burkitt lymphoma 
The clinicopathological features of Burkitt lymphoma are detailed in Table 2.  
The incidence of BL in Africa ranges from 3-6 new cases per year per 100,000 children aged 
0–14 years, accounting for 30-50% of all childhood cancers in equatorial Africa (Martha et 
al., 2012).  The high-incidence eBL form is found exclusively in equatorial Africa and Papua 
New Guinea where Plasmodium falciparum malaria is holoendemic (Burkitt, 1962a, Burkitt, 
1962b, Rainey et al., 2007a, Rainey et al., 2007b). The eBL cases almost always have EBV 
infection, and typically present in young children.  Endemic BL affects extranodal sites 
including the jaw, abdomen and endocrine organs. Suppression of malaria infection correlates 
with reduced incidence of eBL (Geser et al., 1989) suggesting that co-infection with EBV and 
Plasmodium falciparum malaria is important in the development of eBL (Rochford et al., 
2005, Rowe et al., 2014b). Malaria probably increases the pool of EBV-infected BL 
progenitors by inducing an intense polyclonal B cell activation and loss of T cell control of 
EBV (de-Thé et al., 1978, Whittle et al., 1984, Moormann et al., 2007, Moormann et al., 
2011).  There is an association between the incidence of eBL in Africa and high antibody 
titres to both EBV and malaria (Carpenter et al., 2008, Mutalima et al., 2008), yet only a 
relatively small number of co-infected children develop eBL suggesting the role of other 
factors in eBL pathogenesis. 
Sporadic BLs also occurs in children but is a less prevalent form and only 15% of sBLs are 
EBV-positive. AIDS-associated BL often presents as the first AIDS-associated illness in 
relatively immunocompetent patients, and accounts for 30-40% of all AIDS-associated 





Table 2. Clinicopathological features of Burkitt lymphoma (taken from Hecht and Aster, 
2000). 
 Endemic BL Sporadic BL HIV-associated BL 
Incidence 5-15/100000-year 2-3/106-year 
24%-35% of HIV non-
Hodgkin lymphoma 
CD4 usually > 200/μL 
Age 
More prevalent in 
children 
More prevalent in 
children and males 








terminal ileum) than in 
jaw 
Often extranodal (e.g. 
GI tract, bone marrow, 








presentation   
EBV association > 90% EBV 10%-85% EBV Variable (30%-80%) 
c-MYC translocation 
∼ 80% t(8;14), ∼ 15% 
t(2;8), ∼ 5% t(8;22) 









Figure 6. Histopathology of BL. (A) Arrowheads denote some of the phagocytic macrophages 
(also showing the dark coloured nuclear remnant of phagocytosed tumour cells) responsible 
for the characteristic “starry sky” appearance that is displayed by all three subtypes of BL, in 
which the malignant population of medium to large round monomorphic B cells are 
interspersed with macrophages (×200). (B) An enlarged photograph showing a 
monomorphous population of intermediate-sized BL cells and a macrophage containing 
nuclear debris (×400). (C) Strong nuclear reactivity for Ki-67, a marker of proliferating cells, 





Role of EBV in the pathogenesis of Burkitt lymphoma 
The precise role of EBV in BL pathogenesis is still debatable, however BL patients (in 
particular the endemic form) with high antibody titres against the EBV capsid antigen (VCA) 
have increased susceptibility to BL (Henle et al., 1969, de-Thé et al., 1978, Geser et al., 
1982). BL tumours show a restricted EBV latency programme (latency I) which lacks 
expression of the majority of latent antigens, including the major EBV growth transforming 
proteins, EBNA2 and LMP1 (Neri et al., 1991). As described in section 1.6, an alternative 
pattern of viral gene expression was identified in a minority of Wp-restricted BL cell lines 
where, instead of Q-promoter (Qp)-driven EBNA1 expression, the W-promoter (Wp) is 
highly active and drives expression of all EBNAs, except EBNA2 (Kelly et al., 2002b, Kelly 
et al., 2005). The Wp-restricted BLs also express high levels of the BHRF1 gene encoding a 
viral homolog of BCL2 gene (vBCL2) that was previously thought to be exclusively a lytic 
cycle protein (Kelly et al., 2009a, Rowe et al., 2014a). In both forms of latency, non-coding 
EBERs, and some virally encoded microRNAs are expressed.  
Although 95% of humans are infected with EBV, only a very small minority of infected 
individuals develop BL. Additionally, not all cases of BL are EBV-associated. Furthermore, 
the growth-transforming genes necessary for establishing and maintaining LCLs are repressed 
in BL tumours, indicating that the role of EBV exceed further than its ability to growth-
transform B lymphocytes. These data suggest that besides EBV infection several genetic 





Genetic changes in the pathogenesis of Burkitt lymphoma 
Deregulated c-MYC expression is a characteristic feature of all three subtypes of BL, and 
results from a reciprocal translocation of the long arm of chromosome 8 (8q24) in the c-MYC 
gene with either part of chromosome 14 including the IgH gene (accounting for 80% of all 
translocations) or chromosome 2 or 22 in the IGL or IGK genes (termed ‘variant’ 
translocations) (Magrath, 1990; Kroenlein et al., 2012).  Deregulated c-MYC expression in 
BL cells affects cell proliferation, growth and apoptosis. Studies of the ‘common’ t(8;14) 
translocations  show differences between the BL subtypes, where breakpoints in eBLs usually 
occur more than 100 kb upstream of the first exon of the c-MYC gene and in the VDJ region 
of the IgH locus, whereas in sBLs and AIDS-associated BL, break points commonly occur 
within the first exon of the c-MYC gene and in the class switch region of the IgH locus, 
indicating that the translocations may occur at a different stage of B cell differentiation in 
these tumours (Jacobs et al., 1999, Magrath, 1990, Pelicci et al., 1986, Shiramizu et al., 1991). 
 
Although the mechanisms behind translocations in the c-MYC gene are still largely unknown, 
these are thought to arise from mistakes during the maturation of antibody responses in GCs 
(Kuppers, 2003; Kuppers et al., 2005); this could explain the role of malaria and HIV 
infections as high risk factors for BL development. As discussed in the previous section, 
malaria may act as a chronic stimulus to the B-cell system and increase the GC activity and 
also suppress EBV-specific T cell responses resulting in very high levels of EBV DNA in 
children living in holo-endemic malarial areas (Geser et al., 1989, Moormann et al., 2007, 
Moormann et al., 2011, Rasti et al., 2005).  Similarly, HIV infection has also been shown to 
act as a chronic stimulus to the B cell system and increase the EBV load in the HIV infected 





induce persistent generalized lymphadenopathy in these patients, upon which histological 
examination has revealed lymphoid hyperplasia with greatly expanded GC regions which will 
clearly increase the number of cells at risk of a c-MYC translocation (Hecht et al., 2000).   
Several genes have been reported to be frequently mutated in BL (Figure 7), including MYC, 
TP53, FBXO11, ARID1A, RHOA, TCF3 (a.k.a. E2A), and MYD88 (Forbes et al., 2015). 
Next generation sequencing (NGS) studies have confirmed the presence of mutations in these 
genes along with novel mutated genes (Abate et al., 2015, Love et al., 2012, Richter et al., 
2012). For example, Love et al., identified 70 recurrently mutated genes (Love et al., 2012) 
including MYC (40%) and ID3 (34%) which were the most frequently mutated genes. Other 
frequently mutated genes included known suppressor genes ARID1A, SMARCA4 and TP53, 
as well as the oncogene PIK3R1 and NOTCH1. Gene silencing events, such as nonsense and 
frameshift mutations constituted a substantial proportion (∼30% or more) of mutations in 
ID3, GNA13, ARID1A, CREBBP, and CCT6B, suggesting that these genes are inactivated. 
Abate et al., studied 20 BL samples, and also observed recurrent mutations in the genes 
reported by previous NGS studies; including MYC (50% of cases), DDX3X  (35%), ID3 
(30%), ARID1A (25%), RHOA (20%), TCF3 (a.k.a. E2A) and TP53 (15%), and CCND3 







Figure 7. The top 20 most frequently mutated genes in BL. (data from COSMIC data base; 






Role of c-MYC in the pathogenesis of Burkitt lymphoma 
 
Multiple cellular processes that can contribute positively or negatively to cellular 
transformation have been shown to be influenced by c-MYC through binding of MYC to its 
heterodimeric partner, MAX. Myc/Max heterodimers bound to DNA recruit protein 
complexes (TRRAP) associated with histone acetylase activity that modify chromatin and 
activate transcription; binding of c-MYC/Max heterodimers to the promoter elements of a 
discrete set of downstream genes either induce or repress their expression (Grandori et al., 
1996, Hecht and Aster, 2000). Coller et al., screened genes regulated by c-MYC in cultured 
human fibroblasts and detected 27 genes that were induced and nine genes that were repressed 
by c-MYC; some of these c-MYC target genes encode proteins that regulate cell growth, 
division, death, metabolism, adhesion, and motility, all of which are potentially important in 
cellular transformation (Coller et al., 2000). 
A summary of the biological effects of c-MYC over-expression is shown in Figure 8, which is 
taken from Hecht and Aster, 2000 (Hecht and Aster, 2000). Some of the most relevant (to my 
project) biological effects of c-MYC are discussed here. 
 
Cell cycle regulation 
The expression of c-MYC is strongly correlated with proliferation as c-MYC is normally 
expressed in all dividing cells, where it enhances cell cycle progression (Yokoyama et al., 
1987, Prochownik et al., 1988, Karn et al., 1989, Goruppi et al., 1994, Mateyak et al., 1999, 
Schrader et al., 2012). The expression of c-MYC is downregulated in cells undergoing cell 








Figure 8. Summary of the biological effects of c-MYC over-expression. Upregulation of c-
MYC disrupts many aspects of cell function, which leads to tumorigenesis. (taken from Hecht 





 In c-MYC knockout fibroblasts, a marked lengthening of both G1 and G2 and a 12-fold 
reduction in cyclin D1/CDK4 and cyclin D1/CDK6 activity, a pair of protein kinases that 
promote cell cycle progression, was observed which demonstrates the global nature of the 
effects of c-MYC on cell cycle progression (Mateyak et al., 1999). 
In the human EBV positive B-cell line P493-6, in which c-MYC is expressed under the 
control of a tetracycline regulated promoter, P493-6 cells arrest in G0/G1 in the presence of 
serum when the expression of c-MYC is switched off. Re-expression of c-MYC activates the 
cell cycle, without inducing apoptosis, in these cells (Pajic et al., 2000). Furthermore, c-MYC 
overexpression can induce genomic instability, which may contribute to subsequent 
transformation. Transient up-regulation of c-MYC increased the transformation of Rat-1 
fibroblasts at least 50-fold, which is correlated with the appearance of chromosomal 
abnormalities, gene amplification, and hypersensitivity to DNA-damaging agents (Felsher and 
Bishop, 1999).  
 
Differentiation 
As terminal differentiation requires exit from the cell cycle, it is not surprising that the 
overexpression of c-MYC inhibits differentiation in a number of cellular assays. It can also 
inhibit cellular differentiation through the repression of genes that direct differentiation, such 
as C/EBPα (Li et al., 1994, Mink et al., 1996, Kovalchuk et al., 2000).  
 
Metabolism 
BL is usually associated with very high levels of serum lactate dehydrogenase A (LDHA), 
which correlate with the Warburg effect (the tendency for tumour cells to produce increased 





conditions. MYC regulates diverse metabolic pathways; of most obvious pertinence to BL, is 
the observation that c-MYC activates LDH-A transcription (Shim et al., 1997, Vettraino et al., 
2013). These effects of c-MYC and LDH-A on metabolism and survival have been 
demonstrated in Rat fibroblasts, in which stable overexpression of either LDH-A or c-MYC 
produced increased amounts of lactate under aerobic conditions, whereas antisense LDH-A 
RNA antagonizes the growth of c-MYC–transformed fibroblasts under hypoxic conditions 
and reduces the growth of BL cell lines in soft agar (Shim et al., 1997). Furthermore, c-MYC 
has also been shown to regulate genes involved in nucleotide synthesis (Bello-Fernandez et 
al., 1993, Pusch et al., 1997), protein synthesis (Rosenwald et al., 1993, Jones et al., 1996), 
and iron metabolism (Wu et al., 1998). 
 
Apoptosis 
Several studies have reported that c-MYC-induces p53-dependent and p53-independent 
apoptotic pathways. The p53-dependent pathway is triggered by withdrawal of growth factors 
and is accompanied by the upregulation of the regulatory protein phosphatase cdc25A 
(Galaktionov et al., 1996, Hermeking et al., 1994). In the alternative p53-dependent pathway, 
c-MYC over-expression inactivates ARF and thus suppresses p53 expression (Zindy et al., 
1998). The mechanism of the p53-independent pathway is unclear, but is thought to be 
induced upon glucose deprivation and increased levels of LDH-A (Shim et al., 1997). 
However, overexpression of LDHA alone in certain cell types is sufficient to cause apoptosis 








Clinical features of BL 
Patients with BL are clinically staged and classified as low or high risk based on various 
criteria, such as the number of involved sites, the presence of bulky disease, and LDH 
concentration. Various staging systems were developed over the last few decades, and the 
most widely used systems include the Murphy staging system developed for childhood B-
NHL (Murphy, 1980), and more recent staging systems developed in Europe by the French-
American-British/Lymphomes Malins B group and the Berlin-Frankfurt-Muenster (BFM) 
group (Waxman et al., 2011). These systems, along with the classic Ann Arbor classification 
which is still employed in adult patients, are commonly used in children and 
adolescents/young adults (AYAs).   
In the Murphy staging system the clinical stages are defined as follows: 
a) Stage 1: presence of a single nodal/extranodal site excluding mediastinum or abdomen 
b) Stage 2: presence of a single extranodal site with regional involvement, or presence of 
two or more nodal sites with or without regional node involvement on the same side of 
the diaphragm, or presence of a completely resected primary gastrointestinal tumour 
with or without regional involvement 
c) Stage 3: all primary intrathoracic tumours (mediastinum, pleura), by nodal/extranodal 
tumours on both sides of the diaphragm, by un-resectable extensive intra-abdominal 
disease, and by paraspinal/epidural tumours regardless of other involved areas 
d) Stage 4: CNS or bone marrow involvement.  
 
Treatment of BL 
Effective treatment strategies for BL were initially pioneered in paediatric cases and in HIV-





current treatment regimens for BL include the anti-CD20 antibody rituximab (Table 3), which 
resulted in improved outcomes, bringing the 3-year survival close to 90% in younger adults 
(<55–60 years). Favourable outcome with rituximab usage in younger patients was reported 
by Meinhardt et al. In this study, anti-CD20 rituximab was administered, prior to 
chemotherapy, to 136 patients (22 aged ≥15 years), which yielded a response rate of 40% in 
BL/Burkitt leukaemia (Meinhardt et al., 2010). For adults, rituximab is generally added to the 
Hyper-CVAD regimen which includes cyclophosphamide, vincristine, doxorubicin, and 
dexamethasone alternating with HD-MTX and cytarabine. Studies have shown that this 
regimen improved outcome with no additional toxicity compared to Hyper-CVAD alone (Jain 
et al., 2013). 
Dunleavy et al., reported better response and survival rates in a small patient cohort with an 
infusional MTX-free regimen, dose-adjusted (DA) EPOCH-R (etoposide, prednisone, 
vincristine, cyclophosphamide, doxorubicin, rituximab),  retaining a high therapeutic potential 
even without dose adjustment (Dunleavy et al., 2013). Recent improvements in the 
understanding of the pathogenesis of BL led to therapies targeting newly identified pathways 
that are essential for BL pathogenesis, such as ID3/E2A (a.k.a. TCF3)/cyclinD3 pathway 
(Schmitz et al., 2012, Richter et al., 2012, Love et al., 2012). 
Despite the better cure rates with the current multi-agent chemotherapy and immunotherapy, 
relapse following treatment occur in small proportion of BL cases and current results in 
refractory/relapsed BL are extremely poor. Furthermore, the outcome of patients with 
chemotherapy-resistant disease and sporadic adult BLs are poor. Children with BL suffer 
long-term toxic effects of chemotherapy in later stages of their life (Jacobson and LaCasce, 
2014, Ferry, 2006, Oriol et al., 2008, Ngoma et al., 2012, Magrath, 2012, Appelbaum et al., 





Table 3. Comparative features of highly effective, modern treatment regimens for BL (taken 











for BL, high-dose 
MTX-based 
4 (2 alternating 



















schedule A (cycles 
1, 3, 5, 7) and 
schedule B (cycles 

























>55 years (drug 
reduction) 
R-LMB 


































used at NCI/NIH 
MTX, methotrexate; BFM, Berlin-Frankfurt-Muenster; GMALL, German Multicenter Study 
Group for Adult ALL; NCI/NIH, National Cancer Institute/National Institutes of Health; 
CALGB, Cancer and Leukemia Group B; NILG, Northern Italy Leukemia Group; 






1.9.2 Hodgkin lymphoma 
Hodgkin lymphoma (HL) is a malignant lymphoid tumour that was first described in 1932 by 
Thomas Hodgkin in his paper entitled “morbid appearances of the absorbent glands and 
spleen” and which reported the post-mortem findings of patients with enlarged lymph nodes 
and spleen
 
(T, 1832). Carl Sternberg (1898) and Dorothy Reed (1902) had independently 
described the “presence of bi-nucleated and multi-nucleated giant cells within an 
inflammatory milieu” as a characteristic feature of HL. These cells are now known as Reed-
Sternberg (RS) cells. Along with RS cells, variable numbers of mononuclear cells known as 
Hodgkin (H) cells are present in the tumour microenvironment. Neoplastic cells in classical 
HL (cHL) are collectively referred to as Hodgkin and Reed-Sternberg (HRS) cells (Figure 9). 
 
Epidemiology of HL 
HL is one of the most common cancers diagnosed in children and adolescents in the UK and 
accounts for 4.5% of all cancer types in children. In the UK, 2,106 new cases of paediatric HL 
were registered in the year 2014 and 355 children died due to HL in2014 (Cancer Research, 
UK).  HL accounts for approximately 0.9% of all cancers diagnosed in the world with a 0.4% 
mortality rate among all cancers
 
(GLOBOCAN, 2012). Incidence rate for HL vary across 
different parts of the world, with higher incidence rates are seen in southern Europe and 
Northern America and lower rates in Asia and Africa. Children treated for HL are prone to 
develop secondary malignancies in later stages of life. These children also suffer from low 
quality of life, infertility and hormonal imbalances (Lukes and Butler, 1966, Piccaluga et al., 
2011). 
The age distribution of HL for both men and women in the UK shows two distinct peaks. The 





79 years. For women these two peaks occur in the 20-24 and 70-74 year age groups, 
respectively. The lifetime risk of developing HL is approximately 1 in 370 for men and 1 in 
490 for women in the UK (Cancer Research, UK). 
 
Histological classification 
Various histopathological classification schemes have been devised since the first 
comprehensive classification by Jackson and Parker in 1944, in which they described three 
disease entities: paragranuloma, granuloma, and sarcoma. The recently revised World Health 
Organization (WHO) scheme (2016) (Swerdlow et al., 2016), was initially adopted from the 
revised European-American lymphoma (REAL) classification, subdivides HL into two main 
entities: nodular lymphocyte predominant HL (NLPHL) and classical HL (cHL) and further 
divides cHL into nodular sclerosis classical HL (NSCHL), diffuse form of lymphocyte-rich 
(LRCHL), lymphocyte-depleted classical HL (LDCHL), and mixed cellularity classical HL 
(MCCHL) subtypes based on morphological, phenotypic, genotypic, and clinical evidence
 
(Figure 9). Classical HL accounts for about 95% of all HL of which 20-90% harbour EBV 
infection (Piccaluga et al., 2011).  
NSCHL is more common among young adults in the Western populations. Contrary to the 
other types of cHL, it is more prevalent in women and less frequently associated with EBV. 
NSCHL differs from other cHL and NLPHL types in its etiology and histology. The presence 
of broad bands of collagen is a hallmark feature of NSCHL, the fibrosis being due to 
expression of pro-fibrotic cytokines. The NSCHL tumour microenvironment consists of 






MCCHL is predominant in men, occurring in both young and old patients, whereas LDCHL 
occurs mainly in older individuals and is often associated with immune-suppression. Both 
MCCHL and LDCHL are frequently associated with human immunodeficiency virus (HIV) 
infection and are more common among lower socio-economic groups. Both subtypes share 
common clinical, epidemiological, and biological features while differing mainly in the extent 
of depletion of background lymphocytes. The neoplastic cells in both these subtypes are 
usually infected with EBV (Eberle et al., 2009)
.   
As the name indicates, MCCHL consists of a mixture of different inflammatory cell types, 
such as lymphocytes, plasma cells, histiocytes, eosinophils, T-cells, and neutrophils. These 
infiltrating cells usually form rosettes around neoplastic elements. MCCHL usually shows 
disruption of lymph node architecture and sometimes “mummified” cells can be seen due to 
apoptotic changes (Piccaluga et al., 2011). LDCHL appearance varies from patient to patient. 
However, the most striking feature of LDCHL is the presence of abundant HRS cells among a 
relatively lower number of lymphocytes (Eberle et al., 2009). 
The LRCHL subtype accounts for approximately 5% of all cHL cases. LRCHL was first 
described as a follicular Hodgkin disease because of the localization of neoplastic cells in the 
far mantle and marginal zones of the follicles. In Haematoxylin and Eosin staining, LRCHL 
resembles NLPHL due to the predominant lymphocyte background but differ 
immunophenotypically, as it expresses CD30 and CD15 (Piccaluga et al., 2011). Neoplastic 
cells in LRCHL show the typical HRS cell features with small germinal centres at the 
periphery of nodular structures. LRCHL occurs predominantly in men and the median age is 
higher than for NLPHL.  
NLPHL represents 4-5% of all HL cases and shows distinct morphological, phenotypic, 





with a peak incidence around 40 years of age. The neoplastic cells in NLPHL are known as 
‘Lymphocyte-predominant (LP) cells (Mani and Jaffe, 2009). In NLPHL, LP cells are often 
surrounded by activated helper-inducer memory T-cells forming a T-cell rosette also observed 
in cHL. NLPHL usually shows nodular growth affecting single cervical or axillary or inguinal 
nodes rather than groups of nodes. The neoplastic cells are polylobular with finely dispersed 
chromatin and small nucleoli, and are often found adjacent to the nuclear membrane. These 










Figure 9. HL subtypes. cHL: Classic Reed-Sternberg bi-nucleated cell with owl-eye 
inclusion-like nucleoli; each nucleus has a prominent eosinophilic nucleolus with 
perinucleolar halos (x1000). NLPHL: characteristic multi-lobate nucleus and smaller 
basophilic nucleoli (resembling popcorn) are present within the lymphocyte rich background 
(x400). NSCHL: characteristic broad bands of birefringent collagen and with clustering of 
lacunar variants of HRS cells within the nodules. (x100). MCCHL: with a mixture of different 
inflammatory cell types in the background (x400). LDCHL: abundant HRS cells and 
histiocytes along with a few lymphocytes in the background (x200). LRCHL: classic HRS 
cells present in lymphocyte rich background (x400). (taken from Eberle et al., 2009 






Origin and clonality of HRS cells 
HRS cells in cHL are mainly derived from the clonal proliferation of B lymphocytes that have 
undergone somatic hyper-mutation in the immunoglobulin V genes. In rare cases (~2%), HRS 
cells originate from T lymphocytes (Muschen et al., 2000a). On the other hand, LP cells are 
derived from GC B cells that show evidence of ongoing somatic hypermutation (Brauninger 
et al., 2006).   
Most B-cell lymphomas retain their B-cell phenotype during malignant transformation. 
However, the HRS cells of cHL have lost their B-cell phenotype due to extensive 
‘reprogramming’ of B- cell gene expression. HRS cells very rarely, express B-cell typical 
genes, such as immunoglobulins, CD20, spleen tyrosine kinase (SYK), myeloblastosis gene 
(MYB), and CD19. Although recent studies have shed light on several contributing factors for 
HL pathogenesis, underlying genetic mechanisms behind the downregulation of numerous B 
cell transcription factors are still poorly understood (Kuppers, 2009, Kuppers et al., 2012).  
 
Chromosome instability in HL 
Hyper-ploidy is a characteristic feature of HL where an abnormal karyotype is usually 
observed in HRS cells (Figure 10). Structural rearrangements involving chromosome 1 are 
frequently observed in HRS cells and a recurring numerical abnormality in chromosomes 1, 2, 
5, 12, and 21 is seen (Thangavelu and Le Beau, 1989).  HRS cells also show multiple sub-
clonal aberrations, indicating chromosomal instability (CIN) of the tumour (Weber-
Matthiesen et al., 1995). Mutation and dysregulation of kinetochore components are linked to 
chromosomal missegregation in HL, where deletions in the kinetochore protein BUB1 have 
been demonstrated in HL patients (Ru et al., 2002). PTTG1 gene, a homolog of yeast 





lymphomas (Sáez et al., 2002). PTTG1 regulates synchronous sister chromatid separation at 
the metaphase-to-anaphase transition. PTTG1 over-expression is usually seen in the highly 
proliferative cells and is linked to aneuploidy (Yu et al., 2003).  
Furthermore, centrosome amplification is present in nearly all solid and haematological 
malignancies (Zyss and Gergely, 2009), and dysregulation of the centrosome cycle is strongly 
linked to lymphoid malignancy. In Myc-driven B-cell lymphomas, c-MYC has been shown to 
up-regulate Aurora A and B kinases (mitotic serine/threonine kinase that contributes to the 
regulation of cell cycle progression) causing centrosomal amplification and CIN (den 
Hollander et al., 2010). It has been shown that the inability to complete cytokinesis is a cause 
of CIN in B-cell neoplasms. Long-term time-lapse microscopy and single-cell tracking of HL 
cell lines confirmed that multinucleated Reed-Sternberg cells arise from incomplete 
cytokinesis of mitotic daughter cells that remain joined via the mid-body bridge (Rengstl et 
al., 2013). Haploinsuffiency in KLHDC8B, a kelch domain-containing 8B protein which 
localizes to the midbody, is linked to the delay in cytokinesis resulting in mitotic errors and 






Chromosomal abnormalities in HL 
Multiple segmental chromosomal aberrations (SCAs), which represent a mechanism of gene 
amplification by translocating or inserting multiple copies of a certain chromosomal segment 
into different parts of the genome, were detected in the cHL cell lines HDLM-2, KM-H2, 
L428 and L1236; involving mostly telomeric sequences like 4p16, 8q24, 9p24 and 12p13, but 
also intra-chromosomal sequences like 2p13–16 (Joos et al., 2003). Furthermore, 
chromosomal translocations involving the Ig loci are seen in about 20% of classical HLs 
(Martin-Subero et al., 2006), some of which involve the known oncogenes such as BCL1, 
BCL2, BCL3, BCL6, MYC and REL (Martin-Subero et al., 2006, Szymanowska et al., 2008).  
As Ig loci in HRS cells are usually silenced (Kuppers, 2009), the translocations may result in 
the deregulated expression of these oncogenes. 
Array based comparative genomic hybridisation (aCGH) experiments on cHL cases rich in 
HRS cells have revealed genomic imbalances in several components of constitutively 
activated signalling pathways, such as REL/ NF-κB, JAK/STAT and AP1/JUNB pathways. 
These studies have reported recurrent multiple chromosomal break points in chromosomal 
arms 1p, 6q, 7q, 11q, 12q, and 14q. Frequent recurrent gains have been observed on 
chromosomes 2, 5, 9, and 12, and frequent losses are reported on chromosomes 13, 21 and Y. 
The chromosomal regions that have frequent recurrent gains/losses harbour genes that play 
vital roles in the pathways that are important for the survival and proliferation of HRS cells, 








Figure 10. Chromosomes segregation in presence of extra centrosomes. A. Chromosome 
segregation in normal cells where two centrosomes form a bipolar spindle, accurately 
segregated, and cellular ploidy is maintained after proliferation. B. Cells entering mitosis with 
more than two centrosomes can either go through a multipolar mitosis or cluster their 
centrosomes to form a bipolar spindle. Progeny of multipolar divisions are highly aneuploid 
and are usually inviable. Centrosome clustering favours the formation of merotelic 
kinetochore/microtubule attachments resulting in lagging chromosomes. Lagging 
chromosomes can be included in DNA bridges or micronuclei during cell cleavage to produce 
daughter cells. These phenomena induce p53- dependent activation of p21, which inhibits 






Deregulation of transcription factors 
The peculiar phenotype of HRS cells could be a result of the constitutive expression of 
multiple key transcription factors, such as polycomb group family 2 complexes, Notch1, NF-
κB; and JAK/STAT (Table 4). Downregulation of B-cell genes by the polycomb group of 
proteins and irregular expression of distinct haematopoietic cell markers of haematopoietic 
stem cells (HSC) and lymphoid progenitor cells might play vital roles in the distinct 
phenotype of HRS and LP cells (Kuppers, 2009, Kuppers et al., 2012). 
 
NF-κB pathway activation 
The NF-κB transcription factor family play a key role in various cellular responses (Figure 
11). This family consists of five members, Rel A (p65), Rel B, c-Rel, NF-κB1 (p50 and 
p100), and NF-κB2 (p52 and p100), which can act as homo-and/or heterodimers. In the 
unstimulated state, NF-κB is inactive and bound to IκBα, IκBβ, IκBε and p100 and p105 in 
the cytoplasm (Bonizzi and Karin, 2004). In the classical NF-κB pathway the p50/p65 dimer 
is kept in the cytoplasm by binding to IκBα, an NF-κB inhibitor. Cellular receptors such as 
TNF receptor super-family member CD40 activate IKK (IkB kinase complex) kinases. These 
activated IKK kinases phosphorylate IκBα and thereby induce its proteasomal degradation. 
This results in the translocation of NF-κB dimers into the nucleus where they subsequently 
activate multiple target genes.  
Constitutive NFκB activation, which is essential for tumour-cell survival, has been observed 
in HL cell lines and HL primary tumours (Bargou et al., 1997). Furthermore, HRS cells 
express several receptors such as CD30, CD40 and RANK associating with TRAFs (TNF 





receptors are frequently expressed by surrounding cells in the tumour microenvironment 
(Carbone et al., 1995b, Carbone et al., 1995a, Fiumara et al., 2001, Horie et al., 2002). 
The activated IKK complex targets IκBα and IκBβ (NF-κB inhibitors) for ubiquitination and 
proteasomal degradation resulting in the translocation of NF-κB transcription factors into the 
nucleus, which subsequently activate multiple target genes. TNFAIP3 and CYLD also act as 
the negative regulators of the NF-κB signalling pathway. In the alternative NF-κB pathway, 
CD40, BCMA and TACI receptors, upon activation, stimulates the kinase NIK (MAP3K14), 
which then activates IKKα complex. Here, the NIK activity is negatively regulated by 
TRAF3. IKKα targets RELB and p100 for proteasomal degradation, which translocate into 
nucleus as p52/RLB heterodimers. Both pathways are constitutively active in HRS cells. In 
EBV-positive HL cases, EBV-encoded latent membrane protein 1 (LMP1) and other genetic 
lesions play an important role in the deregulation of NF-κB signalling pathway.  
Several genetic aberrations affecting the NF-κB pathway have been identified in HRS cells. 
The REL gene has copy number gains or amplification in 40-50% of HL cases. IκBα and 
IκBε genes, inhibitors of NF-κB, are mutated in 10-20% of HL cases. Recent studies have 
also demonstrated a role for tumour suppressor genes, such as TNFAIP3 and CYLD, in the 
negative regulation of the NF-κB pathway. The TNFAIP3 gene encodes the A20 protein that 
has ubiquitinase and deubiquitinase functions and is a negative regulator of NF-κB signalling 
acting upstream of the IKK kinases (Schmitz et al., 2009). Recent studies have revealed 
mutations and deletions in TNFAIP3 in 30-40% of HL (Kuppers, 2009, Kuppers et al., 2012, 






Table 4. Signalling pathways and transcription factors constitutively active in HRS cells 
(taken fromBrauninger et al., 2006).   
 
Pathway Proposed effect of activation Mechanisms of activation 
JAK-STAT 
Supports proliferation; promotes 
survival 
Autocrine stimulation via IL-
13/IL-13R 
AP-1 Supports proliferation 
Autoregulation of c-Jun; NFκB 
activation of JunB 
Notch1 
Induces proliferation; inhibits 
apoptosis; downregulates B-cell 
phenotype? 
Expression of ligand Jagged1 in 
HRS cells and surrounding cells 
MAPK/ERK 
Supports proliferation; inhibits 
apoptosis 
CD30-, CD40-, RANK-
signalling; RTK signalling? 
PI3K/AKT Promotes survival 
CD40 signalling?; LMP1 and 
LMP2a in EBV-positive cases; 
RTK signalling? 
NFκB 
Inhibits apoptosis; supports 
proliferation; recruits T cells to 
lymphoma; promotes dissemination 
Mutations in IκBα; mutations in 
IκBε genomic c-Rel 
amplifications; CD40 stimulation 
by CD40 ligand expressing T 
cells; CD30 stimulation; ligand 
independent or via CD30 ligand 
expressing T cells; LMP1 
mimicry of active CD40 in EBV-
positive cases 
Receptor tyrosine kinases* Supports proliferation; others? 
Autocrine or paracrine 
stimulation through ligands; no 
indication for mutations 
*DDR2 (discoidin receptor family, member 2); EPHB1 (ephrin receptor EphB1); MET; 
PDGFRA (platelet-derived growth factor receptor A); RON (macrophage-stimulating protein 





JAK/STAT pathway in HL 
Chromosomal gains (in ~ 20% of HL cases) and translocations JAK2 gene, an activator of 
STAT signalling, are seen in HRS cells (Joos et al., 2000, Van Roosbroeck et al., 2011). In 
HRS cells, several members of the STAT family of transcription factors, including STAT3, 
STAT5 and STAT6, are frequently activated (Figure 1.9.6) (Kube, 2001, Skinnider, 2002). 
STATs can be activated by cytokine receptors such as IL-13 and IL-21 via the JAK kinases, 
by RTKs and by 7 transmembrane receptors (Ilhe, 2001). These activated STATs undergo 
phosphorylation to form dimers, which translocate to the nucleus and activate several target 
genes (Levy and Darnell, 2002).  
The constitutive activation of STAT6 in HRS cells, by simultaneous expression of IL-13 and 
its receptor was shown to increase the proliferation of HRS cell lines (Kapp et al., 1999, 
Skinnider, 2001). STAT3 downregulation in an HRS cell line induces apoptosis, indicating 
that STAT3 activity may be essential for HRS cell survival (Holtick et al., 2005).  Genomic 
gains or translocations of JAK2 and frequent silencing mutations in SOCS1 (Weniger et al., 
2006b) have been shown to be able to mediate activation of the JAK/STAT pathway in HRS 
cells. 
In HRS cells, NFκB and the AP-1 transcription factors act synergistically and mediate cell 
cycle promoting and cell-death inhibiting pathways. AP-1 dimer consisting of c-Jun and JunB 
is strongly expressed in HRS cells (Mathas, 2002), and NFκB seems to be essential for the 
strong JunB expression in HL cell lines (Watanabe et al., 2003). Furthermore, AP-1 activates 
CD30 transcription in HL cell lines (Watanabe et al., 2003), creating a positive feedback loop 









Figure 11. The role of NF-κB and JAK/STAT pathways in pathogenesis of HL. The extent of 
viral infections and genetic lesions affecting NF-κB and JAK/STAT pathways are shown in 






Notch1 promotes the degradation of E2A (a.k.a. TCF3), and blocks DNA binding of early B-
cell factor (EBF). This results in the suppression of the B cell differentiation programme, 
while inducing the transcription of T-cell genes. In addition, activation of Notch1 by Jagged1 
inhibits PAX5 at transcriptional and post-translational stages. Overexpression of activated B-
cell factor 1 (ABF1) and inhibitor of differentiation and DNA binding 2 (ID2) also results in 
the degradation of E2A (a.k.a. TCF3) (Hartmann et al., 2008). 
Epigenetic modification is another important factor in the transcriptional downregulation of 
B-cell lineage-specific genes. Simultaneous silencing of master transcriptional regulator(s), 
such as Oct2, BOB.1/OBF.1, and PU.1 suggests the importance of epigenetic modification in 
the reprogramming of HRS cells (Ushmorov et al., 2006). 
 
Anti-apoptotic mechanisms in HRS cells 
Evading apoptosis is a key event in the transformation process of pre-apoptotic GC B-cells, 
leading to the formation of HRS cells. Deregulation of several signalling pathways, including 
NFκB, contribute to the survival of HRS cells.  
Two major apoptotic signalling pathways are reported in B cells (Mizuno et al., 2003), the 
extrinsic pathway of apoptosis involving TNF receptor super-family members carrying a 
death domain (TRADDs), and the intrinsic pathway involving the apoptosome. In the 
extrinsic pathway of apoptosis, TNF receptor super-family members carrying a death domain 
(TRADDs), upon activation, form a multi-molecular death-inducing signalling complex 
(DISC), in which caspase-8 is activated by auto-proteolytic cleavage, leading to the sequential 





(Mizuno et al., 2003). In the intrinsic pathway, pro-apoptotic proteins form a multi-protein 
complex, the apoptosome, where caspase-9 is activated. 
Although CD95 (Fas), CD95-ligand, and TRADDs (such as TNF-R1, TRAIL-R1 and TRAIL-
R2) are expressed in HRS cells (Maggio et al., 2003, Xerri et al., 1995), resistance to CD95 
mediated death was observed in these cells in vitro, indicating CD95 death signalling pathway 
might be impaired in HRS cells (Metkar et al., 1999, Verbeke et al., 2001, Re et al., 
2000)Mutations in CD95, resulting in the impairment of CD95-mediated cell death, was also 
observed in some rare cases of HL (Maggio et al., 2003, Muschen et al., 2000b). In HRS cells, 
high levels of the cellular FLICE-inhibitory protein (c-FLIP), a proximal negative regulator of 
the CD95-induced death program that interferes with formation of the DISC, was observed 
(Maggio et al., 2003, Dutton et al., 2004)  Inhibition of c-FLIP expression in HL cell lines 
restored CD95-mediated apoptosis, suggesting that c-FLIP plays a central role in preventing 
CD95-mediated apoptosis of HRS cells (Dutton et al., 2004, Mathas et al., 2004). 
HRS cells have been reported to evade the intrinsic pathway of apoptosis by inhibiting the 
proteolytic activity of caspases-3, 7, and 9 through the over-expression of several inhibitors of 
apoptosis (IAP), including XIAP (X-linked inhibitor of apoptosis) (Kashkar et al., 2003, 
Kreuz et al., 2001).  
 
Interaction of HRS cells with the inflammatory milieu 
Figure 12 illustrates the tumour microenvironment and various cellular interactions in HL.  
Historically, it was believed that the tumour-induced immune responses simply inhibit tumour 
growth and progression. However, recent studies have demonstrated that the tumour-induced 
inflammatory response has a paradoxical effect which can also contribute to tumour growth 





signals. Reactive cells in the tumour microenvironment may also facilitate tumour 
angiogenesis, and invasion and metastasis by secreting extracellular matrix-modifying 
enzymes (Hanahan and Weinberg, 2011). 
About 99% of the tumour microenvironment in HL is composed of lymphocytes, eosinophils, 
fibroblasts, plasma cells, mast cells, and macrophages. Recent studies have reported that the 
tumour cells actively recruit these infiltrating cells by secreting cytokines and chemokines 
(Kuppers, 2009). The recruitment of these cells and their interaction with HRS cells seems to 
be very important for the survival and proliferation of HRS cells, as HRS cells are usually not 
found in the peripheral blood and HRS cells do not grow well in vitro or in vivo (Kapp et al., 
1993, Vockerodt et al., 1998).  The majority of these infiltrating cells are CD4
+ 
T-cells that 
often demonstrate a T-helper type 2 (Th2)-phenotype. These Th2 cells are recruited via the 
secretion of chemokines such as TARC, CCL5 and CCL22, by the HRS cells (Kuppers, 
2009). These Th2 cells express CD40 ligand which is essential in the expression of CD40 
receptors in the NF-κB pathway (Carbone et al., 1995a, Nozawa et al., 1998). Furthermore, 
the infiltrating Treg cells suppress the tumour-antigen specific NK cells and CD8
+ 
cytotoxic T 
lymphocytes (CTLs) and contribute to the immune escape of HRS cells (Marshall, 2004). 
Cytotoxic T cells are also inhibited through expression of the PDL-1, PDL-2 and CD95 
ligands and secretion of IL-10, TGF-β, and galectin1 by the HRS cells (Yamamoto et al., 








Figure 12. Tumour microenvironment and cellular interactions in HL.  Infiltration and 
activation of various reactive elements into the tumour microenvironment is facilitated by the 
HRS cells via secretion of chemokines and cytokines. The majority of the infiltrate comprises 
of Th2 and Treg cells, which are attracted to HRS cells by TARC, CCL5, CCL20, CCL22, 
and Galectin secreted by the HRS cells. These Th2 and Treg cells interact with HRS cells and 
assist in the activation of some key pathways and protect HRS cells from immune shock 





Recurrent mutations in Hodgkin lymphoma 
Liu et al., 2014, described the mutational spectrum of 7 HL cell lines; SUPHD1, L540, 
KMH2, L428, L1236, DEV, and L591 using exome sequencing technology.  This study 
identified 463 recurrently mutated genes of which 373 were unique to cHLs. Of the 463 genes 
that were mutated in at least two HL cell lines, 346 had a high-impact mutation or a SIFT 
score of 0.05 (Figure 13). The authors identified several genes, including PTPN1, TNFAIP3, 
NFKBIE, CYLD and NFKBIA, which were previously reported to be mutated in primary 
cHL. Furthermore, this study identified recurrent mutations affecting the ATG start codon in 
B2M, and mutations in CIITA. Consistent with the B2M mutations affecting the ATG start 
codon, the authors observed no or very low membrane B2M and HLA class I expression in 
L428 and DEV cell lines. This finding is of importance because several studies have shown 
that in some cases primary HRS cells lack of expression of MHC-I and B2M (Oudejans et al., 
1996, Murray et al., 1998, Diepstra et al., 2005, Lee et al., 1998). Furthermore, lack of MHC-I 
expression in HRS cells was also reported as an independent adverse prognostic factor in cHL 
(Diepstra et al., 2005). 
Reichel et al., described mutation spectrum of purified HRS cells from ten primary HL 
tumours using exome sequencing (Figures 14-15) (Reichel et al., 2015). This study identified 
recurrent gains of a region in chromosome (chr) 2 containing REL (5/10), BCL11A, XPO1, 
and variably MYCN (4/10); focal amplifications involving only NSD1 (chr 5, 4/10); gains 
involving CD274 (chr 9, 4/10) and variably JAK2 and MLLT3 (3/10); gains involving 
UBE2A (chr X, 3/10); gains involving CDK4 (chr 12, 2/10); losses of gene segments 
involving TNFAIP3 (chr 6, 5/10) and variably MLL, MLLT4, PRDM1 (3/10), and MLL; 






This study identified 99 recurrently mutated genes with protein-altering mutations, including 
B2M, TNFAIP3, HIST1H1E, EEF1A1, ITPKB, SOCS1, BCL7A, CSF2RB and RANBP2.  In 
line with Kato et al., study which reported frequent mutual exclusivity of EBV-infection and 
TNFAIP3 mutation (NF-κB-activating events) (Kato et al., 2009), this study did not observe 
any TNFAIP3 mutation in the only EBV-positive case (the only case with NS morphology 
that lacked any TNFAIP3 mutation), indicating that EBV provides alternative molecular 
mechanisms for avoiding tumour immunity. Additionally, they also identified some novel 
genes that have not been previously linked to lymphoid malignancies but have been seen in 
solid cancers and myeloid stem cell disorders, including CSF2RB, NEK1, HECW2, SENP7, 
TBC1D15, TICRR, and ZPF36L1. Mutated genes identified in this study had enrichment in 
the genes responsible for interactions with the immune system, preservation of genomic 
stability, and transcriptional regulation.  
Furthermore, they found statistically significant association with older age among the B2M-
positive cases (median age of 47 vs 30 years; p≤ 0.0001) and stage III/IV disease (p= 0.001), 
and with male predominance (p= 0.037) and bulk disease (p= 0.029) and that the cases that 
lacked B2M expression belonged to a better clinical outcome categor0y (10-year progression-
free survival of 74% vs 49%; p= 0.026; and overall survival of 87% vs 66%; p= 0.013). 
 
The Catalogue of Somatic Mutations in Cancer (COSMIC) 
COSMIC is a comprehensive resource for exploring the impact of somatic mutations in 
human cancer. The COSMIC database provides list of mutations based on tumour type and 
the frequency of these mutations in each cancer. SOCS1, TNFAIP3, NRAS, EZH2, PIK3R1, 
NFKBIE, TP53, CDKN2A, CYLD, and HRAS genes were reported to be mutated frequently 
in HL (Forbes et al., 2015)
 







Figure 13. Recurrently mutated genes and differentially expressed genes in HL cell lines. (a) In all, 463 genes were mutated in at least two 
out of seven HL cell lines. 81 genes (shown in the middle panel) included 67 genes that were mutated in at least three HL cell lines and 14 
genes showing high-impact (stop gain, frame shift and splice site) mutations in two HL cell lines (b) Heat map of the gene expression 


















Table 5. Recurrent mutations in HL (obtained from COSMIC data base; 20 Jan 2017). 
Gene 
Number of  samples 
tested 
Number of samples 
mutated 
Mutation frequency 
SOCS1 33 11 33.3 
TNFAIP3 83 24 28.9 
NRAS 49 6 12.2 
EZH2 10 1 10 
PIK3R1 10 1 10 
NFKBIE 21 2 9.5 
TP53 35 3 8.6 
CDKN2A 14 1 7.1 
CYLD 27 1 3.7 






Role of EBV in the pathogenesis of Hodgkin lymphoma 
The frequency of EBV association in HL patients depends on certain factors such as 
geographical location; the prevalence rate varying across the world, with lower rates in the 
West (approximately 40%) and higher rates in the developing world e.g. Central Africa (90% 
of paediatric cases), age; occurring more frequently in children and elderly patients, sex; more 
prevalent in men, and histological subtype; most often associated with MCCHL and LDCHL 
(Eberle et al., 2009). 
Early reports documented an increased risk of cHL in people with a prior history of IM 
(Connelly and Christine, 1974, Rosdahl et al., 1974). Subsequently, those with a prior history 
of either self-reported or laboratory-confirmed IM were shown to have an increased risk of 
developing EBV-positive cHL; but not EBV-negative cHL (Hjalgrim et al., 2007, Hjalgrim, 
2012). In HRS cells the EBV genome is monoclonal and is maintained throughout the course 
of disease suggesting it is involved in both the initiation and maintenance of disease. EBV 
infected HRS cells express EBNA1, LMP1 and LMP2A/B, together with the non-coding 
EBERs and miRNAs (Deacon, 1993, Young et al., 1991, Niedobitek et al., 1997, Murray et 
al., 1992a, Grasser et al., 1994). 
HRS cells lack pro-survival signals mediated by a functional BCR, instead, EBV latent gene 
products contribute to the survival of HRS progenitors through multiple routes, most of which 
converge on a limited number of cell signalling pathways. CD40 and BCR are required for the 
survival and proliferation of germinal centre B cells. LMP1 and LMP2 have been shown to 
mimic the physiological functions of CD40 and BCR, respectively, thereby provide essential 
signals for survival. LMP1, functions as a constitutively active homologue of the cellular 
CD40 receptor (Lam and Sugden, 2003), and LMP1 expression in HRS cells has been shown 





phospatidylinositol-3-kinase (PI3K)/AKT pathways (Bargou et al., 1997, Kube, 2001, Dutton 
et al., 2005), which could potentially rescue HRS progenitors from apoptosis (Gires et al., 
1999, Huen et al., 1995, Kieser et al., 1997). 
LMP1 also induces the overexpression of FLICE-inhibitory protein (c-FLIP) thus providing 
further protection from death induced by the extrinsic pathway to apoptosis (Dutton et al., 
2004). In HRS cells, LMP1 was also shown to up-regulate pro-survival genes, such as BCL2 
and BFL-1, and downregulate B-cell transcription factors and BCR signalling components 
that are required to maintain B-cell identity; thereby protecting B cells from apoptosis 
(Vockerodt et al., 2008, Henderson et al., 1991, D'Souza et al., 2004). These transcriptional 
changes may be mediated through the induction of ID2 (Vockerodt et al., 2008), or via 
epigenetic mechanisms involving polycomb proteins, DNA methyltransferases and protein 
arginine methyltransferases (Anderton et al., 2011, Leonard et al., 2011, Dutton et al., 2007, 
Leonard et al., 2012).  
The unique N-terminus of LMP2A includes an ITAM motif, which resembles the signalling 
domain of the BCR (Longnecker and Kieff, 1990), and thus LMP2A can mimic a functional 
BCR and can allow B cells to develop in the absence of normal BCR signalling, as shown in 
transgenic mice experiments (Caldwell et al., 1998, Merchant et al., 2000). Importantly, like a 
functional BCR, LMP2A can also induce lytic cycle entry, and can do so even in the absence 
of a functional BCR. However, it cannot do so when certain components of the BCR 
signalling machinery are missing which is the case in HRS cells (Vockerodt et al., 2013). 
Thus, the loss of BCR, as well as of BCR signalling components could prevent both BCR- 
and LMP2A-induced virus replications in HRS cell progenitors. LMP2A was also shown to 
induce several signalling pathways important for B-cell survival, including the activation of 





latently infected HRS cells, LMP2A can also induce the upregulation of genes involved in 
proliferation, such as MKI67 and PCNA, and anti-apoptotic genes, such as BCLXL.  
 
Clinical presentation and staging of HL 
HL patients usually present with painless lymphadenopathy or non-specific features such as 
weight loss, fluctuating fever, night sweats or fatigue. Accurate staging of the disease in 
patients using pathological, clinical, and radiologic data is the most important aspect in 
deciding prognosis. The Ann Arbor system (Carbone et al., 1971) and Costwold modification 
(Lister et al., 1989) are widely used for staging HL patients.  
Currently radiological examination with computerised tomography (CT) and positron 
emission tomography (PET) is widely used for the initial staging assessment.  PET is often 
used to assess response to treatment and to evaluate residual tumour tissue upon completion 
of therapy  (Rathore and Kadin, 2010). 
In addition to the above prognostic factors, the presence of bulky disease (>10 cm in 
diameter), multiple sites of disease, elevated erythrocyte sedimentation rate (ESR), extranodal 
disease, advanced age, are important factors in stratifying patients (Rathore and Kadin, 2010). 
They include:  
1. Early favourable (Stages I-II, no B symptoms) 
2. Early unfavourable (Stages I-II with at least one risk factor), and 
3. Advanced (Stages III-IV or any stage with bulky disease or intra-abdominal disease) 
Long-term survival rates and morbidity due to treatment-related toxicity are significant among 
HL patients. So, there is a need for better prognostic models which would help to identify 





Hasenclever and Diehl is widely used for assessing HL prognosis (Hasenclever and Diehl, 
1998).  
Current treatment strategies for HL 
For early favourable HL, patients are generally treated with two to four chemotherapy courses 
and involved-node radiotherapy. A combined modality therapy with ABVD (Adriamycin, 
Bleomycin, Vinblastine, and Dacarbazine) followed by involved field radiotherapy (IFRT) or 
extended field radio therapy, and with regular PET assessment is a standard treatment 
approach. The above regimen with additional cycles or with BEACOPP (Bleomycin, 
Etoposide, Adriamycin, Cyclophosphamide, oncovin, Procarbazine, Prednisone) treatment 
regime is often used in early unfavourable HL. For advanced HL, the above regimen is 
applied, albeit with more cycles
 
(Rathore and Kadin, 2010). 
These treatments allow for high cure rates but relapse can occur in around 10% of early HL 
cases and 20% of advanced HL cases.  The current treatment regimen for patients with 
relapsed/refractory HL includes salvage chemotherapy such as ICE (ifosfamide, carboplatin 
and etoposide) or DHAP (dexamethasone, high-dose Ara-C and cisplatin) followed by high-
dose chemotherapy and autologous stem cell transplantation (ASCT). However, this treatment 
is not tolerable in some patients, and in others is not sufficient for cure. 
Identifying the risk-groups who will relapse after initial treatment and finding the right 
treatment regime is necessary as these patients (especially young patients) are prone to 
develop secondary malignancies, hormonal imbalances, and sterility (Delwail, et al. 2002; 
Ibrahim, et al. 2012).  Recent advances in the understanding of pathogenic mechanisms have 
led to the approval of several novel agents (Figure 16), such as brentuximab vedotin, the 
antibody–drug conjugate which targets CD30 (Adcetris®, Seattle Genetics, Inc., USA); and 











1.10 Project aims  
In the foregoing sections I have outlined the biology and clinical characteristics of two B cell 
lymphomas, Hodgkin lymphoma and Burkitt lymphoma, both of which are associated with 
infection with the Epstein-Barr virus.  
In the case of HL, treatment with optimised combination chemotherapy regimens offers cure 
as a realistic probability for the majority. However, around 15-20% of HL patients will either 
fail to attain a complete response or will relapse early; these patients have significantly poorer 
long-term survival. Furthermore, multi-agent chemotherapy regimens and radiotherapy are 
associated with high rates of acute and long term toxicity. The appearance of secondary 
malignancies is a particular concern among paediatric HL sufferers as these patients are at the 
highest risk among all childhood cancer survivors. Identifying biomarkers of response to 
conventional chemotherapy in paediatric HL would enable patients to be stratified for more or 
less intensive regimens in turn maximising survival rates while at the same time reducing late 
effects. The development of targeted therapies for HL sufferers, alongside better stratification 
of patients for conventional therapies, should not only improve cure rates but could also help 
intensify conventional treatments.  
For many cancer types the development of new targeted therapies and biomarkers of response 
has been underpinned by improved knowledge of disease biology, especially the contribution 
of genomic changes. This has not been the case for HL, since to date there have only been 
limited studies of the genomic landscape of primary tumours, mainly due to the low 
frequency of HRS cells in tumour biopsies. In Chapter 3, I set out to establish a new 
methodology for the analysis of the whole exomes of HRS cells micro-dissected from tumour 





viable suspensions, however, majority of the patient samples are archived as flash frozen or 
paraffin-embedded. 
Endemic BL is the most common malignancy of children in equatorial Africa comprising 
around 50% of all paediatric malignancies. Sporadic BL is also the most common type (30-
40%) of childhood non-Hodgkin lymphoma. Although better performance was achieved with 
the current multi-agent chemotherapy and immunotherapy, relapse following treatment occur 
in small proportion of BL cases and current results in refractory/relapsed BL are extremely 
poor. Despite the fact that almost all cases of eBL and a sizeable fraction of sporadic BL are 
EBV-positive, there are currently no new EBV targeted therapies available for these patients. 
This is in part due to the previously reported limited expression of viral genes that can be 
targeted by pharmacological or by immunological based therapies. In Chapter 4, I set out to 
address the issue of viral gene expression in eBL, initialling describing global virus gene 
expression then focussing on the potential contribution of a novel latent gene, BILF1. 
 
Specific objectives 
In Part I, I will- 
1. Establish the methodology for the whole exome sequencing of HRS cells micro-
dissected from HL biopsies of paediatric HL. 
2. Use this approach to describe the genomic landscape of paediatric HL  
3. Identify key genes, and biological mechanisms relevant to the pathogenesis of HL 
using established bioinformatics approaches.  
In Part II, I will- 
1. Analyse the viral transcriptome of EBV-associated cancers, with a focus on eBL 





3. Identify the cellular transcriptional targets of BILF1 in B cells and use these data to 







MATERIALS AND METHODS 








2.1.1 Hodgkin and Burkitt lymphoma cell lines 
Hodgkin lymphoma (HL) derived cell lines KM-H2 and L-591, and Burkitt lymphoma (BL) 
cell lines DG-75 and AKATA were maintained in 90% RPMI 1640 (Sigma-Aldrich, UK) 
supplemented with 10% foetal calf serum (FCS), 2mM L-glutamine and 1% penicillin-
streptomycin solution (Sigma-Aldrich, UK), which was exchanged every 72 hours. 
2.1.2 Paediatric Hodgkin lymphoma samples 
35 paediatric HL biopsies (flash frozen) and their matched blood DNA, collected from 
untreated patients, were provided by National Children’s Cancer and Leukaemia Group 
(CCLG) Biological Studies Steering Group (CCLG reference number 2012BS07). This study 
fulfils the criteria mandated by MREC as approved by CCLG Biological Studies Steering 
Group. This study also obtained approval from National Research Ethics Committee 
(Reference number: ERN_13-0570). Samples were stored at -70
o
C. Results shown in my PhD 
thesis were from 13 paediatric patient samples (Table 6). 
2.1.3 Tonsillar samples 
Paediatric tonsils were used to obtain germinal centre B (GC B) cells. These samples were 
obtained from the Children’s Hospital Birmingham following informed consent (reference 
number for ethical approval: 06/Q2702/50).  
 




Table 6. Paediatric Hodgkin lymphoma patient samples. NS= Nodular Sclerosis; MC= Mixed 
Cellular; NS-MC= Nodular Sclerosis-Mixed Cellular. 
Sample HL subtype Gender EBV status 
S1 NS-MC Male EBV-positive 
S2 NS Male EBV-positive 
S3 NS Male EBV-negative 
S4 NS Female EBV-negative 
S5 NS Female EBV-negative 
S6 NS Female EBV-positive 
S7 NS Female EBV-negative 
S8 NS Female EBV-negative 
S9 NS Male EBV-positive 
S10 NS Male EBV-positive 
S11 NS Male EBV-negative 
S12 MC Male EBV-positive 
S13 NS Male EBV-negative 




2.1.4 Samples used in the EBV gene expression analysis 
I performed EBV gene expression analysis, using high-throughput q-PCR (Fluidigm) method, 
on 4 EBV-associated cancers; HL, eBL, NPC, and gastric cancers. All samples used in this 
study were initially diagnosed as EBV-infected. 
HL samples included 24 primary HL tumours and L-591 cell line. Primary HL tumour 
samples were provided by National Children’s Cancer and Leukaemia Group (CCLG) 
Biological Studies Steering Group (CCLG reference number 2012BS07). Work on these HL 
samples is approved by the NRES (National Research Ethics Committee) of the UK 
(Reference number: ERN_13-0570 which falls under an existing ethical approval ERN_12-
0985). 
A total of 41 primary eBL tumour samples were used in this study. These samples were 
collected from the Department of Human Pathology of the Lacor Hospital (Uganda, Africa), 
in endemic areas, with a written permission and informed consent in accordance with the 
Declaration of Helsinki. Ethics approval for this study was obtained from the Ethics and 
Research Committee at the Lacor Hospital (Uganda), from the Ethics and Research 
Committee at Moi University, Eldoret (Kenya), and from the Institutional Review Board at 
the University of Siena (Italy). 
50 primary NPC tumour samples, which also included 9 RNA-amplified samples, and 9 NPC 
cell lines were used in this study. Complementary DNA (cDNA) of 41 primary NPC tumour 
samples and 9 NPC cell lines (which include C666.1 which is a naturally infected cell line, 
and in vitro Akata-infected cell lines CNE1, CNE2, HK1, HONE1, NP460, SUNE1, TWO1, 
and TWO4) were received from Dr. Yap Lee Fah, Faculty of Dentistry, University of Malaya, 
50603, Kuala Lumpur, Malaysia. These NPC samples were obtained with an approval (code: 
KKM/NIHSEC/P13-494) from Medical Research and Ethics Committee, Ministry of Health 




Malaysia. 9 NPC primary tumour samples from amplified RNA were provided by a group at 
the Institute of Cancer and Genomic Sciences, University of Birmingham. Ethical information 
for these samples can be obtained from a previously published paper by this group (Hu et al., 
2012). 
 Four gastric cell lines used in this study were either naturally infected with EBV (SNU-719 
and YCCEL-1) or infected in vitro with the Akata (AGS and OE19). CDNA for these samples 
was provided by Dr. Helena Carley at the Institute of Cancer and Genomic Sciences, 
University of Birmingham. 
2.1.5 Samples used in the RNA in situ hybridization experiment 
I performed RNA in situ hybridization experiment (RNAScope) (Wang et al., 2012) on 15 
eBL and two paediatric HL samples that were initially diagnosed as EBV-infected. Source 
and ethical approval for these samples are described in the previous section. 
2.1.6 RNA sequencing data obtained from SRA and GEO 
RNA sequencing data for 20 eBL samples was obtained from NCBI sequence Read Archive 
(SRA) service (accession number PRJNA292327). RNA sequencing data for four germinal 
centre (GC) B cell samples was obtained from NCBI Gene Expression Omnibus (GEO 
accession number GSE45982).  
2.2 METHODS 
2.2.1 Sample preparation for immunohistochemistry and LCM 
HL cell line KM-H2 was used to optimize methods to obtain good quality tumour DNA for 
exome sequencing, including CD30 staining and laser capture microdissection (LCM) of 
CD30-positive HRS cells.  Culture media with KM-H2 cells was centrifuged at 3000 rpm for 
5 minutes and the pellet was washed and resuspended in 500 µL PBS (pH 7.6). 




Approximately 200,000 cells were used to generate monolayer cell preparations onto RNAse 
and DNAse-free polyethylene naphthalate (PEN) membrane slides (Sample MembraneSlide 
1.0 PEN (D), CarlZeiss Ltd.) by cyto-centrifuging at 1000 rpm for 5 minutes in the Cytospin2 
(Shandon, UK).  PEN membrane slides were air dried for 1 minute and fixed in cold ethanol 
(75%) for 2 minutes. 
Frozen sections of paediatric HL primary tumour samples were prepared at 8 µm using a 
decontaminated, RNAse and DNAse-free standard cryostat and placed onto RNAse and 
DNAse-free PEN membrane slides. PEN membrane slides were air dried for 10-30 minutes 
and fixed in cold ethanol (75%) for 2 minutes. 
2.2.2 Immunohistochemistry 
Tissue sections were stained with Haematoxylin and Eosin (H&E) to investigate morphology 
and abundance of the HRS cells. These sections were later stained for EBER to determine 
EBV status. Tissue sections were stained for CD30 positivity using CD30 antibody and 
Haematoxylin on Leica BOND-MAXTM autostainer (Leica Biosystems) wherein sections 
were treated for antigen retrieval at 65 C for 30 minutes.  Endogenous blocking was 
performed by placing 0.3% hydrogen peroxide H2O2 solution on sections for 15 minutes. 
Primary antibody (monoclonal mouse anti-human CD30 (Clone Ber-H2), Dako, UK Ltd) at 
1:10 dilution was applied on sections for 15 minutes. Secondary antibody (Dako REAL 
EnVision HRP Rabbit/Mouse (ENV)) was applied on sections for 5 minutes. AB substrate 
(980ul Dako REAL substrate buffer + 20ul Dako REAL DAB+ chromogen) was placed on 
sections for 1 minute. Slides were washed twice between each of the above step.   
For staining Formalin-fixed and paraffin-embedded (FFPE) samples, tissue sections (4μ) were 
deparaffinized in xylene and rehydrated by washing in serial dilutions of ethanol (96%, 80% 
and 70%) and rinsed in deionized water. For blocking endogenous peroxidase activity, 




sections were treated with 0.3%  H2O2 solution for 15 min. Sections were then treated for 
antigen retrieval by immersing sections in Citrate buffer (pH6.0; 1.26g sodium citrate+0.25g 
citric acid+1L distilled water) and boiled using microwave for 30 minutes. Sections were 
rinsed in tap and deionized water. Sections were washed in deionized water for 5 min, then 
twice in 0.05M Tris-buffer (pH 7.4-7.6), once in Tris-buffer with 0.5% Tween solution and 
incubated with primary antibody (monoclonal mouse anti-human CD30 (Clone Ber-H2), 
Dako, UK Ltd) at 1:10 dilution was applied on sections for 60 minutes at room temperature in 
a humid chamber. Slides were washed twice in Tris-buffer, once in Tris-buffer with 0.5% 
Tween solution, and incubated with secondary antibody (Dako REAL EnVision HRP 
Rabbit/Mouse (ENV)) was applied on sections for 5 minutes. Slides were washed twice in 
Tris-buffer and AB substrate (980ul Dako REAL substrate buffer + 20ul Dako REAL DAB+ 
chromogen) was placed on sections for 1 minute and then counterstained in haematoxylin, 
dehydrated through alcohols and xylene. 
2.2.3 Laser capture microdissection of HRS cells 
I used ultraviolet (UV) cutting system (PALM MicroBeam, CarlZeiss Ltd) to micro-dissect 
six sets of approximately 50 HRS cells from each patient sample mounted on PEN membrane 
slides. HRS cells were identified with the help of a trained pathologist (Dr. Ghada 
Mohammed).  The microdissected cells were captured on PALM Adhesive cap tubes 
(AdhesiveCap 500 clear (D), CarlZeiss, Ltd). A schematic diagram of the UV-LCM 
procedure is depicted below (Figure 1). For each sample, the six sets were split into two 
groups, each containing 3x50 HRS cells, and the two groups were treated as biological 
replicates from here onwards. 




Figure 17. Laser capture microdissection of HRS cells. The above figure depicts the 
schematic of LCM method. (Cells were pointed with arrows) A. Visualisation of the cells of 
interest, in this case CD30 stained HRS cells (large multi-nucleated cells with membrane 
stained in brown) in a frozen tissue section of a patient biopsy. B. Selection of the cells of 
interest C. Cutting of the selected cells using laser energy D. Visualisation of intact HRS cells 
that were captured on the adhesive cap (images scale to 150 µm and HRS cell shown in a box 
in D is enlarged further to x4). 
 




2.2.4 Whole genome amplification 
HL cell line KM-H2 was used to optimize methods including whole genome amplification 
(WGA) of DNA from microdissected HRS cells, purification of WGA DNA samples, and 
quality and quantity assessment of whole genome amplified DNA samples. Genomic DNA 
from 50 HRS cells in each tube were amplified in a total of 50 µl reaction volume using 
GenomePlex® Single Cell Whole Genome Amplification Kit (WGA4) according to 
manufacturer’s protocol (Sigma-Aldrich Ltd.),  along with a positive control and negative 
control reactions. WGA products from three 50 µl reactions were pooled to obtain a technical 
replicate for that paediatric HL sample. Thus I have two technical replicates from the six sets 
containing 50 HRS cells. These two technical replicates for each sample were sequenced 
separately. 
I performed quality and quantity assessment of WGA products prior to sample submission for 
exome sequencing. WGA products were cleaned according to manufacturer’s protocol using 
Genomic DNA Clean & ConcentratorTM (Zymos Res. Corp.) and eluted with nuclease-free 
distilled water.  Quality and quantity of WGA products and matched blood DNA samples was 
assessed using Nanodrop spectrophotometer (Thermo Scientific) and Qubit (ThermoFisher 
Scientific), respectively. Fragment sizes of the whole genome amplified products ranged 
between 200 base pairs (bp) and 1 kbp when separated on 2% agarose gel confirmed by 
Bioanalyzer (Agilent Technologies). WGA products were also randomly checked for 
coverage by PCR and Sanger sequencing using randomly selected 18 housekeeping genes 
present on various chromosomes (Appendix 2). 
2.2.5 Whole exome sequencing 
Initial sequencing on some samples was performed at Oxford Genomics Centre (Oxford, UK) 
and the remaining samples were sequenced at Edinburgh Genomics Centre (Edinburgh, UK). 




Exome sequencing required at least 1 μg of DNA with quality 1.8-2.0 for 260/280 ratio and 
2.0-2.2 for 260/230 ratio. 3/26 tumour exomes and 4/13 normal exomes were captured using 
NimbleGen SeqCap EZ Exome Kit v3.0, Roche (Hiatt et al., 2010) and the remaining exomes 
in this study were captured using Nextera Rapid Capture Exome enrichment kit, Illumina Inc 
(Caruccio, 2011). The captured exome library was sequenced using Illumina HiSeq 2000 to 
obtain 100-fold average coverage of each base in the targeted region and greater than 95% of 
the exome sequence was expected to be covered at sufficient depth for variant calling (≥20X 
coverage). 
2.2.6 Whole exome sequencing data analysis 
Exome sequence reads for each sample were received in FastQ format from sequencing 
service providers. Exome sequencing data for technical replicates for each sample were 
analysed separately and common variations between these two technical replicates for each 
sample were considered for further investigation.  
Preparation of input files 
Human reference sequence hg19 was downloaded from UCSC (Speir et al., 2016)
 
in order to 
align raw exome sequence reads in FastQ files. Nextera Rapid Capture Exome target BED 
files and Nimblegen exome capture target BED files were used to assess the coverage in the 
exome sequences. Nextera Rapid Capture Exome targeted regions manifest file (.bed) lists the 
212,158 targeted exome regions with start and stop chromosome locations in hg19. 
Nimblegen exome capture target BED file contains 368,146 target regions covering more than 
20,000 genes in the human reference genome (hg19). 
 




Quality assessment of the reads by FastQC software 
FastQC software was used to examine read base quality, sequence quality, length, over-
represented reads and extent of sequence duplication in FastQ files. Sequences with a mean 
Phred quality score greater than 33 were considered as good quality sequence reads and were 
used in further analysis. 
Trimming of adapters and overrepresented sequences 
I used Trimmomatic tool (Bolger et al., 2014) to remove bad quality sequences (Phred quality 
score less than 33), adapters that were used in library preparation, and overrepresented 
sequences from the raw FastQ files. This process is designed to improve mapping of sequence 
reads to the reference sequence. 
Alignment of exome sequencing reads to human reference genome  
I aligned exome sequences to the human reference genome (hg19) using Burrows Wheeler 
Aligner BWA (Li and Durbin, 2009). Reads uniquely mapped to hg19 were considered for 
further statistical analysis. Mate pair reads were used to create SAM (Sequence 
Alignment/Map format) files and these SAM files were then converted to BAM (Binary 
Alignment/Map format) files using Picard tools (McKenna et al., 2010). Reads were sorted 
according to the genomic coordinates and an index file (bai) was created for each BAM 
output file.  Multiple BAM files (of same replicate sample) originating from different 
sequencing lanes were merged using SAMtools (McKenna et al., 2010).  
Marking PCR duplicates in exome sequencing reads 
I marked PCR duplicates using Picard tools. These duplicate reads share the same sequence 
and alignment position and were generated due to artefacts introduced during PCR 
amplification during WGA and sequencing process. Marking and removal of PCR replicates 
will remove most of these artefacts and reduce the number of false positives in variant calling.  




Karyotypic sorting of reads in exome sequencing reads 
I sorted reads in the marked BAM file as per Genome Analysis Tool Kit (GATK) guidelines 
on the ordering of the chromosome contigs in BAM file. This was done to make contigs 
identical to the canonical ordering in the human reference file (hg19) I used to create these 
BAM files. 
Local alignment of exome sequences around Indels using tumour and normal samples 
To reduce false positives during variant calling, I performed local alignment of reads around 
indels using GATK software. Mate pair information between the mates in the BAM files was 
checked and fixed with Picard tools. 
Quality score recalibration and coverage statistics 
I calibrated quality scores using GATK software before calling for variants in these BAM 
files. I calculated the coverage (breadth and depth) of the aligned, de-duplicated, 
karyotypically sorted, realigned, and calibrated sequence reads using Nextera Rapid Capture 
Exome target BED files or Nimblegen exome capture target BED files
 
with BEDTools. 
Coverage statistics was performed were calculated using R program.
 
Variant calling in exome sequencing reads 
I used Strelka (Saunders et al., 2012)
 
(Bayesian), MuTect1.0 (Cibulskis et al., 2013) 
(Bayesian with 7 additional filters), VarScan2.0 (Koboldt et al., 2013) (Heuristic/Statistic), 
and Mutect2.0 to identify somatic mutations in exome sequencing reads. I used default 
settings when calling somatic mutations using Strelka v1.0.14, Mutect v1.0 and Mutect2.0. 
VarScan2.0 needs input files in pileup file format and can be generated from BAM files using 
SAMTools software.  After initial analysis on variants generated using criteria at different 
stringency levels, I adopted the following variant calling criteria that is more sensitive in 




obtaining point mutations: normal read depth of ≥ 8, tumour read depth of ≥ 1, and tumour 
allele frequency of ≥ 0.05, and tumour allele frequency of ≥ 0.005.  
Filtering somatic mutations identified by variant callers 
Following several iterations of analysis on various stringency levels for filtering mutations, I 
adopted the following filtering criteria. Normal allele frequency ≤ 0.005 was applied to 
remove most of the germline mutations.  Somatic indels from VarScan2.0 were further 
filtered using median distance from the nearest end (MDFNE) ≥ 10 criteria using 
VariantTools to remove PCR and sequencing artefacts usually found at the end of the reads 
(San Lucas et al., 2012).   
Annotation of somatic mutations 
I used Ensemble GRCh37.75
 
annotations to annotate somatic mutations using snpEff software 
(version 4.1g (build 2015-05-17)).  
Validation of somatic mutations by Sanger sequencing 
I validated a set of selected somatic mutations called by Strelka, MuTect1.0, and VarScan2.0
 
using Sanger sequencing method. PCR and sequencing primers were designed using Primer-
BLAST in NCBI (Ye et al., 2012). Primers were designed with a maximum PCR product 
length of 200 bp and sequencing products less than 160 bp. PCR was performed on WGA 
products of replicates for each sample. A list of PCR primers can be found in Appendix 2. 
2.2.7 Gene Ontology analysis of mutated genes 
I performed gene ontology (GO) analysis of mutated genes using DAVID version 6.8 (Huang 
da et al., 2009) Functional annotations for biological processes enriched in the mutated genes 
were obtained using GOTERM_ BP-FAT, which filters very broad GO terms based on a 
measured specificity of each term. 




2.2.8 Gene set enrichment analysis of mutated genes 
Gene set enrichment analysis of mutated genes was performed using R program.  Odds ratios 
and p-values were calculated using Chi square test and t-Test.  
2.2.9 RNA extraction 
RNA was isolated from cultured cells using the QIAGEN RNeasy™ MICRO (<5x10
5
 cells) 
kit according to manufacturer’s instructions (Qiagen Ltd, Crawley, UK). Briefly, cells were 
disrupted in RLT lysis buffer containing a denaturant guanidinium isothiocyanate. β-
mercaptoethanol was added to inactivate RNAse enzymes by reducing disulfide bonds in their 
native conformation. Cell lysates were then homogenized by vigorous vortexing for 1 minute. 
Samples were thoroughly mixed with 1 volume of 70% ethanol to provide ideal binding 
conditions and loaded onto the RNeasy silica membrane of MICRO spin columns. This was 
followed by centrifugation at 10000 rpm and washing of the spin column membrane with 
RWI buffer. Samples were then incubated for 15 minutes with DNAse solution (RNase-Free 
DNase Set; QIAGEN Ltd., West Sussex, UK) at room temperature to remove contaminating 
bound DNA. Salts, metabolites and cellular components were washed off in several washing 
steps with RWI, RPE and 80% ethanol buffers. Finally, the spin columns were centrifuged 
with their lids open in order to completely dry column membranes and RNA was eluted with 
DNase/RNase-free.  
RNA from formalin-fixed paraffin-embedded (FFPE) samples RecoverAll™ Total Nucleic 
Acid Isolation Kit for FFPE (ThermoFisher SCIENTIFIC Ltd.). Several FFPE sections at 80 
µm thickness were incubated in 1ml 100% xylene for 3 minutes at 50 C for 3 minutes in 
RNAse-free Eppendorf tube. This tube was centrifuged at maximum speed for 2 minutes and 
xylene was discarded. Then, the pellet was washed twice with 1 mL 100% ethanol. Pellet was 
air dried to remove any residual ethanol. To this pellet protease-digestion buffer was added 




and incubated at 50 C for 30 minutes. Then, isolation buffer was added to the tube and mixed 
before passing through a filter cartridge. Filter cartridge was then washed with 700 µl of 
Wash1 buffer and centrifuge for 1 minute; I repeated this step with 500 µl Wash2 buffer 
followed by Wash3 buffers. DNase buffer was added to the filter cartridge and incubated for 
30 minutes. I then repeated the earlier wash up steps with Wash 1-3 buffers. Cartridge was 
then centrifuged for 1 minute to remove any residual fluid. Then, I added 60 µl of nuclease-
free water at room temperature. This eluate was stored at -20 C until further use.  
2.2.10 Specific target amplification and 48:48 dynamic (Fluidigm) array analysis 
A subset of EBV transcripts (n=45) that include examples of immediate early (IE),  early (E) 
and late (L) lytic cycle genes in addition to latent cycle genes were quantified by Real-Time 
PCR using a 48:48 dynamic array as described (Spurgeon et al., 2008, Tierney et al., 2015). 
These transcripts include 23 latent, 2 immediate early (IE), 11 early (E), 6 late (L) lytic cycle 
transcripts; 3 poorly characterized RNAs (LF1, LF2 and LF3) and 4 non-coding RNAs 
(BARTs and EBERs)). 3 cellular housekeeping genes (B2M, PGK1 and GAPDH) were also 
included in this analysis.  Briefly, 50 ng RNA was used for cDNA synthesis according to the 
manufacturer’s protocol (qScript, VWR). An aliquot of cDNA was then subjected to specific 
target amplification (STA) to pre-amplify 45 EBV amplicons and 3 cellular amplicons in the 
cDNA, RNA (non-reverse transcription control) and AQ-plasmid standards (ranging from 1 to 
10
5
 copies/µl) prior to Fluidigm assay (12- 14 cycles of PCR). Pre-amplified samples were 
loaded onto 48.48 Dynamic Array™ IFC and Real-Time PCR was performed using 
BioMark™ HD System according to manufacturer’s guidelines (Fluidigm Corporation). Real-
Time PCR data was analysed using Biomark & EP1 software (Fluidigm Corporation). After 
subtraction of non-RT values (where present), individual gene expression values of each 
sample were normalized for PGK1 expression. Samples with low or no cellular gene 




expression (B2M, GAPDH, and PGK1) and/or with low EBER expression were excluded 
from further analysis. 
2.2.11 Plasmid vectors 
BILF1 gene expression-vector with a 5′-HA tag and the alternative vector, pLZRS-IRES-
GFP, were obtained from Dr. Jianmin Zuo, Institute of Genomics and Cancer Sciences, 
University of Birmingham  (Zuo et al., 2009). 
2.2.12  BILF1-transfection in DG75 and germinal centre B cells 
In order to identify cellular target genes for EBV gene BILF1 in BL cell line DG75 and 
germinal centre B (GC B) cells, cultured DG-75 cells and GC B cells obtained from tonsillar 
tissue were transfected with BILF1 expression-plasmid. GFP-positive cells were sorted and 
RNA sequencing was performed on the either RNA (DG-75) or amplified RNA (GC B cells) 
from these cells. These methods are described in detail in the following sections.  
All the experimental work on GC B cells in the next sections was performed by Dr. Katerina 
Vrzalikova at the Institute of Cancer and Genomic Sciences, University of Birmingham, UK. 
2.2.13 Purification of tonsillar mononuclear cells (TMCs) 
Tonsils were minced with a scalpel in cold RPMI 1640 medium (Sigma-Aldrich Ltd., 
Gillingham, UK) without foetal calf serum, supplemented with 2mM L-glutamine (Invitrogen 
Ltd., Paisley, UK), 0.5% ciprofloxacin (Bayer, Newbury, UK) and 1% penicillin-streptomycin 
solution (Sigma-Aldrich Ltd., Gillingham, UK). Tonsillar mononuclear cells (TMCs) were 
then isolated by Ficoll-Isopaque centrifugation. 15 ml of Lymphoprep® solution (Axis-Shield 
Diagnostics Ltd. UK, Dundee, UK) was pipetted into universal tubes and carefully overlaid 
with media containing a mixture of tonsillar cells. Tubes were then centrifuged at 2200 rpm at 
room temperature for 30 minutes creating the following visible layers: plasma and other 




constituents (top), mononuclear cells (middle), Ficoll-Paque, and erythrocytes and 
granulocytes debris (pellet). The layer of mononuclear cells was transferred to a fresh tube, 
washed twice with cold media and once with cold autoMACS™ Rinsing Solution 
(autoMACS; Miltenyi Biotec Ltd, Surrey, UK) supplemented with 1% penicillin-streptomycin 
solution (Sigma-Aldrich Company Ltd., Gillingham, UK), 0.5% ciprofloxacin (Bayer, 
Newbury, UK) and 5% MACS® BSA Stock Solution (Miltenyi Biotec Ltd, Surrey, UK); 
each time centrifuged at 900 rpm at 4°C for 10 minutes. 
2.2.14 Purification of GC B cells 
GC B cells (CD10+) were isolated from TMCs by positive enrichment of CD10+ cells using 
magnetic separation with anti-CD10-Phycoerythrin (eBioH35-17.2 (H35-17.2) PE) 
(eBioscience, San Diego, CA, USA), anti-PE microbeads and LS columns (both Miltenyi 
Biotec Ltd, Surrey, UK). Magnet and autoMACS buffer were pre-cooled at 4°C and all 
purification steps performed on ice to prevent rapid apoptosis of GC B cells and unspecific 
antibody binding. First, 10
7
 TMCs were resuspended in 100 µl of autoMACS and CD10-PE 
antibody was added at 1:50 dilution. Following incubation at 4°C for 15 minutes, cells were 
washed with 10 volumes of autoMACS and centrifuged at 900 rpm at 4°C for 10 minutes. 10
7
 
CD10-PE-labelled TMCs were then resuspended in 80 µl of autoMACS and 20 µl of anti-PE 
beads were added. Following incubation at 4°C for 15 minutes, cells were washed with 10 
volumes of autoMACS and centrifuged at 900 rpm at 4°C for 10 minutes. Finally, 10
6
 CD10-
PE-anti-PE-beads-labelled TMCs were resuspended in 500 µl of autoMACS and transferred 
on pre-washed filters (Partec UK Limited, Canterbury, UK) placed on LS columns. When the 
cells passed through; columns and filters were washed three times with 3 ml of autoMACS. 
Finally, columns were removed from the magnet and retained population of CD10+ positive 
GC B cells was eluted with 5 ml of autoMACS.  




2.2.15 Transfection of GC B cells and DG-75 cell line by nucleofection 
10 µg of BILF1 or control plasmid with the marker gene GFP were transiently transfected 
into GC B cells using non-viral Nucleofector technology with the Nucleofector II device 
(Amaxa GmbH, Cologne, Germany). For each reaction, 10
7
 cells were pelleted by 
centrifugation in universal tubes at 636 rpm at room temperature for 10 minutes. Supernatant 
was completely removed and the cell pellets were resuspended in 100 μL of Nucleofector 
reaction mix consisting of Cell Line Nucleofector Solution B mixed with Supplement I. The 
plasmids were combined with the cell suspensions and transferred to a 0.1cm cuvette. The 
cuvette was placed in to the Nucleofector II device and U-15 program was selected. 
Following the pulse, the entire contents of the cuvette were immediately transferred into 24-
well plates (Nalge Europe Ltd., Hereford, UK) using plastic pipettes and a small amount of 
pre-warmed RPMI. The 24-well plates were prepared in advance and filled with 2 ml of 
RPMI containing supplemented with 20% of foetal calf serum.  Cells were then incubated at 
37°C in 5% CO2 for 16 hours (overnight) prior to MoFlo enrichment of transfected cells.   
2 µg of BILF1 or control plasmid with the marker gene GFP were transiently transfected into 
DG-75 cells using the Nucleofector II device. For each reaction, 2x10
6
 cells were centrifuged 
at 720 rpm at room temperature for 10 minutes. After removing the supernatant, the cell 
pellets were resuspended in 100 μL of Nucleofector reaction mix consisting of Cell Line 
Nucleofector Solution V mixed with Supplement I. The plasmids were combined with the cell 
suspensions and transferred to a 0.1cm cuvette. The cuvette was placed in to the Nucleofector 
II device and R-013 program was selected. The latter steps were same as for the GC B cell 
transfection, mentioned in the paragraph above.  




2.2.16  MoFlo enrichment of transfected GC B cells and DG-75 cell line 
Following incubation, transfected GC B cells were pooled together, washed twice with cold 
autoMACS and pelleted at 636 rpm at 4°C for 10 minutes The cell pellets were resuspended 
in 250 µl of autoMACS and re-stained with anti-CD10-Phycoerythrin (PE) (eBioscience, San 
Diego, CA, USA) antibody. Following 10 minutes incubation at 4°C in the dark, cells were 
washed with 6 ml of autoMACS and centrifuged again at 636 rpm at 4°C for 10 minutes. 
Cells were passed through pre-washed filters into sorting tubes and kept on ice in the dark. 
The PE-labelled GFP-positive cells were collected by FACS on a MoFlo sorter (Dako 
Cytomation, Colorado, USA) using propidium iodide (Sigma-Aldrich Ltd., Gillingham, UK) 
to distinguish between viable and dead cells. The transfection efficiency of the living cells 
was generally between 10%-20% and purity of the collected cells was >95%. 
Transfected DG-75 cells were enriched in a similar manner to those of GC B cells as 
described above. Transfection efficiency of the living cells was generally between 15%-20% 
and purity of the collected cells was >95%. Real-time PCR were performed to validate 
successful BILF1 gene expression in transfected cells. 
2.2.17 RNA extraction 
RNA was isolated from BILF1-transfected and empty vector-transfected GC B-cells 
(triplicates) and DG-75 cells (triplicates) as described in methods section 2.7. Quality of 
isolated RNA was determined with a Bioanalyzer 2100 (Agilent, Waldbronn, Germany). Only 
those samples with a 260/280 nm ratio between 1.8 and 2.1 and a 28S/18S ratio within 1.5-2.0 
were processed further.  
2.2.18 Amplification of RNA extracted from BILF1-transfected GC B cells 
As the amount of RNA obtained from BILF1-transfected GC B-cells was not sufficient for 
RNA sequencing, Dr. Katerina Vrzalikova amplified the extracted RNA using Ovation RNA-




Seq System V2 (NuGEN Technologies, San Carlos, California), according to the 
manufacturer’s protocol.   
2.2.19  RNA sequencing 
CDNA obtained from amplification of BILF1-transfected GC B-cells was sent for library 
preparation (TruSeq DNA Nano gel free library (350 bp insert)) and RNA sequencing to 
Edinburgh Genomics (HiSeq2500 50 base paired end sequencing). RNA isolated from BILF1 
and empty vector-transfected DG-75 cells (triplicates) were sent to Macrogen Inc, Seoul, 
Republic of South Korea (http://www.macrogen.com/eng/business/ngs_overview.html) for 
Illumina 100 bp paired-end RNA sequencing.  
2.2.20 RNA sequencing data analysis 
I aligned RNA sequence reads to hg19 and EBV (NC_007605.1) reference sequence using 
Rsubread aligner (Liao et al., 2013). Mapped sequencing reads were assigned to hg19 refGene 
and EBV genes using featureCounts function. RefGene exon coordinates were obtained from 
UCSC table browser. Gene symbol and description was obtained from NCBI gene database. 
EBV exon coordinates were obtained from Eric Flemington's lab 
(http://www.flemingtonlab.com/Resources/chrEBV(B_95_8_Raji).ann). 
Refinement of EBV-annotations  
I made the following changes to the EBV gene annotations obtained from NCBI 
(AJ507799.2), so that it can be used for calculating featureCounts from RNA sequencing data. 
A). I limited the annotation to the known EBV ORFs (coding sequence or CDS) as these 
coordinates are known exactly. I removed the ORFs of BWRF1 (in the W repeats) which has 
recently been shown to give rise to a non- coding RNA of unknown function and does not 
produce protein to the best of my knowledge. B). For RPMS1 and A73, I included the 
coordinates of the exons as the ORFs of RPMS1 and A73 transcripts do not produce 




detectable protein.  C). I excluded the annotations that refer to just exons as, in many cases, 
the true starts or ends of these transcripts are not precisely mapped. The exceptions are the 
alternatively spliced latent transcripts which are well characterised and here I have included 
notes on the untranslated regions (UTR). Thus for the EBNA transcripts I have labelled the 
C1, C2 and W0 exons. W1 and W2 exons encode EBNA-LP but are also present in all EBNA 
transcripts as a common 5’ leader sequence. Thus the presence of W1 and W2 reads does not 
imply expression of EBNA-LP. D). I used coordinates of the miRNA precursors not the 
mature miRNAs, obtained from miRBase (Griffiths-Jones et al., 2006). E). I excluded all 
annotation of regulatory regions and TR. F). The UTR of LMP1 overlapped with CDS of 
BNLF2A and BNLF2B and was therefore removed. G). Redundant overlapping entries for the 
same genes were removed, including LMP2A (genomic coordinate position: 1574-1682), 
LMP2B (59-272), LMP2B (1574-1682). 
Data was normalized using TMM (trimmed mean of M values) method using edgeR 
(Robinson et al., 2010). EBV genes were not used in the normalization of human genes. The 
experiment was paired with each BILF1 treated replicate paired with one control-treated 
replicate. Differentially expressed genes were identified using edgeR with pair number and 
BILF1 status as explanatory variables. 26438 genes (from hg19 refGene) were used to 
generate these differentially expressed genes. For transfected samples, the following criteria 
were applied for obtaining details of differentially expressed genes:  
1. First, differentially expressed gene lists were generated without any CPM criterion, 
2. For upregulated genes, at least two BILF1-transfected samples (in triplicate) must 
have >=1 CPM, and  
3. For downregulated genes: at least two Vector-transfected samples (in triplicate) must have 
>=1 CPM. 




2.2.21   Pathway analysis 
I used Molecular Signatures Database (MSigDB) (Liberzon et al., 2015) to identify 
molecular functions, biological processes, and pathways that were significantly enriched in 
differentially expressed genes. I calculated P value and FDR q-value for the above analyses 
to determine statistical significance of enrichment. 
2.2.22   Lytic cycle induction in Akata cells 
I induced Akata cells into lytic cycle using anti-IgG Capell Ab as follows: Cultured Akata 
cells were split 24 hours before required. Cells were then transferred to a 50ml centrifuge tube 
and spun down at 1600 RPM for 5 minutes. Supernatant was discarded and cell pellet was 
washed once in PBS, and cells were spun-down one more time and supernatant was 
discarded. Cells were resuspended in RPMI + 1% FCS at a concentration of 4 x 106 per ml 
and an aliquot was removed as a negative control. To the remaining cells, Capell anti-IgG 
(ThermoFisher Scientific Inc.)was added to a final concentration of 0.1% v/v. Cells were 
transferred to a 12-well plate (4 x 10
6
 cells per well) and incubated at 37°C for 3 h. 3 ml of 
RPMI + 10% FCS to each well and  incubated at 37°C.  Cells were harvested after 48 hours 
using FACS which was performed by Dr. Rosemary Tierney at the Institute of Cancer and 
Genomic Sciences, University of Birmingham, UK. 
2.2.23 RNA in situ hybridization experiment by RNAScope 
This experiment was performed by Dr. Max Robinson at the Centre for Oral Health Research, 
Newcastle University, UK, using the manufacturer’s protocol. 
BILF-1 RNA in situ hybridisation (ISH) was carried out on 4μm formalin-fixed paraffin-
embedded (FFPE) sections using proprietary reagents (RNAscope, Advanced Cell 
Diagnostics Inc.).  Sections were deparaffinised and pre-treated with heat and protease before 
hybridisation with target-specific probes: BILF-1, PPIB (constitutively expressed endogenous 




gene; positive control probe) and dapB (bacterial mRNA; negative control probe) in a 
dedicated hybridization oven (HybEZ oven, Advanced Cell Diagnostics Inc.).  Probe 
hybridization was detected using the chromogen 3,3’-diaminobenzidine (DAB). BILF-1 RNA 
ISH was optimized using FFPE cell pellets, namely Akata cells (negative control for EBV 
gene expression), EBV-positive Akata cells (positive control for EBV expression), lytic cycle-
induced Akata cells (as lytic cycle positive control).  PPIB RNA ISH was used to demonstrate 
the presence of hybridisable RNA and dapB RNA ISH was used assess non-specific 
hybridisation.  Test samples were classified as BILF-1 positive or negative, a positive result 
was defined as any brown reaction product that co-localised with the malignant cells, a 
negative result was defined as no staining with BILF-1, but evidence of staining with PPIB 
RNA ISH (positive control probe). 




2.2.24 BILF1 antibody peptide design and Immunohistochemistry 
BILF1 antibody was commercially not available, so I designed a custom antibody against 








BILF1 is a membrane protein and the predicted topology is shown in Figure 18. 
A homology search (BLAST) was performed for BILF1 peptide sequence in order to optimise 
any wanted or minimise any unwanted homology to other proteins. The following two 
peptides were selected for immunization programme in rabbits: 
1) aa 298-312: h- C+TVTARYFRRVPSQST –oh  (cytoplasmic tail),  
2) 159-174: ac- ITMGPDANLNRGPNMC –nh2   (part of an extracellular loop) 
These two peptides are 100% conserved in B95, Akata, GD1, C666 and Ag876 (type 2).  
BILF1 protein expression in FFPE sections was performed using the method described in 
section 1.12.2 using BILF1 antibody at 1:20 dilutions. 
 






Figure 18. Serpentine diagram of the human EBV BILF1 receptor (taken from
 
Paulsen et al., 
2005).  In this figure, seven transmembrane helices of BILF1 receptor can be seen. 
Differences between human EBV and rhesus EBV are indicated in black on grey, and 
identical amino acids are indicated in black on white. Computer-predicted glycosylation sites 
are indicated with g, and predicted phosphorylation sites are indicated with p. The alternative 
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3. IDENTIFICATION AND ANALYSIS OF SOMATIC 
MUTATIONS IN PAEDIATRIC HODGKIN LYMPHOMA 
 
3.1 Introduction 
Hodgkin lymphoma (HL) is a malignancy derived from the germinal centre or post-germinal 
centre stages of B cell differentiation that is characterised by the presence of large, often 
multinucleated, malignant cells known as Hodgkin/Reed-Sternberg (HRS) cells. HRS cells 
often show chromosomal instability with frequent aneuploidy, including tetraploidy or near-
tetraploidy (Falzetti et al., 1999, Watanabe et al., 2004). Although chromosomal instability is 
strongly implicated in the pathogenesis of HL, the mechanisms responsible have yet to be 
elucidated.  
Unusually for a cancer, the malignant HRS cells of HL comprise only a small fraction (< 1%) 
of the total tumour mass and are surrounded by a prominent tumour microenvironment that 
promotes HRS cell survival and evasion of tumour-specific immune responses (Kuppers et 
al., 2005, Kuppers et al., 2002). The relative paucity of HRS cells has so far restricted global 
genetic analyses of this tumour to only two exome sequencing studies comprising a total of 
ten primary cases and seven HRS-derived cell lines (Reichel et al., 2015, Liu et al., 2014). For 
this reason our understanding of the contribution of recurrent somatic genetic alterations to 
the pathogenesis of HL has been gained mainly from the sequencing of individual genes 
(Cabannes et al., 1999, Jungnickel et al., 2000, Emmerich et al., 2003, Lake et al., 2009, 
Gunawardana et al., 2014, Joos et al., 2003, Weniger et al., 2006a, Schmitz et al., 2009). 
These studies have revealed the existence of recurrent somatic mutations that deregulate 
multiple cell signalling pathways contributing to HRS cell survival and proliferation. For 
example, regulatory and signal transducing proteins in the nuclear factor kappa B (NF-κB) 
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pathway are frequently mutated, resulting in constitutive NF-κB signalling (Jungnickel et al., 
2000, Emmerich et al., 2003, Lake et al., 2009, Schmitz et al., 2009). Altered signalling 
through JAK/STAT proteins in HRS cells also frequently results from either gain-of-function 
mutations in JAK2 or inactivation of SOCS1 or PTPN1/PTPB1 (Gunawardana et al., 2014, 
Joos et al., 2003, Weniger et al., 2006a). 
The Epstein-Barr virus (EBV) is present in HRS cells in around one-third of cases (Murray et 
al., 1992b, Pallesen et al., 1991a). EBV latent genes expressed in HRS cells include the EBV 
oncogene, latent membrane protein-1 (LMP1), which alone is capable of driving the 
constitutive activation of many of the signalling pathways known to be aberrantly expressed 
in HRS cells, including both NF-κB and JAK/STAT (Huen et al., 1995, Eliopoulos et al., 
2003, Gires et al., 1999, Bolger et al., 2014). The observation that mutations in these cell 
signalling pathways are more frequent in EBV-negative, compared with EBV-positive, cases 
of HL suggests that EBV and cellular mutations provide mutually exclusive means to the 
same pathogenic end-point (Schmitz et al., 2009).  
In this study I have used whole-exome sequencing following whole genome amplification 
(WGA) of HRS cells micro-dissected from 13 paediatric HL to reveal the genomic landscape 
of childhood HL. The data point to the mitotic spindle as a key pathogenic target in HL, the 
disruption of which can occur either by somatic mutation or EBV infection. The results not 
only provide a potential mechanistic explanation for the chromosome instability and 
aneuploidy frequently observed in HRS cells, but also offer potential new insights into the 
mechanisms underpinning resistance to spindle-damaging and topoisomerase poisons 
routinely used for the treatment of patients with HL. 
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3.2 Identification and analysis of somatic mutations 
 
3.2.1 Microgram amounts of good quality WGA products were obtained from 
150 microdissected tumour cells 
Using the methods set out in section 2 of Materials and Methods, I amplified the genomes of 
150 (2 replicates) HRS cells microdissected from tissue sections of each sample. The whole 
genome amplified products ranged between 200 base pairs (bp) and 1000 bp (1kbp) (Figure 
19A) and the majority of these fragments ranged between 200 and 500 bp (Figure 19B).  I 
obtained sufficient quantity (between 2.4 and 4.7 μg of DNA when measured on Qubit) and 
quality (between 1.8 and 2 for 260/280 ratio when measured on Nanodrop) of DNA for 
exome sequencing. Quality measurements for the whole genome amplified samples along 
with their matched blood DNA are detailed in the exome sequencing submission table 
(Appendix 1). WGA products were checked for coverage by PCR and Sanger sequencing 
using 8 housekeeping genes (PTEN, BRAF, PCM1, JAK2, ATM, PIK3CA, TNFAIP3, and 
BCR) (Appendix 2). Similar experiments on the microdissected HRS cells from FFPE 
samples yielded more fragmented (WGA product size lower than 200 bp) (Figure 19C).  Size 
distribution of WGA products obtained from the DNA extracted FFPE samples has similar 
WGA product size distribution to those from microdissected cells from flash frozen samples, 
however these DNA extracted FFPE samples needed greater amount of input DNA (at least 1 
ng) (Figure 19D). 
 




Figure 19. Size distribution for whole genome amplified products.  A. WGA products 
from 150 HRS cells for patients S2, S6 and S9 in the top lane and S10, S5, NC-LCM 
(negative control from LCM procedure onwards, i.e. no DNA), PC (positive control- 
genomic DNA of L-591 cell line) in the bottom lane were separated on 2% agarose gel. 
1Kbp ladder used to mark the size of WGA fragments. B. Bioanalyzer image for a 
typical WGA product showing the majority of the WGA fragments were between 200 
bp and 500 bp in length. C. Size distribution of WGA products obtained from 
microdissected FFPE samples, showing smaller fragment size compared to the frozen 
samples used in the same experiment set up (first 3 wells). D. Size distribution of WGA 
products obtained from the DNA extracted FFPE samples. WGA product sizes are 
much lower in the microdissected FFPE samples (C) compared to those amplified from 
the DNA extracted FFPE samples (D). 
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3.2.2 Good quality exome sequence reads were obtained for all samples 
Mean base quality (Phred) scores for reads across all positions (1-100) were higher than 33 in 
all samples, as shown in a typical FastQ file (Figure 20A). Base quality (Phred) scores for 
positions on either ends (~5 bases) typically ranged between 30 and 33 in all tumour exome 
sequences, whereas in matched normal exome sequences these scores were higher than 33 at 
these positions. All the reads had Phred quality score higher than 26 and the majority (> 90%) 
of the reads had a Phred quality score of 37 or higher (Figure 20B). 
3.2.3 Coverage of sequencing reads of tumour DNA  
Exome sequencing data were obtained from one blood DNA sample and two separate whole 
genome amplification products of tumour DNA for each of the 13 patients. The number of 
raw exome sequencing reads in tumour samples ranged approximately from 13.68 million to 
78.02 million, whereas in normal blood samples this range was from 26.54 million to 173.37 
million. The expected number of reads from NGS providers for non-microdissected and un-
amplified samples is ~37 million; however, I received less than 30 million reads for more 
than half of the tumour samples.  In tumour samples the number of de-duplicated reads 
mapped to hg19 ranged from 10.16 million to 39.09 million, whereas in matched normal 
samples this range was from 23.07 million to 144.25 million (Appendix 3). As expected, the 
number of mapped reads in the majority (12/13) of normal samples (mean= 60.54 million 
reads) was higher than those of the tumour samples (mean= 20.10 million reads). The 
percentage of reads mapped to the human genome after removing PCR duplicates ranged 
between 71.83 and 86.73 (mean = 79.41%) in tumour exomes, whereas a higher percentage 
of reads were mapped in matched normal (ranged between 81.56 and 90.74; mean = 85.29%). 
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3.2.4 Effective coverage of sequencing reads for the identification of somatic mutations 
in the exomes 
In the approach undertaken here, the identification of a somatic mutation at a particular base 
position requires that the base is covered by at least one read from both WGA products and at 
least 8 reads from the matched blood DNA (defined variant calling criteria for tumour 
sequences see Materials and Methods section 2). The percentage of target regions in the 
exome covered by tumour sequences at 1x read depth in 13 samples ranged from 44.80 to  
91.24 (mean = 70.65%) as shown in Table 7. The percentage of target regions in exome 
covered by both tumour replicate sequences at 1x read depth in 13 samples ranged from 
44.18 to 71.16 (mean=56.42 %) as shown in Figure 21 . As expected, higher coverage was 
observed at x8 read depth in normal blood sequences (ranged from 82.25% to 96.50%) with a 
mean coverage of 91.54. Furthermore, the percentage of the target regions covered by tumour 
replicates and matched normal for each sample at the defined variant calling criteria ranged 
from 40.59 to 69.16 with a mean coverage of 54.49%. 
This low coverage is due to the very high stringency criteria that I have applied to filter false 
positive mutations arising from the PCR amplification. I understand that I may miss some 
valuable information but my priority was to obtain good quality mutation data. 





Figure 20. Base and sequence quality scores for a typical FastQ file in my samples. A. Inter-
quartile range (25-75%) was shown in yellow box. Upper and lower whiskers represent the 
10% and 90% points. Central red line was the median value and the blue line represents mean 
quality. Bases on either end of the 100 bp reads show a mean base quality Phred score below 
33. B. Sequence quality score distribution for the same sample as shown in Figure 6 (see 
later) showing majority of reads with Phred quality score of 37 or higher. 
 
 
Figure 21. Coverage graph showing de-duplicated sequences mapped to hg19 in 13 HL 
samples.  Over 70% of tumour exome reads mapped to hg19 (at read depth of x1) were 
retained after removing duplicate sequencing reads, whereas a higher percentage (>81%) of 
de-duplicated reads were mapped to hg19 in matched normal exomes in 13 HL samples (at 
read depth of x8).  
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Table 7. Coverage of 13 samples at variant calling criteria. 
*N = matched normal samples; 1T = first tumour replicate; 2T = second tumour replicate; 
1T+2T = covered in both tumour replicates; N+1T+2T = covered in both tumour replicates 
(1T and 2T) at read depth of x1 and matched normal (N) at read depth of x8. 
Sample 
Coverage in 
N* at x8 read 
depth (%) 
Coverage in 
1T* at x 1read 
depth (%) 
Coverage in 
2T* at x1 read 
depth (%) 
Coverage in 







S1 90.40 73.11 58.75 50.58 49.02 
S2 91.69 91.24 44.80 44.18 42.88 
S3 82.25 58.94 63.90 44.69 40.59 
S4 91.26 51.42 89.69 51.11 50.07 
S5 90.21 81.85 71.57 66.69 63.87 
S6 90.30 72.94 58.40 47.16 46.77 
S7 96.50 64.94 59.99 47.35 47.08 
S8 91.90 75.57 82.26 71.16 69.16 
S9 90.07 74.14 84.09 67.86 62.62 
S10 91.87 77.44 77.89 65.53 61.37 
S11 95.31 65.98 67.03 53.15 52.63 
S12 93.52 71.16 71.64 60.21 59.28 
S13 94.71 76.33 71.83 63.71 63.03 
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3.3 Identification of somatic variants in 13 Hodgkin lymphoma exomes 
As described in the Materials and Methods (section 2.6.9), four variant callers (Strelka 
v1.0.14, Mutect v1.0, VarScan2.0, and MuTect v2.0) were used for calling mutations in my 
cohort. I briefly summarise below the analyses I performed with these variant callers.  
3.3.1 Variant calling by Strelka v1.0.14 and validation of selected mutations 
Strelka v1.0.14 identified a total of 2356 somatic point mutations (sSNVs) in 1647 genes and 
305 somatic indels (insertions/deletions) in 236 genes. Of these, 1331 were protein-altering 
SNVs and 182 were somatic protein-altering indels. Seven mutations in two genes called by 
Strelka (Table 8)  with a tumour allele frequency (TAF) of > 30% were selected for validation 
by Sanger sequencing.  2/6 mutations (33.33%) with good quality Sanger sequences were 
validated. An example of a mutation detected by exome sequencing but not validated by 
Sanger sequencing is shown in Figure 22.  
3.3.2 Variant calling by Mutect v1.0 and validation of selected mutations 
Mutect v1.0
 
called a total of 654 sSNVs  in 858 genes including 454 protein-altering 
mutations in 433 genes. A total of 18 sSNVs identified by Mutect 1.0 and with a tumour allele 
frequency (TAF) of > 30% were selected for validation by Sanger sequencing. Good quality 
Sanger sequences were obtained for 14/18 sSNVs. 13/14 of the sequence variants were 
detected by Sanger sequencing (Table 9). Figure 23 shows an example of a mutation that was 
detected by exome sequencing and validated by Sanger sequencing in at least one of two 
WGA replicates.  
3.3.3 Variant calling by VarScan 2.0 and validation of selected mutations 
Mutect v1.0 software is designed to  call only somatic point mutations. For this reason  
VarScan2.0
73 
was used to identify indels. 681 somatic indels in 856 genes, including 521 
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protein-altering indels in 470 genes were called by VarScan2.0. VarScan2 also called 3294 
sSNVs in 2075 genes. Eight deletions called by VarScan2.0 and with a TAF >30% were 
selected for validation by Sanger sequencing. I obtained good quality Sanger sequences for 
only 4/8 deletions and these four indels showed the same base changes in Sanger sequences to 
those from exome data (Table 10).  
3.3.4 Variant calling by Mutect v2.0 
Mutect v2.0 (which can call both SNVs and indels) was available at the later stages of 
analysis, and it identified only 76 sSNVs and 11 somatic indels in 13 HL exomes. This was 
attributed to the more stringent criteria that Mutect v2.0 employs for variant calling and 
filtering. Unfortunately, further documentation was not available on this software at that time 
and so I was unable to deduce the factors responsible for the low mutation call rate in Mutect 
v2.0. For this reason I did not use Mutect v2.0 further.  
Figure 24A shows the overlap of somatic point mutations detected by these variant callers and 
Figure 24B the overlap of insertions/deletions. 167 somatic point mutations were shared 
among Mutect v1.0, Strelka v1.0.14, and VarScan2. Only 2 indels were shared between 
Mutect v2.0, Strelka v1.0.14, and VarScan2.0. The large variation in the number of calls and 
highly variable agreement from the four variant callers used in this analysis in my sample 
cohort could be due to differences in the sensitivity of the callers to sequencing depth as 
reported in previous studies (Krøigård et al., 2016).  
Mutect v1.0 and VarScan2.0 were used for all subsequent analyses in this study as these two 
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Table 8. Sanger sequencing validation of sSNVs called by Strelka (*chromosome_base 
position_refrence allele_variant allele; **AA= amino acid). 
Primer Mutations* AA** change Samples Sanger sequencing 
ACVR1_PCR1 
chr2_158594977_A_G I457T S3 NOT VALIDATED 
chr2_158594977_A_G I457T S4 NOT VALIDATED 
chr2_158594968_C_G R460T S4 NOT VALIDATED 
chr2_158594968_C_G R460T S8 NOT VALIDATED 
chr2_158594968_C_T R460K S11 VALIDATED 
ACVR1_PCR2 chr2_158595062_G_T P429T S5 NOT VALIDATED 
MSH2_PCR1 chr2_47656991_G_A R396K S7 NOT VALIDATED 
MSH2_PCR1 chr2_47656991_G_A R396K S12 NOT VALIDATED 
MSH2_PCR2 chr2_47707858_A_G I828V S8 NOT VALIDATED 
MSH2_PCR3 chr2_47705572_C_T A791V S11 VALIDATED 
 
Table 9. Sanger sequencing data for 14 sSNVs detected by Mutect v1.0, which confirmed 13 
of the point mutations identified by exome sequencing. (*Stop-gained mutation) 
Gene Mutation AA  change Sample Sanger validation 
AKT2 chr19_40743884_C_T D275N S3 VALIDATED 
FERMT1 chr20_6057912_C_T G648S S3 VALIDATED 
HLA-DQA1 chr6_32609192_A_G E63G S3 VALIDATED 
NR1H4 chr12_100926334_T_C C192R S3 VALIDATED 
PIWIL4 chr11_94335040_G_A W487* S3 VALIDATED 
S100B chr21_48022204_G_T S42Y S3 VALIDATED 
ABCA1 chr9_107576477_A_T F1275I S4 VALIDATED 
BCR chr22_23596126_C_T R474W S5 VALIDATED 
DPYD chr1_97547923_C_T G957D S5 VALIDATED 
F5 chr1_169511277_C_A P1274L S5 VALIDATED 
DPYD chr1_97915760_G_T S587Y S7 VALIDATED 
LIFR chr5_38496642_G_T S576* S11 VALIDATED 
PTPN14 chr1_214551424_C_T A856T S11 VALIDATED 
MLLT4 chr6_168348563_C_A A1187E S12 NOT VALIDATED 
 
Table 10. Sanger sequencing data was obtained for four somatic deletions identified by 
Varscan 2.0 and all of which confirmed the deletions identified by exome sequencing (*Stop-
gained mutation). 
Gene Mutation AA change Samples Sanger validation 
WBP11 chr12_14949846_TC_T R94* S3 VALIDATED 
CTSA chr20_44521061_TCC_T P147* S7 VALIDATED 
ST8SIA6 chr10_17363320_CT_C K251* S11 VALIDATED 
SMG1 chr16_18847426_TG_T G2629* S12 VALIDATED 




Figure 22.   Example of a variant called by Strelka which was not detected by  Sanger sequencing. A. G->T transversion (highlighted in 
rectangle) in ACVR1 gene in sample S5 at 158595062 in Chr2 was absent in (B) sequences obtained by Sanger sequencing method for 
ACVR1 gene. 




Figure 23.    Detection of a mutation in NR1H4 detected by Mutect 1.0 by Sanger sequencing. A. Integrated Genomic Viewer image 
showing  T->C transition in NR1H4 at position 100926334 in Chromosome 12   and also detected in both replicates of sample S3 bySanger 
sequencing (B) . 




Figure 24. Variant caller comparison. A. Overlap of somatic point mutations among Mutect 
v1.0, Strelka v1.0.14, and VarScan2. B. Overlap of somatic insertions/deletions among 
Mutect v2.0, Strelka v1.0.14, and VarScan2. 
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3.4 Whole exome sequencing reveals recurrent somatic mutations in my 
cohort of 13 paediatric Hodgkin lymphoma samples 
 
3.4.1 Types of mutations observed  
A total number of 1335 somatic mutations were observed in 13 paediatric HL samples of 
which 654 were point mutations and 681 were indels. 16 major categories of mutations that 
were observed in my sample cohort were:  3' Flank, 3' UTR, 5' Flank, 5' UTR, Intron, 
Intergenic, RNA, Targeted Region, Silent, In Frame Deletions, In Frame Insertions, Missense, 
Splice site, Frame Shift Deletions, Frame Shift Insertions, and Nonsense mutations (Table 
11). Most of  the mutations were either missense or frameshift indels (Table 11). Annotation 
of these mutations was performed using snpEff and GRCh37.75 database which revealed that 
the 1335 mutations are within or near 1622 genes. A total of 975 protein-altering mutations 
were identified in 857 genes. The number of protein-altering mutations was significantly 
higher than the non-protein-altering mutations (t-Test; p= 0.0016). The number of mutations 
per sample ranged between 36 and 213 (range 30-156 for protein-altering mutations). An 
average of 102 mutations (median = 104) were observed per sample, whereas the mean and 
median number of protein-altering mutations were 75 and 75, respectively. The mean 
mutation rate per million bases (Mb) was 5.18/Mb (range 1.55-9.11). The mean mutation rate 
per Mb for protein-altering mutations was 3.77 (1.29-6.67).  
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Table 11.  Types of mutations observed in my cohort of 13 paediatric Hodgkin lymphoma samples. 
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Total 63 110 131 76 185 51 104 52 36 45 111 158 213 1335 
Mutation rate per 
Mb 3.46 6.91 8.70 4.09 7.81 2.94 5.95 2.03 1.55 1.98 5.68 7.18 9.11  
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3.4.2 Frequently mutated genes in paediatric Hodgkin lymphoma samples 
Two hundred genes with somatic mutations in two or more paediatric Hodgkin lymphoma 
samples are shown in Appendix 4, of which KLF6 and SMG1 were mutated in six and five 
samples, respectively.  Analysis of genes with protein-altering mutations revealed 
considerable heterogeneity between samples. Fifty genes with protein-altering mutations in 
two or more paediatric Hodgkin lymphoma samples are shown in Figure 25 (complete list in 
Appendix 5). SMG1 was the gene most frequently harbouring protein-altering mutations 
(5/13 samples).  
Here onwards I focussed only on protein-altering mutations. 




Figure 25. 50 genes with the most frequent protein-altering mutations in 13 paediatric HL samples are shown here.  
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3.4.3 Identification of genes previously reported in other Hodgkin lymphoma studies 
Having described the genomic landscape of paediatric HL, I next studied the extent to which 
genes mutated in paediatric HL (from here onwards these are referred to as ‘my series’) had 
also been reported to be mutated in other HL studies. I compiled a list of genes reported to be 
mutated in primary HRS cells and HL cell lines from Reichel et al., and Liu et al., studies 
(Reichel et al., 2015, Liu et al., 2014) (here onwards these are referred to as ‘Reichel series’ 
and ‘Liu series’). I found that genes mutated in my series were significantly enriched in genes 
previously reported to be mutated in HRS cells flow sorted from ten cases of primary HL in 
Reichel series (odds ratio=2.23; p< 0.0001) and among genes reported to be mutated in HL 
cell lines in Liu series (odds ratio=1.92; p< 0.0001). 
42 genes with protein-altering mutations ere common in all three HL studies as shown in 
Figure 26 (gene list in Table 12). To understand the biological importance of these 42 genes, 
gene ontology analysis was performed using DAVID (version 6.8) functional annotation tool 
(Huang da et al., 2009) with GOTERM BP-FAT as described in Materials and Methods 
(Section 2.2.7). This analysis revealed a significant enrichment of biological processes which 
included “negative regulation of NF-kappaB transcription factor activity” (GO:0032088; p= 
0.00037) , “cellular component assembly” (GO:0022607; p= 0.00089), “regulation of tumour 
necrosis factor-mediated  signalling pathway” (GO:0010803; p= 0.0045)  “sister chromatid 
segregation” (GO:0000819; p= 0.009), “nuclear chromosome segregation” (GO:0098813; p= 
0.018), “mitotic cell cycle process” (GO:1903047; p= 0.029), and  “centrosome localization” 
(GO:0051642; p= 0.046) (Appendix 6). 






Figure 26. Overlap between all 3 HL studies for protein-altering mutations. Significant 
overlap was seen between the three HL studies. 
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103 genes with protein-altering mutations were common between my series  and ‘Reichel 
series’ (Table 13). Significant enrichment of  “cellular component assembly” (GO:0022607 ; 
p=  0.0004), “negative regulation of NF-kappaB transcription factor activity” (GO:0032088; 
p= 0.0057) ,  “microtubule cytoskeleton organization” (GO:0000226; p= 0.006), and 
“chromosome segregation” (GO:0007059; p= 0.028) processes was observed for these 103 
genes (Appendix 7).  
The 25 most frequently mutated genes in Reichel and Liu series are listed in Table 14, 
together with their frequency in my series. The most frequently mutated genes that are 
common in all 3 HL studies are shown in Table 15, together with their frequency in my series. 
It can be seen that several genes frequently mutated in Reichel and Liu series were either not 
reported as mutated or mutated at a lower frequency in my series. I measured the sequence 
coverage in my series for TNFAIP3, B2M, and SOCS1 genes that were reported to be most 
frequently mutated genes in COSMIC, Reichel and Liu series.  Mean coverage for these genes 
in my series was 54.85%, 79.68%, and 0%, respectively. Besides TNFAIP3 gene, which was 
deleted in one sample in my  series, the other two genes were not mutated in my series. This 
could either be due to low coverage (as in the case of SOCS1gene) or tumour heterogeneity ( 
for B2M gene). 
Gene ontology analysis of genes with protein-altering mutations in all three HL studies 
revealed an overlap in 12 biological processes significantly enriched in the genes with 
protein-altering mutations in these studies (Table 16). These include ‘cellular component 
assembly’ and ‘circulatory system development’ processes. 
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Table 12.  42 genes that were mutated in all 3 HL studies. 
ACACA CSMD3 HNRNPC MACF1 NR1H4 TNFAIP3 
ALMS1 CUBN ITPR1 MUC16 PKHD1 TTN 
ANKRD36 CYLD ITPR2 MUC17 RANBP2 UNC13C 
ANXA2 FAM228A LAMA3 MUC4 SON USH2A 
APOB FAT3 LMLN MYCBP2 SPAG17 VAV2 
CCDC175 FNBP1 LRRIQ1 MYO18B SRRM2 WDR87 
CDH23 GPR98 LST3 NIN STAG1 XPO1 
 
Table 13. 103 genes mutated in my series and Reichel series. 
ACACA CTC-432M15.3 IGHV1-69 NF1 SON 
ADAMTS12 CTD-2370N5.3 IGHV2-70  NHS SPAG17 
ALK CTTNBP2 INVS NIN SRRM2 
ALMS1 CUBN ITPR1 NOL4 STAG1 
ANKHD1 CYLD ITPR2 NPIPB5 SYCP2 
ANKHD1-EIF4EBP3 DDX20 KIAA1462 NR1H4 TNFAIP3 
ANKRD36 ECT2 KIAA1715 NUP50 TRAPPC8 
ANXA2 EGFLAM LAMA3 OR52E2 TRDN 
APOB EPG5 LMLN PDE4DIP TTN 
ARHGAP25 FAM228A LRRIQ1 PKHD1 UBR5 
ATL1 FAT3 LST3 PLS3 UNC13C 
C1orf87 FNBP1 MACF1 PRRC2C USH2A 
CCDC175 FNDC7 MKS1 PTK2 VAV2 
CCDC73 FRG1B MRRF PTPN21 WDR87 
CD109 GLUD2 MUC16 PTPRD XPO1 
CDH23 GPR98 MUC17 RANBP2 XRCC4 
CEACAM8 HBS1L MUC19 RAPGEF6 ZBTB21 
CHD1 HECTD1 MUC4 RNF145 ZNF292 
CHD1L HEPH MYCBP2 SLC14A2 ZNF430 
CHD4 HNRNPC MYO18B SLC25A13  
CSMD3 HNRNPDL MYO5B SMARCAL1 
 
Results part-I: Hodgkin lymphoma 
124 
 
Table 14. Top 25 most frequently mutated genes previously reported in HL exomes. 
Gene 
Number of samples mutated in combined 
Reichel and Liu series (n=17)  
Number of samples mutated 
in my series (n=13) 
TTN 10 3 
MUC4 9 2 
TNFAIP3 9 1 
HIST1H1E 8 0 
B2M 7 0 
CSF2RB 7 0 
DNAH14 7 0 
IGHV2-70 7 2 
IGLL5 7 0 
IGLV3-1 7 0 
ITPKB 7 0 
PCLO 7 0 
SOCS1 7 0 
FAT4 6 0 
GPR112 6 0 
GPR98 6 1 
IGHE 6 0 
LRRN3 6 0 
MUC16 6 1 
ABCA13 5 0 
ACTB 5 0 
C2orf16 5 0 
DMD 5 0 
DNAH11 5 0 
FAT1 5 0 
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Table 15. Most frequently mutated genes that were common in all 3 HL studies. 
Most frequently mutated 
genes common in all 3 HL 
studies 
Number of samples 
mutated in my  series 
(n=13) 
Number of samples mutated 
in combined Reichel and Liu 
series (n=17)  
CSMD3 3 3 
F8 3 2 
MUC17 3 4 
SREK1 3 2 
TTN 3 10 
ZNF717 3 3 
C20orf194 2 2 
ITPR1 2 2 
ITPR2 2 4 
LAMA3 2 2 
LAMA4 2 2 
MUC4 2 9 
NAV3 2 2 
RANBP2 2 4 
SRRM2 2 3 





Table 16. Biological processes common in all 3 HL studies. 
Gene ontology term 
GO:0072359~circulatory system development 
GO:0072358~cardiovascular system development 
GO:0060249~anatomical structure homeostasis 
GO:0000902~cell morphogenesis 
GO:0048646~anatomical structure formation involved in morphogenesis 
GO:0032990~cell part morphogenesis 
GO:0048858~cell projection morphogenesis 
GO:0022607~cellular component assembly 
GO:0048871~multicellular organismal homeostasis 
GO:0042592~homeostatic process 
GO:0007507~heart development 
GO:0051128~regulation of cellular component organization 
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3.4.4 Identification of genes previously reported in other B cell lymphomas 
I next compared genes with protein-altering mutations in my series with those previously 
reported to be mutated in other B-cell lymphoma data sets. For GC-derived non-Hodgkin 
lymphomas, I had available a number of datasets for each tumour type. For this analysis I 
compiled a list of genes mutated in one or more samples of a specified tumour type. Using 
these gene lists I  observed a significant enrichment of genes mutated in my series among 
genes reported to be mutated in DLBCL (odds ratio=2.39; p< 0.0001) (Park et al., 2016, 
Morin et al., 2016, Zhang et al., 2013, Lohr et al., 2012), BL (odds ratio=1.87; p< 0.0001)  
(Love et al., 2012, Abate et al., 2015, Richter et al., 2012), and FL (odds ratio=2.40; p< 
0.0001)  (Pasqualucci et al., 2014, Krysiak et al., 2017, Ozawa et al., 2016).  
Furthermore, I compiled a list of protein-altering mutations in HL (from now on called as HL 
series), which included genes mutated in all 3 HL studies and also two genes (HRAS and 
NRAS) reported to be frequently mutated in HL as seen in COSMIC data base but not present 
in all the three HL series (Forbes et al., 2015) to define a set of genes with protein-altering 
mutations that were present only in HL (including mutations reported in Reichel et al and Liu 
et al) and not in any other B-cell lymphomas (including those tumour types described above 
but also including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and  
chronic lymphocyte leukaemia (CLL). 1310 HL-specific genes were mutated in at least 3/30 
samples from the three 3 HL studies (Table 17). 141 HL-specific genes present only in my 
series are shown in Table 18. This group represent a set of putative paediatric specific 
mutations
1
. The 11 most frequently mutated HL-specific genes unique to my series  are  
shown in Table 19. Gene ontology analysis of 1310 HL-specific genes is presented in Table 
20.  
                                                
1
9/10 patients reported in the Reichel series above 21 years of age. 
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Table 17. HL-specific genes mutated in at least 10% of samples in all three HL studies. 
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Table 18. 141 HL-specific genes unique to my series. 
AC012215.1 CWC27 IGKV1-6 OR1N1 RRH TULP3 
AC112715.2 DLEU2L IGLC3 OR4F4 S100B UGT1A5 
ADAT2 DMTF1 IKZF5 OR4Q2 SC5D UGT1A8 
ALDH3A2 DUS2 IL17RB OR52R1 SCOC USH1C 
ARL14EP DYX1C1 IMPACT PANK1 SEC23B USP46 
ATPAF1 EDRF1 INSIG2 PAQR5 SLC25A14 UTS2B 
ATXN10 EXD1 IPP PBX4 SLC25A3 VAMP4 
B3GALNT1 FAM210A KIAA0125 PDCD2L SLC25A33 VCAM1 
BSPH1 FAM98A KLHL7 PDCL2 SLC5A6 WBP11 
C14orf23 FANCL KLRD1 PGAP1 SNAP29 WNT2B 
C20orf24 FBXO45 LAMTOR2 PGBD1 SPATS1 ZBED6 
C2orf66 FNDC3B LRRC9 PGM1 SRXN1 ZCRB1 
C7orf25 FSIP1 MAN1A2 PIGK STK17B ZFR 
C8orf37 FUNDC1 MESDC2 PITPNC1 SUN3 ZNF12 
CARF GAPT MFAP5 PLSCR1 TAB2 ZNF143 
CASP2 GCNT2 MIER3 PPP3CB TARDBP ZNF567 
CATSPERD GK5 MLEC PRKRA TCTN2 ZNF625-ZNF20 
CDKL4 GLUL MLLT4 PROSER1 TFDP1 ZNF682 
CKLF-CMTM1 GSS MRPS18B PUS7 TIGD7 ZNF69 
CLCN3 HIATL2 MSANTD2 RGS6 TMEM136 ZNF816 
CMPK1 HLF MUC7 RNF138 TMEM50A ZSCAN32 
CMTR2 IFIT3 NPIPA5 RNF7 TMEM97 
 
CSE1L IGHV1-18 NUGGC RP11-53I6.2 TTC12 
 




Table 19. Eleven most frequently mutated HL-specific genes unique to my series. 
Most frequently mutated HL-specific genes unique to my 
series 
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Table 20. Biological process significantly enriched in 1310 genes unique to Hodgkin 
lymphoma. 
Gene ontology term p-value 
Complement activation, classical pathway 3.55E-05 
Fc-gamma receptor  signalling pathway involved in phagocytosis 8.99E-05 
Immune response-regulating cell surface receptor  signalling pathway involved in 
phagocytosis 
8.99E-05 
Fc receptor mediated stimulatory  signalling pathway 1.24E-04 
Fc-gamma receptor  signalling pathway 1.37E-04 
Humoral immune response mediated by circulating immunoglobulin 1.73E-04 
Complement activation 2.96E-04 
Protein activation cascade 5.62E-04 
Immunoglobulin mediated immune response 0.001576 
B cell mediated immunity 0.001813 
Cellular response to fatty acid 0.004092 
Receptor-mediated endocytosis 0.004728 
Fc receptor  signalling pathway 0.005479 
Fc-epsilon receptor  signalling pathway 0.005982 
Lymphocyte mediated immunity 0.01089 
Leukocyte mediated immunity 0.011056 
Adaptive immune response based on somatic recombination of immune receptors built 
from immunoglobulin superfamily domains 
0.011355 
Response to fatty acid 0.012326 
Humoral immune response 0.024109 
Phagocytosis 0.024586 
Cellular response to acid chemical 0.02544 
Immune response-activating cell surface receptor  signalling pathway 0.026786 
Sensory perception of chemical stimulus 0.027145 
Positive regulation of protein secretion 0.033817 
Glycolipid biosynthetic process 0.034139 
Positive regulation of insulin secretion 0.039717 
Membrane lipid metabolic process 0.040114 
Cell wall macromolecule metabolic process 0.040817 
Immune response-regulating cell surface receptor  signalling pathway 0.04429 
Phagocytosis, recognition 0.044989 
Positive regulation of cytokine secretion 0.046605 
Oligosaccharide biosynthetic process 0.048942 
Cell wall organization or biogenesis 0.048942 
Positive regulation of cellular response to insulin stimulus 0.04942 
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3.4.5 Expression of mutated genes in primary HRS cells 
I next investigated whether the expression of mutated genes was more or less likely to be up -
or down-regulated in Hodgkin lymphoma using gene expression datasets GSE12453 (Brune 
et al., 2008) and GSE39133 (Steidl et al., 2012). 377 genes mutated in my series were down-
regulated (Appendix 8) and 141 mutated in my series were up-regulated (Appendices 9) in 
Hodgkin lymphoma compared with GC B cells in at least one dataset. The genes with somatic 
mutations in paediatric HL were significantly enriched (odds ratio = 2.34; p< 0.0001) in genes 
down-regulated in primary HL and significantly depleted (odds ratio = 0.76; p= 0.019) in 
genes up-regulated in HL.  
To understand the biological importance of protein-altering genes that were also 
downregulated in either Brune or Steidl arrays, gene ontology analysis was performed. This 
analysis revealed a significant enrichment of “mitotic cell cycle process“ (GO:1903047; p< 
0.0001), “chromosome organization” (GO:0051276; p<0.0001), “chromosome segregation” 
(GO:0007059; p< 0.0001), and “mitotic cell cycle checkpoint” (GO:0007093; p< 0.0001) 
(Appendix 10 showing 125 most significantly enriched biological processes). Significant 
enrichment of  “blood vessel development” (GO:0001568; p= 0.0045), “cell adhesion” 
(GO:0007155; p= 0.013), and  “angiogenesis” (GO:0001525; p= 0.018) was observed in 
protein-altering genes that were upregulated in either Brune or Steidl arrays (Appendix 11). 
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3.4.6 Differences in the mutational landscape of EBV-positive and EBV-negative HL  
322 genes with protein-altering mutations were present in EBV-positive (n=6) cases 
(Appendix 13) and 587 genes with protein-altering changes were mutated in EBV-negative 
(n=7) cases (Appendix 14). The mutation rate was higher, but not statistically significant (t-
Test; p= 0.167), in EBV-negative cases (Mean=4.46/Mb) compared to EBV-positive cases 
(Mean=2.96/Mb). However, a significantly higher mutation rate in 16 EBV-negative cases 
(Mean=8.92/Mb) compared to 7 EBV-positive cases (Mean=4.82/Mb) was observed in my 
series and Reichel series (from here onwards called as ‘HL primary series’) (t-Test; p= 0.022).  
I also wanted to know if those cellular functions disrupted by mutation were different between 
EBV-positive  and EBV-negative cases. To do this I performed a gene ontology analysis on 
the genes mutated in either EBV-positive or EBV-negative HLs, but not in both, in my  series. 
Gene ontology analysis showed the enrichment of ‘cell cycle’ and ‘DNA repair’ related genes 
in both EBV positive and negative cases. Biological processes enriched in the genes mutated 
in both EBV-negative and EBV-positive cases  in my series are shown in Table 21. 
I observed enrichment of similar GO terms when I repeated the gene ontology analysis 
comparing genes mutated in EBV-negative cases with EBV-positive cases  in the HL primary 
series. Table 22 shows the top 20 genes most frequently mutated in either EBV-positive or 
EBV-negativetumours, but not in both, in the HL primary series (see Appendix 15 for a 
complete list).  
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Table 21. Biological processes that are common in both EBV-positive and EBV-negative 
paediatric HL tumours. 
Gene ontology terms 
GO:0060249~anatomical structure homeostasis 
GO:0001894~tissue homeostasis 
GO:0045494~photoreceptor cell maintenance 
GO:0042592~homeostatic process 
GO:1903047~mitotic cell cycle process 
GO:0051276~chromosome organization 
GO:0000723~telomere maintenance 
GO:0044770~cell cycle phase transition 
GO:0006259~DNA metabolic process 
GO:0022402~cell cycle process 
GO:0006974~cellular response to DNA damage stimulus 
GO:0006281~DNA repair 
GO:0007049~cell cycle 
GO:0032508~DNA duplex unwinding 
GO:0032392~DNA geometric change 
GO:0051592~response to calcium ion 
GO:0042384~cilium assembly 
GO:0006302~double-strand break repair 
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Table 22. 20 genes most frequently mutated exclusively in either EBV-positive or EBV-
negative primery HL series (n=23).  
 








F8 3 Positive IGHV2-70 8 Negative 
TPTE2 3 Positive TNFAIP3 7 Negative 
AGPAT9 2 Positive IGHE 5 Negative 
CCDC175 2 Positive IGLV3-1 5 Negative 
CHD4 2 Positive MUC17 5 Negative 
CMPK1 2 Positive HIST1H1E 5 Negative 
COL9A1 2 Positive B2M 4 Negative 
DNAH12 2 Positive IGLL5 4 Negative 
EML4 2 Positive ITPKB 4 Negative 
EPG5 2 Positive EEF1A1 4 Negative 
ITPR2 2 Positive SOCS1 4 Negative 
LAMA4 2 Positive ITPR1 3 Negative 
MYO6 2 Positive LRRN3 3 Negative 
OR4C5 2 Positive CSMD3 3 Negative 
PDE4DIP 2 Positive HECTD1 3 Negative 
SBF2 2 Positive UBE2A 3 Negative 
SGOL2 2 Positive DNAH14 3 Negative 
TMEM57 2 Positive SRRM2 3 Negative 
TRDN 2 Positive C1orf87 3 Negative 
ZNF717 2 Positive CCDC80 3 Negative 
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Given that it has been shown that TNFAIP3, a negative regulator of NF-κB signalling, is 
more frequently mutated in EBV-negative HL than in EBV-positive HL, I wanted to 
determine if mutations in negative regulators of NF-κB signalling were also more frequent 
among the EBV-negative cases compared with the EBV-positive cases from the HL primary 
series. To do this, I compiled a list of genes (Table 23) reported to negatively regulate NF-κB 
signalling by Warner et al.,  Gewurz et al., and also the gene ontology terms available in 
amiGO (Gene ontology data base (Warner et al., 2013, Gewurz et al., 2012, Gene Ontology, 
2015). Gene enrichment analysis revealed a significant enrichment of negative regulators of 
NF-κB in the  EBV-negative HL but not in EBV-positive HL. 
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Table 23. 174 genes reported to negatively regulate NF-κB signalling. 
  
ACOD1 CNOT6 FBXO31 MINA PIAS4 STAT2 
ACOX1 COMMD1 FLJ12443 MPZL1 PKHD1 STAT3 
AIM1L COMMD4 FLJ35776 MRPL55 PKNOX2 TAX1BP1 
AIM2 COMMD6 FOXJ1 MUC1 PLEKHG2 TCEAL7 
AKAP14 COMMD7 FOXP3 MYLK POGZ TLR9 
ANXA4 CRLF1 FUS MYST4 PPM1B TNFAIP2 
ARRB1 CSDE1 G3BP2 NAP1L2 PPP1R14C TNFAIP3 
ARRB2 CYLD GADD45G NDFIP2 PPP1R3B TNFSF18 
ASB9 CYP1B1 GCKR NFKBIA PPP4R1L TNIP1 
BAG2 DAB2IP GFI1 NFKBID PRMT2 TRAF3 
BEX1 DAP GUCA2B NFKBIL1 PSMD10 TRIB3 
BMP7 DET1 H2AFY NFRKB PTGIS TRIM21 
BRMS1 DKFZP762E1312 HAVCR2 NLRC3 PTPN23 TRIM37 
BZRPL1 DRD2 HEXIM2 NLRC5 PTPRK TRIM40 
C10ORF76 DRD3 HIST1H2BN NLRP12 PYCARD TRY1 
C22ORF4 DRD4 IFIT1 NLRP2B PYDC1 TSG101 
CA2 DUSP16 IL16 NLRP3 PYDC2 UBE2D1 
CABP7 DUSP4 IRAK1 NR1H4 RASA4 UBE2L3 
CACTIN DYRK2 IRAK2 OATL1 RBCK1 UBXN2A 
CAD EDG2 IRAK3 OTUD6B RNF13 UFL1 
CAT ENDOG ITCH OTULIN ROBO4 UGDH 
CCR7 ERBIN KIAA0522 PARP10 RWDD3 USP7 
CDK5RAP3 ERK8 KL pcdh19 SERPINE1 USP8 
CDKN2A EVI5 KLF4 PDLIM2 SETD6 YWHAG 
CHCHD3 EZH1 LOC644168 PDXDC1 SIRT1 ZC3H12A 
CHP1 FASTKD3 MAGEA3 PELI1 SLA ZC3H12B 
CKAP2 FBX039 MAP2K5 PELO SMARCC1 ZFC3H1 
CMKLR1 FBXL2 MAP3K1 PFKP SMARCC2 ZNF675 
CNOT10 FBXL7 MAPK15 PHF7 SSR2 ZNF830 
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3.4.7 Identification of biological functions enriched in genes with protein-altering 
mutations in paediatric HL cases 
Gene ontology analysis of 857 genes with protein-altering mutations in my  series revealed 
the significant enrichment of a number of key biological processes (Appendix 12) of potential 
relevance to HL, including “chromosome organization” (GO: 0051276; p< 0.00001), 
“negative regulation of DNA metabolic process” (GO: 0051053; p= 0.001), “DNA repair” 
(GO: 0006281; p= 0.001), “negative regulation of telomere maintenance” (GO:0032205; p= 
0.001), and “mitotic cell cycle process” (GO: 1903047; p= 0.001).  
Given that gene ontology analysis performed here had shown a consistant enrichment of GO 
terms related to the mitotic spindle associated genes, I decided to pursue this further. I 
compiled a list of 513 mitotic spindle associated genes (spindle (GO:0005819);  mitotic 
spindle check point (GO:0031577); nuclear chromosome segregation (GO:0098813); and 
sister chromatid segregation (GO:0000819)  from amiGO. (Gene Ontology, 2015).  I found 
significant enrichment of these 513 mitotic spindle associated genes in the mutated genes in 
my  series (odds ratio=1.50; p< 0.0001).  Furthermore, I saw a significant enrichment of 
mitotic spindle associated genes in mutated genes that were also downregulated in primary 
HL (odds ratio = 4.12 and p< 0.0001) but not in the mutated genes that were upregulated in 
HL (odds ratio = 0.17 and p= 0.674) in my series.  
Having shown that the mitotic spindle-associated genes were significantly enriched in genes 
with protein-altering mutations and also in a subset of these genes that were also 
downregulated in HRS cells, I next focussed on the subset of mitotic spindle-associated genes 
comprising the mitotic spindle checkpoint, a multi-protein cascade that prevents separation of 
the duplicated chromosomes until all chromosomes are properly attached to the mitotic 
spindle. I derived a comprehensive mitotic spindle checkpoint signature, comprising 103 
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genes (Table 24) including those classified under the GO term ‘GO:0031577’,  those reported 
by Bieche et al., (Bieche et al., 2011) and those identified in an unbiased Pubmed search using 
the search term ‘mitotic spindle checkpoint’. I found that genes with protein-altering 
mutations in 13 paediatric HL exomes were significantly enriched in mitotic spindle 
checkpoint genes (odds ratio=7.87; p<0.0001). Figure 27 shows a heatmap of mitotic spindle 
checkpoint genes across the 13 paediatric HL exomes. I found that at least one mitotic spindle 
checkpoint gene was mutated in 9/13 paediatric HL  samples. 
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Table 24. 103 mitotic spindle check point genes. 
ANAPC1 BUB1 CENPE KNTC1 PTTG1 TPR 
ANAPC10 BUB1B CENPF LCMT1 RAD21 TPX2 
ANAPC11 BUB3 CEP250 MAD1L1 RAE1 TTK 
ANAPC15 CASC5 CLASP1 MAD2L1 RAN UBD 
ANAPC2 CCNA1 CLASP2 MAD2L2 RASSF1A UBE1C 
ANAPC4 CCNA2 CSE1L MRE11A RCC1 UBE2B 
ANAPC5 CCNB1 CSNK2A1 NDC80 RNF2 UBE2N 
ANAPC7 CCNB2 CSNK2A2 NDRG1 SGOL2 USP44 
APC CCNB3 DUSP1 NEDD8 SMC1A XRCC3 
ATM CDC16 DYNC1LI1 NEK2 SMC1B ZNF207 
AURKA CDC2 ESPL1 NUP133 SMC3 ZW10 
AURKAIP1 CDC20 FBXO5 PCID2 SPDL1 ZWILCH 
AURKB CDC23 FBXW7 PLK1 STAG1 ZWINT 
AURKC CDC26 FZR1 PPP1CA STAG2  
BCL2L11 CDC27 GEN1 PPP1R2 TACC1  
BIRC5 CDC34 GSG2 PRCC TACC2  
BRCA1 CDK5RAP2 HSPB1 PRPF4B TACC3  
BRCA2 CDKN1A KLHL22 PSMG2 TEX14  





Figure 27. Nine of the thirteen paediatric Hodgkin lymphoma samples contain protein-altering 
mutations in at least one mitotic spindle checkpoint gene. 
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3.4.8 Transcriptional regulation of mitotic spindle-associated genes by Epstein-Barr 
virus infection 
Mutations in mitotic spindle-associated genes were more frequent in EBV-negative 
(mean=3.85) compared with EBV-positive tumours (mean=3.16). I next explored the 
possibility that EBV might contribute to the inactivation of mitotic spindle functions in HRS 
cells. To do this I re-analysed a previously published dataset which had reported the global 
gene expression changes that follow the infection of primary germinal centre B cells with 
EBV (Leonard et al., 2011). This analysis revealed that genes down-regulated (odds 
ratio=2.23; p< 0.0001), but not those up-regulated (odds ratio=1.14; p= 0.293), by EBV in 
primary GC B cells, were significantly enriched for mitotic spindle-associated genes. I 
repeated this analysis using a previously published dataset that had reported the gene 
expression changes that follow the transfection of GC B cells with the EBV oncogene, latent 
membrane protein-1 (LMP1) (Vockerodt et al., 2008). I found that genes down-regulated 
(odds ratio=1.80; p< 0.0001), but not those up-regulated (odds ratio=1.48; p= 0.778), by 
LMP1 in primary GC B cells, were significantly enriched for mitotic spindle-associated 
genes.  
Furthermore, I showed that the subset of mitotic spindle-associated genes, mitotic spindle 
checkpoint genes, that were transcriptionally down-regulated by either EBV or LMP1, or 
both, and mutated in at least one HL tumour were also significantly more likely to be down-
regulated (for EBV, odds ratio=8.14; p= 0.0006; and for LMP1, odds ratio=17.28; p= 0.0001) 
and not upregulated (for EBV, odds ratio=2.92; p= 0.267 and for LMP1, odds ratio=0.0; p= 
0.806) at the transcriptional level in primary HRS cells (Figure 28).  





Figure 28. Mitotic spindle checkpoint genes enriched in EBV infected HRS cells. Significant enrichment (B and D) of 
mitotic spindle checkpoint genes enriched in EBV infected HRS cells that also results in downregulated transcription in 
EBV infected GCB cells. Mitotic spindle checkpoint genes are either depleted or not enriched in EBV infected HRS cells (A 
and C) that also results in upregulated transcription in EBV infected GCB cells. 





In this chapter I have described the genomic landscape of paediatric Hodgkin lymphoma. 
I have shown that paediatric Hodgkin lymphoma has considerable heterogeneity at the gene 
level. For this reason I focussed on a pathway analysis which would take into account the 
possibility that mutations in different genes might converge on the same biological function 
(s). This analysis revealed the striking enrichment of genes with function in the mitotic 
spindle.  This observation is of importance as dysregulation of the mitotic spindle associated 
genes are reported to be associated with several malignancies, including HL. Additionally, 
several compounds, including microtubule targeting agents such as Vinblastine and 
Vincristine, have been designed to target several mitotic spindle associated genes such as 
AURKA, AURKB, BUB1, CDK1, and shown in the Figure 29 (Dominguez-Brauer et al., 
2015). 
I was interested in the possibility that mitotic spindle functions were mutational targets in HL 
for two main reasons. The first is because HL is characterized by frequent aneuploidy and 
multinucleated condition in HRS cells. As suspected, several mitotic spindle genes were 
mutated in my study cohort as highlighted in purple in Figure 29. The defects of mitotic 
spindle function are well described in chromosome missegregation and in turn aneuploidy (Ru 
et al., 2002, Yu et al., 2003, Zyss and Gergely, 2009, den Hollander et al., 2010, Rengstl et 
al., 2013). The second reason is that the mitotic spindle checkpoint is a target for 
chemotherapy in children with HL such as Doxorubicin, a topoisomerase II inhibitor (Hande, 
2008). 
Although I was unable to deduce the biological effect of mutations affecting mitotic spindle 
functions in HL, analysis of genes differentially expressed in HL revealed that genes 
downregulated in HL but not upregulated in HL were significantly enriched in mitotic spindle 




associated genes. These data suggest that many of the observed mutations in mitotic spindle 
associated genes are likely to be inactivating. In support of this, I observed a high frequency 
of frameshift mutations (23/43) in the mitotic spindle associated genes. 
I also observed that the mutation rate in EBV-negative tumours is significantly higher when 
compared to EBV-positive tumours. This is in keeping with data from other tumours in which 
the frequency of mutations in viral negative forms and viral positive forms were described. 
For example, in gastric cancer the EBV-negative tumours have more frequent mutations than 
in the EBV-positive tumours (Network, 2014), similarly  HPV-negative head and neck 
tumours have more frequent mutations than in HPV-positive tumours (Riaz et al., 2014). 
These observations can be explained by the requirement for cellular mutations to replace viral 
functions in virus negative tumours.  There are already good examples in HL, where it has 
been found that mutations in TNFAIP3 gene are almost exclusively found in EBV-negative 
tumours (Schmitz et al., 2009).  
I observed mutation in TNFAIP3 gene in only one sample in my cohort. This could be 
explained by the relatively low coverage across this gene in my analysis. However, I found 
that genes mutated in EBV-negative tumours but not in EBV-positive tumours were enriched 
in functions involved in NF-κB signalling, including many genes reported to be negative 
regulators of NF-ΚB activation. Therefore, an alternative possibility is that mutations in one 
or more of different negative regulators of NF-κB activation are required to substitute 
TNFAIP3 mutation. Similar to observation made by Schmitz et al., all of the mutations in 
negative regulators of NF-κB activation in my analysis were only seen in EBV-negative 
tumours.





Figure 29. Mitotic Components Targeted for Cancer Therapy (modified from Dominguez-Brauer et al., 2015).




I considered the possibility that in the absence of a cellular mutation, EBV infection could 
disrupt mitotic spindle function through transcriptional downregulation of target genes. I 
found that mutated mitotic spindle associated genes were significantly enriched in 
transcriptionally downregulated genes but not in upregulated genes by LMP1 or EBV 
infection. These data suggest that EBV infection and cellular mutations might provide 





INVESTIGATING EPSTEIN-BARR VIRUS GENE EXPRESSION 
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4. INVESTIGATING EPSTEIN-BARR VIRUS GENE 
EXPRESSION AND THE ROLE OF THE EPSTEIN-BARR 




The association between human cancers and viruses was first described in Epstein-Barr virus 
(EBV) associated tumours (Epstein et al., 1964). EBV was shown to cause cancers originating 
from lymphocytes (e.g. Hodgkin lymphoma and Burkitt lymphoma), epithelial cells 
(nasopharyngeal carcinoma and gastric cancers), and mesenchymal cells (e.g. EBV-associated 
smooth muscle tumour) (Gutensohn and Cole, 1980, Desgranges et al., 1975, Shibata and 
Weiss, 1992).  
Most of the studies that have explored the contribution of individual EBV genes to 
oncogenesis have focussed on the latent genes, making the assumption that induction of the 
lytic cycle is incompatible with transformation. However, recent evidence points to a role for 
the lytic cycle genes in transformation and cancer progression (Woellmer et al., 2012, Wille et 
al., 2012).  Furthermore, genes previously classified as EBV lytic genes have also recently 
been shown to be expressed during latency. For example, BHRF1 the EBV-BCL2 homolog 
has been shown to be expressed as a latent gene in a subset of Burkitt lymphoma where it 
provides a potent anti-apoptotic signal (Kelly et al., 2009a). Recent studies using either high-
throughput qPCR or RNA sequencing suggest that other ‘lytic’ cycle genes might also be 
expressed during latency in tumours (Tierney et al., 2015) to measure the expression of 45 
EBV genes, not only in eBL, but also in NPC, HL, and GC. Having shown that all these 
tumours are characterized by the expression of subsets of ‘lytic’ cycle genes, I then focussed 
on the potential contribution of one of these, BILF1, to the pathogenesis of BL. 
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4.2 EBV gene expression in endemic Burkitt lymphoma, Hodgkin 
lymphoma, nasopharyngeal carcinoma, and gastric cancers  
To measure EBV gene expression in different EBV-associated cancers,  I utilized the same 
assays and qPCR platform described by Tierney et. al., to quantify absolute numbers of a 
subset (n=45) of EBV transcripts that include examples of immediate early (IE), early (E) and 
late (L) lytic cycle genes in addition to latent cycle genes. All these 45 assays have been 
assessed for expression in lytic cycle-induced Akata cells and all the lytic genes are detectable 
at high levels during viral replication (Tierney et al., 2015). This approach has the advantage 
over other approaches that can measure global EBV gene expression, such as RNA 
sequencing, insofar as it is cheaper and uses only nanogram amounts of RNA. Full details of 
this method are described in Section 2.2.10 of the Materials and Methods.   
4.2.1 EBV gene expression in primary endemic Burkitt lymphoma samples 
High-throughput qPCR was performed on 41 EBV-positive endemic BL samples (for details 
of samples, see section 2.1.4 of the Materials and Methods). Three of 41 endemic BL samples 
were excluded from the final analysis due to poor signal for housekeeping genes (GAPDH, 
PGK1, and B2M); while a further 10 samples that contained only very low levels of EBV 
transcripts were also excluded. In the remaining 28 eBL samples, expression levels of 45 
EBV amplicons (23 latent, 2 immediate early (IE), 11 early (E), 6 late (L) lytic cycle 
transcripts; 3 poorly characterized RNAs (LF1, LF2 and LF3) and 4 non-coding RNAs 
(BARTs and EBERs)) and 3 cellular housekeeping genes (B2M, PGK1 and GAPDH) is 
shown in Figure 30. These samples exhibited a Latency I pattern  similar to those previously 
reported (Rowe et al., 1987a), in which Qp-driven QUK spliced EBNA1 transcripts were 
detected in the majority of BL samples, albeit at variable levels. In agreement with previous 
reports, LMP1 transcripts were not detected in the majority (24/28) of the samples 
Results part-II: Burkitt lymphoma 
149 
 
(Niedobitek et al., 1995). LMP2A transcripts were detected in 19/28 cases, albeit at low 
levels. The remaining EBNAs were virtually absent, as were Cp/Wp transcripts. The two 
small non-coding RNAs, EBER 1 and 2, were also expressed. However, in addition to these 
latent transcripts previously reported, many lytic transcripts were also expressed, albeit at 
variable levels. In particular, there were high levels of BILF1, BALF4 and the LF transcripts. 
The lack of other lytic signals in particular BZLF1, indicating that this was not a low level of 
lytic reactivation but selective expression of certain genes.        
For a subset of tumours (n = 9) I had the opportunity to compare the results obtained from the 
high-throughput q-PCR assays of primary eBL with those previously reported by RNA 
sequencing for these samples. I edited annotations obtained from NCBI in order to make this 
comparison. I compared gene expression values normalized to PGK1 gene expression from 
the high-throughput q-PCR assays to those obtained by RNA sequencing that were 
normalized to counts per million human reads (See section 2.2.10 of the Materials and 
Methods). As it can be seen from Figure 31, there was a high similarity between the 
expression values obtained by the two approaches, especially for the latent genes. However, 
the expression for some lytic genes shows different expression pattern in some cases. This 
may be due to the sensitivity of each method, particularly the expression of non-coding RNAs 
(EBERs) which are usually absent from the RNA sequencing data, or the relative scales used 
in each heatmap. 
 




Figure 30. Heatmap summarizing EBV gene expression in endemic BL samples.  Expression 
levels of 45 EBV amplicons (23 latent, 2 immediate early (IE), 11 early (E), 6 late (L) 
transcripts; 3 poorly characterized RNAs (LF1, LF2 and LF3) and 4 non-coding RNAs 
(BARTs and EBERs)) and 3 cellular genes (B2M, PGK1 and GAPDH) in 28 endemic Burkitt 
lymphoma samples was shown here. Absolute expression of the 48 amplicons was normalized 
using the PGK1 expression levels. The scale on the right hand side of the figure shows how 
these numbers correlate to transcripts per cell, based on our earlier finding that BL and LCLs 
cells contain an average of 150 PGK1 transcripts. 





Figure 31. High concordance between the Fluidigm and RNA sequencing methods. Similar expression patterns for most of the EBV genes was 
observed, with the exception of small non-coding RNAs (EBERs) that were mostly absent in the RNA sequencing data.
Results part-II: Burkitt lymphoma 
152 
 
4.2.2 EBV gene expression in primary nasopharyngeal carcinoma 
A total of 50 NPC primary tumour samples (including 9 samples with amplified RNA) and 9 
cell lines were available. 15/50 NPC primary samples were excluded from the analysis due to 
low EBER1 expression. Expression levels of 45 EBV amplicons and 3 cellular housekeeping 
genes in 33 Nasopharyngeal carcinoma (NPC) primary tumours (in green colour), in 3 NPC 
primary tumours from amplified RNA (in blue colour), and 9 NPC cell lines (in purple 
colour) were shown in the Figure 32. Absolute expression of these 48 amplicons was 
normalized using the PGK1 expression levels. EBV expression in these 44 NPC samples was 
consistent, but not identical, with the latency II form of infection (Brooks et al., 1992, Young 
et al., 1988). I detected EBER1 expression as well as variable levels of Qp-driven QUK 
spliced EBNA1 transcripts in the majority of NPC samples. High levels of LMP2A 
transcripts were also detected in most NPC and LMP1 CAO was expressed in 9/35 primary 
tumours. The remaining EBNAs were either absent or expressed at very low levels, similar to 
the Cp/Wp transcripts. Similar to eBL I observed high level expression of EBV lytic 
transcripts, including BILF1, BALF4 and the LF transcripts.   
I was also interested to determine if the NPC cell lines recapitulate the pattern of EBV gene 
expression observed in primary tumours. The nine cell lines included C666.1 which is a 
naturally infected cell line, and in vitro Akata-infected cell lines CNE1, CNE2, HK1, 
HONE1, NP460, SUNE1, TWO1, and TWO4. Although similar EBV gene expression was 
observed between the primary NPC primary tumours and cell lines, expression of early lytic 
gene BHRF11 transcripts with the H2-HF splice (7/9), early lytic gene BGLF5 (6/9), late 
lytic genes BILF2 (7/9) and BVRF2 (8/9), and Fp-initiated transcripts and FUK (5/9) spliced 
EBNA1 transcripts (5/9) were detected more frequently in the NPC cell lines than in primary 
tumours. EBER2 transcripts were also abundantly expressed in the Akata-infected NPC cell 
lines, indicating that EBER2 expression is associated with Akata-strain. 






Figure 32. Heatmap of EBV gene expression in NPC samples.  Expression levels of 45 EBV amplicons and 3 cellular genes in 33 NPC primary 
NPC tumours (in green colour), in 3 RNA amplified primary NPC tumours (in blue colour), and 9 NPC cell lines (in purple colour), were shown 
here. Absolute expression of the 48 amplicons was normalized using the PGK1 expression levels.  
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4.2.3 EBV gene expression in Hodgkin lymphoma samples 
Fifteen primary HL samples (5 FFPE and 10 FF) and one EBV-positive HL cell line L-591 
were available. However, two FFPE HL samples and five FF HL samples were excluded 
from the final analysis as they contained very low levels of EBV transcripts. As shown in 
Figure 33, EBV expression pattern in the remaining eight primary HL samples is consistent 
with latency type II pattern previously reported in HL (Deacon et al., 1993, Pallesen et al., 
1991b), and latency III reported in L-591 (Baumforth et al., 2008). Qp-driven QUK spliced 
EBNA1 transcripts were detected in 3/8 primary HL tumours and in L-591 cells, however at 
very low levels. The remaining EBNAs were virtually absent in primary tumours, as were 
Cp/Wp transcripts. However, L-591 cells had high levels of EBNA2 expression. High levels 
of LMP1 (B95-8) transcripts were detected in four primary HL cases, but surprisingly were 
absent in the L-591 cells. Very low levels of LMP2 expression was observed in half of 
primary tumours and in the L-591 cell line (~10-20 transcripts per cell). Varying levels of 
BNLF2A and BNLF2B transcripts were present in primary HL cases; however this 
expression may also have come from the LMP1 RNA since LMP1 and BNLF2A/B share the 
same 3’ end. High level of BNLF2A expression was observed in the L-591, whereas very low 
levels of BNLF2B expression was observed in the L-591 cell line. Lower levels of BILF1, 
BALF4 and the LF transcripts were observed in two primary HL samples and the L-591 cells. 
The level of expression for these transcripts in the remaining samples was almost negligible. 
There was no significant expression of other lytic genes in these samples. 





Figure 33. EBV gene expression in HL samples.  Expression levels of 45 EBV amplicons (23 
latent, 2 immediate early (IE), 11 early (E), 6 late (L) transcripts; 3 poorly characterized 
RNAs (LF1, LF2 and LF3) and 4 non-coding RNAs (BARTs and EBERs)) and 3 cellular 
genes (B2M, PGK1 and GAPDH) in 8 Hodgkin lymphoma samples and a HL cell line L591 
were shown here. FF: Flash Frozen; FFPE: Formalin-fixed, paraffin-embedded. 
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4.2.4 EBV gene expression in gastric cancer cell lines 
EBV gene expression data was obtained from four gastric cancer cell lines, which include 
two naturally infected cell lines (SNU-719 and YCCEL-1) and two in vitro EBV-infected cell 
lines (AGS and OE19). EBV gene expression showed latency type I pattern in all four cancer 
cell lines (Figure 34), in agreement with the previously published data (Decaussin et al., 
2000, zur Hausen et al., 2000) including low levels of Qp-driven QUK spliced EBNA1 and 
LMP2A, but no LMP1 transcripts were detected. High expression of early lytic transcripts, 
BNLF2A and BNLF2B, were observed. High levels of BILF1, BALF4 and the LF transcripts 
were also observed.   
In summary, Fluidigm analysis of EBV expression indicates that the pattern of EBV gene 
expression is broader than previously recognised, with lytic genes being present in addition to 
the well described latent genes. However lytic expression is selective, i.e. not all genes are 
expressed suggesting this is not full virus replication. This is consistent with the proposed 
hypothesis that virus reactivation must be blocked to allow tumour formation, while still 
allowing certain genes to be expressed that may provide a growth advantage.  
    





Figure 34. Heatmap summarizing EBV gene expression in gastric cancer cell lines.   
Expression levels of 45 EBV amplicons (23 latent, 2 immediate early (IE), 11 early (E), 6 late 
(L) transcripts; 3 poorly characterized RNAs (LF1, LF2 and LF3) and 4 non-coding RNAs 
(BARTs and EBERs)) and 3 cellular genes (B2M, PGK1 and GAPDH) in four gastric cancer 
cell lines were shown here. Absolute expression of the 48 amplicons was normalized using 
the PGK1 expression levels.  
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4.3 BILF1 detection using RNAScope and immunohistochemistry 
The results presented in the foregoing section provide further convincing evidence that some 
genes formerly reported as lytic cycle genes are expressed from moderate to high levels in 
primary EBV-associated malignancies. I decided to focus on BILF1, the only G protein 
coupled receptor (GPCR) encoded by EBV. BILF1 has the highest sequence similarity to the 
chemokine receptor CXCR4 and has been suggested to be important in escaping immune 
recognition by downregulating the surface expression of MHC class I proteins (Zuo et al., 
2009, Griffin et al., 2013). Other studies suggest pathogenic roles for BILF1 through its 
ability to hetero-dimerize with various chemokine receptors in turn altering the 
responsiveness of B lymphocytes to chemokines (Nijmeijer et al., 2010a, Vischer et al., 
2008). BILF1 also inhibits phosphorylated RNA-dependent protein kinase R (PKR), which 
plays a role in anti-viral immune responses (Beisser et al., 2005). BILF1 may also directly 
contribute to tumour development as it has been shown to induce secretion of VEGF and 
tumour formation in nude mice (Lyngaa et al., 2010).  
I utilized RNA in situ hybridization, RNAScope, (Wang et al., 2012) and 
immunohistochemistry methods to detect BILF1 as these methods can localize BILF1 
expression. Furthermore, a major limitation with both RNA sequencing and PCR method is 
that the data are an average of the cell population and does not provide information on what 
proportion of cells are BILF1 positive. This is important as BILF1 expression in the majority 
of cells may be biologically significant while high expression in just 1-2% of tumour cells 
may not. Details of these methods were provided in sections 2.2.22 and 2.2.23 of the 
Materials and Methods. I first made a FFPE block comprising pelleted cells of EBV loss 
Akata cells line, EBV-positive Akata cells, and EBV-positive Akata cells induced into the 
lytic cycle by method described in section 2.2.22 of the Materials and Methods. PPIB 
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(Cyclophilin B) and DapB were used as positive and negative controls for in situ 
hybridization method, respectively.  I detected BILF1 expression in both Akata un-induced 
and induced Akata cells. In un-induced Akata cells BILF1 transcripts were present in all cells 
at low levels and in 1-5% of cells at higher levels (Figure 35) representing the small 
proportion of cells spontaneously undergoing lytic cycle. In induced Akata around 20% of 
cells showed higher levels of expression (Figure 35D) consistent with the expression of 
BILF1 in cells induced into lytic cells although I did not detect the expression of the positive 
control gene, PPIB (Figure 35B).   
I had available to me FFPE sections of 15 BL samples which had already been tested for 
BILF1 expression by qPCR, of which 13 were BILF1-positive and 2 were BILF1-negative. 
These 15 samples were then subjected to RNA in situ hybridization.  7 samples that were 
BILF1-positive by qPCR were also positive by RNA in situ hybridization. 2 samples were 
negative for BILF1 expression in both methods. Four samples that were BILF1-positive by 
qPCR did not show BILF1 expression in the RNA in situ hybridization method, suggesting 
RNA in situ hybridization method may not be as sensitive as qPCR based methods. One 
sample failed in the RNA in situ hybridization method.  Example for RNA in situ 
hybridization in BL samples was shown in the Figure 36, where EBV-positive samples 
(Figures 36A-B) show positive staining for BILF1, where majority of tumour cells show low 
levels of BILF1 expression while few cells show higher level BILF1 expression indicating 
BILF1 is expressed in latency as well. 





Figure 35. Validation of the specificity of BILF1 RNAScope. A- EBER in situ hybridization 
on EBV-positive Akata cells. B. Image Showing the results of RNAScope with the positive 
control probe which detects expression of the housekeeping gene, PPIB. C. No expression of 
BILF1 by RNAScope in Akata-loss cells. D. A small number of cells spontaneously entering 
the lytic cycle, after treatment with a lytic cycle inducing agent, in EBV-positive Akata cells 
show very high levels of BILF1 mRNA. 





Figure 36. BILF1 RNAScope in BL. A-B shows two cases of BL positive for BILF1 mRNA 
showing typical punctate staining. C- shows a case lacking BILF1 mRNA. D. Positive 
staining of this case with the PPIB probe confirms that this was not due to poor RNA quality. 
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Next, I wanted to study the expression of BILF1 protein in tumour sample. As there was no 
commercially available antibody to BILF1, I designed two peptides for BILF1 antibody 
against BILF1 (YP 401711.1) and obtained rabbit polyclonal ab for two BILF1 peptides and   
BILF1 antibody staining was optimized in EBV-negative, EBV-positive, and lytic cycle 
induced Akata cells as described in section 2.2.24 of the Materials and Methods. 
Figure 37A shows no expression of BILF1 in the EBV-negative Akata cells, negative control, 
and the lytic cycle induced Akata cells, positive control, show a strong expression of BILF1 
on membrane and cytoplasm (Figure 37B). An example for the absence of BILF1expression 
was shown in the BL sample BL-782 (Figure 37C) and BL sample BL-668 (Figure 37D) 
show membranous expression of BILF1.  
 
 






Figure 37. BILF1 expression shown by immunohistochemistry method. BILF1 expression 
was absent in the (A) Akata loss cells ( negative control);  (B) and present in in the lytic 
cycle-induced Akata cells,  (positive control); (C) No expression for BILF1 was seen in 
sample BL-782; whereas (D) BL sample BL-668 show nuclear expression of BILF1. 
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4.4 Genes regulated by BILF1 in DG-75 cells and in primary human 
germinal centre B cells 
 
4.4.1 BILF1 expression in DG-75 cells 
Since BILF1 is a constitutively active GPCR I reasoned that it is likely to be a potent 
transcriptional regulator. Therefore, initially I elected to investigate the transcriptional 
consequences of BILF1 over-expression in the EBV-negative BL cell line, DG-75.  
To do this, DG-75 cells were transfected with BILF1-plasmid and empty vector-plasmid. 
After 48 hours following transfection, GFP-positive cells were flow-sorted. GFP-positive 
cells were about 22% of total population in vector-transfected DG-75 and 18% in BILF1-
plasmid transfected cells. BILF1 protein was extracted from these flow sorted DG-75 cells. 
Western blotting was performed on these HA-tagged BILF1-GFP and vector-GFP proteins. A 
50 K-Da BILF1 protein is seen in western blotting for DG-75 cells transfected with BILF1-
GFP, but not in the protein extracted from empty vector transfected DG-75 cells (Figure 38). 
RNA sequencing data for three biological replicates of DG-75 cells following transfection 
with BILF1 or vector, and this data was analysed using the methods described in section 
2.2.12 of the Materials and Methods. 
 





Figure 38. Detection of BILF1 protein in DG-75 cells transfected with BILF1-GFP plasmid. 
BILF1 protein extracted from flow sorted DG-75 cells transfected with BILF1 or empty 
vector. Western blotting was performed on these HA-tagged BILF1-GFP and vector-GFP 
proteins. A 50 K-Da BILF1 protein is seen in western blotting for DG-75 cells transfected 
with BILF1-GFP, but not in the protein extracted from empty vector transfected DG-75 cells. 
BILF1 protein is also absent in the negative control (NC). 
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4.4.2 Gene ontology analysis of genes regulated by BILF1 in DG-75 cells 
I observed 38, 83 and 96 BILF1 CPM in each of the triplicates of BILF1-transfected DG-75. 
In the case of the vector-transfected DG-75 cells I observed 1.24, 1.35, and 1.22 BILF1 CPM, 
which could have been due to the contamination during the preparation of BILF1 and empty-
vector plasmids. 
132 genes were up-regulated and 72 genes were down-regulated in BILF1-transfected DG-75 
cells compared to vector-transfected cells (absolute fold change ≥ 1.5 and p<0.05) (Table 25 
and Table 26). 
As a first step to understand the biological relevance of the genes I had shown to be regulated 
by BILF1 in DG-75 cells, I performed a gene ontology analysis using DAVID6.8. This 
analysis revealed enrichment of several biological processes relevant to lymphomagenesis, 
including ‘regulation of viral life cycle’ (GO: 1903900; p= 0.0021), ‘programmed cell death’ 
(GO: 0012501; p= 0.0051), ‘response to cAMP’ (GO: 0051591; p= 0.013), ‘regulation of G-
protein coupled receptor protein signalling pathway’ (GO: 0008277; p= 0.027), ‘regulation of 
ERK1 and ERK2 cascade’ (GO: 0070372; p= 0.038), and ‘I-kappaB kinase/NF-kappaB 
signalling’ (GO:0007249; p= 0.042) (Table 27).  
Biological processes enriched in down-regulated genes included ‘positive regulation of 
macromolecule biosynthetic process’ (GO: 0010557; p= 0.01), ‘positive regulation of 
nitrogen compound metabolic process’ (GO: 0051173; p= 0.016), and ‘regulation of cell 
differentiation’ (GO: 0045595; p= 0.043) (Table 28). 
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POTEI 3.61 CDRT1 1.83 GPR89B 1.59 
EGR1 3.32 CRB3 1.82 LINC01465 1.59 
OVCA2 2.62 BTBD19 1.81 DFNA5 1.59 
TNF 2.60 EDRF1-AS1 1.80 PLEKHG5 1.59 
EGR2 2.55 POLR2J2 1.79 MAFF 1.59 
RUNDC3B 2.54 FBXL2 1.78 PPP1R15A 1.59 
TIAF1 2.51 LOC441454 1.78 BAIAP3 1.58 
PTPN6 2.45 DRICH1 1.78 ZSWIM8-AS1 1.58 
CD69 2.42 ZP1 1.78 SH3TC1 1.58 
C1QTNF6 2.31 NHLRC4 1.77 C10orf95 1.58 
SSUH2 2.27 FAM53B-AS1 1.76 RPL13AP20 1.58 
F2 2.19 FTH1P3 1.75 THBS4 1.57 
ITGB2-AS1 2.17 MIR22HG 1.75 MTRNR2L5 1.57 
MUC6 2.14 NUTM2B 1.74 TCF7 1.56 
PCSK4 2.13 SLIT1 1.74 TCTN1 1.56 
LBX2 2.10 CMTM4 1.74 CLTCL1 1.56 
FCMR 2.08 POPDC2 1.73 TSC22D3 1.56 
TMCC2 2.08 TPH1 1.73 LOC101928100 1.56 
GLYATL2 2.08 JUN 1.71 RPS14P3 1.55 
CXCL8 2.07 FAM20A 1.70 MAP3K12 1.55 
PKD2L2 2.06 POMZP3 1.70 ANGPTL1 1.55 
TRPV3 2.06 CPLX3 1.68 C16orf86 1.55 
LPAR6 2.05 JOSD2 1.68 PTPRE 1.55 
PIP5K1P1 2.03 ARID5A 1.68 ANKRD30BL 1.55 
MIR663A 2.02 LOC439994 1.67 CKMT2 1.55 
BRD7P3 1.99 DUSP1 1.67 MIR8072 1.54 
BCL2L15 1.99 KIAA0513 1.67 ZFP36 1.54 
LOC644936 1.98 CILP2 1.66 ZNF192P1 1.54 
ADHFE1 1.96 FERMT2 1.65 IL10RB-AS1 1.53 
FOS 1.96 CDC42EP2 1.65 TAGAP 1.53 
SERPINE3 1.96 GJB7 1.64 LOXL4 1.53 
MIR186 1.92 FFAR1 1.64 SH2D2A 1.53 
FOSB 1.89 RGS1 1.64 PLCH2 1.53 
ZNF382 1.89 ROCK1P1 1.64 STAT5A 1.52 
POTEE 1.88 LINC00116 1.63 ZSWIM4 1.52 
OSCAR 1.87 EFCAB2 1.62 VPS37B 1.52 
CYP3A5 1.86 DOCK10 1.61 SPAG5-AS1 1.52 
FLRT1 1.86 LOC100506990 1.61 PRKRIP1 1.52 
COLQ 1.85 PRKXP1 1.61 CHMP3 1.52 
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BEST1 1.85 GREB1L 1.60 MAGEH1 1.51 
ST3GAL1 1.84 TUBA3D 1.60 RSPH4A 1.51 
NPB 1.83 NCF1 1.60 KCNJ13 1.51 
KLHL22 1.83 PRDM11 1.60 RFX3-AS1 1.50 














SNORA80A -2.79 SNORA52 -1.75 HMGN5 -1.63 
ID4 -2.65 TSPAN15 -1.74 TUBB4A -1.62 
SNORA54 -2.58 SNORA73B -1.72 HIST2H2BA -1.61 
MIR4539 -2.52 LINC01560 -1.72 KATNBL1P6 -1.61 
FEZF2 -2.15 LINC01226 -1.72 SCARNA5 -1.60 




SCARNA22 -2.06 SNORD75 -1.71 SNORA12 -1.58 




-1.70 LINC01225 -1.57 
SNORD54 -2.03 PFKFB4 -1.70 SH3BP5 -1.56 
CATIP-AS2 -2.03 SERPINA9 -1.69 SNORA21 -1.56 
NUDT6 -2.02 SNORA71D -1.69 SNORD60 -1.55 
LOC101927415 -2.00 CTAGE7P -1.68 SLC16A13 -1.55 
SNORA63 -1.99 SNORD38A -1.67 SNORD10 -1.54 
SNORD94 -1.99 CXorf21 -1.67 NRCAM -1.54 
SNORA48 -1.95 SAMD13 -1.67 MYLK-AS1 -1.53 
SNORA71A -1.93 SNORA70 -1.66 SNORD97 -1.53 
SNORD1B -1.93 CCDC67 -1.66 KIAA1107 -1.53 
SCARNA28 -1.86 EGFR -1.66 ANKRD19P -1.53 
SNORA37 -1.84 LOC100506801 -1.65 HNRNPA1 -1.52 
SNORA49 -1.83 KRT17 -1.65 VSIG10 -1.51 
SNORA53 -1.77 SNORA7B -1.64 P2RX2 -1.51 
LOC100129697 -1.76 TGFBI -1.64 SNORD78 -1.50 
SNORD100 -1.75 ANP32AP1 -1.63 SNORD133 -1.50 
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Table 27.  Selected biological processes enriched in the 132 genes up-regulated by BILF1 in 
DG-75 cells. 
Gene ontology term p-value 
GO:1903900~regulation of viral life cycle 0.002 
GO:0012501~programmed cell death 0.005 
GO:0006915~apoptotic process 0.007 
GO:1903901~negative regulation of viral life cycle 0.011 
GO:0051591~response to Camp 0.014 
GO:0008277~regulation of G-protein coupled receptor protein signalling pathway 0.027 
GO:0070372~regulation of ERK1 and ERK2 cascade 0.039 




Table 28. All biological processes enriched in the 72 genes down-regulated by BILF1 in DG-
75 cells. 
Gene ontology term p-value 
GO:0021543~pallium development 0.009 
GO:0010557~positive regulation of macromolecule biosynthetic process 0.011 
GO:0031328~positive regulation of cellular biosynthetic process 0.015 
GO:0032846~positive regulation of homeostatic process 0.015 
GO:0009891~positive regulation of biosynthetic process 0.016 
GO:0051173~positive regulation of nitrogen compound metabolic process 0.016 
GO:0021537~telencephalon development 0.018 
GO:0007413~axonal fasciculation 0.019 
GO:0021895~cerebral cortex neuron differentiation 0.021 
GO:0008038~neuron recognition 0.029 
GO:0051240~positive regulation of multicellular organismal process 0.034 
GO:0030900~forebrain development 0.041 
GO:0045595~regulation of cell differentiation 0.044 
GO:0007417~central nervous system development 0.045 
GO:0010605~negative regulation of macromolecule metabolic process 0.047 
GO:0031324~negative regulation of cellular metabolic process 0.049 
GO:0001558~regulation of cell growth 0.050 
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4.4.3 Pathway analysis of the genes regulated by BILF1 in DG-75 cells 
I performed a gene set enrichment analysis using canonical pathways (BIOCARTA CP) and 
Hallmark pathways gene sets from MSigDB database. As described in section 2.2.21 of the 
Materials and Methods, this approach enables the identification of genes enriched in 
signalling pathways or other biological processes.   
I found significant enrichment in lymphomagenesis-related pathways in the genes up-
regulated by BILF1 in DG-75 cells, including ‘EPO signalling pathway’ (EPO pathway; p= 
9E
-08
), ‘oxidative stress induced gene expression via Nrf2’ (ARENRF2 pathway;  p= 3E
-06
),  
‘PDGF signalling pathway’ (p= 5E
-05
),   ‘pertussis toxin-insensitive CCR5 signalling in 
macrophage’ (CCR5pathway; p= 7E
-04
), and ‘signalling pathway from G-Protein families’ 
(GPCR pathway; p= 3E
-03
) (Table 29). A complete list of pathways enriched in the genes up-
regulated by BILF1 in DG-75 cells is given in Appendix 18. Hallmark pathway analysis for 





), ‘inflammatory response’ (p= 0.0031), ‘apoptosis’ (p= 0.0086), and   
‘p53 pathway’ (p= 0.017) (Table 29).  
In the case of genes down-regulated by BILF1 in DG-75 cells, canonical pathway analysis 
revealed enrichment in several pathways, including ‘Map Kinase Inactivation of SMRT 
Corepressor’ (p= 0.013), ‘CBL mediated ligand-induced downregulation of EGF receptors’ 
(p= 0.016), ‘sprouty regulation of tyrosine kinase signals’ (p= 0.022), ‘role of ERBB2 in 
signal transduction and oncology’ (HER2 pathway;   (p= 0.026),  and ‘Erk1/Erk2 MAPK 
signalling pathway’ (p= 0.033) (Table 30).  Hall mark pathway analysis for down-regulated 
by BILF1 in DG-75 cells revealed a significant enrichment of pathways related to ‘hypoxia’ 
(p= 0.019), ‘glycolysis’ (p= 0.019), ‘apical junction’ (p= 0.02), and ‘Hedgehog signalling’ 
(p= 0.037) (Table 30). 
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Table 29. Selected canonical and all hallmark pathways enriched in the 132 genes up-
regulated by BILF1 in DG-75 cells. 
Canonical pathway p-value 
EGFR SMRTE pathway 0.013 
CBL pathway 0.016 
Cardiac EGF pathway 0.022 
SPRY pathway 0.022 
TEL pathway 0.022 
TFF pathway 0.025 
HER2 pathway 0.026 
MCALPAIN pathway 0.030 
ERK pathway 0.033 
EGF pathway 0.037 
AT1R pathway 0.040 
Hallmark pathway p-value 
TNFA signalling via NFκB 1.35E-12 
 Hypoxia 6.16E-05 
 Inflammatory response 0.003176 
 Apoptosis 0.008663 
 P53 pathway 0.017729 
  
 
Table 30. All canonical and hallmark pathways enriched in the 72 genes down-regulated by 
BILF1 in DG-75 cells 
Canonical pathway p-value 
EGFR SMRTE pathway 0.013 
CBL pathway 0.016 
Cardiac EGF pathway 0.022 
SPRY pathway 0.022 
TEL pathway 0.022 
TFF pathway 0.025 
HER2 pathway 0.026 
MCALPAIN pathway 0.030 
ERK pathway 0.033 
EGF pathway 0.037 
AT1R pathway 0.040 
AGR pathway 0.043 
Hallmark pathway p-value 
 Hypoxia 0.019 
 Glycolysis 0.019 
 Apical junction 0.020 
 Hedgehog signalling 0.037 
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4.4.4 Overlap between genes regulated by BILF1 in DG-75 cells and genes 
differentially expressed in BILF1-positive eBL 
I next wanted to compare the extent to which the BILF1-targets I had identified in DG-75 
cells were also concordantly differentially expressed in primary eBL. To do this, I re-
analysed RNA sequencing data previously published by Abate et al., derived from 20 
endemic BL samples (SRA accession PRJNA292327) and RNA sequencing data from 4 
germinal centre B cell (GC B) samples (GSE45982) published by Béguelin et al., 2013 
(Abate et al., 2015, Béguelin et al., 2013) using EBV annotations I refined as described in 
section 2.2.20 of the Materials and Methods. The number of mapped sequencing reads for 
BILF1 in each of these samples is shown in Table 31. I next compared cellular gene 
expression in the 17 BILF1-expressing eBL with that in the 3 GC B cell samples which do 
not show BILF1 expression.  4030 genes were up-regulated and 3217 genes were down-
regulated in BILF-expressing eBL samples compared to GC B cells (fold change ≥1.5 and 
p<0.05).   
I observed no significant enrichment of genes downregulated by BILF1 in DG-75 cells in the 
genes either up-regulated or down-regulated in BILF1-positive eBL (OR=1.00; p= 0.99 and 
OR=1.16; p= 0.67), respectively (Figure 39). Furthermore, I observed no significant 
enrichment of genes up-regulated by BILF1 in DG-75 cells in the genes up-regulated in 
BILF1-positive eBL cases (OR=1.05; p= 0.84). However, I did observe a significant 
enrichment of genes up-regulated by BILF1 in the genes down-regulated in   BILF1-positive 
eBL cases (OR=2.72; p< 0.0001) (Figure 39A).  
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Table 31. Number of reads in endemic Burkitt lymphoma samples mapped to human 
reference genome (hg19). 
Sample Reads mapped to hg19 Total BILF1 reads BILF1 reads (CPM) 
eBL81 27951602 63 2.25 
eBL22 43088688 77 1.79 
eBL84 23470600 34 1.45 
eBL30 17223517 18 1.05 
eBL19 21106346 22 1.04 
eBL50 36587265 16 0.44 
eBL35 31537781 11 0.35 
eBL60 29521251 9 0.3 
eBL80 33066993 9 0.27 
eBL23 26199978 6 0.23 
eBL69 30622512 7 0.23 
eBL49 23333219 4 0.17 
eBL40 35807489 6 0.17 
eBL27 27812284 4 0.14 
eBL45 17284461 2 0.12 
eBL62 33414770 2 0.06 
eBL15 25893798 1 0.04 
GCB 4 112690263 1 0.01 
eBL20 31850521 0 0 
eBL43 25776475 0 0 
eBL48 26847694 0 0 
GCB 1 110098531 0 0 
GCB 2 83663270 0 0 
GCB 3 73605144 0 0 
 




Figure 39. Overlap between the genes regulated by BILF1 in DG-75 cells and BILF1-positive endemic Burkitt lymphoma. A. Significant 
enrichment of genes up-regulated by BILF1 in DG-75 cells was only observed in genes down-regulated by BILF1 in BILF1-positive eBL. B. No 
significant enrichment of BILF1-down-regulated genes in DG-75 cells was observed in differentially expressed genes in BILF1-positive eBL.
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4.5 BILF1 regulated genes in primary human germinal centre B cells 
In light of the disappointing overlap between genes differentially expressed following BILF1 
expression in DG75 cells and those concordantly differentially expressed in eBL, I decided to 
adopt an alternative approach in which primary human germinal centre B cells transfected 
with BILF1 were subjected to RNA sequencing. Transfection was performed using well 
established protocols (sections 2.2.13-2.2.17 of the Materials and Methods) previously used to 
elucidate the transcriptional program of individual viral genes in GC B cells (Vockerodt et 
al., 2008). 
RNA sequencing data obtained for BILF1-transfected and vector-transfected GC B cells was 
normalized as described earlier. The number of BILF1 gene counts per million reads in 
BILF1-transfected GC B cells (samples T25-T27) was 9386, 23208 and 8123, respectively. 
Low levels of BILF1 expression were observed in empty vector transfected GC B samples 
(11, 4.8, and 6 CPM in samples T25, T26, and T27, respectively). 
4.5.1 Genes regulated by BILF1 in primary human germinal centre B cells 
463 genes were up-regulated (Appendix 20) and 356 down-regulated (Appendix 21) in 
BILF1-transfected GC B samples compared to empty vector controls (fold change ≥1.5 and 
p<0.05).  A list of 50 genes (25 up, 25 down) with the highest fold change in expression are 
shown in Table 32. 
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Table 32. 25 most differentially expressed genes in BILF1-transfected GC B cells. 
Genes up-regulated by BILF1  
in GC B cells 
Genes down-regulated by BILF1  
in GC B cells 
Gene Fold Change Gene Fold Change 
PNMA2 6.76 IL26 -7.41 
LINC01269 6.61 LOC100129924 -6.96 
CNIH3 6.33 WDR38 -5.56 
TCONS 00029157 5.58 KSR2 -5.12 
DOK2 4.77 TRHR -4.15 
FMR1-AS1 4.01 NAALADL2 -4.06 
CAMK2A 3.97 GRPR -4.06 
TIAF1 3.74 LOC339807 -3.77 
CST7 3.49 LAG3 -3.71 
LOC102724919 3.40 CD28 -3.54 
SLC37A2 3.40 HIST1H3H -3.45 
GNA14 3.40 ELOVL3 -3.42 
SPTLC3 3.39 TMEM59L -3.34 
SLC19A1 3.32 LOC442497 -3.32 
CACNG7 3.32 TRPV4 -3.28 
WNT1 3.30 LOC102724484 -3.27 
NPR1 3.18 ULBP2 -3.25 
NACAD 3.10 LOC101060553 -3.23 
MTVR2 3.06 JHDM1D-AS1 -3.21 
TRAPPC2L 2.91 NOD2 -3.17 
RCAN2 2.90 MIR4324 -3.14 
GREB1 2.89 SMCO3 -3.12 
IL24 2.86 CCNI2 -3.12 
CDC14B 2.84 MIR554 -3.05 
OSTCP1 2.82 WNK2 -3.04 
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4.5.2 Gene ontology analysis of BILF1-regulated genes in germinal centre B cells 
An ontology analysis revealed that genes up-regulated by BILF1 in GC B cells were enriched 
for several biological process potentially relevant to lymphomagenesis, including ‘oxidative 
phosphorylation’ (GO:0006119; p= 1.81E
-15
), ‘ATP metabolic process’ (GO: 0046034; p= 
1.45E
-13
), ‘viral transcription’ (GO: 0019083; p= 1.16E
-07
), ‘viral life cycle’ (GO: 0019058; 
p= 8.27E
-05
), ‘tumour necrosis factor-mediated signalling pathway’ (GO: 0033209; p= 
0.0011), and ‘regulation of B cell receptor signalling pathway’ (GO: 0050855; p= 0.0011) 
(Table 33 and Appendix 22 showing 125 most significantly enriched biological processes).  
The 356 genes down-regulated by BILF1 in GC B cells, were enriched for ‘regulation of 
phosphorylation’ (GO: 0042325; p= 4.01E
-06
), ‘MAPK cascade’ (GO: 0000165; p= 7.
23E-05
), 
‘negative regulation of angiogenesis’ (GO: 0016525; p= 3.45E
-03
), ‘lymphocyte aggregation’ 
(GO: 0071593; p= 0.0189), and ‘chemokine production’ (GO: 0032602; p= 0.0195) (Table 
34 and Appendix 23). 
Results part-II: Burkitt lymphoma 
178 
 
Table 33. Selected biological processes enriched in 463 genes up-regulated by BILF1 in GC 
B cells. 
Gene ontology term p-value 
GO:0042773~ATP synthesis coupled electron transport 6.53E-16 
GO:0006119~oxidative phosphorylation 1.81E-15 
GO:0046034~ATP metabolic process 1.45E-13 
GO:0019083~viral transcription 1.16E-07 
GO:0019080~viral gene expression 2.84E-07 
GO:0019058~viral life cycle 8.27E-05 
GO:0033209~tumour necrosis factor-mediated signalling pathway 0.0011 
GO:0050855~regulation of B cell receptor signalling pathway 0.0374 
GO:0042769~DNA damage response, detection of DNA damage 0.0450 
 
Table 34. Selected biological processes enriched in 356 genes down-regulated by BILF1 in 
GC B cells. 
Gene ontology term p-value 
GO:0042325~regulation of phosphorylation 4.01E-06 
GO:0043549~regulation of kinase activity 6.65E-05 
GO:0000165~MAPK cascade 7.23E-05 
GO:1901343~negative regulation of vasculature development 1.30E-04 
GO:0009967~positive regulation of signal transduction 4.08E-04 
GO:0008283~cell proliferation 5.76E-04 
GO:0016525~negative regulation of angiogenesis 3.45E-03 
GO:0071593~lymphocyte aggregation 0.0189 
GO:0032602~chemokine production 0.0195 
GO:0051249~regulation of lymphocyte activation 0.0248 
GO:0045786~negative regulation of cell cycle 0.0261 
GO:0050864~regulation of B cell activation 0.0291 
GO:0042094~interleukin-2 biosynthetic process 0.0294 
GO:0032660~regulation of interleukin-17 production 0.0352 
GO:0070373~negative regulation of ERK1 and ERK2 cascade 0.0437 
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4.5.3 Pathway analysis of genes regulated by BILF1in GC B cells 
I next performed a pathway analysis using gene sets from MSigDB database. Analysis of 
genes up-regulated by BILF1in GC B cells revealed the enrichment of several pathways, 
including ‘TCA cycle and respiratory electron transport’ (p= 9E
-28
), ‘Influenza viral RNA 
transcription and replication’ (p= 3E
-24
), ‘DNA repair’ (p= 2E
-4
), signalling by NOTCH1 (p= 
2E
-4
), ‘Vif-mediated degradation of APOBEC3G’ (p= 7E
-4
),  ‘p53 dependent G1 DNA 
damage response’ (p= 9E
-4
), ‘TRIF mediated TLR3 signalling’ (p= 3E
-3
),  and ‘G-alpha Q 
signalling pathway’ (p= 3E
-3
) (Table 35 and complete list in Appendix 24).  Hallmark 
pathway analysis for these genes revealed a significant enrichment in pathways including 
‘oxidative phosphorylation’ (p= 4.68E
-13
), ‘p53 pathway’ (p= 0.00023), ‘MYC target genes’ 
(p= 0.0066), and ‘mitotic spindle’ (p= 0.037) (Table 36). 
Genes down-regulated by BILF1in GC B cells were enriched for several pathways including 
‘G-protein coupled receptor ligand binding’ (p= 4E
-6
), and ‘chemokine receptors bind 
chemokines’ (p= 4E
-2
) (Table 37 and complete list in Appendix 25).  Hallmark pathway 
analysis revealed enrichment of several pathways, including ‘KRAS signalling up-regulated’ 
(p= 4.76E
-5
), ‘TNFA signalling via NF-κB’ (p= 0.001), and ‘inflammatory response’ (p= 
0.0031) (Table 38). 
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 Table 35. Selected canonical and all Hallmark pathways enriched in 463 genes up-regulated 
by BILF1 in GC B cells. 
Canonical pathway p-value 
TCA cycle and respiratory electron transport 3E-24 
Influenza viral RNA transcription and replication 5E-17 
DNA repair 2E-04 
Signalling by NOTCH1 2E-04 
Vif mediated degradation of APOBEC3G 7E-04 
P53 dependent G1 DNA damage response 9E-04 
Cell cycle checkpoints 2E-03 
NFκB and map kinases activation mediated by TLR4 signalling repertoire 2E-03 
TRIF mediated TLR3 signalling 3E-03 
G alpha q signalling events 3E-03 
Traf6 mediated induction of NFκB and MAP kinases upon TLR7 8 or 9 
activation 
3E-03 
G alpha I signalling events 4E-03 
G alpha Z signalling events 5E-03 
Signalling by ERBB4 5E-03 
Viral messenger RNA synthesis 5E-03 
P53 independent G1 S DNA damage checkpoint 7E-03 
PD1 signalling 9E-03 
Signalling by EGFR in cancer 1E-02 
Regulation of apoptosis 1E-02 
Signalling by the B cell receptor BCR 2E-02 
Hallmark pathway p-value 
 Oxidative phosphorylation 4.68E-13 
 P53 pathway 0.000237 
 Adipogenesis 0.000727 
 MYC targets V2 0.006656 
 DNA repair 0.009433 
 MTORC1 signalling 0.021359 
 Allograft rejection 0.022619 
 Unfolded protein response 0.026873 
 NOTCH signalling 0.027355 
 Mitotic spindle 0.037863 
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Table 36. Selected canonical and all Hallmark pathways enriched in 356 genes down-
regulated by BILF1 in GC B cells. 
Canonical pathway p-value 
GPCR ligand binding 4E-06 
Signalling by GPCR 1E-04 
Activated TLR4 signalling 2E-03 
PI3K cascade 8E-03 
GPCR downstream signalling 9E-03 
Signalling by PDGF 3E-02 
MAP kinase activation in TLR cascade 3E-02 
Chemokine receptors bind chemokines 4E-02 
Hallmark pathway p-value 
Estrogen response late 4.76E-05 
 KRAS signalling up 0.00086 
 TNFA signalling via NFκB 0.000993 
 Spermatogenesis 0.007149 
 Inflammatory response 0.012757 
 Estrogen response early 0.013423 
 TGF beta signalling 0.030734 
 Androgen response 0.039133 
 Interferon gamma response 0.040076 
 UV response up 0.046988 
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4.5.4  Overlap between genes regulated by BILF1 in both DG-75 and GC B cells 
I next compared the extent to which the genes regulated by BILF1 in DG-75 and GC B cells 
overlapped. Significant overlap was seen for the genes down-regulated by BILF1 in both DG-
75 and GC B cells (p< 0.0001), but not in the genes up-regulated by BILF1 in both DG-75 
and GC B cells (p= 0.078) (Figure 40).  
4.5.5 Overlap between genes regulated by BILF1 in GC B cells and genes 
differentially expressed in BILF1-positive eBL 
I next studied the extent to which genes regulated by BILF1 in GC B cells overlapped those 
differentially expressed in BILF1-positive primary eBL. I observed a significant enrichment 
of genes up-regulated by BILF1 in GC B cells among those genes up-regulated in BILF1-
positive eBL (OR=3.90; p<0.0001). Furthermore, I observed a significant enrichment of 
genes down-regulated by BILF1 in GC B cells among genes up-regulated in BILF1-positive 
eBL cases (OR=1.67; p<0.0001) (Figure 41).  





Figure 40. Genes concordantly regulated by BILF1 in DG-75 and GC B cells.     A. No statistically significant overlap was observed between the 
genes up-regulated by BILF1 in DG-75 and GC B samples. B. Overlap between BILF1 down-regulated genes in DG-75 and GC B samples.  
Statistically significant overlap was observed for genes down- regulated by BILF1 in DG-75 and GC B cells. 





Figure 41. Overlap between the genes regulated by BILF1 in GC B cells and BILF1-positive endemic Burkitt lymphoma. A. Significant 
enrichment of BILF1-up-regulated genes in GC B cells was observed in the up-regulated genes in BILF1-positive eBL. B. No significant 
enrichment of BILF1-down-regulated genes in GC B cells was observed in the genes down-regulated in BILF1-positive eBL, however 
significant enrichment of down-regulated genes by BILF1 in GC B cells was observed in the up-regulated genes in BILF1-positive eBL.
Results part-II: Burkitt lymphoma 
185 
 
4.6 MYC-target genes are enriched in genes regulated by BILF1 in GCB 
genes  
Having shown that the genes up-regulated by BILF1 were enriched in ‘MYC target genes’ 
(p= 0.0066), I next wanted to further explore the potential overlap between the transcriptional 
programmes controlled by BILF1 and MYC. I first used a previously published dataset which 
had reported the transcriptional changes that follow the expression of MYC in primary GC B 
cells (Schrader et al., 2012). To further confirm a relationship between the transcriptional 
programmes of BILF1 and MYC I used a second published dataset which reported the gene 
expression changes that follow the induction of a tet-regulatable MYC gene in P493-6 cells, a 
variant of the lymphoblastoid cell line, EREB2-5 (Li et al., 2005).  
4.6.1 Overlap between genes regulated by BILF1 in GC B cells and genes regulated by 
MYC in primary GC B cells 
The MYC targets were taken from an experiment in which MYC was over-expressed in 
primary GC B cells (Schrader et al., 2012) this array platform had 20219 unique genes. There 
were 19423 genes that were common between the Myc targets in primary GC B cells array 
platform and the RNA sequencing genome build (total genes 26438). 
346 genes were down-regulated by MYC in GC B cells. 340 are on both arrays. All 62 genes 
up-regulated by MYC were on both arrays. For obvious reasons I excluded MYC from this 
analysis, leaving 61 up-regulated genes and reducing the number of genes on both platforms 
to 19422. There were 447 genes up-regulated and 347 genes down-regulated by BILF1 in GC 
B cells; 396 of the up-regulated genes and 280 of the down-regulated genes were on both 
arrays.  
Four genes were up-regulated in both BILF1-transfected GCB and Myc-transfected primary 
GC B cells (OR = 3.39; p= 0.0135) (Figure 42A). Four genes down-regulated by BILF1 were 
also present in genes up-regulated by MYC in primary GC B cells (OR = 4.85; p= 0.0009) 
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(Figure 42A). Furthermore, two genes were common in genes down-regulated in both data 
sets (OR = 0.40; p= 0.19) (Figure 42B). Eleven genes up-regulated by BILF1 in GC B cells 
were also downregulated by MYC in primary GC B cells (OR = 1.62; p= 0.12) (Figure 42B). 
 
4.6.2 Overlap between genes regulated by BILF1 in GC B cells and genes regulated by 
MYC in P493-6 cells 
Li et al used P493-6 cells, a variant of the lymphoblastoid cell line EREB2-5, which is stably 
transfected with a tetracyclin-regulatable MYC gene.  
4115 genes were up-regulated by MYC in P493-6 cells, and 3413 genes were down-regulated 
by MYC in these cells; 3371 up-regulated genes and 2822 down-regulated genes were on 
both arrays. As before, I excluded the MYC gene from these analyses, the denominator was 
therefore 14124, and the number of MYC up-regulated genes, 3370. 339 genes up-regulated 
and 196 genes down-regulated by BILF1 in GC B cells were present on both arrays. 
I observed a significant enrichment of genes up-regulated by BILF1 in GC B cells in the 
genes up-regulated by MYC in P493-6 cells (OR = 1.64; p< 0.0001) (Figure 43A). No 
significant enrichment of genes up or down-regulated by BILF1 was observed in the genes 
down-regulated by MYC in P493-6 cells (OR = 1.19; p= 0.213 and OR = 0.69; p= 0.104) 
(Figure 43B).   I also observed no significant enrichment of genes down-regulated by BILF1 
in the genes up-regulated by MYC in P493-6 cells (OR = 0.68; p= 0.085) (Figure 43A).   





Figure 42. Overlap between differentially expressed genes between BILF1-transfected GCB and Myc-target genes from Shrader et al., 2012. A. 
Significant overlap of up-regulated genes by Myc in GC B cells was observed in genes regulated by BILF1 in GC B cells.  B. However, no 
significant overlap of down-regulated genes by Myc in the down-regulated genes by BILF1 in GC B cells. Significant enrichment of down-
regulated genes by Myc was observed in the up-regulated genes by BILF1 in GC B cells. 





Figure 43. Overlap between differentially expressed genes between BILF1-transfected GCB and Myc-target genes in P493-6.  
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4.7 Enrichment of metabolic signatures in the genes regulated by BILF1 in 
GC B cells 
One of the striking observations I made during the gene ontology/ pathway analyses of genes 
was the significant enrichment of genes up-regulated by BILF1 in GC B cells in the genes 
involved in oxidative phosphorylation (p<0.0001). This is of interest because recent studies 
have shown that the malignant transformation of mutated cells is accompanied by profound 
alterations in cellular metabolism that fulfil the energy requirements of cancer cell growth 
and proliferation (Hanahan and Weinberg, 2011). Furthermore, Birkenmeier et al., suggested 
that the HRS cells increase oxidative phosphorylation capacity by inducing mitochondrial 
proliferation, thereby promoting cell survival and tumour progression. This group also 
suggested that NFκB promotes tumour progression and survival by increasing oxidative 
phosphorylation capacity even in the presence of an optimal glucose supply (Birkenmeier et 
al., 2016). 
To further explore the potential regulation by BILF1 of genes with function in oxidative 
phosphorylation I re-analysed the transcriptional signatures of 96 metabolic pathways 
reported by Gaude E and Frezza C et al (Gaude and Frezza, 2016).  I performed gene set 
enrichment analysis on the overlapping gene sets. I found a striking enrichment of genes up-
regulated by BILF1 among genes comprising the ‘oxidative phosphorylation’ signature (OR= 
50.24; p<0.0001) (Figure 44A). I also observed weaker but statistically significant 
enrichment of genes involved in ‘Thiamine metabolism’, ‘Pyrimidine biosynthesis’, ‘ROS 
detoxification’, ‘Cyclic nucleotides metabolism’, Folate metabolism’, ‘Lysine metabolism’, 
‘Glutathione metabolism’, and ‘Lysosomal transport’ among genes up-regulated by BILF1.  
I also found significant enrichment of ‘glycolysis and gluconeogenesis’ signature (OR=3.25; 
p=0.0367) in the genes down-regulated by BILF1 in GC B cells (Figure 44B). 





Figure 44. Metabolic signatures enriched in genes regulated by BILF1 in GC B cells. 
Significant enrichment of genes in oxidative phosphorylation signature was observed in the 
genes up-regulated by BILF1 in GC B cells and eBL (A). Glycolysis signatures were 
enriched in genes downregulated by BILF1 in GC B cells (B). 






The majority of the studies that have investigated the contribution of individual EBV genes 
have focussed almost entirely on the latent genes. However, more recently it has become 
apparent that some genes formerly thought to be expressed only during EBV lytic cycle and 
may also be expressed during latency. The prototypic example of this is the viral encoded 
BHRF1 gene, which is a homolog of the cellular anti-apoptotic gene, BCL2. BHRF1 has 
been shown to be expressed during latency in a subset of Burkitt lymphomas carrying an 
EBV genome with an EBNA2 deletion and in which viral latent transcripts, including 
BHRF1, are expressed from the alternative latency promoter Wp. BHRF1 has been shown to 
provide protection from apoptosis in BL cells (Kelly et al., 2009a). 
The high-throughput qPCR analysis showed high levels of expression of a number of so 
called lytic cycle genes, these included BILF1, BALF4 and less well characterized RNAs 
LF1, LF2, and LF3.  LF1, LF2, and LF3 were poorly characterized as they were deleted in 
the B95-8 prototypic strain. Previous studies on the function of BALF4 (gp 100 precursor) 
reported that BALF4 gene is not required for DNA lytic replication and lytic protein 
production (Neuhierl et al., 2009). However, BILF1, another gene originally thought to be 
exclusively expressed in the virus lytic cycle, was previously reported to be important for 
viral pathogenesis (Beisser et al., 2005, Nijmeijer et al., 2010a, Zuo et al., 2009) 
BILF1 is a member of a distinct GPCR-like family whose sequences and genomic positions 
are conserved among all of the currently known γ-1-herpesviruses and in a subset of γ-2-
herpesvirus species (Beisser et al., 2005). BILF1-family genes are positioned at the 5’ end of 
a conserved gene block that includes the viral DNA polymerase gene, except the ORF74-like 
genes that are positioned near another conserved gene block that includes the large tegument 
protein gene (Figure 45). Beisser et al., showed that BILF1-encoded protein increases CRE-
mediated transcription in EBV-positive Burkitt lymphoma cells and lymphoblastoid B cells 




transfected with BILF1 through Gi/Go coupling. They also showed a reduction in the levels 
of phosphorylated RNA-dependent antiviral protein kinase R (PKR) in COS-7 and Burkitt 
lymphoma cells transfected with BILF1. These data suggest that BILF1 encodes a 
constitutively active GPCR capable of modulating various intracellular signalling pathways, 
as the above observed effects do not require a ligand to interact with the BILF1 gene product 
(Beisser et al., 2005, Nijmeijer et al., 2010a). 
Paulsen, S.J., et al., showed that BILF1 is heavily glycosylated protein (~50 K-Da) localized 
on the plasma membrane similar to KSHV-encoded GPCR, ORF74, suggesting that BILF1 
and ORF74 have similar functions during γ-herpesvirus replication. They also showed that 
BILF1 inhibited forskolin-triggered CREB activation via stimulation of endogenous G 
proteins thus suggesting that EBV may use BILF1 to regulate Gi-activated pathways during 
viral lytic replication, thereby affecting disease progression (Paulsen et al., 2005). Canonical 
pathways analysis on the up-regulated genes by BILF1 in GC B cells in my study also 
showed enrichment for genes involved in ‘Gastrin-CREB signalling pathway via PKC  and 
MAPK’ (p=0.005), supporting the previously reported functions of BILF1. 







Figure 45.  BILF1-like genes conserved in γ-1 and 2 herepesviruses.  EBV BILF1 and KSHV 
ORF74 belong to different viral GPCR gene families. The lines represent herpesvirus 
genomes. The symbols indicate gene positions, which were derived from GenBank accession 
nos. AY037858, NC 001345, NC 001650, NC 001826, NC 002531, NC 003409, and NC 
004367. Open symbols represent viral GPCR genes. The names of viral GPCR genes are 
indicated above their corresponding symbols. Genomes and gene positions are drawn to 
scale. EBV, Epstein-Barr virus; CeHV15, cercopithecine herpesvirus 15; CaHV-3, 
callitrichine herpesvirus 3; AlHV-1, alcephaline herpesvirus 1; EHV2, equine herpesvirus 2; 
KSHV, Kaposi’s sarcoma-associated herpesvirus; MHV-68, murine gammaherpesvirus 68 
(This figure is reproduced from Beisser et al., 2005). 




Vischer et al., demonstrated the ability of BILF1 to hetero-dimerize with chemokine 
receptors CXCR4, CXCR3, CCR9, and CC10 altering the responsiveness of B lymphocytes 
to chemokines there by altering homing and homeostasis of infected B lymphocytes and 
might be essential for EBV dissemination and/or be involved in EBV-induced pathogenesis 
(Vischer et al., 2008). The chemokine receptor CXCR4 is expressed on tumour cells, 
including B cell lymphoma and EBV-associated nasopharyngeal carcinoma, and plays a key 
role in B cell homing (Kunkel and Butcher, 2003). CXCR4 expression allows tumour cells to 
metastasize toward CXCL12-secreting organs (Hu, 2005, Niu et al., 2012). BILF1 forms 
hetero-oligomeric complexes with CXCR4 and inhibits CXCL12 binding to this receptor and 
attenuates  migration of BILF1-expressing plasma B cells to CXCL12 gradients allowing 
these cells to home and/or remain at sites that are most optimal for viral replication and 
dissemination (Nijmeijer et al., 2010b). 
Previous studies have shown the ability of EBV to evade immune mechanisms during lytic 
replication by targeting the MHC class I antigen processing pathway at the level of 
translation through BGLF5 (Rowe et al., 2007)and peptide transport through BNLF2a 
(Hislop et al., 2007b).  Several studies have shown that BILF1 can down-regulate surface 
HLA class I expression and thus preventing the presentation of viral antigens and cytotoxic T 
cell recognition of the infected cell (Zuo et al., 2009, Griffin et al., 2013). BGLF5 and 
BNLF2a are both products of early lytic cycle genes (Zuo et al., 2009, Yuan et al., 2006).  
Previous studies showed conflicting views on the early/late status of BILF1 (Paulsen et al., 
2005, Beisser et al., 2005, Yuan et al., 2006), however present study indicates that BILF1 can 
also be expressed during latent infection in B cells. The high-throughput qPCR revealed a 
high level of BILF1 expression in BL samples, whereas levels of BZLF1 expression were 
substantially lower. BZLF1 is required for the entry of B cells into the viral lytic cycle and is 
therefore a good marker of cells undergoing the replicative cycle. The possibility that BILF1 




is expressed in virus latency is supported by the observation that Akata cells lacking BZLF1 
contained low levels of BILF1 transcripts (in the RNA in situ hybridization experiment). 
Furthermore, it has been shown that BILF1 is expressed in lymphoblastoid cell lines 
generated by infection of B cells with a recombinant virus lacking a BZLF1 gene (Rowe and 
Zuo, 2010). The RNAScope on primary tissues provided confirmation of BILF1 expression 
in the majority of tumour cells in EBV positive cases, which might be expected were BILF1 a 
latent gene. Taking together these observations suggest that BILF1 is expressed during virus 
latency in B cells.  
Because BILF1 is a constitutively active GPCR, I reasoned that its effects are likely to be 
manifest in altered transcription. For this reason I studied the transcriptional changes that 
followed BILF1 expression. My initial experiments were focussed on a well utilized model, 
DG-75, an EBV-negative BL cell line. However, comparison of those transcriptional changes 
that followed by BILF1 expression in DG-75 with those observed when BILF1-positive eBL 
were compared with normal GC B cells yielded no significant overlap in concordantly 
expressed genes. With hindsight I realized that DG-75 may not have been the most 
appropriate model to identify BILF1-transcriptional targets as it is a fully transformed cell 
line, presumably having acquired the necessary changes without the requirement for EBV or 
BILF1. Therefore, I next studied the transcriptional changes that followed the expression of 
BILF1 in normal primary human germinal centre B cells. Our group has extensively used 
these cells as a model to identify the transcriptional consequences of the over-expression of 
viral cellular genes relevant to lymphomagenesis. This model would seem to be particularly 
appropriate to the study of BL, which is a tumour of the GC stages of B cell differentiation. 
In contrast to the DG-75 system I found that BILF1 induced more transcriptional changes in 
primary GC B cells many of which overlapped with genes differentially expressed in BILF1-
positive eBL. 




The pathway analysis using Hallmark gene sets showed that genes up-regulated by BILF1 in 
GC B cells were enriched in MYC-targets. This was of particular interest because MYC is 
over-expressed in BL as a consequence of the consistent presence of one of three 
translocations involving the c-Myc gene on chromosome 8. Furthermore, I also observed a 
striking overlap between genes up-regulated by BILF1 and those up-regulated by MYC in 
two different experimental settings; one in which MYC had been over-expressed in GC B 
cells and another in which MYC expression was induced in the P493-6 lymphoblastoid cell 
line. However, MYC itself was not itself apparently a transcriptional target of BILF1 in either 
DG-75 or GC B cells, so at this time it is unclear if MYC expression is modified directly by 
BILF1. Alternatively, MYC and BILF1 may engage similar cell signalling pathways resulting 
in similar transcriptional end points. In this respect, it is interesting to note that MYC is a 
potent inducer of oxidative phosphorylation.  
Previous studies have established the link between MYC and the upregulation of glucose 
metabolism. In particular, one of its target genes, lactate dehydrogenase A (LDH-A) is known 
to convert pyruvate through glycolysis (Shim et al., 1997). Subsequent studies have reported 
that several other genes involved in glucose metabolism are directly regulated by MYC, 
including glucose transporter GLUT1, hexokinase 2 (HK2), phosphofructokinase (PFKM), 
and enolase 1 (ENO1) (Kim et al., 2004, Kim et al., 2007, Osthus et al., 2000).  An interplay 
between MYC and HIF (hypoxia inducible factor) is also well documented (Figure 16) where 
glycolytic genes may be regulated by both transcription factors (Dang et al., 2009).  
MYC and HIF-1 regulate genes involved in glycolysis (glucose transporter Glut1, hexokinase 
2 (HK2), pyruvate kinase M2 (PKM2), lactate dehydrogenase A (LDHA), and pyruvate 
dehydrogenase kinase 1 (PDK1)), converting glucose to lactate (Figure 46). Myc can also 
stimulate glutamine metabolism through the regulation of transporters (SLC1A5) and 
glutaminase (GLS), where glutamine is converted to α-ketoglutarate (α-KG) for catabolism 




through the tricarboxylic acid (TCA) cycle to malate, which is transported into the cytoplasm 
and converted to pyruvate and then to lactate (glutaminolysis) (Dang et al., 2009). 
The pathway analysis of genes up-regulated by BILF1 in my study showed a significant 
enrichment of genes involved in the ‘HIF pathway’ (p=0.003), ‘Regulation of hypoxia 
inducible factor HIF by oxygen’ (p=0.02), ‘EPO signalling pathway’ (p= 9E
-08
), and ‘TCA 
cycle and respiratory electron transport’ (p= 9E-28), along with ‘MYC target genes’ (p= 
0.0066). 
The pathway analysis of genes up-regulated by BILF1 in GC B cells showed a significant 
enrichment of genes involved in oxidative phosphorylation (p<0.0001). Nearly a century ago 
Otto Warburg first described the dysregulation of cellular metabolism in cancer cells, where 
metabolism of cancer cells relies mostly on glycolysis even in the presence of oxygen, 
whereas normal cells fully oxidize glucose in the mitochondria (Warburg, 1924). Recent 
advances in the technologies that enable a more comprehensive examination of the intricacies 
of cancer metabolism show that the metabolic reprogramming of cancer goes beyond 
activation of glycolysis (Hu et al., 2013). Furthermore, a recent study on metabolic profiling 
of NCI-60 cell lines found that increased glycine uptake strongly correlates with proliferation 
rates of cancer cells, suggesting an increased requirement of building blocks for nucleotide 
biosynthesis in cancer cells (Jain et al., 2012). Genomic (Monti et al., 2005, Park et al., 2016) 
and metabolomic (Caro et al., 2012) studies on DLBCL showed enrichment of genes 
involved in oxidative phosphorylation in OxPhos-DLBCL subset. 
Gene set enrichment analysis of transcriptional signatures of 96 metabolic pathways in the 
genes up-regulated by BILF1 in GC B cells and up-regulated genes in BILF1-positive eBL 
revealed a striking enrichment of genes up-regulated by BILF1 among genes comprising the 
‘oxidative phosphorylation’ signature (OR= 50.24; p<0.0001) (Gaude and Frezza, 2016). 







Figure 46. Myc and HIF-1 regulate glucose metabolism.  Myc and HIF-1 are shown to 
regulate (dotted lines) genes involved in glucose metabolism (glucose transporter Glut1, 
hexokinase 2 (HK2), pyruvate kinase M2 (PKM2), lactate dehydrogenase A (LDHA), and 
pyruvate dehydrogenase kinase 1 (PDK1)), favouring the conversion of glucose to lactate 
(glycolysis). Myc is also shown to stimulate glutamine metabolism through the regulation of 
transporters (SLC1A5) and glutaminase (GLS). Glutamine is shown converted to α-
ketoglutarate (α-KG) and then to malate through the tricarboxylic acid (TCA) cycle. Malate 
is then transported into the cytoplasm and converted to pyruvate and then to lactate 
(glutaminolysis). PDH = pyruvate dehydrogenase. PDH = pyruvate dehydrogenase 
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5. CONCLUSIONS AND FUTURE WORK 
 
This thesis has explored the pathogenesis of two childhood B cell lymphomas, Hodgkin 
lymphoma (HL) and Burkitt lymphoma (BL). Both of these tumours present particular 
clinical problems. In the case of HL, cure rates, especially in children, are high. However, 
toxicity associated with the use of combination chemotherapy and radiotherapy is 
problematic, resulting in excess morbidity and mortality in HL survivors. Furthermore, there 
are no biomarkers available which can detect the small proportion of HL patients, who will 
either relapse or have refractory disease. This is mainly because the biological factors that 
underpin the more aggressive forms of HL are largely unknown.  
Deficiencies in our understanding of the biology of HL are in part due to a paucity of 
knowledge of the genetic abnormalities that characterize this tumour. This is in turn a 
consequence of the low abundance of tumour cells in affected tissues which is compromised 
genetic studies. For this reason to date there has only been one study which has reported the 
global genome of the HRS cell, this study included only ten cases and importantly relied on 
the isolation of the tumour cell population by flow sorting (Reichel et al., 2015). This is not 
an approach that can be employed for the analysis of archived tumour samples and for this 
reason it is unlikely to be a practical solution to the analysis of HRS genomes in retrospective 
studies, including samples from clinical trials.  
In the first results chapter, I present an entirely new approach to the analysis of HRS cell 
exomes based upon the amplification of DNA from HRS cells microdissected from snap 
frozen tumour tissues. This analysis allowed the description of the exomes of 13 cases of 
paediatric HL. As might have been anticipated from the analysis of only 150 cells per case, 




coverage was somewhat lower than has been reported for previous exome studies in other 
tumour settings using many more cells as a starting point. This low coverage was presumably 
responsible for a somewhat lower sensitivity. However, the sequencing of two separate 
biological replicates from each patient together with the use of stringent variant calling and 
filtering criteria ensured a high degree of specificity reflected in the high concordance 
between exome sequencing and Sanger sequencing in the validation steps. Work ongoing in 
the laboratory is investigating approaches to improve the sensitivity of the exome sequencing 
including the microdissection of more tumour cells. Furthermore, although, my initial 
experiments with cells microdissected from Formalin Fixed Paraffin Embedded (FFPE) 
samples yielded smaller amplification products than obtained from frozen material, it is not 
clear if these would be suited to exome sequencing and also requires further work. 
My analysis of the paediatric exomes revealed some novel insights into the biology of HL. 
First, I observed striking heterogeneity between samples reflected by the relatively small 
numbers of recurrently mutated genes. However, a pathway analysis revealed that many of 
the affected genes converge on a relatively small number of pathogenic pathways, 
highlighting the importance of considering pathway level analysis, rather than simply gene 
level analysis, when exploring whole exome data especially in tumours that display 
considerable heterogeneity at the gene level. In particular, I observed enrichment of genes 
with mitotic spindle functions among genes with protein-altering mutations. This is of 
particular importance given that HRS cells are characterized by chromosomal instability. 
Furthermore, the mitotic spindle checkpoint is a target of a number of chemotherapeutic 
drugs that are used routinely to treat patients with HL (Dominguez-Brauer et al., 2015, 
Hande, 2008). At present it is expected that once optimized the approach adopted in this 
thesis could be applied to a larger cohort of patients with paediatric HL such as those that will 
be enrolled to EuroNet-PHL-C2 (European Network-Paediatric Hodgkin Lymphoma Study 




Group Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children 
and Adolescents) trial about to open in the UK (ClinicalTrials.gov identifier: NCT02684708). 
This international, multicentre, randomised controlled trial aims to reduce the indication for 
radiotherapy in newly diagnosed patients with cHL without compromising cure rates. It also 
aims to investigate a chemotherapy intensification randomisation in intermediate and 
advanced cHL to compensate for reduction in radiotherapy. Given that in this trial, patients 
are assessed by PET scan after two cycles of chemotherapy, the genomic analysis of this 
cohort would provide an ideal opportunity to explore the impact of the HRS genome on 
chemotherapy responses.  
A second important observation was that mutations were significantly more frequent in EBV-
negative HL cases than in EBV-positive HL. This observation is in keeping with other studies 
of viral associated malignancies including EBV-positive and EBV-negative gastric cancers 
and HPV-positive and HPV-negative head and neck cancers (Network., 2014, Riaz et al., 
2014), where it has been shown that viral negative forms of the same cancer have more 
mutations than viral positive forms. A further striking observation in head and neck cancer is 
that patients with HPV-positive cancer have significantly longer survival than patients with 
HPV-negative tumours. Analysis of the impact of EBV on survival in paediatric HL shows a 
significantly longer progression-free survival for patients with EBV-positive disease 
compared with those with EBV-negative disease (Powell et al., unpublished work). However, 
it remains to be seen if these survival differences are a consequence of the lower mutation 
rates observed in virus-positive tumours.  
I also observed that EBV-negative HL is characterized by higher frequency of mutations in 
mitotic spindle associated genes compared with EBV-positive HL. I found that EBV could 
transcriptionally downregulate mitotic spindle associated genes, suggesting that the 
inactivation of the mitotic spindle is likely to be critical for the development of HL, and also 




that it could be achieved by distinct mechanisms; transcriptional downregulation in the 
presence of EBV, and by mutations in the absence of EBV. These mechanisms are unlikely to 
be entirely mutually exclusive.  
The molecular biology of BL, including the EBV-positive endemic forms, is already well 
described. So, in the case of BL, I turned my attention to a relatively unexplored area, that of 
viral gene expression and its potential contribution to BL pathogenesis. It is already been 
shown that the EBV-encoded BHRF1 gene, formerly thought to be exclusively expressed 
during the viral lytic cycle, is a bona fide latent gene. Therefore, I considered it likely that 
BHRF1 was not the only lytic cycle gene to be expressed in latently infected BL cells. Using 
a combination of high-throughput qPCR (Fluidigm), the re-analysis of RNA sequencing data, 
and RNAScope experiments, I showed BILF1 is expressed in a subset of primary eBL, where 
it appears to be present in most if not all of the tumour cells.  
The over-expression of BILF1 in primary GC B cells revealed that BILF1 could partially 
recapitulate the transcriptional programme of primary BL. Gene set enrichment analysis of 
BILF1 target genes suggested a potential role of BILF1 in oxidative phosphorylation. Future 
studies will explore the extent to which BILF1 can re-programme the metabolome of B cells 
and how this might contribute to the pathogenesis of BL. I also observed striking overlap 
between the transcriptional programme induced by BILF1 and that induced by MYC. 
However, I did not observe that MYC was a transcriptional target of BILF1 in GC B cells and 
so several other possibilities remain to explain this overlap, including the potential regulation 
of BILF1 by MYC.  
My observations are consistent with a potent role of BILF1 and pathogenesis of lymphoma, 
which is different from its established role in the immune escape of lytically infected cells 
mediated by the downregulation of surface HLA class I (Zuo et al., 2009). These effects are 
likely to be mediated by the functions of BILF1 as a constitutively active GPCR.  Future 




studies will investigate the signalling pathways engaged by BILF1 in B cells and the extent to 
which these can explain the transcriptional effects observed in this study. Furthermore, as a 
GPCR BLF1 is an attractive therapeutic target. Once important phenotypic effects of BILF1 
in B cells are confirmed, then the potential therapeutic targeting of BILF1 could be explored. 
It is noteworthy that the primary observation made here that BILF1 is also expressed in a 
subset of NPC is now being followed up in collaboration with colleagues in Southeast Asia 
and a manuscript is already in preparation. In addition to BILF1, I also identified a number of 
other highly expressed ‘lytic cycle’ genes about which a little or nothing is known, including 
the LF family These are obvious candidates to be taken forward in future studies. 
Future work 
The work presented here suggests several specific avenues for future study. A subset of 
recurrently mutated genes in my series and/or in Reichel and Liu series were selected to 
perform targeted sequencing (Tables 37 and 39) in a larger cohort of paediatric HLs. 
Additionally, we also selected a subset (Table 39) of mitotic spindle associated genes mutated 
in paediatric HLs that were also downregulated by EBV in GC B cells (Leonard et al., 
2011)and /or downregulated in HRS cells (Brune et al., 2008) for validation by q-PCR and 
IHC methods.  
Furthermore, a subset of MYC-target genes (Schrader et al., 2012) that are also differentially 
expressed in GC B cells regulated by BILF1 (Table 38) have been selected for validation by 
high-throughput q-PCR (Fluidigm) method in a larger cohort of BL samples. I am also 
designing an experiment to obtain metabolomics data from a larger cohort of BL samples for 
a subset of genes involved in oxidative phosphorylation that are upregulated by BILF1 in GC 
B cells and that are also upregulated in BILF1-positive eBLs (Table 40).  
 
I am currently preparing manuscripts for publication which will include these new data. 




Table 37. Genes with protein-altering mutations selected for targeted sequencing. 
Gene 
symbol 
Number of samples mutated in combined 
Reichel and Liu series (n=17)  
Number of samples mutated in 







B2M 7 0 




IGLL5 7 0 
ITPKB 7 0 
PCLO 7 0 
SOCS1 7 0 
FAT4 6 0 
GPR112 6 0 
GPR98 6 1 
IGHE 6 0 
LRRN3 6 0 




ACTB 5 0 




FAT1 5 0 
SMG1 0 5 
TPTE2 0 4 
OR4C5 1 4 
ZNF717 1 3 
SREK1 1 3 
SGOL2 0 3 
SF3B2 0 3 
PROM1 0 3 
HCFC2 1 3 
F8 1 3 
F5 1 3 







ITPR2 4 2 





Table 38. Genes selected for metabolomics profiling in a larger cohort of BL samples. 
ATP5E COX5B COX6C NDUFA1 NDUFB2 NDUFB10 NDUFA13 
ATP5G1 COX6A1 COX7B NDUFA7 NDUFB7 NDUFS8 NDUFA11 
ATP5I COX6B1 COX7C NDUFA8 NDUFB9 UQCR10  




Table 39. Selected mitotic spindle associated genes mutated in paediatric HLs for validation 
by q-PCR and IHC methods. 
Mitotic spindle associated 




(Leonard et al., 2011) 
Downregulated in 
HRS cells  
(Brune et al., 2008)  
Validation 
by IHC 
AGO4 AGO4 AGO4 AGO4 














CTCF CTCF CTCF CTCF 











PDS5B PDS5B PDS5B PDS5B 



















Table 40. MYC-target genes regulated by BILF1 in GC B cells for validation. 


























Appendix 1: Paediatric HL samples submitted for exome sequencing 
 
Sample Exome capture method  260/280 260/230 Quantity (ng) 
 S1 Normal Nextera 1.78 2.2 400 
 S1 1 Tumour (Sigma) Nextera 1.84 2.46 400 
 S1 2 Tumour (Sigma) Nextera 1.87 2.65 400 
 S2 Normal Nextera 1.9 2 400 
 S2 1 Tumour (Sigma) Nextera 1.85 2.15 400 
 S2 2 Tumour (Sigma) Nextera 1.95 2.49 400 
 S3  Normal Nextera 1.86 2.3 400 
 S3  1 Tumour (Sigma) Nextera 1.82 2.36 400 
 S3 2 Tumour (Sigma) Nextera 1.89 2.7 400 
 S4 Normal Nimblegen 2.01 2.28 2270 
 S4 1 Tumour (Sigma) Nextera 1.9 2.24 400 
 S4 2 Tumour (Sigma) Nextera 1.88 2.4 400 
 S5 Normal Nextera 1.86 2.4 400 
 S5 1 Tumour (Sigma) Nextera 1.85 2.4 400 
 S5 2 Tumour (Sigma) Nextera 1.92 2.6 400 
 S6 Normal Nimblegen 1.92 2.37 2145 
 S6 1 Tumour (Sigma) Nimblegen 1.96 2.18 1135 
 S6 2 Tumour (Sigma) Nextera 1.9 2.6 400 
 S7  Normal Nextera 2 2.3 400 
 S7  1 Tumour (Sigma) Nextera 1.83 2.5 400 
 S7 2 Tumour (Sigma) Nextera 1.96 2.7 400 
 S8 Normal Nextera 1.9 2.6 400 
 S8 1 Tumour (Sigma) Nextera 1.8 2.29 400 
 S8 2 Tumour (Sigma) Nextera 1.86 2.6 400 
 S9 Normal Nimblegen 2.00 1.87 1000 
 S9 1 Tumour (Sigma) Nimblegen 1.94 2.34 1037 
 S9 1 Tumour (Sigma) Nextera 1.8 2.4 400 
 S10 Normal Nimblegen 1.88 2.16 1457 
 S10 1 Tumour (Sigma) Nimblegen 1.94 2.30 1125 
 S11  Normal Nextera 1.93 2.27 400 
 S11 1 Tumour (Sigma) Nextera 1.9 2.6 400 
 S11 2 Tumour (Sigma) Nextera 1.86 2.6 400 
 S12  Normal Nextera 1.88 2.29 400 
 S12 1 Tumour (Sigma) Nextera 1.9 2.3 400 
 S12 2 Tumour (Sigma) Nextera 1.87 2.49 400 
 S13 Normal Nextera 1.93 2.28 400 
 S13 1 Tumour (Sigma) Nextera 1.9 2.4 400 
 S13 2 Tumour (Sigma) Nextera 1.92 2.79 400 
 S1 Normal Nextera 1.78 2.2 400 
 S1 1 Tumour (Sigma) Nextera 1.84 2.46 400 
 S1 2 Tumour (Sigma) Nextera 1.87 2.65 400 
 S2 Normal Nextera 1.9 2 400 
 S2 1 Tumour (Sigma) Nextera 1.85 2.15 400 




Appendix 2: PCR and sequencing primers for house-keeping genes 
 
Name Sequence (5' to 3') PCR-product (bp) 
ATM forward CTACCCCAACAGCGACATGG 
461 
ATM reverse TCTGCAGGCTGACCCAGTAA 
BCR  forward GGCTGCCCTACATTGATGACT 
403 
BCR  reverse AGGCTATGAAGCAAAGGGACC 
BRAF forward CCTCTGTTTGTTGGGCAGGA 
478 
BRAF reverse TGGAATCTCTGGGGAACGGA 
CDKN2A forward GTGAGATCTGGAAGGAGGTGG 
422 
CDKN2A reverse TCTAAGCATGGCTGTTCGAGG 
CYLD forward AGAATGCAGCGTTACAGACAAAC 
596 
CYLD reverse TCCGGAGACTGTCCTCTCTG 
ETV6 forward ATGCCCTGCTGCCAACTTAT 
477 
ETV6 reverse GCAGGCCTTAGGAAGTCTGG 
HRAS forward GCCACAGAGCCGAAGAAAAC 
492 
HRAS reverse GGCCTGGCATGAGGTATGTC 
JAK2 forward TTCGAGCAAAGATCCAAGACTATCA 
451 
JAK2 reverse ACTGAATTCCACCGTTTCCAGT 
KDM6A forward TTTCCCCAGAACACTCAGGC 
328 
KDM6A reverse GCTCCACGCCTCCTCAATAC 
NPM1 forward AAGAAATGGATTTGCACAGTAAGT 
518 
NPM1 reverse CCTGGAAAGATAGCTATGCCACA 
NRAS forward TCAGGAATGTTGGGTCTCAGTT 
403 
NRAS reverse ACTTCACACTTGCACCGAAAT 
PCM1 forward ATTCCCAAGGTAGAGCAACAGC 
301 
PCM1 reverse CTCCATTGCAGGTTCTCCCC 
Pik3ca forward AGAACAATGCCTCCACGACC 
236 
Pik3ca reverse TTCTTCACGGTTGCCTACTGG 
PTEN forward ACCATAACCCACCACAGCTAGA 
252 
PTEN reverse TCTAGGGCCTCTTGTGCCTT 
SOCS1 forward CACAAAGTGCTCAAACGCGA 
273 
SOCS1 reverse GGTCCCCCTGGTTGTTGTAG 
SUFU forward GAGTCTCACCCACCGAGTCC 
200 
SUFU reverse GATAGCGGTAACCTGGAGCG 
TNFAIP3 ex8forward ACTGTCAGCATCTCTGTATCGGTG 
188 
TNFAIP3 ex8reverse ATGAGGAGACAGAACCTGGCAGAG 
TP53 forward CGTGTTCCTAAAATGAGGGGGA 
265 
TP53 reverse AGGCCAGCTCTGCTACACTA 
ATM internal-Reverse TGGCTCCAAGTAAGCCAAAGT 204 
BCR internal-Reverse CTCCACGCTCAGTTCAAAGC 328 
BCR internal-Forward TTGTGGTGACTTGGGGTTGC 161 




CYLD internal-Forward ATGCCCTGCTGCCAACTTAT 254 
ETV6 internal-Forward CAGCCTTGACAGTGGTTGTG 350 
HRAS internal-Reverse ATAGCCTTTGGGAGGGGGAG 368 
JAK2 internal-Forward GCGAATAAGGTACAGATTTCGCAG 212 
KDM6A internal-Forward GGAAGGTTACACAACTGAGCC 538 
NPM1 internal-Forward CACAGTAAGTAGAGCAGGCAC 463 
NRAS internal-Forward GCGCCAATTGTACCATGTCC 344 
PCM1 internal-Forward AGTGAAAACCGAAAGCCCTTCA 193 
PI3KCA internal-Forward GAACTGTGGGGCATCCACTT 271 
PTEN internal-Reverse TGACCAATGGCTAAGTGAAGATGA 135 
SOCS1 internal-Reverse AACTCGCACCTCCTACCTCT 401 
SUF internal-Forward CCTCTCCAGTTCCCCCAGT 209 









Number of reads 
mapped to hg19 
Number of de-
duplicated reads 
mapped to hg19 
Percentage of reads 
de-duplicated reads 
mapped to hg19 
S1_1T 52982418 49388813 39098426 79.16 
S1_2T 18457784 15109232 10853837 71.84 
S1_Normal 43459734 42723024 34844738 81.56 
S2_1T 45170576 39295454 29607223 75.35 
S2_2T 30160728 25468631 18986498 74.55 
S2_Normal 44016574 43407422 37090820 85.45 
S3_1T 30792566 26354149 20099545 76.27 
S3_2T 26970450 23097204 18128259 78.49 
S3_Normal 26543008 26106778 23075364 88.39 
S4_1T 13688500 11876421 10165504 85.59 
S4_2T 24437198 20975247 17344225 82.69 
S4_Normal 1.73E+08 1.68E+08 1.44E+08 85.68 
S5_1T 38075914 34515232 27658719 80.13 
S5_2T 31270904 25394165 19875062 78.27 
S5_Normal 36918370 36379083 31788530 87.38 
S6_1T 47525522 20632679 17873878 86.63 
S6_2T 40490738 36266864 27927501 77.01 
S6_Normal 1.28E+08 1.24E+08 1.06E+08 85.86 
S7_1T 18233490 13406234 10741397 80.12 
S7_2T 27383540 21722212 17010090 78.31 
S7_Normal 71048628 70131419 63635432 90.74 
S8_1T 27180052 23998343 19382890 80.77 
S8_2T 39987020 32195493 25088072 77.92 
S8_Normal 44108778 43390475 39337216 90.66 
S9_1T 62436382 25162228 21823801 86.73 
S9_2T 24198644 21035810 17101118 81.3 
S9_Normal 1.05E+08 83559457 64064749 76.67 
S10_1T 78022084 34099910 29012204 85.08 
S10_2T 23838192 17298606 14682956 84.88 
S10_Normal 1.57E+08 1.27E+08 93608826 73.64 
S11_1T 33858398 27558083 20844841 75.64 
S11_2T 28138442 22537498 17495344 77.63 
S11_Normal 60749026 59737127 50348182 84.28 
S12_1T 21905612 17792530 14178459 79.69 
S12_2T 32410952 26554604 20323830 76.54 
S12_Normal 50020384 49311261 43679423 88.58 
S13_1T 25248462 21351419 16920239 79.25 
S13_2T 34537668 27326475 20521960 75.1 
S13_Normal 62109966 61217081 54985887 89.82 
*Samples failed in exome sequencing, as confirmed in data analysis, were marked in Red. 




Appendix 4: List of most frequently mutated genes in my series  
 
KLF6 ZNF292 SMC1B PDE4DIP GAPVD1 CLOCK 
SMG1 ZFR SMARCC1 PCCA GALC 
CKLF−CMT
M1 




TTN Z85986.1 SMARCAD1 NDUFB5 FUS CEP41 
TPTE2 YTHDF3 SLC36A1 NAV3 FIP1L1 CDK5RAP2 
OR4C5 XIST SLC35A1 NAA16 FGFR4 CDH3 
CSMD3 WDR35 SEC31A MYO6 ETNK1 CDC27 
ZNF717 USP15 RYR2 MUC19 EPN2 CCT6B 
STAG3L2 UPF2 RP11−888D10.4 MUC16 EPG5 CCIN 
SREK1 UGT1A9 RP11−799N11.1 MICU3 EML4 CCDC73 
snoU13 UGT1A8 RP11−403P17.2 MICAL1 EIF3H C6orf165 
SGOL2 UGT1A7 RP11−388M20.1 MATR3 EFCAB7 C20orf194 
SF3B2 UGT1A6 RP11−382A20.7 LNX1 EDRF1−AS1 C1orf87 






UGT1A10 RP11−382A20.5 LAMA4 EAPP BTBD1 
RGS3 TSIX RP11−21J18.1 LAMA3 DYNC2H1 BSPH1 
R3HDM2 TRIP13 RP11−135L13.4 KLHL7 DPYD BRD9 
PSMG2 TRIOBP RP11−123K3.4 KLHL1 DPCR1 BNIP2 
PROM1 TNFRSF9 RP11−115F18.1 KIF3A DNAH12 BBS4 




NF1 TMEM131 RNF213 JAKMIP1 DLEU2L ATXN2 
MUC4 TEX15 RN7SKP64 ITPR2 DLEC1 ATAD2 
MUC17 TEX10 RMDN2−AS1 ITPR1 DIAPH3 APIP 
MIR4273 TAF2 RMDN2 ITGB3BP DFNB59 ANKRD44 
JMJD1C SYNE1 RIMS2 IPP DCBLD2 ANKRD12 











RAD50 HIVEP1 CTD−2047H16.4 AC004237.1 
F5 ST3GAL6 QSER1 HECTD1 CTC−297N7.11 ABCC2 
CHD4 SRRM2 PROS1 HCG21 COL9A1 ABCA1 
CEP76 SOX5 PRKRA GTF3C1 CMTM2 
 
















Appendix 5: List of most frequently mutated genes (protein-altering) in my series 
 
SMG1 ZNF292 RALGPS2 KIF3A DPYD BTBD1 
TPTE2 ZFR RAD50 KIAA1009 DNAH12 BSPH1 
OR4C5 USP15 QSER1 JMJD1C DMTF1 BRD9 
ZNF717 UGT1A8 PROS1 ITPR2 DLEU2L BNIP2 
TTN TRIOBP PRKRA ITPR1 CYSLTR1 BBS2 
SREK1 TMEM57 PDE4DIP IPP COL9A1 ATAD2 
SGOL2 SYNE1 NF1 IGHV2−70 CMTM1 APIP 
SF3B2 STK38 NDUFB5 HECTD1 CMPK1 ANKRD12 
PROM1 ST3GAL6 NAV3 GTF3C1 CKLF−CMTM1 AGPAT9 
MUC17 SRRM2 MYO6 GNE CHD4 ADAMTS12 
HCFC2 SNRNP200 MUC4 GARS CHD2 ABCA1 
F8 SMC1B MICU3 EPN2 CEP76 
 
F5 SMARCC1 LAMA4 EPG5 CCT6B 
 
CSMD3 SBF2 LAMA3 EML4 CCDC73 
 
CCDC80 RYR2 KLHL7 EIF3H C20orf194 






Appendix 6: Biological processes enriched in 42 genes common in all 3 HL studies 
 
Gene ontology term p-value 
GO:0042592~homeostatic process 1.1E-06 
GO:0001894~tissue homeostasis 4.1E-05 
GO:0060249~anatomical structure homeostasis 5.9E-05 
GO:0032088~negative regulation of NF-kappaB transcription factor activity 3.7E-04 
GO:0048871~multicellular organismal homeostasis 3.7E-04 
GO:0044085~cellular component biogenesis 7.1E-04 
GO:0048878~chemical homeostasis 8.2E-04 
GO:0022607~cellular component assembly 8.9E-04 
GO:0045184~establishment of protein localization 1.2E-03 
GO:0007010~cytoskeleton organization 1.4E-03 
GO:0055088~lipid homeostasis 1.9E-03 
GO:0043433~negative regulation of sequence-specific DNA binding transcription factor 
activity 
2.5E-03 
GO:0032886~regulation of microtubule-based process 2.9E-03 
GO:1902589~single-organism organelle organization 3.3E-03 
GO:0042060~wound healing 4.0E-03 
GO:0007049~cell cycle 4.2E-03 
GO:0010803~regulation of tumour necrosis factor-mediated signalling pathway 4.6E-03 
GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signalling 4.9E-03 
GO:0032845~negative regulation of homeostatic process 5.0E-03 
GO:0019725~cellular homeostasis 5.3E-03 
GO:0033036~macromolecule localization 5.8E-03 
GO:0008104~protein localization 5.8E-03 
GO:0016266~O-glycan processing 6.3E-03 
GO:0060113~inner ear receptor cell differentiation 6.3E-03 
GO:0048646~anatomical structure formation involved in morphogenesis 6.5E-03 
GO:0007017~microtubule-based process 7.0E-03 
GO:0042490~mechanoreceptor differentiation 7.1E-03 
GO:0051641~cellular localization 7.7E-03 
GO:0009611~response to wounding 8.5E-03 
GO:0030031~cell projection assembly 9.1E-03 
GO:0000819~sister chromatid segregation 9.7E-03 
GO:0000226~microtubule cytoskeleton organization 9.8E-03 
GO:0032844~regulation of homeostatic process 1.2E-02 
GO:1902532~negative regulation of intracellular signal transduction 1.2E-02 
GO:0055082~cellular chemical homeostasis 1.2E-02 
GO:0071705~nitrogen compound transport 1.3E-02 
GO:0022402~cell cycle process 1.5E-02 
GO:0048514~blood vessel morphogenesis 1.6E-02 




GO:0022610~biological adhesion 1.6E-02 
GO:0048739~cardiac muscle fibre development 1.8E-02 
GO:0006493~protein O-linked glycosylation 1.8E-02 
GO:0098813~nuclear chromosome segregation 1.9E-02 
GO:0010927~cellular component assembly involved in morphogenesis 2.0E-02 
GO:0070507~regulation of microtubule cytoskeleton organization 2.4E-02 
GO:0015031~protein transport 2.6E-02 
GO:0001568~blood vessel development 2.6E-02 
GO:0061041~regulation of wound healing 2.7E-02 
GO:0007062~sister chromatid cohesion 2.7E-02 
GO:0007059~chromosome segregation 2.8E-02 
GO:0016925~protein sumoylation 2.8E-02 
GO:0044872~lipoprotein localization 2.9E-02 
GO:0042953~lipoprotein transport 2.9E-02 
GO:1903047~mitotic cell cycle process 3.0E-02 
GO:0007596~blood coagulation 3.0E-02 
GO:0001944~vasculature development 3.1E-02 
GO:0001959~regulation of cytokine-mediated signalling pathway 3.3E-02 
GO:0007605~sensory perception of sound 3.3E-02 
GO:0007599~hemostasis 3.3E-02 
GO:0050817~coagulation 3.3E-02 
GO:1903034~regulation of response to wounding 3.4E-02 
GO:0060759~regulation of response to cytokine stimulus 3.5E-02 
GO:0072358~cardiovascular system development 3.7E-02 
GO:0072359~circulatory system development 3.7E-02 
GO:0032703~negative regulation of interleukin-2 production 3.7E-02 
GO:0051090~regulation of sequence-specific DNA binding transcription factor activity 3.7E-02 
GO:0051649~establishment of localization in cell 3.8E-02 
GO:0070925~organelle assembly 3.9E-02 
GO:0050954~sensory perception of mechanical stimulus 3.9E-02 
GO:0002221~pattern recognition receptor signalling pathway 3.9E-02 
GO:0030030~cell projection organization 4.0E-02 
GO:0000278~mitotic cell cycle 4.0E-02 
GO:0030168~platelet activation 4.0E-02 
GO:0006897~endocytosis 4.1E-02 
GO:0006874~cellular calcium ion homeostasis 4.2E-02 
GO:0090181~regulation of cholesterol metabolic process 4.3E-02 
GO:0032692~negative regulation of interleukin-1 production 4.5E-02 
GO:0055074~calcium ion homeostasis 4.5E-02 
GO:0051642~centrosome localization 4.7E-02 
GO:0071379~cellular response to prostaglandin stimulus 4.7E-02 
GO:0050796~regulation of insulin secretion 4.7E-02 
GO:0072503~cellular divalent inorganic cation homeostasis 4.8E-02 




Appendix 7: Biological processes enriched in 103 genes shared between my study and 
Reichel et al., 2015 
 
Gene ontology term p-value 
GO:1902589~single-organism organelle organization 4.06E-04 
GO:0022607~cellular component assembly 4.29E-04 
GO:0042592~homeostatic process 5.24E-04 
GO:0001894~tissue homeostasis 5.26E-04 
GO:0044085~cellular component biogenesis 9.67E-04 
GO:0048871~multicellular organismal homeostasis 0.001177 
GO:0007010~cytoskeleton organization 0.001856 
GO:0060249~anatomical structure homeostasis 0.002138 
GO:0016266~O-glycan processing 0.003563 
GO:0060113~inner ear receptor cell differentiation 0.003563 
GO:0051170~nuclear import 0.004258 
GO:0042490~mechanoreceptor differentiation 0.004275 
GO:0016925~protein sumoylation 0.004783 
GO:0032088~negative regulation of NF-kappaB transcription factor activity 0.005716 
GO:0000226~microtubule cytoskeleton organization 0.006233 
GO:0006913~nucleocytoplasmic transport 0.009622 
GO:0060122~inner ear receptor stereocilium organization 0.010212 
GO:0051169~nuclear transport 0.010504 
GO:0034504~protein localization to nucleus 0.01064 
GO:0071705~nitrogen compound transport 0.011529 
GO:0032845~negative regulation of homeostatic process 0.012582 
GO:0007017~microtubule-based process 0.013514 
GO:0006606~protein import into nucleus 0.014286 
GO:0044744~protein targeting to nucleus 0.014286 
GO:1902593~single-organism nuclear import 0.014488 
GO:0032446~protein modification by small protein conjugation 0.014712 
GO:0051641~cellular localization 0.015249 
GO:0070647~protein modification by small protein conjugation or removal 0.015618 
GO:0006493~protein O-linked glycosylation 0.016154 
GO:0007160~cell-matrix adhesion 0.016814 
GO:0034329~cell junction assembly 0.016814 
GO:0048878~chemical homeostasis 0.017438 
GO:0031589~cell-substrate adhesion 0.020174 
GO:0030031~cell projection assembly 0.020231 
GO:0042060~wound healing 0.020725 
GO:0060119~inner ear receptor cell development 0.022123 
GO:0046822~regulation of nucleocytoplasmic transport 0.023946 




GO:0045184~establishment of protein localization 0.025295 
GO:0055088~lipid homeostasis 0.025592 
GO:0017038~protein import 0.026554 
GO:0002433~immune response-regulating cell surface receptor signalling pathway 
involved in phagocytosis 
0.027215 
GO:0038096~Fc-gamma receptor signalling pathway involved in phagocytosis 0.027215 
GO:0032844~regulation of homeostatic process 0.027767 
GO:0061041~regulation of wound healing 0.027768 
GO:0050810~regulation of steroid biosynthetic process 0.027938 
GO:0010803~regulation of tumour necrosis factor-mediated signalling pathway 0.027938 
GO:0007059~chromosome segregation 0.028094 
GO:1902532~negative regulation of intracellular signal transduction 0.028558 
GO:0002431~Fc receptor mediated stimulatory signalling pathway 0.028891 
GO:0038094~Fc-gamma receptor signalling pathway 0.029462 
GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signalling 0.029999 
GO:0048646~anatomical structure formation involved in morphogenesis 0.031882 
GO:0010035~response to inorganic substance 0.032733 
GO:0043433~negative regulation of sequence-specific DNA binding transcription 
factor activity 
0.033013 
GO:0032886~regulation of microtubule-based process 0.037425 
GO:0006464~cellular protein modification process 0.038411 
GO:0036211~protein modification process 0.038411 
GO:0034330~cell junction organization 0.038602 
GO:1903034~regulation of response to wounding 0.039404 
GO:0048514~blood vessel morphogenesis 0.039549 
GO:0043933~macromolecular complex subunit organization 0.039765 
GO:0002757~immune response-activating signal transduction 0.041895 
GO:0032790~ribosome disassembly 0.045029 
GO:0048739~cardiac muscle fibre development 0.045029 
GO:0051649~establishment of localization in cell 0.045288 
GO:0075733~intracellular transport of virus 0.045988 
GO:1902581~multi-organism cellular localization 0.047228 
GO:1902583~multi-organism intracellular transport 0.047228 
GO:0009611~response to wounding 0.047843 
GO:0007155~cell adhesion 0.048319 
GO:1903779~regulation of cardiac conduction 0.04848 
GO:0070925~organelle assembly 0.04916 
GO:0022610~biological adhesion 0.049521 




Appendix 8: 377 protein-altering genes in my series that were also downregulated in 
Brune or Steidl array 
 
ABCA1 CEBPZ GIGYF2 MRPS30 QSER1 TAB2 
ACBD3 CEP192 GLUL MSANTD2 RAB14 TAF2 
AGO4 CEP57 GNB2L1 MSH2 RAD50 TANK 
AKAP8 CEP76 GNE MSL2 RAD51C TARDBP 
AKT2 CEP78 GNL2 MTDH RALGPS2 TBC1D1 
ALDH18A1 CHD1L GPCPD1 MTRR RANBP2 TBC1D7 
ALDH3A2 CHD9 GTF2I MUT RASGRP2 TBCEL 
ALMS1 CLCN3 HBS1L MX1 RB1 TBP 
AMY2B CMPK1 HCFC2 MYCBP2 RBBP7 TEP1 
ANAPC5 CMTR2 HEATR3 MYEF2 RBM48 TEX10 
ANKHD1 CNTN1 HEATR5A MYO6 RC3H1 TFDP1 
ANKMY2 COG1 HEATR5B MYO9A RFC3 TMEM131 
ANKRD12 CPNE3 HECTD1 NAA15 RIF1 TMEM156 
ANO5 CSE1L HEG1 NAA16 RMDN2 TMEM183A 
ANXA2 CTCF HLA-DQA1 NASP RNASEH2A TMEM50A 
APIP CUX1 HMCN1 NAT10 RNF138 TMTC3 
APPL1 CWC27 HNRNPC NBN RNF7 TNKS2 
ARFGAP3 CYB5R4 HNRNPDL NCAPG2 RPL9 TOP2B 
ARFGEF2 DDX20 HSD17B4 NCOR1 RSPRY1 TOPBP1 
ARHGAP25 DDX6 HSPA13 NDUFB5 RUFY1 TPP1 
ARID4A DHX38 HSPA8 NEMF SC5D TRAPPC8 
ARL13B DIAPH3 ICA1 NF1 SCAI TRIM26 
ARL14EP DMTF1 IFRD1 NFKB1 SCO1 TRIM66 
ARNT DNAJC10 IGHV1-69 NIN SCOC TRIOBP 
ARV1 DOCK7 IKZF5 NOL11 SEC23B TRIP12 
ASCC3 DOCK9 IMPACT NUP50 SEC31A TTC12 
ATAD2 DUS2 INADL OCIAD2 SEL1L TTN 
ATF7 DYNC1LI1 INSIG2 ODC1 SENP2 UBE3A 
ATM EAPP INVS OFD1 SETD2 UGGT2 
ATPAF1 ECT2 IPO7 PANK1 SETD7 USH1C 
ATXN10 EDRF1 IPP PCOLCE2 SETX USP15 
AVL9 EFHC1 IRF8 PDCD2L SF3B3 USP46 
B3GALNT1 EIF3H ITGB8 PDCD6 SGOL1 VAMP4 
BAZ2B EIF4G2 ITPR1 PDE7A SGOL2 VCAM1 
BBS12 EIF4G3 ITPR2 PDS5B SLC12A2 VEGFB 
BBS2 EML6 JMJD1C PDSS1 SLC1A1 VPS13A 
BCLAF1 EP300 KIAA0125 PGM1 SLC25A12 XPNPEP1 
BCR EPC1 KIAA0922 PHF23 SLC25A13 XPO1 
BIRC6 ERCC6 KIAA1551 PIBF1 SLC25A3 XRCC4 




BTBD1 ETF1 KLHL7 PIK3CB SLC35A1 YTHDF3 
C10orf76 EVI2B KMT2A PITPNC1 SLC4A1AP ZBTB21 
C11orf30 EWSR1 LAMA3 PIWIL4 SLC4A7 ZCRB1 
C11orf54 FAF1 LBR PLSCR1 SLC7A6 ZFR 
C1S FAM111B LIFR PMS1 SMARCC1 ZIK1 
C20orf24 FAM114A2 LPGAT1 PNRC1 SMC1A ZNF12 
C5 FAM120B LRBA POLQ SMC6 ZNF143 
C5orf22 FAM210A LRPPRC PPFIA1 SMG1 ZNF23 
C6orf89 FAM83D LSM5 PPP3CA SNAP29 ZNF253 
C7orf31 FAR1 LYSMD3 PPP3CB SNAPC1 ZNF292 
CARF FAS MAN1A2 PPP6C SNRNP200 ZNF33B 
CASD1 FAT3 MBD4 PREPL SON ZNF430 
CASP2 FBXO45 MBNL2 PRKDC SP4 ZNF439 
CCDC113 FBXO7 MCCC1 PRKRA SPG11 ZNF567 
CCNL1 FCRL5 MCM6 PROSER1 SREK1 ZNF625 
CCT6B FNBP1 MCM9 PRPF3 SRPR ZNF644 
CDC7 FUNDC1 MCPH1 PRRC2C SSB ZNF682 
CDCA2 GALC MCTP2 PSME3 STK17B ZNF700 
CDK13 GAPT MEF2A PTEN STK38 ZNF708 
CDK5R1 GAPVD1 MFN1 PTK2 STK38L ZNF717 
CDK5RAP2 GARS MIER3 PTPN14 SUCLA2 ZNF91 
CDR2 GBA3 MRPL15 PTPRC SUGP2 ZNF93 





Appendix 9: 141 protein-altering genes in my series that were also upregulated in Brune 
or Steidl array  
 
ABI3BP CD109 FAT3 LMLN PGAP1 SRXN1 
ACACA CD96 FBXO40 LRPPRC PRRC2C ST8SIA4 
ACVR1 CDH8 FERMT1 MACF1 PSME3 STAT5B 
ADAMTS6 CEACAM1 FGF7 MED13L PTPRD SVEP1 
ADAMTSL4 CHD2 FMNL2 MESDC2 RBFOX2 SYNPO 
AKAP13 CIT FNDC3B MKS1 RELN TARS 
AKT3 CLEC12A GALNT10 MLEC RNF145 TMEM136 
ALDH3A2 CLOCK GLDC MLLT4 RNF213 TMEM50A 
ALK CSMD3 GLUL MOGS RNF217 TMEM97 
ALPK2 CTSA GNB2L1 MTTP RNF7 TMTC2 
ANAPC5 CYP1B1 GSS MUC4 RPL9 TNFAIP3 
ANKRD36 CYSLTR1 GTF3C1 MYO10 RTCB TRPS1 
ANKS1B DIAPH1 HEPH NAV3 RYR2 TSPAN5 
ANXA2 DNAH12 HTR2A NEDD4L S100B USH1C 
ARHGAP10 DNAH6 IFIT3 NEK11 SAMHD1 UTS2B 
BCS1L DOCK10 IL12RB2 NFE2L1 SEC61A2 VAV2 
C12orf45 DPCR1 JAG1 OCIAD2 SIM1 VCAM1 
C1S DYNC2H1 JAKMIP1 OTUD7A SLC20A1 WDR43 
C20orf194 EHBP1 KCNA1 PAFAH1B3 SLC28A2 ZBED6 
C6orf89 ELOVL7 KIF5A PBX4 SLC4A4 ZCRB1 
CACHD1 EPN2 KNOP1 PCCA SLC5A6 ZNF462 
CALCOCO2 ERAP1 LAMA4 PDCD2L SNCAIP 
 
CAMSAP2 F5 LAMTOR2 PDE4DIP SQLE 
 





Appendix 10: 125 biological processes that are significantly enriched in protein-altering 
genes that were also down-regulated in Brune or Steidl array 
 
Gene ontology term p-value 
GO:0034645~cellular macromolecule biosynthetic process 1.3E-08 
GO:0006259~DNA metabolic process 3.8E-08 
GO:1903047~mitotic cell cycle process 1.0E-07 
GO:0022402~cell cycle process 2.5E-07 
GO:0010467~gene expression 3.2E-07 
GO:0051276~chromosome organization 3.5E-07 
GO:0000278~mitotic cell cycle 3.5E-07 
GO:0051171~regulation of nitrogen compound metabolic process 3.9E-07 
GO:0006974~cellular response to DNA damage stimulus 5.1E-07 
GO:0007049~cell cycle 6.4E-07 
GO:0006281~DNA repair 9.0E-07 
GO:0044770~cell cycle phase transition 1.7E-06 
GO:0033554~cellular response to stress 2.1E-06 
GO:2000112~regulation of cellular macromolecule biosynthetic process 2.7E-06 
GO:0010468~regulation of gene expression 3.6E-06 
GO:0019219~regulation of nucleobase-containing compound metabolic process 6.0E-06 
GO:0010564~regulation of cell cycle process 8.3E-06 
GO:0010556~regulation of macromolecule biosynthetic process 1.1E-05 
GO:0051053~negative regulation of DNA metabolic process 1.2E-05 
GO:0016070~RNA metabolic process 1.3E-05 
GO:0044772~mitotic cell cycle phase transition 1.5E-05 
GO:0007059~chromosome segregation 2.0E-05 
GO:0006302~double-strand break repair 3.7E-05 
GO:0060249~anatomical structure homeostasis 4.0E-05 
GO:0000723~telomere maintenance 4.6E-05 
GO:0007093~mitotic cell cycle checkpoint 4.8E-05 
GO:0045930~negative regulation of mitotic cell cycle 7.1E-05 
GO:0051592~response to calcium ion 7.8E-05 
GO:0006464~cellular protein modification process 8.5E-05 
GO:0036211~protein modification process 8.5E-05 
GO:0051726~regulation of cell cycle 8.6E-05 
GO:0044839~cell cycle G2/M phase transition 9.3E-05 
GO:0006261~DNA-dependent DNA replication 9.4E-05 
GO:0034654~nucleobase-containing compound biosynthetic process 9.6E-05 
GO:0018130~heterocycle biosynthetic process 1.0E-04 
GO:0032200~telomere organization 1.1E-04 
GO:0032205~negative regulation of telomere maintenance 1.1E-04 
GO:0019438~aromatic compound biosynthetic process 1.2E-04 




GO:0006310~DNA recombination 1.4E-04 
GO:1901991~negative regulation of mitotic cell cycle phase transition 1.6E-04 
GO:0000724~double-strand break repair via homologous recombination 1.7E-04 
GO:0000725~recombinational repair 1.8E-04 
GO:0000086~G2/M transition of mitotic cell cycle 1.8E-04 
GO:0044774~mitotic DNA integrity checkpoint 1.9E-04 
GO:0010948~negative regulation of cell cycle process 1.9E-04 
GO:0044843~cell cycle G1/S phase transition 2.2E-04 
GO:0006351~transcription, DNA-templated 2.9E-04 
GO:1901988~negative regulation of cell cycle phase transition 3.1E-04 
GO:0000819~sister chromatid segregation 3.3E-04 
GO:0010605~negative regulation of macromolecule metabolic process 3.4E-04 
GO:0043933~macromolecular complex subunit organization 3.4E-04 
GO:0051246~regulation of protein metabolic process 3.6E-04 
GO:0098813~nuclear chromosome segregation 3.7E-04 
GO:0000075~cell cycle checkpoint 4.1E-04 
GO:0032268~regulation of cellular protein metabolic process 4.3E-04 
GO:2000134~negative regulation of G1/S transition of mitotic cell cycle 4.5E-04 
GO:0000726~non-recombinational repair 5.2E-04 
GO:0044773~mitotic DNA damage checkpoint 5.9E-04 
GO:1902807~negative regulation of cell cycle G1/S phase transition 5.9E-04 
GO:1902806~regulation of cell cycle G1/S phase transition 6.4E-04 
GO:0051252~regulation of RNA metabolic process 8.2E-04 
GO:0018193~peptidyl-amino acid modification 8.6E-04 
GO:0016310~phosphorylation 8.9E-04 
GO:1902589~single-organism organelle organization 9.1E-04 
GO:0031325~positive regulation of cellular metabolic process 1.0E-03 
GO:1901796~regulation of signal transduction by p53 class mediator 1.0E-03 
GO:2001251~negative regulation of chromosome organization 1.1E-03 
GO:0009892~negative regulation of metabolic process 1.1E-03 
GO:0006355~regulation of transcription, DNA-templated 1.1E-03 
GO:0000082~G1/S transition of mitotic cell cycle 1.1E-03 
GO:0033044~regulation of chromosome organization 1.2E-03 
GO:0051172~negative regulation of nitrogen compound metabolic process 1.2E-03 
GO:1903506~regulation of nucleic acid-templated transcription 1.4E-03 
GO:0044085~cellular component biogenesis 1.4E-03 
GO:0097659~nucleic acid-templated transcription 1.4E-03 
GO:2000045~regulation of G1/S transition of mitotic cell cycle 1.4E-03 
GO:0090329~regulation of DNA-dependent DNA replication 1.5E-03 
GO:2001141~regulation of RNA biosynthetic process 1.6E-03 
GO:0010212~response to ionizing radiation 1.6E-03 
GO:0006312~mitotic recombination 1.7E-03 
GO:0051052~regulation of DNA metabolic process 1.8E-03 




GO:0042770~signal transduction in response to DNA damage 1.8E-03 
GO:0018205~peptidyl-lysine modification 1.9E-03 
GO:0006303~double-strand break repair via nonhomologous end joining 1.9E-03 
GO:0032774~RNA biosynthetic process 1.9E-03 
GO:0010604~positive regulation of macromolecule metabolic process 1.9E-03 
GO:0045934~negative regulation of nucleobase-containing compound metabolic 
process 
2.0E-03 
GO:0051173~positive regulation of nitrogen compound metabolic process 2.1E-03 
GO:0010038~response to metal ion 2.1E-03 
GO:1901990~regulation of mitotic cell cycle phase transition 2.4E-03 
GO:0010639~negative regulation of organelle organization 2.5E-03 
GO:0035556~intracellular signal transduction 2.7E-03 
GO:0006796~phosphate-containing compound metabolic process 2.7E-03 
GO:0045935~positive regulation of nucleobase-containing compound metabolic 
process 
2.8E-03 
GO:0006793~phosphorus metabolic process 2.9E-03 
GO:0022607~cellular component assembly 2.9E-03 
GO:0031399~regulation of protein modification process 3.0E-03 
GO:0031570~DNA integrity checkpoint 3.0E-03 
GO:0031324~negative regulation of cellular metabolic process 3.0E-03 
GO:0032508~DNA duplex unwinding 3.1E-03 
GO:0000722~telomere maintenance via recombination 3.3E-03 
GO:0006468~protein phosphorylation 3.3E-03 
GO:1904354~negative regulation of telomere capping 3.4E-03 
GO:0045786~negative regulation of cell cycle 3.5E-03 
GO:0016925~protein sumoylation 3.7E-03 
GO:0010608~posttranscriptional regulation of gene expression 3.7E-03 
GO:0032392~DNA geometric change 4.2E-03 
GO:0016071~mRNA metabolic process 4.2E-03 
GO:0042325~regulation of phosphorylation 4.7E-03 
GO:0009893~positive regulation of metabolic process 4.7E-03 
GO:0000070~mitotic sister chromatid segregation 5.4E-03 
GO:0007346~regulation of mitotic cell cycle 5.5E-03 
GO:0051649~establishment of localization in cell 6.3E-03 
GO:0010557~positive regulation of macromolecule biosynthetic process 6.3E-03 
GO:0000729~DNA double-strand break processing 6.8E-03 
GO:0000077~DNA damage checkpoint 6.9E-03 
GO:0006278~RNA-dependent DNA biosynthetic process 7.0E-03 
GO:0048285~organelle fission 7.1E-03 
GO:0000280~nuclear division 7.1E-03 
GO:0006913~nucleocytoplasmic transport 7.2E-03 
GO:0006396~RNA processing 7.3E-03 
GO:0051129~negative regulation of cellular component organization 7.4E-03 




Appendix 11: Gene ontology terms enriched in protein-altering genes that were also 
upregulated in Brune or Steidl array  
 
Gene ontology term p-value 
GO:0022603~regulation of anatomical structure morphogenesis 0.001315 
GO:0072359~circulatory system development 0.003426 
GO:0072358~cardiovascular system development 0.003426 
GO:0006768~biotin metabolic process 0.003671 
GO:0001568~blood vessel development 0.004505 
GO:0001944~vasculature development 0.006681 
GO:0006928~movement of cell or subcellular component 0.012059 
GO:0022604~regulation of cell morphogenesis 0.012232 
GO:0061443~endocardial cushion cell differentiation 0.013051 
GO:0007155~cell adhesion 0.013913 
GO:0022610~biological adhesion 0.014402 
GO:2000026~regulation of multicellular organismal development 0.015774 
GO:0003013~circulatory system process 0.018823 
GO:0001525~angiogenesis 0.018848 
GO:0043616~keratinocyte proliferation 0.019647 
GO:0002715~regulation of natural killer cell mediated immunity 0.021954 
GO:0045824~negative regulation of innate immune response 0.025613 
GO:0048813~dendrite morphogenesis 0.025814 
GO:0071947~protein deubiquitination involved in ubiquitin-dependent protein 
catabolic process 
0.025932 
GO:0032787~monocarboxylic acid metabolic process 0.030389 
GO:0045088~regulation of innate immune response 0.030998 
GO:0030029~actin filament-based process 0.032166 
GO:0034394~protein localization to cell surface 0.032214 
GO:0030334~regulation of cell migration 0.035697 
GO:0051270~regulation of cellular component movement 0.037331 
GO:0042592~homeostatic process 0.038726 
GO:0044255~cellular lipid metabolic process 0.04003 
GO:0040011~locomotion 0.040617 
GO:0030001~metal ion transport 0.040644 
GO:0035249~synaptic transmission, glutamatergic 0.040909 
GO:0048514~blood vessel morphogenesis 0.042396 
GO:0019752~carboxylic acid metabolic process 0.044154 
GO:0006643~membrane lipid metabolic process 0.045081 
GO:0043436~oxoacid metabolic process 0.045676 
GO:0035051~cardiocyte differentiation 0.046032 
GO:0030856~regulation of epithelial cell differentiation 0.046965 




Appendix 12: Biological processes enriched in 857 genes with protein-altering mutations 
in my series 
 
Gene ontology term p-value 
GO:0060249~anatomical structure homeostasis 0.000 
GO:0001894~tissue homeostasis 0.000 
GO:0045494~photoreceptor cell maintenance 0.000 
GO:0051276~chromosome organization 0.000 
GO:0051053~negative regulation of DNA metabolic process 0.001 
GO:0006281~DNA repair 0.001 
GO:0007049~cell cycle 0.001 
GO:0032205~negative regulation of telomere maintenance 0.001 
GO:1903047~mitotic cell cycle process 0.001 
GO:0001895~retina homeostasis 0.001 
GO:0098656~anion transmembrane transport 0.001 
GO:0022402~cell cycle process 0.001 
GO:0044770~cell cycle phase transition 0.001 
GO:0006259~DNA metabolic process 0.001 
GO:0006974~cellular response to DNA damage stimulus 0.001 
GO:0042592~homeostatic process 0.001 
GO:0048871~multicellular organismal homeostasis 0.002 
GO:0007059~chromosome segregation 0.002 
GO:0006464~cellular protein modification process 0.002 
GO:0036211~protein modification process 0.002 
GO:0032508~DNA duplex unwinding 0.002 
GO:0006302~double-strand break repair 0.002 
GO:0042787~protein ubiquitination involved in ubiquitin-dependent protein catabolic 
process 
0.002 
GO:0051592~response to calcium ion 0.002 
GO:0044772~mitotic cell cycle phase transition 0.002 
GO:0000723~telomere maintenance 0.002 
GO:0010038~response to metal ion 0.002 
GO:0000278~mitotic cell cycle 0.002 
GO:0044839~cell cycle G2/M phase transition 0.002 
GO:0006820~anion transport 0.003 
GO:0032392~DNA geometric change 0.003 
GO:0000086~G2/M transition of mitotic cell cycle 0.003 
GO:0000724~double-strand break repair via homologous recombination 0.003 
GO:0000725~recombinational repair 0.003 
GO:0098813~nuclear chromosome segregation 0.004 
GO:0042384~cilium assembly 0.004 
GO:0060113~inner ear receptor cell differentiation 0.004 




GO:0007131~reciprocal meiotic recombination 0.004 
GO:0044085~cellular component biogenesis 0.005 
GO:0010035~response to inorganic substance 0.005 
GO:0032200~telomere organization 0.005 
GO:0044782~cilium organization 0.005 
GO:0044179~hemolysis in other organism 0.006 
GO:0052331~hemolysis in other organism involved in symbiotic interaction 0.006 
GO:0051801~cytolysis in other organism involved in symbiotic interaction 0.006 
GO:0019836~hemolysis by symbiont of host erythrocytes 0.006 
GO:0001897~cytolysis by symbiont of host cells 0.006 
GO:0051715~cytolysis in other organism 0.006 
GO:1902589~single-organism organelle organization 0.006 
GO:0022607~cellular component assembly 0.006 
GO:0042490~mechanoreceptor differentiation 0.006 
GO:0044774~mitotic DNA integrity checkpoint 0.007 
GO:0044257~cellular protein catabolic process 0.007 
GO:0010564~regulation of cell cycle process 0.007 
GO:0033044~regulation of chromosome organization 0.008 
GO:0050885~neuromuscular process controlling balance 0.008 
GO:0051603~proteolysis involved in cellular protein catabolic process 0.008 
GO:0032204~regulation of telomere maintenance 0.009 
GO:0007093~mitotic cell cycle checkpoint 0.010 
GO:0032845~negative regulation of homeostatic process 0.010 
GO:0034645~cellular macromolecule biosynthetic process 0.010 
GO:0006261~DNA-dependent DNA replication 0.011 
GO:0006310~DNA recombination 0.011 
GO:0019752~carboxylic acid metabolic process 0.011 
GO:0007130~synaptonemal complex assembly 0.012 
GO:0060271~cilium morphogenesis 0.012 
GO:0044248~cellular catabolic process 0.012 
GO:0006511~ubiquitin-dependent protein catabolic process 0.012 
GO:0003006~developmental process involved in reproduction 0.013 
GO:0060119~inner ear receptor cell development 0.013 
GO:0043436~oxoacid metabolic process 0.013 
GO:0007017~microtubule-based process 0.013 
GO:0032006~regulation of TOR signalling 0.014 
GO:1904353~regulation of telomere capping 0.014 
GO:0033554~cellular response to stress 0.014 
GO:0044265~cellular macromolecule catabolic process 0.014 
GO:0019941~modification-dependent protein catabolic process 0.015 
GO:0035058~nonmotile primary cilium assembly 0.015 
GO:0044380~protein localization to cytoskeleton 0.015 
GO:0045930~negative regulation of mitotic cell cycle 0.015 




GO:2000780~negative regulation of double-strand break repair 0.017 
GO:0006835~dicarboxylic acid transport 0.017 
GO:0019218~regulation of steroid metabolic process 0.017 
GO:0006629~lipid metabolic process 0.017 
GO:0001907~killing by symbiont of host cells 0.017 
GO:0001915~negative regulation of T cell mediated cytotoxicity 0.017 
GO:1904354~negative regulation of telomere capping 0.017 
GO:0044004~disruption by symbiont of host cell 0.017 
GO:0044702~single organism reproductive process 0.018 
GO:0008202~steroid metabolic process 0.018 
GO:0043632~modification-dependent macromolecule catabolic process 0.018 
GO:1901990~regulation of mitotic cell cycle phase transition 0.018 
GO:0010927~cellular component assembly involved in morphogenesis 0.018 
GO:0070925~organelle assembly 0.019 
GO:0015711~organic anion transport 0.019 
GO:0070193~synaptonemal complex organization 0.019 
GO:0030163~protein catabolic process 0.019 
GO:0007127~meiosis I 0.019 
GO:0051641~cellular localization 0.020 
GO:0032787~monocarboxylic acid metabolic process 0.020 
GO:2001251~negative regulation of chromosome organization 0.020 
GO:0006768~biotin metabolic process 0.021 
GO:0035864~response to potassium ion 0.021 
GO:0043933~macromolecular complex subunit organization 0.021 
GO:0051726~regulation of cell cycle 0.021 
GO:1901987~regulation of cell cycle phase transition 0.022 
GO:0048285~organelle fission 0.022 
GO:0000075~cell cycle checkpoint 0.023 
GO:0006888~ER to Golgi vesicle-mediated transport 0.023 
GO:0048193~Golgi vesicle transport 0.023 
GO:0010212~response to ionizing radiation 0.023 
GO:0051321~meiotic cell cycle 0.024 
GO:0033036~macromolecule localization 0.024 
GO:0014896~muscle hypertrophy 0.024 
GO:0000732~strand displacement 0.025 
GO:0034454~microtubule anchoring at centrosome 0.025 
GO:0045738~negative regulation of DNA repair 0.025 
GO:0007507~heart development 0.025 
GO:0048813~dendrite morphogenesis 0.025 
GO:0031589~cell-substrate adhesion 0.027 
GO:0070085~glycosylation 0.028 
GO:0000002~mitochondrial genome maintenance 0.028 
GO:0044773~mitotic DNA damage checkpoint 0.030 




GO:0045132~meiotic chromosome segregation 0.032 
GO:0015721~bile acid and bile salt transport 0.032 
GO:0006664~glycolipid metabolic process 0.033 
GO:0050905~neuromuscular process 0.034 
GO:0000280~nuclear division 0.034 
GO:0051052~regulation of DNA metabolic process 0.034 
GO:0010389~regulation of G2/M transition of mitotic cell cycle 0.034 
GO:0048814~regulation of dendrite morphogenesis 0.034 
GO:0048646~anatomical structure formation involved in morphogenesis 0.035 
GO:2000779~regulation of double-strand break repair 0.035 
GO:0000226~microtubule cytoskeleton organization 0.035 
GO:1902806~regulation of cell cycle G1/S phase transition 0.035 
GO:0072358~cardiovascular system development 0.036 
GO:0072359~circulatory system development 0.036 
GO:0006082~organic acid metabolic process 0.036 
GO:0000819~sister chromatid segregation 0.036 
GO:0043413~macromolecule glycosylation 0.037 
GO:0006486~protein glycosylation 0.037 
GO:0006687~glycosphingolipid metabolic process 0.037 
GO:1901991~negative regulation of mitotic cell cycle phase transition 0.037 
GO:0051640~organelle localization 0.037 
GO:0006493~protein O-linked glycosylation 0.037 
GO:0051128~regulation of cellular component organization 0.038 
GO:0008206~bile acid metabolic process 0.038 
GO:0070647~protein modification by small protein conjugation or removal 0.038 
GO:1903509~liposaccharide metabolic process 0.038 
GO:0007018~microtubule-based movement 0.039 
GO:0044843~cell cycle G1/S phase transition 0.039 
GO:0000902~cell morphogenesis 0.039 
GO:0045922~negative regulation of fatty acid metabolic process 0.040 
GO:0072698~protein localization to microtubule cytoskeleton 0.040 
GO:0010467~gene expression 0.041 
GO:0007160~cell-matrix adhesion 0.041 
GO:0010468~regulation of gene expression 0.042 
GO:0046939~nucleotide phosphorylation 0.042 
GO:0031023~microtubule organizing center organization 0.042 
GO:0071103~DNA conformation change 0.042 
GO:0031570~DNA integrity checkpoint 0.043 
GO:2000045~regulation of G1/S transition of mitotic cell cycle 0.044 
GO:0009812~flavonoid metabolic process 0.044 
GO:0032990~cell part morphogenesis 0.044 
GO:0000726~non-recombinational repair 0.044 
GO:0072393~microtubule anchoring at microtubule organizing center 0.045 





Appendix 13: Genes with protein-altering mutations in EBV-positive cases in my series 
 
ABCA1 CCDC73 FAM228A MCTP2 PTK2 ST3GAL6 
ABCA5 CCNL1 FANCL MED24 PTPRC STAG1 
ABCC5 CCT6B FAR1 MFN1 RAB14 STAMBPL1 
ADAMTS12 CD34 FAT3 MICU3 RAD50 STAT5B 
ADAMTSL4 CDC27 FBXO40 MKS1 RAD51C STOX1 
AGO4 CDC7 FBXW10 MLLT4 RAPGEF6 SUCLA2 
AGPAT9 CDCA2 FGF7 MROH8 RASGEF1B SUGP2 
ALB CDH3 FRG1B MRPL15 RASGRP2 SUN3 
ANAPC5 CDK5RAP2 FUNDC1 MRPS18B RB1 SYNE1 
ANK2 CDYL GALC MRPS30 RBM44 TAB2 
ANKMY2 CEACAM8 GALNT10 MRRF RBM48 TAF15 
ANKRD12 CEP192 GAPVD1 MSL2 RC3H1 TARS 
ANKRD36 CEP76 GARS MTDH RDH12 TEX11 
ANKS1B CHD2 GPR128 MTMR7 RFC3 TMEM196 
APIP CHD4 GSS MTRR RNF138 TMEM50A 
APOB CLCA4 GTF2I MUC12 ROBO2 TMEM57 
ARFGAP3 CLCN3 HBS1L MUC19 ROS1 TMPRSS6 
ARHGAP10 CLEC12A HCFC2 MUC4 RP11-53I6.2 TNXB 
ARID4A CMPK1 HEATR3 MYO6 RPL9 TOP2B 
ARL14EP CMTR2 HEATR5B MYO9A RPS6KA6 TPP1 
ARV1 CNTN4 HLF MYOM2 RRH TPTE2 
ATAD2 COL9A1 HMCN1 NAT10 SAMHD1 TRDN 
ATL1 CSMD3 HNRNPC NAV3 SBF2 TRIM49C 
ATM CTC-432M15.3 HSPA13 NCOR1 SCN9A TRIOBP 
ATXN10 CWC27 HSPA8 NDUFB5 SEC31A TRIP12 
ATXN2 CYSLTR1 IGLC3 NEDD4L SEC61A2 TTBK2 
B3GALNT1 DCDC1 IKZF5 NF1 SF3B2 TTN 
BBS2 DEFB115 IL12RB2 NSUN2 SF3B3 TUBA1C 
BCLAF1 DIAPH1 INSIG2 OCIAD2 SGOL2 TULP3 
BCS1L DIAPH3 IPP OFD1 SLC1A1 UBE3A 
BEND5 DLEC1 ITPR2 OR10A6 SLC20A1 UBR4 
BRD9 DLEU2L JMJD1C OR1N1 SLC25A12 UGT2B17 
BSPH1 DNAH12 KCNA1 OR4C5 SLC25A13 USH1C 
BTBD1 DNAH6 KCNB2 PDCD11 SLC25A3 USH2A 
BTBD9 DOCK10 KIAA0895 PDE4DIP SLC30A3 VAV2 
C10orf76 DOCK7 KIAA0922 PDE7A SLC35A1 VWDE 
C11orf54 DUS2 KIAA1009 PDS5B SLC5A1 WDR35 
C12orf45 DYNC1LI1 KIAA1462 PDZD2 SLC5A6 WDR64 
C14orf23 DYNC2H1 KIAA1551 PGM1 SLC6A14 XPNPEP1 
C17orf85 EHBP1 KIAA1715 PHF23 SLC9A2 ZCRB1 
C1orf27 EIF3H KIF3A PIK3CB SLCO1C1 ZNF292 




C20orf24 EPC1 LAMA3 PMS1 SMARCAL1 ZNF416 
C5orf22 EPG5 LAMA4 POLQ SMARCC1 ZNF439 
C6orf89 EPN2 LBR PPFIA1 SMG1 ZNF625 
C7orf31 ERCC4 LIMCH1 PPIL6 SNCAIP ZNF625-ZNF20 
C9 ERCC6 LMAN1 PPP1R10 SNRNP200 ZNF714 
CACNG3 ERCC6L2 LMLN PPP6C SON ZNF717 
CAMSAP2 ERVMER34-1 LRP6 PREX2 SPAG17 ZNF816 
CARF F5 MAN1A2 PRKRA SPATS1 ZNF91 
CASD1 F8 MBD4 PROM1 SPTAN1 ZNF93 
CASP2 FAF1 MCCC1 PROS1 SREK1 ZNF99 
CCDC175 FAIM3 MCHR2 PRPF3 SRPR 
 






Appendix 14: Genes with protein-altering mutations in EBV-negative cases in my series  
 
ABCA1 CEP78 GK5 MUC17 R3HCC1L TBL3 
ABCC2 CHD1 GLDC MUC7 R3HDM2 TBP 




ABI3BP CHD2 GLUD2 MX1 RAD50 TCTN2 
AC012215.1 CHD9 GLUL MYCBP2 RALGPS2 TEP1 
AC112715.2 CIT GNB2L1 MYEF2 RANBP2 TEX10 
ACACA CKLF-CMTM1 GNE MYH4 RBBP7 TEX15 
ACAD10 CLOCK GNL2 MYH8 RBFOX2 TFDP1 
ACBD3 CLSPN GPCPD1 MYO10 RBM27 TIGD7 
ACVR1 CMTM1 GPR98 MYO18B RELN TLN2 
ADAM9 CNTN1 GTF3C1 MYO5B RGPD3 TMEM131 
ADAMTS12 COG1 HCFC2 MYOM1 RGS6 TMEM136 




HECTD1 NAA16 RMDN2 
TMEM183
A 




AHNAK CSE1L HEPH NAV3 RNF145 TMTC2 
AHNAK2 CSMD3 HIATL2 NBN RNF169 TMTC3 
AKAP13 CTCF HIVEP1 NCAPG2 RNF213 TNFAIP3 
AKAP8 CTCFL HKDC1 NDUFB5 RNF217 TNKS2 
AKT2 CTD-2370N5.3 HLA-DQA1 NEK11 RNF7 TOB1 
AKT3 CTSA HNRNPDL NEMF RRAGB TOPBP1 
ALDH18A1 CTTNBP2 HSD17B4 NF1 RSPRY1 TP53BP2 
ALDH3A2 CUBN HTR2A NFE2L1 RTCB TPTE2 
ALK CUX1 ICA1 NFKB1 RUFY1 TRAPPC8 
ALMS1 CYB5R4 IFIT3 NHS RYR2 TRHR 
ALPK2 CYLD IFRD1 NIN S100B TRIM26 
ALPK3 CYP1B1 IGHV1-18 NKRF SARDH TRIM66 
AMY2B CYP7B1 IGHV1-69 NOL11 SASS6 TRIM72 






NPIPA5 SCAI TRPS1 
ANKRD12 DDX6 IGKV1-6 NPIPB5 SCO1 TSPAN5 
ANO5 DDX60 IL17RB NR1H4 SCOC TTC12 
ANP32D DEPDC7 IMPACT NUDT19 SEC23B TTN 
ANXA2 DHX38 INADL NUGGC SEL1L TXNRD3 
APIP DHX9 INVS NUP210L SENP2 UBE4B 
APOL5 DLEU2L IPO7 NUP50 SETD2 UBN1 
APPL1 DLG2 IPP OCA2 SETD7 UBR5 
ARFGEF2 DMTF1 IRF8 ODC1 SETX UGGT2 




ARL13B DOCK5 ITGB7 OR4F4 SGOL1 UGT1A5 
ARMC10 DOCK9 ITGB8 OR4Q2 SGOL2 UGT1A8 
ARNT DPCR1 ITIH1 OR52E2 SIM1 UNC13C 
ARSF DPRX ITPR1 OR52R1 SLC12A2 USP15 
ASCC3 DPYD ITPR2 OR5AR1 SLC14A2 USP26 
ATAD2 DSPP JAG1 OR6C75 SLC22A14 USP45 
ATF7 DTHD1 JAKMIP1 OTUD4 SLC25A14 USP46 
ATG16L1 DYX1C1 JMJD1C OTUD7A SLC25A33 UTS2B 
ATPAF1 EAPP KDM8 OVCH1 SLC26A5 VAMP4 




BAZ2B EDRF1 KIAA0125 PALB2 SLC28A2 VEGFB 
BBS12 EFHC1 KIAA1009 PANK1 SLC35F4 VPS13A 
BBS2 EGFLAM KIAA1199 PAQR5 SLC44A4 VRK2 
BBS4 EIF3H KIAA2026 PARP14 SLC4A1AP WBP11 
BCR EIF4G2 KIF24 PBX4 SLC4A4 WDR43 
BHMT EIF4G3 KIF3A PCCA SLC4A7 WDR87 
BIRC6 ELF5 KIF5A PCDHAC1 SLC7A6 WNT2B 
BIVM-ERCC5 ELOVL7 KLHL1 PCOLCE2 SLCO1B3 XPO1 
BNIP2 EML6 KLHL7 PDCD2L SMARCA2 XRCC4 
BRD9 EMR1 KLRD1 PDCD6 SMARCC1 YKT6 
BSCL2 ENPP3 KMT2A PDCL2 SMC1A YME1L1 
BSPH1 ENTHD1 KNDC1 PDLIM5 SMC1B YTHDF3 
BTBD1 EP300 KNOP1 PDSS1 SMC6 ZBED6 
C10ORF68 EPN2 KRT76 PGAP1 SMEK2 ZBTB21 
C11orf30 ERAP1 LAMA3 PGBD1 SMG1 ZDBF2 
C12orf45 ERCC5 LAMTOR2 PIBF1 SMG5 ZFR 
C1orf110 ESRP1 LEPREL1 PIGK SNAP29 ZIK1 
C1orf87 ETF1 LIFR PITPNC1 SNAPC1 ZNF12 
C1S EVI2B LNX1 PIWIL3 SNRNP200 ZNF143 
C20orf194 EWSR1 LPA PIWIL4 SOGA3 ZNF157 
C2orf66 EXD1 LPGAT1 PKHD1 SORBS2 ZNF23 
C5 F5 LPPR5 PKLR SP4 ZNF253 
C6orf10 FADS2 LRBA PLCH1 SPAG9 ZNF263 
C7orf25 FAHD2B LRPPRC PLS3 SPG11 ZNF292 
C8orf37 FAM111B LRRC9 PLSCR1 SQLE ZNF33B 
CACHD1 FAM120B LRRIQ1 PNRC1 SREK1 ZNF343 
CALCOCO2 FAM210A LRTOMT POLG SRRM2 ZNF384 




CATSPERD FAM98A LST3 PPFIA4 ST3GAL6 ZNF462 
CCDC113 FAS LYSMD3 PPP3CA ST8SIA4 ZNF530 
CCDC129 FBXO45 MACF1 PPP3CB ST8SIA6 ZNF549 
CCDC73 FBXO7 MAP3K4 PREPL STAT2 ZNF560 




CCIN FER1L6 MCM9 PRKRA STK31 ZNF577 
CCT6B FERMT1 MCPH1 PROM1 STK38 ZNF644 
CD109 FHL5 MED13L PROS1 STK38L ZNF660 
CD96 FHOD1 MEF2A PROSER1 STT3A ZNF662 
CDH10 FMNL2 MESDC2 PRRC2C SVEP1 ZNF682 
CDH23 FNBP1 MFAP5 PSMC5 SYCP1 ZNF69 
CDH8 FNDC3B MICU3 PSME3 SYCP2 ZNF700 
CDHR5 FNDC7 MIER3 PTEN SYNE1 ZNF708 
CDK13 FREM2 MLEC PTPN14 SYNPO ZNF717 
CDK5R1 FSIP1 MOGS PTPN21 TAAR8 ZNF724P 
CDKL4 GABRB1 MSANTD2 PTPRD TAF2 ZNF729 
CDR2 GAPT MSH2 PTPRQ TANK ZNF793 
CEACAM1 GARS MSTN PTX3 TARDBP ZNF799 
CEBPZ GBA3 MTBP PUS10 TBC1D1 ZNF804B 
CEP57 GCNT2 MTTP PUS7 TBC1D7 ZSCAN32 





Appendix 15: List of most frequently mutated genes in 23 primary HL cases 
 
Gene Number of 
patients 
mutated 




F8 3 POS NUP50 2 NEG 
TPTE2 3 POS PCLO 2 NEG 
AGPAT9 2 POS SLIT2 2 NEG 
CCDC175 2 POS VPS13C 2 NEG 
CHD4 2 POS ZNF430 2 NEG 
CMPK1 2 POS EGFLAM 2 NEG 
COL9A1 2 POS IGHV1-24 2 NEG 
DNAH12 2 POS IGLV3-10 2 NEG 
EML4 2 POS LAMA3 2 NEG 
EPG5 2 POS MFSD5 2 NEG 
ITPR2 2 POS NPAS3 2 NEG 
LAMA4 2 POS TRAPPC8 2 NEG 
MUC4 2 POS ZBTB21 2 NEG 
MYO6 2 POS ADSSL1 2 NEG 
OR4C5 2 POS CTTNBP2 2 NEG 
PDE4DIP 2 POS EBF1 2 NEG 
SBF2 2 POS FNDC7 2 NEG 
SGOL2 2 POS IGHG4 2 NEG 
SMG1 2 POS MUC2 2 NEG 
TMEM57 2 POS MYCBP2 2 NEG 
TRDN 2 POS PCDHA5 2 NEG 
TTN 2 POS POLE 2 NEG 
ZNF717 2 POS RALGPS2 2 NEG 
IGHV2-70 8 NEG RYR2 2 NEG 
TNFAIP3 7 NEG SF3B2 2 NEG 
IGHE 5 NEG SLC14A2 2 NEG 
TTN 5 NEG UBR5 2 NEG 
IGLV3-1 5 NEG UNC13C 2 NEG 
MUC17 5 NEG ZFHX3 2 NEG 
HIST1H1E 5 NEG ZFP36L1 2 NEG 
MUC4 4 NEG ANXA1 2 NEG 
B2M 4 NEG BNIP2 2 NEG 
IGLL5 4 NEG CTD-2370N5.3 2 NEG 
ITPKB 4 NEG DNAH11 2 NEG 
EEF1A1 4 NEG FLNC 2 NEG 
SOCS1 4 NEG HECW2 2 NEG 
ITPR1 3 NEG IGLV2-23 2 NEG 




CSMD3 3 NEG PROCA1 2 NEG 
HECTD1 3 NEG SEC23IP 2 NEG 
SMG1 3 NEG TRIP11 2 NEG 
UBE2A 3 NEG ABL1 2 NEG 
DNAH14 3 NEG ADAMTS12 2 NEG 
SRRM2 3 NEG CCDC60 2 NEG 
C1orf87 3 NEG CKLF-CMTM1 2 NEG 
CCDC80 3 NEG CTD-3088G3.8 2 NEG 
GPR98 3 NEG EAPP 2 NEG 
IGHJ5 3 NEG F5 2 NEG 
CHD1 3 NEG FAT4 2 NEG 
MUC16 3 NEG GNA13 2 NEG 
RANBP2 3 NEG GTF3C1 2 NEG 
ACTG1 2 NEG HCFC2 2 NEG 
LPHN3 2 NEG IGHV1-69 2 NEG 
CMTM1 2 NEG LRP1B 2 NEG 
ANXA2 2 NEG NBPF10 2 NEG 
ARIH2 2 NEG NHS 2 NEG 
MACF1 2 NEG PTPN21 2 NEG 
PTPRD 2 NEG SETDB1 2 NEG 
ACTB 2 NEG SMC1B 2 NEG 
CYLD 2 NEG SREK1 2 NEG 
SOX6 2 NEG SYCP2 2 NEG 
EFCAB5 2 NEG TICRR 2 NEG 
NOL4 2 NEG USP15 2 NEG 
PROM1 2 NEG WDR87 2 NEG 
ALMS1 2 NEG WEE1 2 NEG 
KLHL7 2 NEG ZFC3H1 2 NEG 
PLS3 2 NEG ZNF292 2 NEG 
ANKHD1 2 NEG ZNF644 2 NEG 
DMD 2 NEG ALK 2 NEG 
GNE 2 NEG CUBN 2 NEG 
CDH23 2 NEG GPATCH2 2 NEG 
COL4A6 2 NEG IGKV1D-8 2 NEG 
CPM 2 NEG ITPR2 2 NEG 
DMTF1 2 NEG PKHD1 2 NEG 
HEPH 2 NEG SLCO1B7 2 NEG 
NR1H4 2 NEG TMEM235 2 NEG 
BCL7A 2 NEG ABCA13 2 NEG 
CRYM 2 NEG ALOX12 2 NEG 
FSIP2 2 NEG ANKHD1-EIF4EBP3 2 NEG 
GPR112 2 NEG CCDC73 2 NEG 
NEK1 2 NEG DDX20 2 NEG 




RNF145 2 NEG FLG 2 NEG 
SPTB 2 NEG GLUD2 2 NEG 
TBC1D15 2 NEG IGKJ2 2 NEG 
XRCC4 2 NEG IGKV2-24 2 NEG 
ARHGAP25 2 NEG IGLV7-46 2 NEG 
ECT2 2 NEG LRRIQ1 2 NEG 
IGKV4-1 2 NEG LST3 2 NEG 
PRRC2C 2 NEG MUC19 2 NEG 
PRSS3 2 NEG MYO5B 2 NEG 
ZNF217 2 NEG OR4C5 2 NEG 
ACACA 2 NEG OR52E2 2 NEG 
CHD1L 2 NEG PIM2 2 NEG 
CSF2RB 2 NEG QSER1 2 NEG 
DGKI 2 NEG SMCR8 2 NEG 
FNBP1 2 NEG STAB2 2 NEG 
HNRNPDL 2 NEG STK38 2 NEG 
IGLV3-25 2 NEG UGT1A8 2 NEG 
MYO18B 2 NEG ZFR 2 NEG 




Appendix 16: Biological processes enriched in EBV-negative tumours my series 
 
Gene ontology term p-value 
GO:0051276~chromosome organization 0.002 
GO:0060249~anatomical structure homeostasis 0.002 
GO:0006464~cellular protein modification process 0.003 
GO:0036211~protein modification process 0.003 
GO:0014896~muscle hypertrophy 0.003 
GO:0051171~regulation of nitrogen compound metabolic process 0.004 
GO:0051603~proteolysis involved in cellular protein catabolic process 0.005 
GO:0048814~regulation of dendrite morphogenesis 0.005 
GO:0044257~cellular protein catabolic process 0.005 
GO:0007507~heart development 0.006 
GO:0010468~regulation of gene expression 0.006 
GO:0010564~regulation of cell cycle process 0.007 
GO:0032508~DNA duplex unwinding 0.008 
GO:0000002~mitochondrial genome maintenance 0.008 
GO:0044248~cellular catabolic process 0.008 
GO:0048813~dendrite morphogenesis 0.009 
GO:0060113~inner ear receptor cell differentiation 0.009 
GO:0006664~glycolipid metabolic process 0.009 
GO:0006281~DNA repair 0.010 
GO:1903509~liposaccharide metabolic process 0.010 
GO:0032392~DNA geometric change 0.011 
GO:0060119~inner ear receptor cell development 0.011 
GO:0044265~cellular macromolecule catabolic process 0.011 
GO:0007049~cell cycle 0.012 
GO:0071103~DNA conformation change 0.012 
GO:0016358~dendrite development 0.012 
GO:0042490~mechanoreceptor differentiation 0.012 
GO:0034454~microtubule anchoring at centrosome 0.012 
GO:0006629~lipid metabolic process 0.013 
GO:2000112~regulation of cellular macromolecule biosynthetic process 0.013 
GO:0034645~cellular macromolecule biosynthetic process 0.013 
GO:0006511~ubiquitin-dependent protein catabolic process 0.015 
GO:0044774~mitotic DNA integrity checkpoint 0.015 
GO:0033036~macromolecule localization 0.015 
GO:0019219~regulation of nucleobase-containing compound metabolic process 0.015 
GO:0045444~fat cell differentiation 0.016 
GO:0007286~spermatid development 0.016 
GO:0042787~protein ubiquitination involved in ubiquitin-dependent protein catabolic 
process 
0.016 




GO:0019941~modification-dependent protein catabolic process 0.017 
GO:0045494~photoreceptor cell maintenance 0.018 
GO:0035058~nonmotile primary cilium assembly 0.018 
GO:0044380~protein localization to cytoskeleton 0.018 
GO:0006974~cellular response to DNA damage stimulus 0.018 
GO:0022402~cell cycle process 0.019 
GO:0030163~protein catabolic process 0.019 
GO:0044782~cilium organization 0.019 
GO:0016070~RNA metabolic process 0.020 
GO:0006643~membrane lipid metabolic process 0.020 
GO:0048515~spermatid differentiation 0.020 
GO:0043632~modification-dependent macromolecule catabolic process 0.020 
GO:0016053~organic acid biosynthetic process 0.021 
GO:0006687~glycosphingolipid metabolic process 0.021 
GO:0050885~neuromuscular process controlling balance 0.021 
GO:0034453~microtubule anchoring 0.021 
GO:0006351~transcription, DNA-templated 0.021 
GO:0007281~germ cell development 0.021 
GO:0042384~cilium assembly 0.021 
GO:0006302~double-strand break repair 0.021 
GO:0032006~regulation of TOR signalling 0.022 
GO:0072393~microtubule anchoring at microtubule organizing center 0.022 
GO:0031589~cell-substrate adhesion 0.022 
GO:0010038~response to metal ion 0.024 
GO:0006913~nucleocytoplasmic transport 0.024 
GO:0019752~carboxylic acid metabolic process 0.024 
GO:0044702~single organism reproductive process 0.024 
GO:0010035~response to inorganic substance 0.025 
GO:0051592~response to calcium ion 0.025 
GO:0010556~regulation of macromolecule biosynthetic process 0.026 
GO:0051128~regulation of cellular component organization 0.026 
GO:0051641~cellular localization 0.026 
GO:0046394~carboxylic acid biosynthetic process 0.027 
GO:0043436~oxoacid metabolic process 0.027 
GO:1904353~regulation of telomere capping 0.027 
GO:0008104~protein localization 0.027 
GO:0051169~nuclear transport 0.028 
GO:0052697~xenobiotic glucuronidation 0.028 
GO:0060537~muscle tissue development 0.028 
GO:0032886~regulation of microtubule-based process 0.029 
GO:0032787~monocarboxylic acid metabolic process 0.030 
GO:0044773~mitotic DNA damage checkpoint 0.030 
GO:0033365~protein localization to organelle 0.032 




GO:0050773~regulation of dendrite development 0.033 
GO:0003300~cardiac muscle hypertrophy 0.033 
GO:0000077~DNA damage checkpoint 0.034 
GO:0042592~homeostatic process 0.034 
GO:0022603~regulation of anatomical structure morphogenesis 0.034 
GO:0014706~striated muscle tissue development 0.035 
GO:0006259~DNA metabolic process 0.035 
GO:0055006~cardiac cell development 0.035 
GO:0008610~lipid biosynthetic process 0.036 
GO:0022604~regulation of cell morphogenesis 0.036 
GO:0001894~tissue homeostasis 0.036 
GO:0033554~cellular response to stress 0.037 
GO:0014897~striated muscle hypertrophy 0.038 
GO:0045833~negative regulation of lipid metabolic process 0.038 
GO:0007276~gamete generation 0.039 
GO:0072359~circulatory system development 0.039 
GO:0072358~cardiovascular system development 0.039 
GO:0048646~anatomical structure formation involved in morphogenesis 0.039 
GO:0021987~cerebral cortex development 0.040 
GO:0044770~cell cycle phase transition 0.040 
GO:1902806~regulation of cell cycle G1/S phase transition 0.041 
GO:0001573~ganglioside metabolic process 0.042 
GO:1903047~mitotic cell cycle process 0.042 
GO:0015701~bicarbonate transport 0.042 
GO:0070646~protein modification by small protein removal 0.042 
GO:0006355~regulation of transcription, DNA-templated 0.043 
GO:0071705~nitrogen compound transport 0.045 
GO:0016310~phosphorylation 0.046 
GO:0009062~fatty acid catabolic process 0.046 
GO:0021543~pallium development 0.047 
GO:0010565~regulation of cellular ketone metabolic process 0.048 
GO:0031570~DNA integrity checkpoint 0.048 
GO:0000723~telomere maintenance 0.048 
GO:0010225~response to UV-C 0.048 
GO:0007093~mitotic cell cycle checkpoint 0.050 
GO:1903506~regulation of nucleic acid-templated transcription 0.050 




Appendix 17: Biological processes enriched in EBV-positive tumours in my series 
 
Gene ontology term p-value 
GO:0060249~anatomical structure homeostasis 1.1E-06 
GO:1902589~single-organism organelle organization 4.3E-05 
GO:0043933~macromolecular complex subunit organization 4.9E-05 
GO:0001894~tissue homeostasis 9.0E-05 
GO:0001895~retina homeostasis 1.3E-04 
GO:0044085~cellular component biogenesis 1.4E-04 
GO:0045494~photoreceptor cell maintenance 2.0E-04 
GO:0022607~cellular component assembly 3.0E-04 
GO:0051053~negative regulation of DNA metabolic process 5.8E-04 
GO:0032205~negative regulation of telomere maintenance 7.4E-04 
GO:0042592~homeostatic process 9.8E-04 
GO:0007131~reciprocal meiotic recombination 1.0E-03 
GO:0035825~reciprocal DNA recombination 1.0E-03 
GO:0051304~chromosome separation 1.1E-03 
GO:0000280~nuclear division 1.2E-03 
GO:0006820~anion transport 1.6E-03 
GO:2001251~negative regulation of chromosome organization 1.9E-03 
GO:0048871~multicellular organismal homeostasis 1.9E-03 
GO:0000724~double-strand break repair via homologous recombination 2.2E-03 
GO:0032845~negative regulation of homeostatic process 2.2E-03 
GO:0006888~ER to Golgi vesicle-mediated transport 2.3E-03 
GO:0000725~recombinational repair 2.3E-03 
GO:0007017~microtubule-based process 2.5E-03 
GO:0048285~organelle fission 2.7E-03 
GO:0007010~cytoskeleton organization 3.0E-03 
GO:0007059~chromosome segregation 3.1E-03 
GO:0098656~anion transmembrane transport 4.6E-03 
GO:0010639~negative regulation of organelle organization 4.9E-03 
GO:1903047~mitotic cell cycle process 4.9E-03 
GO:0051276~chromosome organization 5.1E-03 
GO:0000723~telomere maintenance 6.0E-03 
GO:0098813~nuclear chromosome segregation 7.0E-03 
GO:0000278~mitotic cell cycle 7.4E-03 
GO:0051235~maintenance of location 7.5E-03 
GO:0007127~meiosis I 8.0E-03 
GO:0015810~aspartate transport 8.6E-03 
GO:0070925~organelle assembly 9.6E-03 
GO:0000086~G2/M transition of mitotic cell cycle 9.7E-03 




GO:0032200~telomere organization 9.8E-03 
GO:0007067~mitotic nuclear division 1.0E-02 
GO:0051301~cell division 1.2E-02 
GO:0045132~meiotic chromosome segregation 1.2E-02 
GO:0015740~C4-dicarboxylate transport 1.3E-02 
GO:0044839~cell cycle G2/M phase transition 1.5E-02 
GO:0048193~Golgi vesicle transport 1.5E-02 
GO:0044770~cell cycle phase transition 1.6E-02 
GO:0065003~macromolecular complex assembly 1.6E-02 
GO:0070192~chromosome organization involved in meiotic cell cycle 1.7E-02 
GO:0048208~COPII vesicle coating 1.7E-02 
GO:0048207~vesicle targeting, rough ER to cis-Golgi 1.7E-02 
GO:0089711~L-glutamate transmembrane transport 1.8E-02 
GO:0006259~DNA metabolic process 1.8E-02 
GO:0033044~regulation of chromosome organization 1.9E-02 
GO:0006901~vesicle coating 1.9E-02 
GO:0022402~cell cycle process 1.9E-02 
GO:0071822~protein complex subunit organization 1.9E-02 
GO:0044772~mitotic cell cycle phase transition 2.0E-02 
GO:0008589~regulation of smoothened signalling pathway 2.1E-02 
GO:0048199~vesicle targeting, to, from or within Golgi 2.1E-02 
GO:0090114~COPII-coated vesicle budding 2.1E-02 
GO:0032366~intracellular sterol transport 2.1E-02 
GO:0006974~cellular response to DNA damage stimulus 2.1E-02 
GO:0032204~regulation of telomere maintenance 2.4E-02 
GO:0006281~DNA repair 2.5E-02 
GO:0006310~DNA recombination 2.7E-02 
GO:0032984~macromolecular complex disassembly 2.7E-02 
GO:0000712~resolution of meiotic recombination intermediates 2.7E-02 
GO:0071826~ribonucleoprotein complex subunit organization 2.8E-02 
GO:0007049~cell cycle 2.9E-02 
GO:0006811~ion transport 2.9E-02 
GO:0000819~sister chromatid segregation 2.9E-02 
GO:0007091~metaphase/anaphase transition of mitotic cell cycle 3.0E-02 
GO:0030301~cholesterol transport 3.0E-02 
GO:0007018~microtubule-based movement 3.0E-02 
GO:0032844~regulation of homeostatic process 3.1E-02 
GO:0043603~cellular amide metabolic process 3.1E-02 
GO:0070894~regulation of transposon integration 3.2E-02 
GO:0043490~malate-aspartate shuttle 3.2E-02 
GO:0070895~negative regulation of transposon integration 3.2E-02 
GO:0070893~transposon integration 3.2E-02 
GO:0007224~smoothened signalling pathway 3.3E-02 




GO:0010971~positive regulation of G2/M transition of mitotic cell cycle 3.3E-02 
GO:0015813~L-glutamate transport 3.3E-02 
GO:1903046~meiotic cell cycle process 3.4E-02 
GO:0032508~DNA duplex unwinding 3.4E-02 
GO:0006835~dicarboxylic acid transport 3.4E-02 
GO:0006903~vesicle targeting 3.6E-02 
GO:1902751~positive regulation of cell cycle G2/M phase transition 3.7E-02 
GO:0051052~regulation of DNA metabolic process 3.8E-02 
GO:0006312~mitotic recombination 3.8E-02 
GO:0051298~centrosome duplication 4.0E-02 
GO:0051307~meiotic chromosome separation 4.1E-02 
GO:0015800~acidic amino acid transport 4.1E-02 
GO:0006897~endocytosis 4.1E-02 
GO:0032392~DNA geometric change 4.2E-02 
GO:0051592~response to calcium ion 4.2E-02 
GO:0045995~regulation of embryonic development 4.2E-02 
GO:0015711~organic anion transport 4.2E-02 
GO:0051650~establishment of vesicle localization 4.3E-02 
GO:0048259~regulation of receptor-mediated endocytosis 4.3E-02 
GO:0010965~regulation of mitotic sister chromatid separation 4.4E-02 
GO:0000729~DNA double-strand break processing 4.4E-02 
GO:0016071~mRNA metabolic process 4.5E-02 
GO:0051129~negative regulation of cellular component organization 4.5E-02 
GO:0044784~metaphase/anaphase transition of cell cycle 4.6E-02 
GO:0060271~cilium morphogenesis 4.7E-02 
GO:0019836~hemolysis by symbiont of host erythrocytes 4.8E-02 
GO:0051715~cytolysis in other organism 4.8E-02 
GO:0001897~cytolysis by symbiont of host cells 4.8E-02 
GO:0044179~hemolysis in other organism 4.8E-02 
GO:0052331~hemolysis in other organism involved in symbiotic interaction 4.8E-02 
GO:0051801~cytolysis in other organism involved in symbiotic interaction 4.8E-02 
GO:0045787~positive regulation of cell cycle 4.8E-02 
GO:0051306~mitotic sister chromatid separation 4.9E-02 
GO:0010927~cellular component assembly involved in morphogenesis 4.9E-02 
GO:0042384~cilium assembly 5.0E-02 




Appendix 18: Biological processes enriched in 132 genes up-regulated by BILF1 in DG-
75 cells 
 
Gene ontology term p-value 
GO:1903900~regulation of viral life cycle 0.002 
GO:0035914~skeletal muscle cell differentiation 0.004 
GO:0012501~programmed cell death 0.005 
GO:0001938~positive regulation of endothelial cell proliferation 0.005 
GO:0051384~response to glucocorticoid 0.006 
GO:0006915~apoptotic process 0.007 
GO:0031960~response to corticosteroid 0.009 
GO:0008219~cell death 0.009 
GO:1903901~negative regulation of viral life cycle 0.011 
GO:0050792~regulation of viral process 0.011 
GO:0007519~skeletal muscle tissue development 0.011 
GO:0043900~regulation of multi-organism process 0.013 
GO:0048566~embryonic digestive tract development 0.013 
GO:0060538~skeletal muscle organ development 0.013 
GO:0051591~response to cAMP 0.014 
GO:0007339~binding of sperm to zona pellucida 0.015 
GO:0001936~regulation of endothelial cell proliferation 0.015 
GO:0043903~regulation of symbiosis, encompassing mutualism through parasitism 0.015 
GO:0048525~negative regulation of viral process 0.018 
GO:0051924~regulation of calcium ion transport 0.021 
GO:0001935~endothelial cell proliferation 0.021 
GO:0034097~response to cytokine 0.021 
GO:0051592~response to calcium ion 0.023 
GO:0035556~intracellular signal transduction 0.024 
GO:0035036~sperm-egg recognition 0.025 
GO:1990441~negative regulation of transcription from RNA polymerase II promoter in 
response to endoplasmic reticulum stress 
0.025 
GO:0002763~positive regulation of myeloid leukocyte differentiation 0.026 
GO:0050790~regulation of catalytic activity 0.027 
GO:0010646~regulation of cell communication 0.027 
GO:0008277~regulation of G-protein coupled receptor protein signalling pathway 0.027 
GO:0071277~cellular response to calcium ion 0.029 
GO:0009725~response to hormone 0.030 
GO:0023051~regulation of signalling 0.032 
GO:0050673~epithelial cell proliferation 0.032 
GO:0046683~response to organophosphorus 0.032 
GO:0002521~leukocyte differentiation 0.034 
GO:0009628~response to abiotic stimulus 0.036 




GO:0071495~cellular response to endogenous stimulus 0.038 
GO:0070372~regulation of ERK1 and ERK2 cascade 0.039 
GO:0006816~calcium ion transport 0.040 
GO:0006470~protein dephosphorylation 0.042 
GO:0007249~I-kappaB kinase/NF-kappaB signalling 0.043 
GO:0014074~response to purine-containing compound 0.043 
GO:0043547~positive regulation of GTPase activity 0.043 
GO:1902533~positive regulation of intracellular signal transduction 0.043 
GO:0043618~regulation of transcription from RNA polymerase II promoter in response 
to stress 
0.044 
GO:0051345~positive regulation of hydrolase activity 0.044 
GO:0009988~cell-cell recognition 0.046 
GO:0070588~calcium ion transmembrane transport 0.046 
GO:0043901~negative regulation of multi-organism process 0.046 
GO:0045682~regulation of epidermis development 0.047 
GO:0043549~regulation of kinase activity 0.048 
GO:0043902~positive regulation of multi-organism process 0.048 
GO:0010243~response to organonitrogen compound 0.048 
GO:0050679~positive regulation of epithelial cell proliferation 0.049 
GO:0070509~calcium ion import 0.049 
GO:0043620~regulation of DNA-templated transcription in response to stress 0.050 
GO:0097201~negative regulation of transcription from RNA polymerase II promoter in 
response to stress 
0.050 











EPO pathway 9.00E-08 
ARENRF2 pathway 3.00E-06 
IL3 pathway 5.00E-06 
CDMAC pathway 6.00E-06 
PPARA pathway 9.00E-06 
IL2 pathway 2.00E-05 
GLEEVEC pathway 2.00E-05 
TPO pathway 2.00E-05 
EGF pathway 5.00E-05 
PDGF pathway 5.00E-05 
IL2RB pathway 8.00E-05 
Keratinocyte pathway 2.00E-04 
DREAM pathway 4.00E-04 
IL10 pathway 6.00E-04 
Cardiac EGF pathway 7.00E-04 
CCR5 pathway 7.00E-04 
ETS pathway 7.00E-04 
NGF pathway 7.00E-04 
MAPK pathway 1.00E-03 
IGF1 pathway 1.00E-03 
IL6 pathway 1.00E-03 
Insulin pathway 1.00E-03 
NTHI pathway 1.00E-03 
Stress pathway 1.00E-03 
GH pathway 2.00E-03 
TNFR1 pathway 2.00E-03 
IL1R pathway 2.00E-03 
BCR pathway 3.00E-03 
GPCR pathway 3.00E-03 
MET pathway 3.00E-03 
TOLL pathway 3.00E-03 
FCER1 pathway 3.00E-03 
Biopeptides pathway 4.00E-03 
TCR pathway 5.00E-03 
Neurotransmitters pathway 1.00E-02 
FREE pathway 2.00E-02 
SODD pathway 2.00E-02 
CDK5 pathway 2.00E-02 




D4GDI pathway 3.00E-02 
Extrinsic pathway 3.00E-02 
Granulocytes pathway 3.00E-02 
Platelet app pathway 3.00E-02 
RANKL pathway 3.00E-02 
CD40 pathway 3.00E-02 
HIF pathway 3.00E-02 
HSP27 pathway 3.00E-02 
B cell survival pathway 3.00E-02 
IL22BP pathway 3.00E-02 
LAIR pathway 3.00E-02 
RELA pathway 3.00E-02 
41BB pathway 4.00E-02 
IL7 pathway 4.00E-02 
PML pathway 4.00E-02 
TNFR2 pathway 4.00E-02 
TID pathway 4.00E-02 
AMI pathway 4.00E-02 
ATM pathway 4.00E-02 
Cytokine pathway 4.00E-02 
NK cells pathway 4.00E-02 
IL12 pathway 5.00E-02 
SPPA pathway 5.00E-02 
Intrinsic pathway 5.00E-02 















PNMA2 6.76 LOC101927780 1.86 ZNF444 1.63 
LINC01269 6.61 ZNF576 1.86 PDE1B 1.63 
CNIH3 6.33 MYOF 1.86 NDUFA7 1.63 
TCONS 00029157 5.58 IZUMO4 1.86 JAGN1 1.62 
DOK2 4.77 NDUFB11 1.85 TSPO 1.62 
FMR1-AS1 4.01 CCDC167 1.85 CKLF 1.62 
CAMK2A 3.97 NDUFS8 1.85 PHLDA3 1.62 
TIAF1 3.74 ZNF787 1.85 PHPT1 1.62 
CST7 3.49 MAP2K6 1.84 ITPA 1.62 
LOC102724919 3.40 ELOF1 1.84 RPS21 1.62 
SLC37A2 3.40 BIN2 1.84 TIMM8B 1.62 
GNA14 3.40 RPL23P8 1.84 REXO4 1.62 
SPTLC3 3.39 C19orf24 1.84 HSF5 1.61 
SLC19A1 3.32 PYM1 1.83 CORO1A 1.61 
CACNG7 3.32 C1orf145 1.82 TOMM7 1.61 
WNT1 3.30 ZNF593 1.82 NEDD8 1.61 
NPR1 3.18 SSSCA1 1.82 NR2C2AP 1.61 
NACAD 3.10 VWCE 1.82 RNF26 1.61 
MTVR2 3.06 EXOSC4 1.82 LIPE 1.61 
TRAPPC2L 2.91 ATP6V1F 1.82 DYNLRB1 1.61 
RCAN2 2.90 RAB13 1.81 PNOC 1.61 
GREB1 2.89 LOC100507346 1.81 GCHFR 1.61 
IL24 2.86 FAM96B 1.81 KIAA1024 1.61 
CDC14B 2.84 LOC100506136 1.81 FIBP 1.61 
OSTCP1 2.82 NDUFB7 1.81 RBX1 1.61 
RAB33A 2.79 CENPW 1.81 TWF2 1.60 
PSENEN 2.78 HIST1H1E 1.81 ZNF485 1.60 
C9orf142 2.78 COX7B 1.81 CDIPT 1.60 
GABRR1 2.77 LMO2 1.80 CARD8-AS1 1.60 
ARMCX5-
GPRASP2 
2.75 ALDOC 1.80 LSM7 1.60 
MIR650 2.71 ATP13A2 1.80 TRMT61A 1.60 
NKD1 2.70 RPS19 1.80 PEX26 1.59 
PGPEP1L 2.69 CCR6 1.79 EDF1 1.59 
SLC24A3 2.68 FLJ44635 1.79 CFAP43 1.59 
KDM4D 2.67 CPXM1 1.79 SSR4 1.59 
PLAC8L1 2.61 APOL3 1.78 TRIAP1 1.59 
SPAG8 2.60 ABRACL 1.78 ATP5E 1.59 




ATP8B4 2.59 SNRPD2 1.78 MPEG1 1.59 
LRRTM2 2.58 PFDN2 1.78 PHB 1.59 
PDCD1 2.58 GEMIN6 1.78 FEZ1 1.59 
MROH6 2.57 ZNF582 1.78 MRPL22 1.58 
TNFRSF11A 2.54 CD52 1.77 RPL18 1.58 
PXT1 2.51 CCDC51 1.77 ZNF513 1.58 
MAMLD1 2.51 SLC26A11 1.77 GALNT6 1.58 
PLG 2.50 POLR2I 1.77 CXorf65 1.58 
CACNA1E 2.48 TMEM258 1.77 MRPS11 1.58 
PDE4A 2.46 POLR2J 1.77 MRPL17 1.58 
EPS8L2 2.45 TMEM25 1.77 ALS2CR12 1.58 
C1orf101 2.45 WDR18 1.76 YDJC 1.58 
NTN4 2.42 DHCR24 1.76 RPL30 1.58 
TMEM160 2.39 CDK5R1 1.76 TPRG1 1.58 
ABHD1 2.39 ANXA2R 1.76 RNF181 1.57 
FAM195B 2.36 PSMB9 1.76 LAPTM4B 1.57 
VWA7 2.35 PSMB3 1.76 ZNF229 1.57 
ADGRA2 2.35 PRDX5 1.75 RRP9 1.57 
THAP7 2.33 RPL35 1.75 SH3GL1 1.57 
DOK6 2.32 FAM43A 1.75 MIR142 1.57 
LAMTOR2 2.31 XKR8 1.75 PQLC1 1.57 
ARHGEF37 2.31 HSD17B10 1.75 TP53I11 1.57 
MT2A 2.31 VAMP8 1.74 FOSL2 1.57 
C22orf23 2.30 MOB2 1.74 NOP10 1.57 
PRKX-AS1 2.28 RPS14P3 1.74 NLGN3 1.57 
TBXAS1 2.28 MRPS23 1.74 ATP5D 1.56 
TFR2 2.26 FAM98C 1.74 PDCL3P4 1.56 
PARVB 2.25 ANAPC11 1.74 PTRHD1 1.56 
MDP1 2.24 MRPL14 1.74 TNFRSF13B 1.56 
PDE6C 2.24 MCAM 1.73 AGAP5 1.56 
ITGAX 2.23 FAM162A 1.73 NDUFAF4 1.56 
UQCR11 2.22 EMP3 1.73 PRKCH 1.56 
TMEM74B 2.21 CACNA2D3 1.73 CD320 1.56 
LINC01279 2.20 RPL36 1.73 IFITM2 1.56 
FAM86FP 2.20 RPLP2 1.73 NDUFA1 1.55 
MRPL12 2.20 NDUFA11 1.72 SLC17A9 1.55 
C11orf98 2.19 LINC01560 1.72 RBKS 1.55 
RNF144A 2.19 RPL37 1.72 PTGS1 1.55 
PLEKHA6 2.19 PRDX1 1.72 MYL12A 1.55 
TBC1D30 2.16 USMG5 1.72 CLIC1 1.55 
SDC4 2.16 APRT 1.72 SQRDL 1.55 
ALKBH7 2.15 STK11 1.72 SBNO2 1.55 
DGAT2 2.14 C1orf21 1.72 MED27 1.55 




HTR3B 2.13 OST4 1.72 TMEM261 1.55 
PTPN6 2.12 ITGB3 1.72 GAS7 1.55 
MGMT 2.11 SSNA1 1.71 UQCRHL 1.55 
SPATA21 2.10 NDUFB2 1.71 FAU 1.55 
FARSA 2.09 HIST2H2AB 1.71 RPS14 1.55 
CD63 2.08 SUFU 1.71 CLIC5 1.54 
CAMKK1 2.08 IL4I1 1.71 COMMD1 1.54 
NRROS 2.08 MRPL51 1.71 MAD2L2 1.54 
LINC00987 2.08 PFDN6 1.71 HIRIP3 1.54 
CHMP6 2.07 SLC22A13 1.70 NDUFB10 1.54 
C6orf99 2.07 UBA52 1.70 LTB 1.54 
MPST 2.06 RPL38 1.70 RHOBTB3 1.54 
ZNF774 2.06 SYNGR2 1.70 LIX1L 1.54 
FGR 2.05 FIS1 1.70 NDUFB9 1.54 
CATSPER3 2.05 LINC00589 1.70 RPS18 1.54 
SLC24A2 2.05 YIF1A 1.69 SHFM1 1.54 
FRMD3 2.04 DDRGK1 1.69 ARFGAP1 1.54 
HSD17B1 2.04 ORAOV1 1.69 MAGEF1 1.53 
CRIP1 2.02 LOC101243545 1.69 RAB1B 1.53 
AMZ1 2.01 RGS9 1.69 MRPL27 1.53 
LOC101927472 2.01 FRAT1 1.69 HSD17B7 1.53 
TMEM53 2.01 ITGB2 1.69 SPRYD7 1.53 
ZNF491 2.00 TRMT112 1.69 ATP5I 1.53 
ATP10A 2.00 CHID1 1.69 ATP5G1 1.53 
CYP1A1 2.00 RGS19 1.68 CCDC12 1.53 
NDUFA8 2.00 CMTM3 1.68 ASNA1 1.53 
TBC1D9 2.00 SLC25A1 1.68 LMNA 1.53 
SLC16A13 1.99 TMSB10 1.68 CDKN1A 1.53 
PPP1R14B 1.99 PBX4 1.68 PLOD3 1.53 
TMSB4X 1.99 COMMD5 1.68 UBL5 1.53 
CRYM 1.99 HTR3A 1.68 PSMG3 1.53 
TSTD1 1.98 SH3BGRL3 1.68 UMPS 1.53 
ISG15 1.98 IQCD 1.68 COX6B1 1.53 
MIR663AHG 1.97 LHFPL3-AS2 1.67 FDXR 1.53 
PET117 1.97 PTPRCAP 1.67 OR5B21 1.53 
ATAD3A 1.96 MRPL24 1.67 MRPS21 1.53 
ZBED2 1.96 RPL27 1.67 LOC101929450 1.52 
BRMS1 1.96 LIN37 1.67 PTMA 1.52 
NFKBIL1 1.95 NOL7 1.67 PPP1R35 1.52 
ECEL1 1.95 G6PC3 1.67 USE1 1.52 
HIST1H2AI 1.95 PEPD 1.67 MYEOV2 1.52 
LTA 1.94 SNRNP25 1.66 GSTP1 1.52 
ARL14EPL 1.94 POU6F1 1.66 COX7C 1.52 




HIST1H3I 1.93 C7orf50 1.66 GPR132 1.52 
HIST1H2AL 1.93 RFXANK 1.66 TALDO1 1.52 
NDUFA13 1.93 RPLP1 1.66 UQCC2 1.52 
IL27RA 1.93 DTX2 1.65 POMP 1.52 
KRTCAP2 1.93 ST8SIA5 1.65 C19orf53 1.51 
CHCHD1 1.92 UQCR10 1.65 N4BP3 1.51 
NME1 1.92 MYDGF 1.65 SLCO4A1 1.51 
TNFRSF9 1.91 RPS27L 1.65 ADPRHL2 1.51 
CD96 1.91 RPS19BP1 1.65 CSTB 1.51 
IFI30 1.90 ZBTB32 1.65 TBC1D10C 1.51 
COX5B 1.90 MYL6 1.65 PSKH1 1.51 
ANKRD30BL 1.90 ZFPL1 1.65 HIST2H2AC 1.51 
CRYM-AS1 1.90 LOC101929470 1.65 COX8A 1.51 
MRPL52 1.90 GNB2 1.65 SF3B5 1.51 
APOA1-AS 1.90 KLK1 1.65 PPP1CA 1.51 
RIN3 1.90 MIR6087 1.65 PFDN5 1.50 
TRAPPC5 1.90 RPL37A 1.65 ALOX5AP 1.50 
SH2D2A 1.90 RINL 1.64 MRPS18B 1.50 
DLG5 1.89 ACTA1 1.64 RNH1 1.50 
MRPL36 1.88 SMAGP 1.64 TNFRSF18 1.50 
CCT6B 1.88 CHRNA1 1.64 SPCS1 1.50 
MTFP1 1.88 ZNF213-AS1 1.64 PADI2 1.50 
AHRR 1.88 SLC25A11 1.64 RNF187 1.50 
ARL4C 1.88 TMA7 1.64 ICT1 1.50 
ZNF71 1.88 MRPS12 1.63 COA6 1.50 
AP2S1 1.88 DUSP4 1.63 COX6C 1.50 
STK31 1.87 RPS16 1.63 ERP27 1.50 
TRABD2A 1.87 COX6A1 1.63 
  
















IL26 -7.41 ERICH6 -2.09 LOC285074 -1.71 
LOC100129924 -6.96 OLMALINC -2.09 TENM1 -1.71 
WDR38 -5.56 LINC01140 -2.09 ARC -1.70 
KSR2 -5.12 PHOSPHO2 -2.08 STAG3L5P -1.69 
TRHR -4.15 NFIX -2.06 FAM221A -1.69 
NAALADL2 -4.06 RDH10-AS1 -2.06 KCTD6 -1.69 
GRPR -4.06 MOB4 -2.05 DEPDC1 -1.69 
LOC339807 -3.77 CTSV -2.05 NKX3-1 -1.69 
LAG3 -3.71 SNORD144 -2.05 STARD4-AS1 -1.69 
CD28 -3.54 ARHGAP33 -2.04 KLF5 -1.69 
HIST1H3H -3.45 SUGCT -2.03 INCA1 -1.69 
ELOVL3 -3.42 ADRA2B -2.03 TXNDC16 -1.68 
TMEM59L -3.34 MYOZ3 -2.03 C6orf163 -1.68 
LOC442497 -3.32 ABCG1 -2.02 OSBPL10-AS1 -1.67 
TRPV4 -3.28 KCNH1 -2.02 MIR133A1HG -1.67 
LOC102724484 -3.27 LRRC45 -2.02 GPR22 -1.67 
ULBP2 -3.25 SNORA29 -2.02 PCDH9 -1.66 
LOC101060553 -3.23 FZD7 -2.01 ACACB -1.66 
JHDM1D-AS1 -3.21 P2RY13 -2.01 BRE-AS1 -1.66 
NOD2 -3.17 MLLT10P1 -2.01 TMC5 -1.66 
MIR4324 -3.14 KCCAT333 -2.00 KIF20A -1.65 
SMCO3 -3.12 RYR1 -2.00 CASD1 -1.65 
CCNI2 -3.12 HAVCR1P1 -1.99 GSTM3 -1.65 
MIR554 -3.05 EPB41L4B -1.99 TC2N -1.65 
WNK2 -3.04 LINC01504 -1.98 VASN -1.65 
DNMBP-AS1 -3.03 TMEM120A -1.98 CETN3 -1.64 
JPH1 -3.03 CPED1 -1.97 HOXA6 -1.64 
GPX8 -3.02 CHPT1 -1.97 PLCE1 -1.64 
CCL27 -2.96 SNORD29 -1.97 ASTL -1.64 
OSBPL6 -2.91 MAF -1.97 PRKCA-AS1 -1.64 
TRNP1 -2.91 ZNF704 -1.97 KBTBD11 -1.63 
ALDH1A3 -2.83 LOC100289495 -1.96 ASAP1-IT2 -1.63 
PYCARD-AS1 -2.82 PVRL1 -1.96 WNT16 -1.63 
NCKAP5 -2.80 GAPDHS -1.96 CFL2 -1.62 
C1QTNF6 -2.75 PRKAR2B -1.96 ASPN -1.62 
ST7-OT3 -2.73 LARGE-AS1 -1.95 SNORD28 -1.62 
CD14 -2.72 LOC730101 -1.95 SMIM4 -1.62 
ZC2HC1B -2.71 RASAL2 -1.94 KCNQ5-AS1 -1.62 




FMN2 -2.70 ZNF385C -1.93 HYMAI -1.62 
IPCEF1 -2.70 TAS2R19 -1.93 AHNAK -1.62 
ALPL -2.69 LECT1 -1.92 STX1A -1.61 
NPHP1 -2.69 COL2A1 -1.92 NUP50-AS1 -1.61 
SNORD50A -2.67 TAS2R46 -1.92 ZPBP2 -1.61 
EIF1AX-AS1 -2.67 SNORA48 -1.92 SGCE -1.61 
AZIN2 -2.63 TTLL13P -1.92 MAFB -1.61 
GAREM -2.62 LOC645434 -1.92 MORC4 -1.61 
STARD13 -2.62 SYCE1L -1.91 FOS -1.60 
PTGER3 -2.61 KIF9-AS1 -1.91 ALG6 -1.60 
DSEL -2.60 PHF24 -1.91 CCNE2 -1.60 
FNIP2 -2.59 PIWIL4 -1.91 LOC101927543 -1.60 
PTPN13 -2.57 PYGO1 -1.90 LOC400958 -1.60 
TP63 -2.57 UBAC2-AS1 -1.90 NR1D2 -1.60 
SPRY1 -2.56 GRHL1 -1.90 DEPDC1B -1.59 
LOC400997 -2.55 PDE3B -1.90 KCNQ1OT1 -1.59 
MYO7B -2.55 SNORA31 -1.89 SNAI1 -1.59 
ASMTL-AS1 -2.54 CFAP46 -1.88 FLT1 -1.59 
TRPC5 -2.51 PDCD4-AS1 -1.88 TBC1D2B -1.59 
LYPLAL1-AS1 -2.50 FAM227A -1.88 FOSB -1.59 
ZACN -2.49 FYB -1.87 LMLN -1.59 
SEPT3 -2.49 SNORD97 -1.86 KLB -1.59 
SNX24 -2.48 TMEM9B-AS1 -1.86 PAXBP1-AS1 -1.58 
FRK -2.46 PYHIN1 -1.86 SNORA4 -1.58 
FNDC1 -2.46 TJP2 -1.86 DPY19L2 -1.58 
CAMK2N1 -2.45 CTAGE7P -1.86 YPEL2 -1.58 
FBXO43 -2.45 SNORA33 -1.85 NPTX2 -1.58 
CLIC6 -2.43 PCDHGC4 -1.85 E2F8 -1.57 
FER1L4 -2.41 MCTP1 -1.85 HSPA1L -1.57 
CACNA1D -2.41 BTLA -1.84 SLC9A9 -1.57 
IFNG -2.39 ARHGAP32 -1.84 EML6 -1.57 
SEMA3B -2.39 SEPN1 -1.83 WNK3 -1.57 
ZNF404 -2.39 LOC100131635 -1.82 FZD5 -1.57 
ZNF365 -2.38 HCK -1.82 SNORD71 -1.57 
BAMBI -2.36 ACVR1 -1.82 LOC100507156 -1.57 
MFI2-AS1 -2.35 BPGM -1.82 CFAP54 -1.57 
ICOS -2.33 SLC16A10 -1.81 CLEC2B -1.57 
GPR137C -2.33 F5 -1.81 RORA-AS1 -1.56 
RASGRP4 -2.31 HBEGF -1.81 SNORD99 -1.56 
SNORD50B -2.31 ZNF80 -1.80 MTRNR2L5 -1.56 
SGCD -2.30 LOC101927190 -1.80 ZBTB20-AS4 -1.56 
KIAA1656 -2.30 LOC145474 -1.80 SH3D19 -1.56 
RHBDF1 -2.30 DDR2 -1.80 KIF13A -1.56 




LINC00861 -2.29 IRS2 -1.79 ADRB2 -1.55 
WBP1 -2.28 LOC102723704 -1.79 CLSPN -1.55 
IL13RA1 -2.27 KDELC2 -1.79 DNAJC3-AS1 -1.55 
BAIAP3 -2.26 TJP3 -1.79 TIMM8A -1.55 
MIR186 -2.26 CDC20B -1.79 KIAA1211 -1.55 
INPP4B -2.25 RIMS2 -1.78 GTSE1 -1.55 
SYNM -2.24 LRRC70 -1.78 SLC38A6 -1.55 
SBSPON -2.22 NUDT9P1 -1.78 SLC30A1 -1.55 
OR2B2 -2.22 DLGAP5 -1.78 NANOS1 -1.55 
RHEBL1 -2.21 PLN -1.78 SENCR -1.55 
AVPI1 -2.20 GAS2L3 -1.77 LINC01184 -1.55 
CEP70 -2.20 SLC2A12 -1.77 ANGPTL1 -1.54 
DIP2C -2.20 SHANK2 -1.77 TMEM81 -1.54 
MTCL1 -2.19 NAALAD2 -1.77 C1GALT1C1 -1.54 
TIPARP-AS1 -2.18 TSIX -1.77 KCNA3 -1.54 
NUP62CL -2.18 C1QL3 -1.76 DLEU1 -1.54 
ATP1B2 -2.18 TIGIT -1.76 C15orf41 -1.53 
FERMT2 -2.17 NPY6R -1.76 CACYBP -1.53 
SNORD12 -2.17 IFI44L -1.76 CDC25A -1.53 
SLC4A9 -2.17 DTHD1 -1.75 EYS -1.53 
AKAP6 -2.16 SCARNA9L -1.75 FAM98B -1.53 
ANKRD36BP2 -2.15 SNORA76A -1.75 STRIP2 -1.53 
MIR4742 -2.15 LOC100507557 -1.75 MBNL2 -1.52 
TBX21 -2.15 PELI2 -1.75 IFNG-AS1 -1.52 
ANKDD1B -2.14 CCDC149 -1.74 RAB23 -1.52 
IL18 -2.14 P2RY14 -1.74 ID2 -1.51 
BMP7 -2.13 RPS16P5 -1.74 TUFT1 -1.51 
LPL -2.11 POU3F1 -1.73 NUDT4 -1.51 
MIR597 -2.11 FAM83D -1.73 SPRY4 -1.50 
CD200 -2.10 SLC16A2 -1.73 DYNC2H1 -1.50 
PTGS2 -2.10 MLLT3 -1.73 BACE2 -1.50 
CA13 -2.10 KLF4 -1.73 FRY -1.50 
THBS1 -2.10 MLF1 -1.73 RNF103 -1.50 
TOB2P1 -2.10 IFI44 -1.73 TRIM2 -1.50 
PFN2 -2.10 CAV1 -1.71 CREG1 -1.50 






Appendix 22:  Biological processes enriched in 463 genes up-regulated by BILF1in GC 
B cells 
 
Gene ontology term p-value 
GO:0042773~ATP synthesis coupled electron transport 6.53E-16 
GO:0006119~oxidative phosphorylation 1.81E-15 
GO:0042775~mitochondrial ATP synthesis coupled electron transport 7.62E-15 
GO:0022904~respiratory electron transport chain 2.64E-14 
GO:0022900~electron transport chain 3.88E-14 
GO:0009205~purine ribonucleoside triphosphate metabolic process 4.31E-14 
GO:0009199~ribonucleoside triphosphate metabolic process 7.95E-14 
GO:0009144~purine nucleoside triphosphate metabolic process 8.75E-14 
GO:0046034~ATP metabolic process 1.45E-13 
GO:0009161~ribonucleoside monophosphate metabolic process 7.74E-13 
GO:0009141~nucleoside triphosphate metabolic process 7.74E-13 
GO:0009167~purine ribonucleoside monophosphate metabolic process 1.48E-12 
GO:0009126~purine nucleoside monophosphate metabolic process 1.62E-12 
GO:0009123~nucleoside monophosphate metabolic process 2.63E-12 
GO:0007005~mitochondrion organization 3.55E-12 
GO:0046128~purine ribonucleoside metabolic process 8.58E-11 
GO:0042278~purine nucleoside metabolic process 1.06E-10 
GO:0045047~protein targeting to ER 1.24E-10 
GO:0009119~ribonucleoside metabolic process 1.40E-10 
GO:0072599~establishment of protein localization to endoplasmic reticulum 2.29E-10 
GO:0045333~cellular respiration 2.93E-10 
GO:0006415~translational termination 3.24E-10 
GO:0006614~SRP-dependent cotranslational protein targeting to membrane 3.24E-10 
GO:0070125~mitochondrial translational elongation 5.06E-10 
GO:0070126~mitochondrial translational termination 6.01E-10 
GO:0009116~nucleoside metabolic process 8.25E-10 
GO:0006613~cotranslational protein targeting to membrane 9.53E-10 
GO:0032543~mitochondrial translation 1.08E-09 
GO:0006412~translation 1.09E-09 
GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 1.83E-09 
GO:0019693~ribose phosphate metabolic process 1.83E-09 
GO:1901657~glycosyl compound metabolic process 2.98E-09 
GO:0009259~ribonucleotide metabolic process 3.22E-09 
GO:0070972~protein localization to endoplasmic reticulum 3.41E-09 
GO:0043043~peptide biosynthetic process 3.48E-09 
GO:1902600~hydrogen ion transmembrane transport 3.85E-09 
GO:0009150~purine ribonucleotide metabolic process 5.36E-09 
GO:0006518~peptide metabolic process 5.94E-09 




GO:0006414~translational elongation 8.71E-09 
GO:0033108~mitochondrial respiratory chain complex assembly 1.06E-08 
GO:0006163~purine nucleotide metabolic process 1.92E-08 
GO:0009117~nucleotide metabolic process 3.36E-08 
GO:0006364~rRNA processing 3.52E-08 
GO:0015980~energy derivation by oxidation of organic compounds 4.04E-08 
GO:0006753~nucleoside phosphate metabolic process 4.61E-08 
GO:0043241~protein complex disassembly 4.84E-08 
GO:0043604~amide biosynthetic process 5.64E-08 
GO:0016072~rRNA metabolic process 5.66E-08 
GO:0072521~purine-containing compound metabolic process 6.64E-08 
GO:0032984~macromolecular complex disassembly 9.67E-08 
GO:0006091~generation of precursor metabolites and energy 1.03E-07 
GO:0006402~mRNA catabolic process 1.10E-07 
GO:0019083~viral transcription 1.16E-07 
GO:0055086~nucleobase-containing small molecule metabolic process 1.18E-07 
GO:0010257~NADH dehydrogenase complex assembly 1.20E-07 
GO:0032981~mitochondrial respiratory chain complex I assembly 1.20E-07 
GO:0097031~mitochondrial respiratory chain complex I biogenesis 1.20E-07 
GO:0042254~ribosome biogenesis 1.28E-07 
GO:0000956~nuclear-transcribed mRNA catabolic process 1.71E-07 
GO:0006401~RNA catabolic process 1.76E-07 
GO:0006120~mitochondrial electron transport, NADH to ubiquinone 2.11E-07 
GO:1902582~single-organism intracellular transport 2.82E-07 
GO:0019080~viral gene expression 2.84E-07 
GO:0043603~cellular amide metabolic process 2.95E-07 
GO:0015992~proton transport 2.97E-07 
GO:0044033~multi-organism metabolic process 3.10E-07 
GO:0006818~hydrogen transport 3.55E-07 
GO:0043624~cellular protein complex disassembly 3.58E-07 
GO:0071822~protein complex subunit organization 5.65E-07 
GO:0006413~translational initiation 1.09E-06 
GO:0006605~protein targeting 2.55E-06 
GO:0090150~establishment of protein localization to membrane 2.56E-06 
GO:1901566~organonitrogen compound biosynthetic process 2.96E-06 
GO:0055114~oxidation-reduction process 3.03E-06 
GO:0006123~mitochondrial electron transport, cytochrome c to oxygen 3.39E-06 
GO:0034655~nucleobase-containing compound catabolic process 4.46E-06 
GO:0046700~heterocycle catabolic process 5.41E-06 
GO:0034470~ncRNA processing 5.41E-06 
GO:0072594~establishment of protein localization to organelle 5.62E-06 
GO:0044270~cellular nitrogen compound catabolic process 7.31E-06 
GO:0022411~cellular component disassembly 7.73E-06 




GO:0022613~ribonucleoprotein complex biogenesis 9.66E-06 
GO:0043933~macromolecular complex subunit organization 1.38E-05 
GO:0061024~membrane organization 2.06E-05 
GO:1901361~organic cyclic compound catabolic process 2.12E-05 
GO:0046907~intracellular transport 3.05E-05 
GO:0072657~protein localization to membrane 3.72E-05 
GO:0044802~single-organism membrane organization 4.74E-05 
GO:0034660~ncRNA metabolic process 7.51E-05 
GO:0019058~viral life cycle 8.27E-05 
GO:0034220~ion transmembrane transport 2.01E-04 
GO:0015985~energy coupled proton transport, down electrochemical gradient 3.99E-04 
GO:0015986~ATP synthesis coupled proton transport 3.99E-04 
GO:0006811~ion transport 4.11E-04 
GO:1902580~single-organism cellular localization 4.14E-04 
GO:0019637~organophosphate metabolic process 4.60E-04 
GO:0033365~protein localization to organelle 4.77E-04 
GO:0070887~cellular response to chemical stimulus 5.07E-04 
GO:0051649~establishment of localization in cell 6.05E-04 
GO:0006886~intracellular protein transport 6.31E-04 
GO:0009057~macromolecule catabolic process 6.79E-04 
GO:0044085~cellular component biogenesis 7.06E-04 
GO:0098660~inorganic ion transmembrane transport 7.92E-04 
GO:0098655~cation transmembrane transport 0.0010 
GO:0000028~ribosomal small subunit assembly 0.0011 
GO:0042776~mitochondrial ATP synthesis coupled proton transport 0.0011 
GO:0016071~mRNA metabolic process 0.0011 
GO:0033209~tumour necrosis factor-mediated signalling pathway 0.0011 
GO:0043623~cellular protein complex assembly 0.0011 
GO:0015031~protein transport 0.0011 
GO:0051641~cellular localization 0.0014 
GO:0055085~transmembrane transport 0.0015 
GO:0044265~cellular macromolecule catabolic process 0.0019 
GO:0034613~cellular protein localization 0.0019 
GO:0006396~RNA processing 0.0021 
GO:0033036~macromolecule localization 0.0021 
GO:0070727~cellular macromolecule localization 0.0023 
GO:0009206~purine ribonucleoside triphosphate biosynthetic process 0.0025 
GO:1901135~carbohydrate derivative metabolic process 0.0026 
GO:0009145~purine nucleoside triphosphate biosynthetic process 0.0027 
GO:0008104~protein localization 0.0029 
GO:0034622~cellular macromolecular complex assembly 0.0030 
GO:0009156~ribonucleoside monophosphate biosynthetic process 0.0034 
GO:0006839~mitochondrial transport 0.0037 




GO:0009201~ribonucleoside triphosphate biosynthetic process 0.0039 
GO:0098662~inorganic cation transmembrane transport 0.0040 
GO:0006754~ATP biosynthetic process 0.0045 
GO:0045184~establishment of protein localization 0.0048 
GO:1990542~mitochondrial transmembrane transport 0.0049 
GO:0042455~ribonucleoside biosynthetic process 0.0050 
GO:0009124~nucleoside monophosphate biosynthetic process 0.0058 
GO:0006812~cation transport 0.0060 
GO:0015672~monovalent inorganic cation transport 0.0061 
GO:0009168~purine ribonucleoside monophosphate biosynthetic process 0.0068 
GO:0009127~purine nucleoside monophosphate biosynthetic process 0.0068 
GO:0042451~purine nucleoside biosynthetic process 0.0068 
GO:0046129~purine ribonucleoside biosynthetic process 0.0068 
GO:0071310~cellular response to organic substance 0.0078 
GO:0016310~phosphorylation 0.0081 
GO:0071345~cellular response to cytokine stimulus 0.0081 
GO:0031397~negative regulation of protein ubiquitination 0.0081 
GO:0009163~nucleoside biosynthetic process 0.0081 
GO:0006796~phosphate-containing compound metabolic process 0.0081 
GO:0006793~phosphorus metabolic process 0.0086 
GO:0009142~nucleoside triphosphate biosynthetic process 0.0086 
GO:0000462~maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 
5.8S rRNA, LSU-rRNA) 
0.0088 
GO:1901659~glycosyl compound biosynthetic process 0.0088 
GO:0002532~production of molecular mediator involved in inflammatory response 0.0106 
GO:0071493~cellular response to UV-B 0.0126 
GO:1903321~negative regulation of protein modification by small protein conjugation 
or removal 
0.0128 
GO:0050854~regulation of antigen receptor-mediated signalling pathway 0.0137 
GO:0044419~interspecies interaction between organisms 0.0144 
GO:0044403~symbiosis, encompassing mutualism through parasitism 0.0144 
GO:0016032~viral process 0.0152 
GO:0044764~multi-organism cellular process 0.0167 
GO:0065003~macromolecular complex assembly 0.0172 
GO:0006461~protein complex assembly 0.0192 
GO:0070271~protein complex biogenesis 0.0195 
GO:0042989~sequestering of actin monomers 0.0196 
GO:0030490~maturation of SSU-rRNA 0.0215 
GO:0044248~cellular catabolic process 0.0218 
GO:0019221~cytokine-mediated signalling pathway 0.0227 
GO:0060252~positive regulation of glial cell proliferation 0.0236 
GO:0070527~platelet aggregation 0.0262 
GO:0010467~gene expression 0.0291 
GO:0010821~regulation of mitochondrion organization 0.0319 




Appendix 23: 125 biological processes most significantly enriched in 356 genes down-
regulated by BILF1in GC B cells 
 
Gene ontology term p-value 
GO:0051049~regulation of transport 2.71E-06 
GO:0042325~regulation of phosphorylation 4.01E-06 
GO:0001932~regulation of protein phosphorylation 4.83E-06 
GO:0019220~regulation of phosphate metabolic process 1.03E-05 
GO:0051174~regulation of phosphorus metabolic process 1.04E-05 
GO:0035556~intracellular signal transduction 1.28E-05 
GO:0006468~protein phosphorylation 1.41E-05 
GO:0023014~signal transduction by protein phosphorylation 2.11E-05 
GO:0031399~regulation of protein modification process 2.30E-05 
GO:0034762~regulation of transmembrane transport 3.90E-05 
GO:1902531~regulation of intracellular signal transduction 4.65E-05 
GO:0042327~positive regulation of phosphorylation 6.17E-05 
GO:0043549~regulation of kinase activity 6.65E-05 
GO:0001934~positive regulation of protein phosphorylation 7.16E-05 
GO:0000165~MAPK cascade 7.23E-05 
GO:0072358~cardiovascular system development 7.83E-05 
GO:0072359~circulatory system development 7.83E-05 
GO:0045937~positive regulation of phosphate metabolic process 8.10E-05 
GO:0010562~positive regulation of phosphorus metabolic process 8.10E-05 
GO:0034765~regulation of ion transmembrane transport 8.99E-05 
GO:0065009~regulation of molecular function 1.22E-04 
GO:0051050~positive regulation of transport 1.24E-04 
GO:1901343~negative regulation of vasculature development 1.30E-04 
GO:0014066~regulation of phosphatidylinositol 3-kinase signalling 1.35E-04 
GO:0045859~regulation of protein kinase activity 1.47E-04 
GO:0019216~regulation of lipid metabolic process 1.49E-04 
GO:0016310~phosphorylation 1.77E-04 
GO:0051338~regulation of transferase activity 2.27E-04 
GO:0051246~regulation of protein metabolic process 2.73E-04 
GO:0043408~regulation of MAPK cascade 3.59E-04 
GO:0048646~anatomical structure formation involved in morphogenesis 4.04E-04 
GO:0009967~positive regulation of signal transduction 4.08E-04 
GO:0010647~positive regulation of cell communication 4.84E-04 
GO:0006796~phosphate-containing compound metabolic process 5.31E-04 
GO:0023056~positive regulation of signalling 5.33E-04 
GO:0043269~regulation of ion transport 5.47E-04 







GO:1904062~regulation of cation transmembrane transport 6.54E-04 
GO:1904951~positive regulation of establishment of protein localization 6.82E-04 
GO:0070201~regulation of establishment of protein localization 7.52E-04 
GO:0031401~positive regulation of protein modification process 7.80E-04 
GO:0023051~regulation of signalling 8.22E-04 
GO:2000026~regulation of multicellular organismal development 8.64E-04 
GO:0048015~phosphatidylinositol-mediated signalling 9.07E-04 
GO:0032412~regulation of ion transmembrane transporter activity 9.44E-04 
GO:0060341~regulation of cellular localization 9.45E-04 
GO:0022603~regulation of anatomical structure morphogenesis 9.94E-04 
GO:0048017~inositol lipid-mediated signalling 1.02E-03 
GO:0032268~regulation of cellular protein metabolic process 1.08E-03 
GO:0051093~negative regulation of developmental process 1.09E-03 
GO:0022898~regulation of transmembrane transporter activity 1.14E-03 
GO:0009966~regulation of signal transduction 1.15E-03 
GO:0050790~regulation of catalytic activity 1.19E-03 
GO:0009893~positive regulation of metabolic process 1.20E-03 
GO:0051223~regulation of protein transport 1.22E-03 
GO:0051241~negative regulation of multicellular organismal process 1.32E-03 
GO:1902533~positive regulation of intracellular signal transduction 1.45E-03 
GO:0010959~regulation of metal ion transport 1.49E-03 
GO:0032270~positive regulation of cellular protein metabolic process 1.49E-03 
GO:0060537~muscle tissue development 1.51E-03 
GO:0051222~positive regulation of protein transport 1.52E-03 
GO:0010646~regulation of cell communication 1.56E-03 
GO:0051240~positive regulation of multicellular organismal process 1.69E-03 
GO:0031325~positive regulation of cellular metabolic process 1.71E-03 
GO:0019935~cyclic-nucleotide-mediated signalling 1.84E-03 
GO:0032409~regulation of transporter activity 1.86E-03 
GO:0051924~regulation of calcium ion transport 1.86E-03 
GO:0006928~movement of cell or subcellular component 1.89E-03 
GO:0010604~positive regulation of macromolecule metabolic process 1.97E-03 
GO:0048870~cell motility 2.00E-03 
GO:0051674~localization of cell 2.00E-03 
GO:0071900~regulation of protein serine/threonine kinase activity 2.11E-03 
GO:0001568~blood vessel development 2.17E-03 
GO:0031214~biomineral tissue development 2.31E-03 
GO:0016477~cell migration 2.71E-03 
GO:0030335~positive regulation of cell migration 2.86E-03 
GO:0001837~epithelial to mesenchymal transition 2.88E-03 
GO:0014706~striated muscle tissue development 2.96E-03 
GO:0048584~positive regulation of response to stimulus 3.11E-03 
GO:0010038~response to metal ion 3.21E-03 




GO:0032844~regulation of homeostatic process 3.38E-03 
GO:0007166~cell surface receptor signalling pathway 3.40E-03 
GO:0016525~negative regulation of angiogenesis 3.45E-03 
GO:0044057~regulation of system process 3.62E-03 
GO:0048659~smooth muscle cell proliferation 3.63E-03 
GO:0001503~ossification 3.63E-03 
GO:0008015~blood circulation 3.77E-03 
GO:2000147~positive regulation of cell motility 3.84E-03 
GO:2000181~negative regulation of blood vessel morphogenesis 3.87E-03 
GO:0051247~positive regulation of protein metabolic process 3.88E-03 
GO:0003013~circulatory system process 3.95E-03 
GO:0001944~vasculature development 3.96E-03 
GO:0010628~positive regulation of gene expression 4.04E-03 
GO:0001525~angiogenesis 4.17E-03 
GO:0030855~epithelial cell differentiation 4.22E-03 
GO:0007267~cell-cell signalling 4.25E-03 
GO:0001667~ameboidal-type cell migration 4.26E-03 
GO:0006811~ion transport 4.27E-03 
GO:0048660~regulation of smooth muscle cell proliferation 4.34E-03 
GO:0048596~embryonic camera-type eye morphogenesis 4.50E-03 
GO:0051128~regulation of cellular component organization 4.50E-03 
GO:0006816~calcium ion transport 4.51E-03 
GO:0019932~second-messenger-mediated signalling 4.52E-03 
GO:0042592~homeostatic process 0.0046 
GO:0060429~epithelium development 0.0047 
GO:0051272~positive regulation of cellular component movement 0.0048 
GO:0048304~positive regulation of isotype switching to IgG isotypes 0.0048 
GO:0040011~locomotion 0.0048 
GO:0043405~regulation of MAP kinase activity 0.0050 
GO:0040017~positive regulation of locomotion 0.0050 
GO:0050729~positive regulation of inflammatory response 0.0051 
GO:0044093~positive regulation of molecular function 0.0051 
GO:0007167~enzyme linked receptor protein signalling pathway 0.0052 
GO:0032880~regulation of protein localization 0.0057 
GO:0098662~inorganic cation transmembrane transport 0.0057 
GO:2000021~regulation of ion homeostasis 0.0057 
GO:0034220~ion transmembrane transport 0.0058 
GO:0007179~transforming growth factor beta receptor signalling pathway 0.0059 
GO:0001775~cell activation 0.0060 
GO:0034764~positive regulation of transmembrane transport 0.0060 
GO:2000242~negative regulation of reproductive process 0.0061 
GO:0048291~isotype switching to IgG isotypes 0.0061 









Respiratory electron transport ATP synthesis by chemi-osmotic coupling and heat 
production by uncoupling proteins 
9E-28 
TCA cycle and respiratory electron transport 3E-24 
Respiratory electron transport 3E-23 
Influenza viral RNA transcription and replication 5E-17 
SRP dependent cotranslational protein targeting to membrane 1E-16 
Influenza life cycle 2E-15 
Peptide chain elongation 2E-15 
Translation 6E-15 
Metabolism of RNA 1E-14 
3 UTR mediated translational regulation 2E-14 
Nonsense mediated decay enhanced by the exon junction complex 2E-14 
Metabolism of proteins 3E-14 
Metabolism of mRNA 6E-14 
Hemostasis 4E-06 
Formation of ATP by chemiosmotic coupling 5E-06 
Formation of the ternary complex and subsequently the 43S complex 2E-05 
Immune system 4E-05 
Activation of the mRNA upon binding of the cap binding complex and EIFS and 
subsequent binding to 43S 
4E-05 
Ion channel transport 6E-05 
DNA repair 2E-04 
Signalling by NOTCH1 2E-04 
Platelet activation signalling and aggregation 2E-04 
MRNA SPLICING MINOR pathway 3E-04 
Transmembrane transport of small molecules 4E-04 
DIABETES pathways 5E-04 
Response to elevated platelet cytosolic Ca2  5E-04 
Ligand gated ion channel transport 6E-04 
Transmission across chemical synapses 6E-04 
Cell surface interactions at the vascular wall 6E-04 
VIF mediated degradation of APOBEC3G 7E-04 
Neurotransmitter receptor binding and downstream transmission in the postsynaptic cell 7E-04 
SCFSKP2 mediated degradation of P27 P21 8E-04 
HIV infection 9E-04 
P53 dependent G1 DNA damage response 9E-04 
Signalling by NOTCH 1E-03 
Activated NOTCH1 transmits signal to the nucleus 1E-03 
Autodegradation of CDH1 by CDH1 APC C 1E-03 




Cytokine signalling in immune system 1E-03 
Interferon signalling 1E-03 
Cyclin e associated events during G1 s transition  1E-03 
Signalling by WNT 1E-03 
Regulation of the Fanconi anaemia pathway 2E-03 
APC C CDH1 mediated degradation of CDC20 and other APC C CDH1 targeted proteins 
in late mitosis early G1 
2E-03 
ORC1 removal from chromatin 2E-03 
APC C CDC20 mediated degradation of mitotic proteins 2E-03 
Cell cycle checkpoints 2E-03 
Gluconeogenesis 2E-03 
Integration of energy metabolism 2E-03 
Metabolism of nucleotides 2E-03 
NFκB and map kinases activation mediated by TLR4 signalling repertoire 2E-03 
TRIF mediated TLR3 signalling 3E-03 
PECAM1 interactions 3E-03 
Adaptive immune system 3E-03 
G alpha Q signalling events 3E-03 
Platelet homeostasis 3E-03 
TRAF6 mediated induction of NFκB and map kinases upon TLR7 8 or 9 activation 3E-03 
Unfolded protein response 3E-03 
Host interactions of HIV factors 3E-03 
The NLRP3 inflammasome 3E-03 
Regulation of mitotic cell cycle 3E-03 
Developmental biology 3E-03 
G alpha I signalling events 4E-03 
Hormone sensitive lipase HSL mediated triacylglycerol hydrolysis 4E-03 
MYD88 mal cascade initiated on plasma membrane 4E-03 
Regulation of MRNA stability by proteins that bind au rich elements 4E-03 
Metabolism of lipids and lipoproteins 4E-03 
Mitotic G1 G1-S phases 4E-03 
Cell cycle 5E-03 
G alpha Z signalling events 5E-03 
GASTRIN CREB signalling pathway via PKC and MAPK 5E-03 
Signalling by ERBB4 5E-03 
Viral messenger RNA synthesis 5E-03 
Activation of chaperone genes by XBP1S 5E-03 
Notch1 intracellular domain regulates transcription 5E-03 
nucleotide binding domain leucine rich repeat containing receptor NLR signalling 
pathways 
5E-03 
Innate immune system 5E-03 
Synthesis of DNA 6E-03 
Apoptosis 6E-03 
CDK mediated phosphorylation and removal of CDC6 6E-03 




NRIF signals cell death from the nucleus 6E-03 
Neuronal system 6E-03 
Downstream signalling events of B cell receptor BCR 6E-03 
Autodegradation of the E3 ubiquitin ligase COP1 7E-03 
Mitochondrial protein import 7E-03 
P53 independent G1 S DNA damage checkpoint 7E-03 
Signalling by NGF 7E-03 
Inflammasomes 7E-03 
Platelet sensitization by LDL 7E-03 
SCF beta TRCP mediated degradation of EMI1 7E-03 
Destabilization of mRNA by AUF1 HNRNP D0 7E-03 
Protein folding 7E-03 
MicroRNA miRNA biogenesis 9E-03 
Oxygen dependent proline hydroxylation of hypoxia inducible factor alpha 9E-03 
PD1 signalling 9E-03 
Synthesis and interconversion of nucleotide di and triphosphates 9E-03 
CDT1 association with the cdc6 orc origin complex 9E-03 
mRNA splicing 9E-03 
Abortive elongation of HIV1 transcript in the absence of tat 9E-03 
Signalling by EGFR in cancer 1E-02 
S phase 1E-02 
Regulation of apoptosis 1E-02 
Fanconi anaemia pathway 1E-02 
G1 s transition 1E-02 
Metabolism of carbohydrates 1E-02 
Cell cycle mitotic 1E-02 
APC CCDC20 mediated degradation of cyclin B 1E-02 
Cholesterol biosynthesis 1E-02 
Regulatory RNA pathways 1E-02 
ER phagosome pathway 1E-02 
Interferon gamma signalling 1E-02 
Downregulation of TGF beta receptor signalling 1E-02 
Toll receptor cascades 1E-02 
Activation of NF kappa-B in B cells 1E-02 
Interferon alpha beta signalling 1E-02 
APC CDC20 mediated degradation of NEK2A 1E-02 
Thromboxane signalling through tp receptor 1E-02 
Assembly of the pre replicative complex 1E-02 
Glucose metabolism 1E-02 
Signalling by the B cell receptor BCR 2E-02 
ADP signalling through P2RY1 2E-02 
EGFR downregulation 2E-02 
Regulation of hypoxia inducible factor HIF by oxygen 2E-02 




Phase1 functionalization of compounds 2E-02 
Membrane trafficking 2E-02 
Endosomal sorting complex required for transport ESCRT 2E-02 
Myogenesis 2E-02 
Trafficking of AMPA receptors 2E-02 
RIG I MDA5 mediated induction of IFN ALPHA BETA pathways 2E-02 
Elongation arrest and recovery 2E-02 
Antigen processing cross presentation 2E-02 
Processing of capped intron containing pre mRNA 2E-02 
NGF signalling via TRKA from the plasma membrane 2E-02 
Formation of the hiv1 early elongation complex 2E-02 
Formation of transcription coupled NER TC NER repair complex 2E-02 
mRNA capping 2E-02 
Antigen processing ubiquitination proteasome degradation 2E-02 
Opioid signalling 2E-02 
Biological oxidations 2E-02 
Integrin cell surface interactions 2E-02 
M G1 transition 2E-02 
NEG regulators of RIG I MDA5 signalling 2E-02 
Signal amplification 2E-02 
Amyloids 3E-02 
Thrombin signalling through proteinase activated receptors pars 3E-02 
Ion transport by p type ATPases 3E-02 
Post NMDA receptor activation events 3E-02 
Signal transduction by L1 3E-02 
Triglyceride biosynthesis 3E-02 
mRNA processing 3E-02 
Regulation of insulin secretion 3E-02 
Activation of NMDA receptor upon glutamate binding and postsynaptic events 3E-02 
G1 phase 3E-02 
Nuclear signalling by ERBB4 4E-02 
IIL1 signalling 4E-02 
Formation of RNA polymerase II elongation complex  4E-02 
RNA polymerase II transcription pre initiation and promoter opening 4E-02 
Fatty acid triacylglycerol and ketone body metabolism 4E-02 
Late phase of HIV life cycle 4E-02 
Signalling by ERBB2 4E-02 
Axon guidance 4E-02 
Class I MHC mediated antigen processing presentation 4E-02 
Transcription coupled NER TC NER 5E-02 
Lipid digestion mobilization and transport 5E-02 








GPCR ligand binding 4E-06 
Class A1 rhodopsin like receptors 7E-05 
Signalling by GPCR 1E-04 
Immune system 4E-04 
G alpha I signalling events 1E-03 
Hemostasis 2E-03 
P2Y receptors 2E-03 
Activated TLR4 signalling 2E-03 
Lipid digestion mobilization and transport 2E-03 
Transmembrane transport of small molecules 3E-03 
Signalling by ILS 4E-03 
Nucleotide like purinergic receptors 4E-03 
Toll receptor cascades 5E-03 
Cytokine signalling in immune system 5E-03 
Co-stimulation by the CD28 family 6E-03 
Metabolism of lipids and lipoproteins 8E-03 
PI3K cascade 8E-03 
GPCR downstream signalling 9E-03 
NFκB and MAP kinases activation mediated by TLR4 signalling repertoire 9E-03 
Transcriptional regulation of white adipocyte differentiation 9E-03 
G0 and early G1 1E-02 
TRAF6 mediated induction of NFκB and MAP kinases upon TLR7 8 or 9 activation 1E-02 
Mitotic G2 G2-M phases 1E-02 
Basigin interactions 1E-02 
Lipoprotein metabolism 1E-02 
The role of NEF in HIV1 replication and disease pathogenesis 1E-02 
MYD88 MAL cascade initiated on plasma membrane 1E-02 
Class B 2 secretin family receptors 1E-02 
Insulin receptor signalling cascade 1E-02 
SLC mediated transmembrane transport 1E-02 
Transport of inorganic cations anions and amino acids oligopeptides 2E-02 
Amine ligand binding receptors 2E-02 
Peptide ligand binding receptors 2E-02 
IL1 signalling 2E-02 
Signalling by insulin receptor 3E-02 
Voltage gated potassium channels 3E-02 
Developmental biology 3E-02 




Cell-cell communication 3E-02 
Signalling by PDGF 3E-02 
MAP kinase activation in TLR cascade 3E-02 
Adaptive immune system 4E-02 
Chemokine receptors bind chemokines 4E-02 
Cell cycle mitotic 4E-02 
Phospholipase C mediated cascade 4E-02 
Factors involved in megakaryocyte development and platelet production 4E-02 
Loss of NLP from mitotic centrosomes 4E-02 
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